BR112014009069A2 - polipeptídeos de anticorpo que antagonizam cd40l - Google Patents

polipeptídeos de anticorpo que antagonizam cd40l Download PDF

Info

Publication number
BR112014009069A2
BR112014009069A2 BR112014009069-6A BR112014009069A BR112014009069A2 BR 112014009069 A2 BR112014009069 A2 BR 112014009069A2 BR 112014009069 A BR112014009069 A BR 112014009069A BR 112014009069 A2 BR112014009069 A2 BR 112014009069A2
Authority
BR
Brazil
Prior art keywords
bms2h
evollesggg
seq
adsvkgrfti srdnskntly
lomnslraed
Prior art date
Application number
BR112014009069-6A
Other languages
English (en)
Inventor
Steven G. Nadler
Olga Ignatovich
Philip DREW
James K. Tamura
Laura Price
Robert P. Rehfuss
Suzanne J. Suchard
Anish SURI
James William BRYSON
Aaron YAMNIUK
Steven Grant
Original Assignee
Bristol-Myers Squibb Company
Domantis Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014009069(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company, Domantis Limited filed Critical Bristol-Myers Squibb Company
Publication of BR112014009069A2 publication Critical patent/BR112014009069A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)

Abstract

polipeptídeos de anticorpo que antagonizam cd40l, seu uso, ácido nucleico, vetor, célula hospedeira e composição farmacêutica. a presente invenção refere-se a polipeptídeos de anticorpo que se ligam especificamente ao cd40l humano. os polipeptídeos de anticorpo não ativam as plaquetas. os polipeptídeos de anticorpo são úteis no tratamento de doenças que envolvem a ativação de cd40l, tais como doenças relacionadas a enxerto e doenças autoimunes. os polipeptídeos de anticorpo podem ser anticorpos de domínio (dabs) que compreendem um único domínio vh ou vk. a meia-vida dos polipeptídeos de anticorpo pode ser aumentada através da modificação dos polipeptídeos de anticorpo para serem reagentes específicos duais que também podem se ligar à albumina do soro humano (hsa) ou outro antígeno. a presente invenção também se refere a um ácido nucleico que codifica um polipeptídeo de anticorpo, a um vetor compreendendo o referido ácido nucleico, a uma célula hospedeira compreendendo o referido vetor, a uma composição farmacêutica compreendendo um polipeptídeo de anticorpo e ao uso de um polipeptídeo de anticorpo para a preparação de um medicamento para o tratamento de um paciente que tem ou está em risco de ter uma doença imune.

Description

da superfície celular, uma característica comum da família de TNFR. À expressão mais alta de CD40 foi observada em células apresentado- ras de antígeno (APCs), tais como células B, macrófagos e células dendríticas, enquanto uma expressão menor deste receptor é obser- vadaem uma variedade de outros tipos de células, incluindo células estromais e epitélio tímico. A interação CD40-CD40L é essencial para as interações de células T-B normais, incluindo maior coestimulação, promoção de células T, produção de citocinas, alteração de classe dos anticorpos e maturação da afinidade e produção de anticorpos e auto- anticorpos.
[005] A função crucial das interações CD40-CD40L nas respostas imunológicas e inflamatórias as tornou um alvo promissor para o tra- tamento de processos imuno-inflamatórios patológicos. O bloqueio das interações CD40-CD40L através de anticorpos monoclonais (mAbs) para CD40L específicos previne de forma bem sucedida a rejeição a aloenxertos em primatas e trata doenças autoimunes e aterosclerose em modelos com animais. Montgomery e outros, Transplantation 74: 1365-1369 (2002).
[006] Em seres humanos, dois clones de mAb anti-CD40L dife- rentes foram utilizados em testes clínicos para o tratamento de doen- ças autoimunes diferentes. Maribel e outros, Mol. Immunol. 45: 937-44 (2008). Anticorpos monoclionais, entretanto, podem exibir incidência surpreendentemente alta de complicações tromboembólicas (TE), tais como eventos do sistema nervoso central aterotrombóticos, enfarte do miocárdio, embolia pulmonar e trombose de veia profunda. Por exem- plo, a utilidade do clone de mAb anti-CD40L hu5c8 (anti-CD40L mAb, Biogen) é limitada por uma incidência surpreendentemente alta de complicações TE. Acredita-se que as TE por estes anticorpos resultem da formação de complexos imunológicos (IC) de ordem superior dos —mAbs com CD40L ligado à membrana nas plaquetas ou derramamen-
to de sSCD40L partindo das plaquetas, que podem se ligar e dessa ma- neira agregar plaquetas vizinhas através de seus receptores de FcgRI- la, resultando na formação de coágulos sanguíneos. O risco de trom- boembolia levou a uma suspensão em todos os testes clínicos em an- damento. Boumpas e outros, Arthritis & Rheumatism 48: 719-727 (2003).
SUMÁRIO
[007] Os antagonistas de anticorpos anti-CD40L que são menos prováveis que causem agregação de plaquetas e assim causem trom- boembolia ainda são necessários em um cenário clínico. Novos poli- peptídeos de anticorpo que se ligam especificamente ao CD40L hu- mano são fornecidos. Os polipeptídeos de anticorpo vantajosamente não causam agregação de plaquetas. Os polipeptídeos de anticorpo são úteis no tratamento de doenças que envolvem a ativação de CDA40L, incluindo doenças autoimunes, rejeição a transplante e res- postas alérgicas. Os polipeptídeos de anticorpo compreendem um domínio variável. Os exemplos de polipeptídeos de anticorpo estão na forma de um anticorpo de domínio (dAb) que contém um único domí- nio variável. Alternativamente, os dAbs podem ser reagentes biespecí- ficos que compreendem um segundo domínio variável que pode se ligar com outro antígeno, tal como a albumina do soro humano (HSA), por exemplo.
[008] É fornecido um polipeptídeo de anticorpo que compreende um primeiro domínio variável que se liga especificamente ao CD40L humano, em que o primeiro domínio variável compreende a sequência de aminoácidos de um dos domínios variáveis selecionados da linha- gem BMS2h. É adicionalmente fornecido um polipeptídeo de anticorpo isolado que compreende um primeiro domínio variável que se liga es- pecificamente ao CD40L humano, em que CD40L compreende a se- quênciade aminoácidos da SEQ ID NO: 1, em que a sequência de a-
minoácidos do primeiro domínio variável compreende: (a) uma região de CDR1 que difere da região de CDR1 de BMS2h-572-633 em até três aminoácidos, (b) uma região de CDR2 que difere da região de CDR?2 de BMS2h-572-633 em até três aminoácidos, (c) uma região de CDR3 que difere da região de CDR3 de BMS2h-572-633 em até três aminoácidos, (d) uma região de FR1 que difere da região de FR1 de BMS2h-572-633 em até três aminoácidos, (e) uma região de FR2 que difere da região de FR2 de BMS2h-572-633 em até três aminoácidos, (f) uma região de FR3 que difere da região de FR3 de BMS2h-572-633 em até três aminoácidos e (g) uma região de FR4 que difere da região de FR4 de BMS2h-572-633 em até três aminoácidos; e em que o poli- peptídeo de anticorpo inibe a ligação de CD40L ao CD40 com uma EC50 de 100 pM até 100 nM. Também é fornecido um polipeptídeo de anticorpo, em que a sequência de aminoácidos do primeiro domínio variável compreende: (a) uma região de CDR1 que difere da região de CDR1 de BMS2h-572-633 em até três aminoácidos, (b) uma região de CDR?2 que difere da região de CDR2 de BMS2h-572-633 em até três aminoácidos e (c) uma região de CDR3 que difere da região de CDR3 de BMS2h-572-633 em até três aminoácidos. Alternativamente, a se- quência de aminoácidos do primeiro domínio variável pode diferir da sequência de aminoácidos de BMS2h-572-633 em até e incluindo 10 aminoácidos. Além disso, a sequência de aminoácidos do primeiro domínio variável pode diferir da sequência de aminoácidos de BMS2h- 572-633 em até e incluindo 5 aminoácidos. A sequência de aminoáci- dosdo primeiro domínio variável também pode diferir da sequência de aminoácidos de BMS2h-572-633 em até e incluindo 2 aminoácidos. Alternativamente, o primeiro domínio variável difere da sequência de aminoácidos de BMS2h-572-633 em 1 aminoácido.
[009] Também é fornecido um polipeptídeo de anticorpo selecio- nado do grupo de linhagem de BMS2h-572, em que a sequência de aminoácidos do primeiro domínio variável compreende ainda: (a) uma região de CDR1 que possui uma sequência Trp-X,-Leu-Met-Gly (SEQ ID NO: 2), em que X, é Glu ou Gln; (b) uma região de CDR2 que pos- sui uma sequência Gly-lle-Glu-Gly-Pro-Gly-Asp-Val-Thr-Tyr-Tyr-Ala- —Asp-Ser-Val-Lys-Gly (SEQ ID NO: 3); e (c) uma região de CDR3 que possui uma sequência Lys-X,-Y,- Z>-Ser-Asp-Tyr (SEQ ID NO: 4), em que X, é Asp ou Glu, Y, é Ala ou Ser e Z>? é Lys, Asn ou Arg. Também é fornecido o polipeptídeo de anticorpo, em que a sequência de ami- noácidos do primeiro domínio variável compreende ainda: (a) uma re- giãode FR1 que possui uma sequência Glu-Val-Gln-Leu-Leu-Glu-Ser- Gly-Gly-Gly-Leu-Val-GlIn-Pro-Gly-Gly-Ser-Leu-Arg-Leu-Ser-Cys-Ala- Ala-Ser-Gly-Phe-Thr-Phe-Asn (SEQ ID NO: 5); (b) uma região de FR2 que possui uma sequência Trp-X,-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu- Glu-Trp-Val-Ser (SEQ ID NO: 6), em que X; é Ala ou Val; (c) uma regi- ão de FR3 que possui uma sequência Arg-Thr-Phe-lle-Ser-Arg-Asp- Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-GlIn-Met-Asn-Ser-Leu-Arg-Ala-Glu- Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Val-Lys-Val-Gly (SEQ ID NO: 7); e (d) uma região de FR4 que possui uma sequência Arg-Gly-Gln-Gly-Thr- Leu-Val-Thr-Val-Ser-Ser (SEQ ID NO: 8). Alternativamente, o primeiro domínio variável do polipeptídeo de anticorpo pode compreender a se- quência de aminoácidos de BMS2h-572-633;
[0010] Também é fornecido um polipeptídeo de anticorpo selecio- nado do grupo de linhagem de BMS2h-719, que compreende um pri- meiro domínio variável com a sequência consenso a seguir: Glu-Val- Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Leu- Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-X,-Y,-Tyr-Glu-Met-Z,- Trp-Val-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser-Ser-lle-Ser- Ser-Asp-Gly-Ser-Phe-Thr-Tyr-Tyr-Ala-A,-Ser-Val-Lys-Gly-Arg-Phe-Thr- Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-Met-Asn-Ser- Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Ala-B,-Pro-Phe-Thr-Glu-
C,-Asp-Tyr-Trp-Gly-His-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser (SEQ ID NO: 9), em que X, é Lys ou Asn; Y, é Arg, Lys, Ser ou Thr; Z, é Met ou Gln; A, é Asp ou Glu; B, é Asp ou Glu; e C, é Phe, Met ou Leu.
[0011] Também é fornecido um polipeptídeo de anticorpo selecio- nado do grupo de linhagem de BMS2h-503, que compreende um pri- meiro domínio variável com a sequência consenso a seguir: Asp-lle- Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-Ala-Ser-Val-Gly-Asp-Arg- Val-Thr-Ile-Thr-Cys-Arg-Ala-Ser-His-X,-lle-GIn-Arg-Tyr-Leu-Ser-Trp- Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-Leu-lle-Leu-Trp-Gly-Ser- Gln-Leu-Gln-Ser-Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly- Thr-Asp-Phe-Thr-Leu-Thr-lle-Ser-Ser-Leu-Gln-Pro-Glu-Asp-Phe-Ala- Thr-Tyr-Tyr-Cys-Gly-Gln-Trp-Trp-Ala-Pro-Pro-Gln-Thr-Phe-Gly-Gln- Gly-Thr-Lys-Val-Glu-lle-Lys-Arg (SEQ ID NO: 10), em que X, é His ou Asp.
[0012] Também é fornecido um polipeptídeo de anticorpo selecio- nado do grupo de linhagem de BMS2h-116, que compreende um pri- meiro domínio variável com a sequência consenso a seguir: Asp-lle- Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-Ala-X,-Val-Gly-Asp-Arg-Val- Thr-lle-Thr-Cys-Arg-Ala-Ser-Gln-Pro-lle-Gly-Pro-Asp-Leu-Leu-Trp-Tyr- GIn-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-Leu-lle-Tyr-GlIn-Thr-Ser-lle- Leu-Arg-Ser-Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Glu-Thr- Asp-Phe-Thr-Leu-Thr-lle-Ser-Asn-Leu-Gln-Pro-Glu-Asp-Y-Ala-Z,-Tyr- Tyr-Cys-GlIn-Gln-Tyr-Trp-Ala-Phe-Pro-Val-Thr-Phe-Gly-A,-Gly-Thr-Lys- Val-Val-lle-Lys-Arg (SEQ ID NO: 11), em que X, é Ser ou Tyr; Y; é Leu ouPhe;Z,éThrouLys;eA, é Lys, Arg ou Gln.
[0013] Também é fornecido um polipeptídeo de anticorpo que compreende um primeiro domínio variável que se liga especificamente ao CD40L humano, em que o polipeptídeo de anticorpo é um anticorpo de domínio (dAb). O polipeptídeo de anticorpo pode ser um polipeptí- deo de fusão que compreende o primeiro domínio variável e um domí-
nio Fc. Alternativamente, o polipeptídeo de fusão pode compreender um domínio Fc de IgG4. O polipeptídeo de fusão também pode com- preender um domínio Fc de IgG1. O polipeptídeo de fusão também pode compreender um domínio Fc de IgG1. Alternativamente, o poli- peptídeo de fusão pode compreender um domínio CT-Long. O polipep- tídeo de fusão também pode compreender um domínio CT-short. Al- ternativamente, o polipeptídeo de fusão pode compreender um domí- nio Fc de N297Q Long. O polipeptídeo de fusão pode alternativamente compreender um domínio Fc de N297Q Short.
[0014] Também é fornecido um polipeptídeo de anticorpo que compreende um primeiro domínio variável que se liga especificamente ao CD40L humano, em que o polipeptídeo de anticorpo compreende ainda um segundo domínio variável que se liga especificamente a um segundo antígeno, em que o segundo antígeno é um antígeno sem ser CD40L humano. O segundo antígeno pode ser uma molécula de clus- ter de diferenciação (CD) ou uma molécula de Complexo de Histo- compatibilidade Principal (MHC) de Classe Il. Alternativamente, o se- gundo antígeno pode ser albumina do soro (SA).
[0015] Também é fornecido um ácido nucleico que codifica qual- quer um dos polipeptídeos de anticorpo fornecidos aqui. É também considerado um vetor que compreende o ácido nucleico. Uma célula hospedeira isolada pode compreender tal vetor.
[0016] É fornecida uma composição farmacêutica que compreende uma quantidade terapeuticamente eficaz do polipeptídeo de anticorpo fornecido aqui e um veículo farmaceuticamente aceitável. A composi- ção farmacêutica pode compreender ainda um agente imunossupres- sorlimunomodulador e/ou anti-inflamatório.
[0017] É fornecido um método de tratamento de uma doença imu- ne em um paciente que necessita de tal tratamento que compreende a administração ao paciente de uma quantidade terapeuticamente eficaz da composição farmacêutica descrita aqui. Um exemplo de método administra a composição farmacêutica em combinação com agente imunossupressor/imunomodulador e/ou anti-inflamatório. A doença imune pode ser uma doença autoimune ou uma doença relacionada a enxerto. Alternativamente, a doença imune é uma doença relacionada a enxerto. Além disso, a doença relacionada a enxerto pode compre- ender rejeição a transplante de órgão sólido, tecido e/ou célula. Alter- nativamente, a doença relacionada a enxerto é a doença de enxerto versus hospedeiro (GVHD). A doença relacionada a enxerto pode ser ainda uma rejeição a transplante aguda. Alternativamente, a doença relacionada a enxerto pode ser uma rejeição a transplante crônica.
[0018] Também é fornecido o método de tratamento de uma doen- ça relacionada a enxerto, em que a composição farmacêutica é coad- ministrada com uma molécula de CTLA4 mutante. A molécula de CTLA4 mutante pode ser L104EA29Y-lg (belatacept).
[0019] É também fornecido um método de tratamento de uma do- ença imune em um paciente que necessita de tal tratamento que com- preende a administração ao paciente de uma quantidade terapeutica- mente eficaz da composição farmacêutica fornecida aqui, em que a doença imune é selecionada do grupo que consiste em doença de Ad- dison, alergias, espondilite anquilosante, asma, aterosclerose, doen- ças autoimunes do ouvido, doenças autoimunes do olho, hepatite au- toimune, parotidite autoimune, colite, doença cardíaca coronariana, doença de Crohn, diabetes, incluindo diabetes do Tipo 1 e/ou do Tipo 2, epididimite, glomerulonefrite, doença de Graves, síndrome de Guil- lain-Barre, doença de Hashimoto, anemia hemolítica, púrpura trombo- citopênica idiopática, doença inflamatória do intestino, resposta imuno- lógica a produtos de fármacos recombinantes, lúpus eritematoso sis- têmico, infertilidade do sexo masculino, esclerose múltipla, miastenia grave, pênfigo, psoríase, febre reumática, artrite reumatoide, sarcoido-
se, escleroderma, síndrome de Sjogren, espondiloartropatias, tireoidi- te, rejeição a transplante, vasculite, AIDS, alergia atópica, asma bron- quial, eczema, lepra, esquizofrenia, depressão herdada, transplante de tecidos e órgãos, síndrome de fadiga crônica, doença de Alzheimer, doença de Parkinson, enfarte do miocárdio, derrame, autismo, epilep- sia, fenômeno de Arthus, anafilaxia, alcoolismo e dependência de dro- gas. Alternativamente, a doença imune pode ser miastenia grave, púr- pura trombocitopênica idiopática ou esclerose sistêmica.
[0020] Também é fornecido um uso de um polipeptídeo de anti- corpo isolado divulgado aqui para a preparação de um medicamento para o tratamento de um paciente, em que o paciente tem ou está em risco de ter uma doença imune. É adicionalmente fornecido um uso de um polipeptídeo de anticorpo isolado divulgado aqui para a preparação de um medicamento para o alívio de pelo menos um sintoma de uma doença imune em um paciente que necessita do mesmo.
[0021] É adicionalmente fornecido aqui um polipeptídeo de anti- corpo isolado que compreende um primeiro domínio variável, em que o dito polipeptídeo de anticorpo se liga especificamente ao CD40L hu- mano, em que o CD40L compreende a sequência de aminoácidos da SEQIDNO:1,em que o polipeptídeo de anticorpo compete com a li- gação de BMS2h-572-633 e em que o polipeptídeo de anticorpo inibe a ligação de CD40L ao CD40 com uma EC50 de 100pM até 100nM. Em um aspecto, o primeiro domínio variável compreende a sequência de aminoácidos de um dos polipeptídeos de anticorpo selecionado do grupo de linhagem que consiste em BMS2h-572, BMS2h-719, BMS2h- 503 e BMS2h-116. Em outro aspecto, o primeiro domínio variável compreende uma sequência de aminoácidos pelo menos 95% idêntica a BMS2h-572-6, BMS2h-572-608, BMS2h-572-614, BMS2h-572-619, BMS2h-572-633, BMS2h-572-634, BMS2h-572-635, BMS2h-719-2, BMS2h-719-202, BMS2h-719-203, BMS2h-719-213, BMS2h-719-214,
BMS2h-719-215, BMS2h-719-218, BMS2h-719-225, BMS2h-503-1, BMS2h-503-2, BMS2h-116-1312, BMS2h-116-1313 ou BMS2h-116-
1320. Ainda em outro aspecto, o primeiro domínio variável compreen- de a sequência de aminoácidos de BMS2h-572-6, BMS2h-572-608, BMS2h-572-614, BMS2h-572-619, BMS2h-572-633, BMS2h-572-634, BMS2h-572-635, BMS2h-719-2, BMS2h-719-202, BMS2h-719-203, BMS2h-719-213, BMS2h-719-214, BMS2h-719-215, BMS2h-719-218, BMS2h-719-225, BMS2h-503-1, BMS2h-503-2, BMS2h-116-1312, BMS2h-116-1313 ou BMS2h-116-1320.
BREVE DESCRIÇÃO DAS FIGURAS
[0022] A FIG. 1A descreve o anticorpo de domínio que compreen- de um domínio variável de V, BMS2h-572-633 fundido com uma cau- da Fc modificada do IgG1 Abatacept.
[0023] A FIG. 1B mostra a sequência de aminoácidos (SEQ ID NO: 1355) do domínio variável BMS2h-572-633. A proteína de fusão de Fc é um dímero de peso molecular de 77.984 Dáltons, com cada cadeia polipeptídica consistindo de 354 aminoácidos. O domínio variá- vel é fundido por um ligante com a construção de Fc mutada de I9G1 humana, em que três resíduos de cisteína são substituídos por serina euma prolina é substituída por um resíduo de serina.
[0024] A FIG. 2 descreve um modelo de trabalho para a via de CD40-40L. O painel superior demonstra estágios iniciais de um encon- tro entre uma célula T e uma APC. O encontro inicial controlado pelo compromisso do receptor de célula T (TCR) do complexo de pMHC (sinal 1) acoplado com uma interação inicial CD28-CD80 (sinal 2) é suficiente para a expressão na superfície celular de CD40L trimérico (painel inferior). O compromisso de CD40 por CD40L resulta em várias respostas biológicas esquematizadas na caixa cinzenta.
[0025] A FIG. 3 fornece sequências (SEQ ID NOS 1356-1361, res- pectivamente, na ordem de aparecimento) de vários domínios Fc. As regiões ligantes são mostradas nas caixas.
[0026] A FIG. 4 mostra exemplos de vários anticorpos com domí- nio formatado com Fc (SEQ ID NOS 1362-1365, respectivamente, na ordem de aparecimento). As regiões ligantes são indicadas pelas cai- xas.
[0027] A FIG. 5 descreve dados de sensorgrama de SPR para a ligação de 12,5-0,39nM de BMS-986004 (série de diluição de 2:1) com biot-IZ-hCD40L capturado sobre um chip sensor de SPR de estrepta- vidina a 25ºC. As linhas coloridas mostram os dados do sensorgrama com referência dupla e as linhas em preto mostram o ajuste de Lang- muir de 1:1 Langmuir aos dados, com um valor de Kd aparente influ- enciado pela avidez de 0,11 nM.
[0028] A FIG. 6 mostra dados de ITC para titulações de 19 uM de IZ-hCD40L dentro de 2 uM de BMS-986004 (em preto) ou 18 uM de BMS-986004 dentro de 2 UM de IZ-hCD40L (em azul). A proporção molar (estequiometria aparente) é definida por mol de trímero de |Z- hCD40L e por mol de dímero de BMS-986004 Fc bivalente. Os valores de proporção molar obtidos na forma de pontos de equivalência sobre a abscissa sugerem que mais de um mol de BMS-986004 pode se |i- gar por mol de trímero de IZ-hCD40L; entretanto, um modelo estrutural exato para o complexo não pode ser determinado partindo apenas dos dados de ITC. Os quadrados representam o calor integrado dos dados de ligação e as linhas sólidas representam o melhor ajuste a um "mo- delo de 2 conjuntos de sítios".
[0029] A FIG. 7 mostra a eficácia in vivo do representante de CDA40L de camundongo dAb-Fc (resposta de anticorpo induzida por KLH).
[0030] A FIG. 8 demonstra que o dAb BMS-2m-126-24-Fc de ca- mundongo e o anticorpo MR-1 inibem a colite induzida por TNBS em camundongos.
[0031] A FIG. 9 mostra que BMS-2m-126-24-Fc e CTLA4-Ig fun- cionam de forma sinérgica para prolongar a sobrevivência de aloenxer- tos cardíacos.
[0032] A FIG. 10 fornece um modelo hipotético para a agregação de plaquetasmediada por anticorpo monoclonal anti-CD40.
[0033] A FIG. 11A mostra a concentração no plasma vs. o perfil de tempo de BMS-986004 após a dosagem IV de 11 mg/kg em macacos.
[0034] A FIG. 11B demonstra a concentração no plasma vs. os perfis de tempo de BMS-986003 após a dosagem |V de 2 mg/kg em macacos.
[0035] A FIG. 12 apresenta as concentrações no plasma vs. os perfis de tempo de BMS-986003 (após a dosagem SC a 0,2, 2 e 20 mg/kg em macacos) e de 5c8 IgG1 (após a dosagem IV a 20 mg/kg em macacos).
[0036] A FIG. 13 mostra as concentrações no plasma vs. os perfis de tempo de BMS-2m-126-24-CT após 1 mg/kg de dosagem IVe SC e 10 mg/kg de dosagem SC a camundongos.
[0037] A FIG. 14 demonstra a modelagem de PK/PD de exposi- ções do plasma a BMS-986003 e 5c8-lgG1 e resposta de anticorpo anti-KLH (Títulos de IgG).
[0038] A FIG. 15 mostra a modelagem de PK/PD de exposições do plasma a BMS-986004 e RO ex vivo sobre células mononucleares do sangue periférico (PBMC).
[0039] A FIG. 16 demonstra que IV.3 bloqueia a ativação mediada por 5c8/sCD40L IC de plaquetas no sangue humano.
[0040] A FIG. 17 mostra o efeito de variantes de Fc sobre a ativa- ção de plaquetas no sangue humano.
[0041] A FIG. 18 demonstra a ativação de plaquetas com 5c8- CT/sCDA40L IC no sangue de doadores humanos genotipados em rela- ção ao polimorfismo FcegRlla.
[0042] A FIG. 19 diagrama a ativação de plaquetas por vários anti- corpos no sangue de doadores humanos.
[0043] A FIG. 20 mostra os níveis de ativação de plaquetas por vários anticorpos, incluindo BMS-986003, em camundongos transgêni- cos que expressam hFcgRlla.
[0044] As Figuras 21, 22, 23 e 24 mostram alinhamentos de Clus- talW2 de polipeptídeos de anticorpo de domínio representativos de li- nhagens BMS2h-572, BMS2h-719, BMS2h-503 e BMS2h-116, respec- tivamente. A FIG. 21 mostra as SEQ ID NOS 243, 251, 257, 262 e 274-276, respectivamente, na ordem de aparecimento, a FIG. 22 mos- tra as SEQ ID NOS 352, 354-355 e 357-361, respectivamente, na or- dem de aparecimento, a FIG. 23 mostra as SEQ ID NOS 1087-1088, respectivamente, na ordem de aparecimento e a FIG. 24 mostra as SEQ ID NOS 970-971 e 974, respectivamente, na ordem de apareci- mento.
[0045] A FIG. 25 mostra dados do sensorgrama de SPR para ex- perimentos de ligação utilizando dAbs BMS2h-503-1, BMS2h-572-6, BMS2h-719-17 monovalentes e fragmento de Fab monovalente de 5c8, em que as moléculas indicadas competem com cada outra pela ligaçãocom CDA40L (IZ-hCD40L biotinilado).
[0046] A FIG. 26 mostra dados do sensorgrama de SPR para ex- perimentos que testam a ligação de moléculas de BMS2h-572-619-CT- long, BMS2h-572-633-CT-long, BMS2h-572-6-CT-long, BMS2h-719- 202-CT-long, = BMS2h-572-608-CT-long, — BMS2h-572-634-CT-long, BMS2h-572-614-CT-long, BMS2h-572-635-CT-long e 5c8-CT-long a um monômero de CDA40L (3 painéis superiores) ou um trímero de CD40L (3 painéis inferiores).
DESCRIÇÃO DETALHADA
[0047] São fornecidos polipeptídeos de anticorpo que se ligam es- pecificamente ao CD40L humano. Os polipeptídeos de anticorpo não ativam as plaquetas e os polipeptídeos de anticorpo são úteis no tra- tamento de doenças que envolvem a ativação de CD40L, tais como doenças relacionadas a enxerto e doenças autoimunes. Os polipeptí- deos de anticorpo podem ser selecionados utilizando uma seleção primária que utiliza ensaios de ligação celular, seguida por uma ou mais rodadas de maturação da afinidade propensa a erros ou direcio- nada a oligonucleotídeos degenerados. Como um resultado, é forneci- do um gênero de polipeptídeos de anticorpo que se ligam especifica- mente a CD40L.
[0048] Uma "linhagem" é um conjunto de polipeptídeos de anticor- po relacionados que foram preparados partindo de precursor comum através de maturação de afinidade propensa a erros ou direcionada a oligonucleotídeos degenerados, que é divulgada nos exemplos a se- guir e que se espera que se liguem ao CD40L. A nomenclatura dos polipeptídeos de anticorpo é utilizada para designar as várias linha- gens. A nomenclatura "BMS2h-572," por exemplo, refere-se a polipep- tídeos de anticorpo da linhagem 572, que foram produzidos contra o CDA40L humano. Os polipeptídeos de anticorpo da "linhagem BMS2h- 572" incluem BMS2h-572-1 até BMS2h-572-19, BMS2h-572-21 até BMS2h-572-24, BMS2h-572-601 até BMS2h-572-627 e BMS2h-572- 630 até BMS2h-572-635.
[0049] Consequentemente, em um aspecto, um polipeptídeo de anticorpo compreende um domínio variável que se liga especificamen- te ao CD40L humano, em que o polipeptídeo de anticorpo compete coma ligação de qualquer um dos anticorpos de domínio (dAbs) lista- dos na TABELA 1 ou na TABELA 3. Por exemplo, o polipeptídeo de anticorpo pode competir comum dAb selecionado da linhagem 2h. O dAb também pode ser selecionado de uma linhagem selecionada do grupo que consiste em BMS2h-116, BMS2h-503, BMS2h-572 e BMS2h-719, tal como o dAb BMS2h-572-633, BMS2h-572-608 ou
BMS2h-572-614, por exemplo. Em outro aspecto, um polipeptídeo de anticorpo se liga especificamente ao CD40L humano como qualquer um dos dAbs listados na TABELA 1 e na TABELA 3. Por exemplo, o polipeptídeo de anticorpo pode compreender um domínio variável que seliga especificamente ao CD40L humano como o dAb BMS2h-572- 633, BMS2h-572-608 ou BMS2h-572-614, por exemplo.
[0050] Os polipeptídeos de anticorpo podem ser um anticorpo de domínio que contém um único domínio variável. Os polipeptídeos de anticorpo também podem compreender domínios adicionais, tal como um domínio Fc. Por exemplo, o polipeptídeo de anticorpo pode com- preender um segundo domínio variável que se liga especificamente à albumina do soro humano (HSA). Tais polipeptídeos de anticorpo es- pecíficos duais podem ter uma maior meia-vida, por exemplo.
[0051] Como utilizado aqui, "ligação específica" refere-se à ligação de um antígeno por um polipeptídeo de anticorpo com uma constante de dissociação (K4g) de aproximadamente 1 uM ou inferior que é medi- da, por exemplo, pela ressonância de plasmon de superfície (SPR). Os sistemas de ensaio adequados incluem o sistema de ressonância de plasmon de superfície BlAcore"" e o software de avaliação cinética BlAcore"" (por exemplo, versão 2.1). A afinidade ou a Ka para a inte- ração de ligação específica pode ser de aproximadamente 1 uM ou inferior, aproximadamente 500 nM ou inferior ou aproximadamente 300 nM ou inferior.
[0052] O termo "aproximadamente" será entendido por peritos co- muns na arte e variará até alguma extensão sobre o contexto em que é utilizado. Geralmente, abrange aproximadamente uma faixa de valo- res que são mais/menos 10% de um valor referido.
[0053] De acordo com esta descrição detalhada, as abreviações e as definições a seguir se aplicam. Tem que ser observado que como utilizado aqui, as formas no singular "um", "uma", "o" e "a" incluem re-
ferentes no plural a não ser que o contexto determine claramente o contrário. Assim, por exemplo, referência a "um anticorpo" inclui um grande número de tais anticorpos e referência à " dosagem" inclui refe- rência a uma ou mais dosagens e equivalentes das mesmas conheci- das pelos versados na técnica e assim por diante.
1. CD40L e Atividades de CD40L
[0054] São fornecidos polipeptídeos de anticorpo que se ligam ao CD40L humano. O CD40L é também conhecido como CD154, gp39, proteína de ativação relacionada ao TNF (TRAP), antígeno 5c8 ou T- BAM. Informação estrutural relevante para o CD40L humano pode ser encontrada, por exemplo, no Número de Acesso UniProt P29965. "CD40L humano" refere-se ao CD40L que compreende a sequência de aminoácidos a seguir: 10 20 30 40 50 60
MIETYNOTSP RSAATGLPIS MKIFMYLLTV FLITOMIGSA LFAVYLHRRL
DKIEDERNLH 70 80 90 100 110 120
EDFVFMKTIQ RCNTGERSLS LLNCEEIKSQ FEGFVKDIML NKEETKKENS
FEMQKGDQNP 130 140 150 160 170 180
QIAAHVISEA SSKTTSVLQW AEKGYYTMSN NLVTLENGKO LTVKROGLYY
IYAQVTFCSN 190 200 210 220 230 240
REASSQAPFI ASLCLKSPGR FERILLRAAN THSSAKPCGQ QSIHLGGVFE
LOPGASVFVN 250 260
VTDPSQVSHG TGFTSFGLLK L (SEQ ID NO. 1)
[0055] O CD40L também foi sequenciado em Sus scrofa, Mus musculus, Canis familiaris, Bos ffini, Macaca mulatta, Aotus tivirgatus, Callithrix jacchus, Cercocebus torquatus atys, Macaca nemestrina,
Rattus norvegicus, Gallus gallus, Felis catus e Sus scrofa.
[0056] A ligação dos presentes polipeptídeos de anticorpo ao CD40L antagoniza a atividade de CD40L. "Atividades de CD40L" in- cluem, mas não estão limitadas a, coestimulação e ativação de uma APCem associação com estimulação do receptor de células T por mo- léculas de MHC sobre a APC, secreção de todos os isotipos de imu- noglobulina na presença de citocinas, estimulação de proliferação de células B, produção de citocina, troca de classe do anticorpo e matu- ração da afinidade. Por exemplo, pacientes com síndrome de hiper- IgM ligada ao X expressam CD40 funcional sobre suas células B, mas suas células T ativadas possuem uma proteína CD40L defeituosa, re- sultando em sua incapacidade de ativar células B e induzir troca de subtipo da imunoglobulina. Aruffo e outros, Cell 72:291-300 (1993).
[0057] As atividades de CD40L podem ser mediadas através da interação com outras moléculas. "Atividades de CD40L" incluem a inte- ração funcional entre CD40L e as moléculas a seguir: CD40 (receptor de CD40L), integrina a5B1 e allbB3. Por exemplo, CD40L se liga a seu receptor, CD40, que é expresso sobre uma variedade de APCs, tais como células B, macrófagos e células dendríticas, bem como sobre célulasdo estroma, células endoteliais vasculares e plaquetas.
[0058] Como utilizado aqui, os termos "ativam", "ativa" e "ativa- do(a)" referem-se a um aumento em uma atividade de CD40L mensu- rável fornecida em pelo menos 10% em relação a uma referência, por exemplo, pelo menos 10%, 25%, 50%, 75% ou até mesmo 100% ou mais. A atividade de CD40L é "antagonizada" se a atividade for redu- zida em pelo menos 10% e em um exemplo de modalidade, pelo me- nos 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97% ou até mesmo 100% (isto é, sem atividade detectável), em relação à ausên- cia do antagonista. Por exemplo, um polipeptídeo de anticorpo pode antagonizar parte ou toda a atividade de CD40L. Em uma modalidade,
o polipeptídeo de anticorpo não ativa a proliferação de células B. Em outra modalidade, o polipeptídeo de anticorpo não ativa a secreção de citocinas pelas células T ou pelas células dendríticas (DCs), em que a citocina é pelo menos uma citocina selecionada do grupo que consiste emliL-2,1L-6,1L-10, 1L-12, 11-13, IL-17, 11-23, TNF-a e IFN-y.
2. Polipeptídeos de Anticorpo
[0059] Os polipeptídeos de anticorpo compreendem um domínio variável. Em uma modalidade, os polipeptídeos de anticorpo estão na forma de um dAb que contém um único domínio variável. Os polipeptí- deos de anticorpo podem ser moléculas de imunoglobulina anti-CD40L de comprimento completo que compreendem duas cadeias pesadas (H) e duas cadeias leves (L) interconectadas por ligações dissulfeto. Nesta modalidade, a porção amino terminal de cada cadeia inclui um domínio variável (V, ou Vy4) de aproximadamente 100-120 aminoáci- dos. As regiões de determinação de complementaridade (CDRs) con- tidas ali são primariamente responsáveis pelo reconhecimento de antí- genos, embora os resíduos estruturais possam desempenhar uma função na ligação de epítopos. A "metade" carbóxi-terminal de cada cadeia pesada define uma região constante (Fc) primariamente res- ponsável pela função efetora.
[0060] Os polipeptídeos de anticorpo também podem ser "frag- mentos" que compreendem uma porção da molécula de imunoglobuli- na anti-CD40L de comprimento completo que compreende um domínio variável que se liga especificamente ao CD40L. Assim, o termo "poli- peptídeos de anticorpo" inclui uma cadeia pesada de ligação ao antí- geno, uma cadeia leve, um dímero de cadeia pesada-cadeia leve, um fragmento Fab, um fragmento F(ab'),, um fragmento Fv, um Fv de ca- deia simples (scFv) e um dAb, por exemplo. O termo "polipeptídeos de anticorpo" inclui assim polipeptídeos produzidos através de engenharia recombinante e expressão, bem como anticorpos monoclonais produ-
zidos por recombinação natural e secreção por clones de células de hibridoma.
[0061] As cadeias leves são classificadas como kappa (K) ou lambda (A) e são caracterizadas por uma região constante particular, C, como é conhecido na arte. As cadeias pesadas são classificadas como y, u, q, à ou e e definem o isotipo de um anticorpo como IgG, IgM, IgA, IgD ou IgE, respectivamente. A região constante de cadeia pesada é compreendida de três domínios (CH1, CH2 e CH3) para IgG, IgD e IgA; e quatro domínios (CH1, CH2, CH3 e CH4) para IgM e IgE.
Os anticorpos anti-cCD40L podem possuir uma região constante de ca- deia pesada selecionada de qualquer uma das classes de imunoglobu- lina (IGA, IGD, IgG, IgM e IgE).
[0062] Cada domínio variável de cadeia leve (V,) e cada domínio variável de cadeia pesada (V4) é composto de três CDRs e quatro re- giões estruturais (FRs), dispostas do terminal amino para o terminal carbóxi na ordem a seguir: FR1, CDR1, FR2, CDR2, FR3, CDR3 e FR4. As três CDRs da cadeia leve são referidas como "LCDRI1, LCDR?2 e LCDR3" e as três CDRs da cadeia pesada são referidas co- mo "HCDR1, HCDR2 e HCDR3".
[0063] Como utilizado aqui, o termo "domínio Fc" refere-se às se- quências de anticorpo de região constante que compreendem os do- mínios constantes CH2 e CH3 que são delimitados de acordo com Ka- bat e outros, Sequences of Immunological Interest, 5º ed., U.S. Dept. Health & Human Services, Washington, D.C. (1991). O domínio Fc po- de ser derivado de uma região Fc de IgG1 ou de IgG4, por exemplo.
[0064] Um domínio variável pode ser fundido com um domínio Fc. Os exemplos de vários anticorpos com domínio formatado com Fc e sua potência são fornecidos na TABELA 6. A FIG. 3 fornece as se- quências de vários domínios Fc fornecidos aqui. As regiões ligantes são mostradas nas caixas. Como utilizado na TABELA 6, "Fc" indica que o dAb é fundido com um Fc curto de IgG1 humana. "CT Long Fc", também chamado de CT-L2, refere-se ao Fc de CTLA4. O S sublinha- do representa mutações pontuais cisteína-para-serina feitas para eli- minar os dissulfetos na dobradiça de Fc. "CT Short", também chamado deCT-S1,émaiscurto que CT Long em 7 aminoácidos. "N297Q Long Fc", também referido como N297Q-LA4, é o domínio Fc da IgG1 huma- na com uma mutação N297Q feita para eliminar o carboidrato ligado a N no Fc. "N297Q Short Fc", também chamado de N297Q-S3, é mais curto que N297Q Long Fc em 7 aminoácidos e é uma IgG1 humana com uma mutação pontual N297Q feita para eliminar o carboidrato |li- gado a N no domínio Fc. "CT-Fc SP5" é o CT Long Fc, em que SP5 refere-se ao peptídeo sinal da octeonectina utilizado para a secreção partindo do hospedeiro de expressão mamífero. O sítio de clivagem é indicado por """. A FIG. 4 fornece ainda exemplos de vários formados dedomínioFc.
[0065] Quando um domínio variável é fundido com um domínio Fc, o terminal carboxila do domínio variável (um domínio V, ou Vu, incluin- do dAbs) pode ser ligado ou fundido ao terminal amino do domínio CH2 de Fc. Alternativamente, o terminal carboxila do domínio variável pode ser ligado ou fundido ao terminal amino de um domínio CH1, que por si só é fundido com o domínio CH2 de Fc. A proteína pode com- preender a região de dobradiça entre os domínios CH1 e CH2 como um todo ou em parte.
[0066] As CDRs contêm a maioria dos resíduos que forma intera- ções específicas com o antígeno. Em uma modalidade, o domínio va- riável de um polipeptídeo de anticorpo compreende regiões de CDR1, CDR?2 e CDR3 que possuem a mesma sequência de aminoácidos que as regiões de CDR1, CDR2 e CDR3 de um dos dAbs listados na TABELA 1 ou na TABELA 3 ou que cada um difere das regiões de CDRI1,CDR?2eCDR3 em um, dois ou três aminoácidos. Por exemplo,
o polipeptídeo de anticorpo pode compreender regiões de CDR1, CDR?2 e CDR3 que possuem a mesma sequência de aminoácidos que as regiões de CDR1, CDR2 e CDR3 de BMS2h-572-633, BMS2h-572- 608 ou BMS2h-572-614, por exemplo.
[0067] Um "anticorpo de domínio" (dAb) compreende um único domínio variável (V, ou Vu) domínio que é capaz de se ligar especifi- camente e de forma monovalente com um antígeno, tal como CD40L. Por exemplo, um dAb pode ter uma estrutura Vu, característica de um dAb de camelídeo. Entende-se que um "domínio V4" como utilizado aquiinclua uma estrutura Vu. Em outra modalidade, os domínios Vu" (incluindo todas as características e a combinação de características apresentadas como modalidades aqui) são domínios sem ser V4n. Os dAbs podem formar homo- ou heterodímeros em solução. Embora não limitado por qualquer teoria particular, acredita-se que os dAbs divul- gados aqui não causem agregação de plaquetas, porque os anticorpos contendo construções de Fc mutadas não se ligam a FeyRlla (também conhecido como CD32a) sobre a superfície das plaquetas e não ati- vam as plaquetas.
[0068] Como utilizado aqui, o termo "domínio variável" refere-se a domínios variáveis de imunoglobulina definidos por Kabat e outros, Sequences of Immunological Interest, 5º ed., U.S. Dept. Health & Hu- man Services, Washington, D.C. (1991). A numeração e o posiciona- mento dos resíduos de aminoácidos da CDR dentro dos domínios va- riáveis estão de acordo com a convenção de numeração de Kabat bem conhecida.
[0069] O termo "humano", quando aplicado aos polipeptídeos de anticorpo, significa que o polipeptídeo de anticorpo possui uma se- quência, por exemplo, regiões estruturais e/ou domínios de CH, deri- vados de uma imunoglobulina humana. Uma sequência é "derivada de" uma sequência que codifica imunoglobulina humana quando a se-
quência for qualquer uma: (a) isolada de um indivíduo humano ou de uma célula ou de uma linhagem de célula de um indivíduo humano; (b) isolada de uma biblioteca de sequências gênicas de anticorpos huma- nos clonadas ou de sequências de domínio variável de anticorpos hu- manos; ou (c) diversificada por mutação e seleção de um ou mais dos polipeptídeos anteriores. Um composto "isolado" como utilizado aqui significa que o composto é removido de pelo menos um componente com o qual o composto está naturalmente associado na natureza.
[0070] Os polipeptídeos de anticorpo podem ser administrados a pacientes humanos enquanto se evita enormemente a resposta imuno- lógica de anticorpo frequentemente provocada pela administração de anticorpos de outras espécies, por exemplo, camundongo. Por exem- plo, anticorpos murinos podem ser "humanizados" através do enxerto de CDRs murinas em uma FR de domínio variável humano, de acordo com procedimentos bem conhecidos na técnica. Os anticorpos huma- nos que são divulgados aqui, entretanto, podem ser produzidos sem a necessidade de manipulação genética de uma sequência de anticorpo murino.
[0071] Os domínios variáveis podem compreender uma ou mais FR coma mesma sequência de aminoácidos que uma região estrutu- ral correspondente codificada por um segmento gênico de anticorpo de linhagem germinativa humana. Por exemplo, um anticorpo de domínio pode compreender os segmentos gênicos de linhagem germinativa de Vu DP47, DP45 ou DP38, o segmento gênico de linhagem germinativa deWV.DPK9,o segmento de J' JH4b ou o segmento de J. J.1.
[0072] Podem ser feitas alterações nas sequências de polipeptí- deo de anticorpo enquanto se mantém a capacidade de se ligar ao CD40L especificamente. Especificamente, os polipeptídeos de anticor- po (por exemplo, um dAb) podem compreender um domínio variável variante que mantém a função de se ligar especificamente ao CD40L como o dAb BMS2h-572-633. Em uma modalidade, o domínio variável variante pode competir com BMS2h-572-633 pela ligação específica ao CD40L. A maturação da afinidade propensa a erros, que é divulga- da nos exemplos a seguir, fornece um exemplo de método para a pro- duçãoe a identificação de polipeptídeos de anticorpo com sequências variantes que se ligam especificamente ao CD40L.
[0073] Por exemplo, um domínio variável variante pode diferir de um dos domínios variáveis listados na TABELA 1 e na TABELA 3 em até 10 aminoácidos ou qualquer valor integral intermediário, em que o domínio variável variante se liga especificamente ao CD40L. Alternati- vamente, o domínio variável variante pode ter pelo menos 90% de i- dentidade de sequência (por exemplo, pelo menos 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% ou 99% de identidade de sequência) em relação a uma sequência listada na presente Listagem de Sequências. Os resíduos de aminoácidos não idênticos ou os aminoácidos que di- ferem entre duas sequências podem representar substituições, adi- ções ou deleções de aminoácidos. Os resíduos que diferem entre duas sequências aparecem na forma de posições não idênticas, quando as duas sequências são alinhadas por qualquer algoritmo de alinhamento de sequências de aminoácidos apropriado, tal como BLAST.
[0074] Em uma modalidade, as substituições de aminoácidos po- dem ser feitas em regiões FR individuais, de forma que uma FR com- preenda 1, 2, 3, 4 ou 5 diferenças de aminoácidos em relação à se- quência de aminoácidos da FR correspondente codificada por um segmento gênico de anticorpo de linhagem germinativa humana. Em outra modalidade, o domínio variável variante pode conter uma ou du- as substituições de aminoácidos em uma CDR. Em outras modalida- des, as substituições de aminoácidos nas regiões de FR e de CDR podem ser combinadas. Os domínios variáveis representativos que se ligam especificamente ao CD40L são listados na TABELA 1 e na
TABELA 3.
[0075] A informação em relação aos limites dos domínios de V, ou de V", de genes de cadeias pesada e leve pode ser utilizada para pro- jetar iniciadores de PCR para amplificar o domínio variável partindo de uma sequência codificadora de cadeia pesada ou leve clonada que codifica um polipeptídeo de anticorpo conhecido por se ligar ao CD40L. O domínio variável amplificado pode ser inserido dentro de um vetor de expressão adequado, por exemplo, pHEN-1 (Hoogenboom e outros (1991) Nucleic Acids Res. 19:4133-4137) e expresso, isolada- mente ou na forma de uma fusão com outra sequência polipeptídica, utilizando técnicas bem conhecidas na técnica. Com base nas se- quências de aminoácidos e de polinucleotídeos divulgadas, a proteína de fusão pode ser produzida e purificada utilizando apenas perícia comum em qualquer linhagem de célula hospedeira de mamífero ade- quada,tal como CHO, 293, COS, NSO e similares, seguida pela purifi- cação utilizando um ou uma combinação de métodos, incluindo croma- tografia por afinidade com a proteína A, troca iônica, técnicas de fase inversa ou similar.
[0076] Em um aspecto, o polipeptídeo de anticorpo é um polipeptí- deode anticorpo "específico dual" que compreende um primeiro domí- nio variável que se liga especificamente ao CD40L humano. Os poli- peptídeos de anticorpo específicos duais compreendem um segundo domínio variável que se liga especificamente a um segundo antígeno que não é o CD40L humano.
[0077] Em outra modalidade, o segundo antígeno pode ser uma molécula de superfície celular de uma célula efetora imunológica ou uma molécula solúvel tal como uma citocina, por exemplo. A ligação do polipeptídeo de anticorpo de especificidade dual poderia ser utiliza- da para antagonizar o CD40L e antagonizar uma atividade biológica do segundo antígeno. As moléculas de superfície celular de células efeto-
ras imunológicas incluem as moléculas de cluster de diferenciação (CD). Os marcadores de CD representativos estão listados na Internet no protocolo de transferência de hipertexto http://en.wikipedia.org/wiki/List of human clusters of differentiation (modificado por último em 8 de agosto de 2012). As moléculas de su- perfície celular de células efetoras imunológicas também incluem mo- léculas de Complexo de Histocompatibilidade Principal (MHC) de Classe Il. Os anticorpos contra estas moléculas de superfície celular são conhecidos na técnica e podem ser utilizados como uma fonte de um domínio variável para construir um polipeptídeo de anticorpo espe- cífico dual.
[0078] Em uma modalidade, os polipeptídeos de anticorpo de um ligante específico dual podem ser ligados por um "ligante de aminoáci- do" ou um "ligante". Por exemplo, um dAb pode ser fundido ao terminal Nde um ligante de aminoácido e outro dAb pode ser fundido com o terminal C do ligante. Embora os ligantes de aminoácidos possam ter qualquer comprimento e consistir de qualquer combinação de aminoá- cidos, o comprimento do ligante pode ser relativamente curto (por e- xemplo, cinco ou menos aminoácidos) para reduzir as interações entre osdomínios ligados. A composição de aminoácidos do ligante também pode ser ajustada para reduzir o número de aminoácidos com cadeias laterais volumosas ou aminoácidos que provavelmente introduzem es- trutura secundária. Os ligantes de aminoácidos adequados incluem, mas não estão limitados aqueles de até 3, 4, 5, 6, 7, 10, 15, 20 ou 25 aminoácidos de comprimento. As sequências de ligantes de aminoáci- dos representativas incluem (GGGGS), (SEQ ID NO: 12), em que n pode ser qualquer número inteiro entre 1 e 5. Outras sequências de ligantes adequadas podem ser selecionadas do grupo que consiste em AS, AST, TVAAPS (SEQ ID NO: 13), TVA e ASTSGPS (SEQ ID NO: 14).
[0079] A ligação do segundo antígeno pode aumentar a meia-vida in vivo do polipeptídeo de anticorpo. Por exemplo, o segundo domínio variável do polipeptídeo de anticorpo específico dual pode se ligar es- pecificamente à albumina do soro (SA), por exemplo, albumina do soro humano (HSA).O polipeptídeo de anticorpo formatado para se ligar a | pode ter uma meia-vida t-a ("meia-vida alfa") ou t-B ("meia-vida beta") in vivo aumentada em relação ao mesmo polipeptídeo de anticorpo não formatado. As meias-vidas t-a e t-B medem o quão rapidamente uma substância é distribuída dentro e eliminada do corpo. A ligação a | pode ser realizada por fusão do polipeptídeo de anticorpo com um se- gundo domínio variável capaz de se ligar especificamente a |, por e- xemplo. Os anticorpos anti-albumina do soro humano são bem conhe- cidos na técnica. Vide, por exemplo, Abcam&O, Anticorpos para Albu- mina do Soro Humano ab10241, ab2406 e ab8940, disponíveis na In- ternet no protocolo de transferência de hipertexto www.abcam.com/index.html ou GenWay, anticorpo ALB, disponível na Internet no protocolo de transferência de hipertexto www.genwaybio.com. Os domínios variáveis que se ligam especifica- mente a | podem ser obtidos partindo de qualquer um destes anticor- pose então fundidos com um polipeptídeo de anticorpo da divulgação utilizando técnicas recombinantes que são bem conhecidas na técnica.
[0080] Alternativamente, a ligação do polipeptídeo de anticorpo para | pode ser realizada através de fusão de forma direta da sequên- cia de polipeptídeo de anticorpo com uma sequência que codifica | uti- lizando técnicas bem conhecidas pelo versado na técnica. As sequên- cias que codificam | podem ser obtidas através de PCR utilizando ini- ciadores derivados da sequência de cDNA disponível no No. de Aces- so do GenBank NMOO00477, por exemplo.
[0081] Em uma modalidade, a meia-vida ta da composição de an- ticorpo de domínio ligado a | é aumentada em 10% ou mais. Em outra modalidade, a meia-vida tua da composição de anticorpo de domínio ligado a | está na faixa de 0,25 hora até 6 horas. Em outra modalidade, a meia-vida tê da composição de anticorpo de domínio ligado a | é aumentada em 10% ou mais. Em outra modalidade, a meia-vida tê da composição de anticorpo de domínio ligado a | está na faixa de 12 até 48 horas.
[0082] Em outra modalidade, um polipeptídeo de anticorpo pode ser formatado para aumentar sua meia-vida in vivo através de PEGUuUi- lação. Em uma modalidade, o PEG está ligado de forma covalente. Em outramodalidade, o PEG está ligado ao polipeptídeo de anticorpo em um resido de cisteína ou de lisina. Ainda em outra modalidade, o poli- peptídeo de anticorpo ligado a PEG possui um tamanho hidrodinâmico de pelo menos 24 kD. Ainda em outra modalidade, o tamanho total de PEG é de 20 até 60 kD, inclusive. Ainda em outra modalidade, o anti- corpo de domínio ligado a PEG possui um tamanho hidrodinâmico de pelo menos 200 kD.
[0083] A PEGuilação pode ser atingida utilizando vários grupa- mentos de ligação de PEG incluindo, mas não limitados a éster ativo de N-hidroxilsuccinimida, propionato de succinimidila, maleimida, vinil sulfona ou tiol. Um polímero de PEG pode ser ligado a um polipeptídeo de anticorpo em uma posição pré-determinada ou pode ser ligado ale- atoriamente à molécula de anticorpo de domínio. A PEGuilação tam- bém pode ser mediada através de um ligante peptídico ligado a um anticorpo de domínio. Isto é, o grupamento de PEG pode ser ligado a um ligante peptídico fundido a um polipeptídeo de anticorpo, em que o ligante fornece o sítio (por exemplo, uma cisteína ou uma lisina livre) para a ligação do PEG. Os métodos de PEGuilação de anticorpos são bem conhecidos na técnica, como divulgado em Chapman, e outros, "PEGylated antibodies and antibody fragments for improved therapy: a review", Adv. Drug Deliv. Rev. 54(4):531-45 (2002), por exemplo.
[0084] Os polipeptídeos de anticorpo também podem ser planeja- dos para formar um dímero, um trímero, um tetrâmero ou outro multí- mero. Os polipeptídeos de anticorpo, por exemplo, dAbs, podem ser ligados para formar um multímero através de vários métodos conheci- dosna técnica, incluindo, mas não limitados a, expressão de monôme- ros na forma de uma proteína de fusão, ligação de dois ou mais mo- nômeros através de um ligante peptídico entre monômeros ou através da união quimicamente de monômeros após a tradução, com cada ou- tro diretamente ou através de um ligante por ligações dissulfeto ou a- través de ligação a um grupamento de ligação di-, tri- ou multivalente (por exemplo, um PEG de vários braços). Em uma modalidade, o mul- tímero pode se ligar a uma única molécula de CD40.
3. Composições Farmacêuticas e Métodos de Tratamento
[0085] Uma composição farmacêutica compreende uma quantida- de terapeuticamente eficaz de um ou mais polipeptídeos de anticorpo e opcionalmente um veículo farmaceuticamente aceitável. Os veículos farmaceuticamente aceitáveis incluem, por exemplo, água, solução salina, solução salina tamponada com fosfato, dextrose, glicerol, eta- nol e similares, bem como combinações dos mesmos. Os veículos farmaceuticamente aceitáveis podem compreender ainda quantidades menores de substâncias auxiliares, tais como agentes umectantes ou emulsificantes, preservantes ou tampões que aumentam a meia-vida ou a efetividade da proteína de fusão. As composições podem ser formuladas para fornecer liberação rápida, controlada ou retardada do(s) ingrediente(s) ativo(s) após a administração. As composições farmacêuticas adequadas e os processos para a preparação das mesmas são bem conhecidos na técnica. Vide, por exemplo, Reming- ton, THE SCIENCE AND PRACTICE OF PHARMACY, A. Gennaro e outros, eds., 21º ed., Mack Publishing Co. (2005).
[0086] A composição farmacêutica pode compreender ainda agen-
te imunossupressor/imunomodulador e/ou anti-inflamatório. Um méto- do de tratamento de uma doença imune em um paciente que necessita de tal tratamento pode compreender a administração ao paciente de uma quantidade terapeuticamente eficaz da composição farmacêutica. A ativação de células T mediada por CD40L antagonizante poderia inibir respostas de células T indesejadas que ocorrem durante a auto- imunidade, a rejeição a transplante ou as respostas alérgicas, por e- xemplo. A inibição da ativação de células T mediada por CD40L pode- ria moderar a progressão e/ou a gravidade destas doenças.
[0087] Como utilizado aqui, um "paciente" significa um animal, por exemplo, mamífero, incluindo humanos. O paciente pode ser diagnos- ticado com uma doença imune. "Tratamento" ou "tratar" ou "tratando" refere-se ao processo que envolve o alívio da progressão ou da gravi- dade de um sintoma, um distúrbio, um estado de saúde ou uma doen- ça. Uma "doença imune" refere-se a qualquer doença associada com o desenvolvimento de uma reação imunológica em um indivíduo, inclu- indo uma reação imunológica celular e/ou humoral. Os exemplos de doenças imunes incluem, mas não estão limitadas a doença relacio- nada a enxerto, inflamação, alergia e doença autoimune. A doença autoimune pode ser selecionada do grupo que consiste em lúpus eri- tematoso sistêmico, esclerose múltipla, artrite reumatoide, diabetes, psoríase, escleroderma, aterosclerose, doença inflamatória do intesti- no e colite ulcerativa.
[0088] As doenças que podem ser tratadas através da administra- ção da composição farmacêutica podem ser selecionadas do grupo que consiste em doença de Addison, alergias, espondilite anquilosan- te, asma, aterosclerose, doenças autoimunes do ouvido, doenças au- toimunes do olho, hepatite autoimune, parotidite autoimune, colite, do- ença cardíaca coronariana, doença de Crohn, diabetes, incluindo dia- betes do Tipo 1 e/ou do Tipo 2, epididimite, glomerulonefrite, doença de Graves, síndrome de Guillain-Barre, doença de Hashimoto, anemia hemolítica, púrpura trombocitopênica idiopática, doença inflamatória do intestino, resposta imunológica a produtos de fármacos recombi- nantes (por exemplo, Fator VIl em hemofílicos), lúpus eritematoso sis- têmico, infertilidade do sexo masculino, esclerose múltipla, miastenia grave, pênfigo, psoríase, febre reumática, artrite reumatoide, sarcoido- se, escleroderma, síndrome de Sjogren, espondiloartropatias, tireoidi- te, rejeição a transplante e vasculite. Os estados de saúde mediados de forma autoimune incluem, mas não estão limitados a, estados de saúde em que o tecido afetado é o alvo primário e em alguns casos, o alvo secundário. Tais estados de saúde incluem, mas não estão limi- tados a, AIDS, alergia atópica, asma bronquial, eczema, lepra, esqui- zofrenia, depressão herdada, transplante de tecidos e órgãos, síndro- me de fadiga crônica, doença de Alzheimer, doença de Parkinson, en- farte do miocárdio, derrame, autismo, epilepsia, fenômeno de Arthus, anafilaxia, dependência de álcool e dependência de drogas.
[0089] As indicações preferidas para a administração das presen- tes composições farmacêuticas são, por exemplo, púrpura trombocito- pênica imune, esclerose sistêmica, miastenia grave, rejeição a aloen- xertoe doença de enxerto-versus-hospedeiro.
[0090] A composição farmacêutica pode ser administrada isola- damente ou em terapia de combinação, (isto é, simultaneamente ou sequencialmente) com agente imunossupressor/imunomodulador e/ou anti-inflamatório. Doenças imunes diferentes podem requerer o uso de compostos auxiliares específicos úteis para o tratamento de doenças imunes, que podem ser determinados em uma base de paciente-para- paciente. Por exemplo, a composição farmacêutica pode ser adminis- trada em combinação com um ou mais adjuvantes adequados, por e- xemplo, citocinas (IL-10 e I1L-13, por exemplo) ou outros estimuladores imunológicos, por exemplo, quimiocinas, antígenos e peptídeos asso-
ciados a tumor. Os adjuvantes adequados são conhecidos na técnica.
[0091] Por exemplo, a composição farmacêutica divulgada pode ser coadministrada, concomitantemente ou sequencialmente, com uma molécula mutante de antígeno 4 de linfócito T citotóxico (CTLAA4), talcomoL104EA29Y-lg (belatacept). O CTLA4 se liga a CD80 (B7-1) e a CD86 (B7-2) com maior avidez que CD28 e é expresso de forma transitória sobre as células T após sua ativação, quando esta inter- rompe a interação entre CD28 e CD80/86. Oosterwegel e outros, Curr. Opin. Immunol. 11: 294-300 (1999). Isto cria um sinal de feedback ne- gativopara a ativação de células T.
[0092] As moléculas mutantes de CTLAA, incluindo L1I04EA29Y-lg, possuem maior avidez de ligação a CD80/86 comparadas com CTLA4 do tipo selvagem. A intervenção da via de CD28-CD80/86 por L104EA29Y-lg foi adotada de forma bem sucedida, por exemplo, para tratar doenças relacionadas a enxerto em modelos de transplante com primatas não humanos, isoladamente ou em combinação com outros agentes imunossupressores. Larsen e outros, Amer. J. Transplant. 5: 443 (2005). O Pedido de Patente U.S. número 2010/0166774 descreve a estrutura de L1I04EA29Y-lg, os métodos de produção do mesmo e uma formulação que compreende uma molécula de CTLAA4; e o pedido de patente é incorporado aqui como referência. As Patentes U.S. Nos
7.094.874 e 7.482.327 divulgam ainda a administração (incluindo a coadministração com um ou mais outros fármacos) e a progração de dosagem de L104EA29Y-lg e as divulgações destas patentes são in- corporadas aqui como referência.
[0093] Qualquer método ou rota adequada pode ser utilizada para administrar o polipeptídeo de anticorpo ou a composição farmacêutica. As rotas de administração incluem, por exemplo, administração oral, intravenosa, intraperitoneal, subcutânea ou intramuscular. Uma dose terapeuticamente eficaz do(s) polipeptídeo(s) de anticorpo administra-
da depende de vários fatores, incluindo, por exemplo, o tipo e a gravi- dade da doença imune que será tratada, o uso de terapia de combina- ção, a rota de administração do(s) polipeptídeo(s) de anticorpo ou da composição farmacêutica e o peso do paciente. Uma faixa não limitan- te para uma quantidade terapeuticamente eficaz de um anticorpo de domínio é de 0,1-20 mg/kg e em um aspecto, 1-10 mg/kg, em relação ao peso corporal do paciente. A dose do(s) polipeptídeo(s) de anticor- po pode ser adicionalmente guiada pela quantidade de polipeptídeo(s) de anticorpo necessária para o antagonismo de CD40 em modelos in vitro e/ou in vivo de estados de doença. Os exemplos representativos são descritos a seguir e nos exemplos.
4. Modelos In Vitro e In Vivo
[0094] A capacidade dos polipeptídeos de anticorpo da divulgação de antagonizar CD40L pode ser testada em um dos vários sistemas de modelos in vitro ou in vivo disponíveis. Sistemas de modelo de huma- nos, animais e células apropriados são descritos a seguir. Sistemas de ensaio de células adicionais são descritos nos exemplos.
4.1. Modelo de Púrpura Trombocitopênica Imune (ITP) In Vivo:
[0095] A função potencial de CD40-CD40L na patogênese de ITP é relatada por Patel e outros, British J. Haematology 141: 545-548 (2008). Os autoanticorpos antiplaqueta em pacientes com ITP se ligam às plaquetas circulantes e aceleram sua destruição. O mecanismo primário através do qual se acredita que os anticorpos anti-CD40L aumentam a contagem de plaquetas na ITP é através do bloqueio da ativação baseada em células T de células B autorreativas que produ- zem anticorpos antiplaqueta. Os anticorpos anti-CD40L também po- dem bloquear a expressão de CD40L sobre as plaquetas, prevenindo assim a autoapresentação de antígenos de glicoproteína de plaqueta aos macrófagos. Além disso, os mAbs anti-CD40L inibem as intera- ções diretas entre CD40L de plaqueta e outras células, tais como célu-
las dendríticas (DCs) plasmacitoides, que foram recentamente impli- cadas no controle da resposta ao interferon (IFN) do tipo 1 em pacien- tes humanos com lúpus. Duffau e outros, Sci. Transl. Med. 2: 47 (2010).
[0096] Patel e outros demonstraram a eficácia de dois anticorpos anti-CD40L monoclionais humanizados, hu5c8 e IDEC-131, em 46 pa- cientes humanos com ITP crônica refratária a terapias convencionais. Os pacientes tiveram uma taxa de resposta geral de 24%, caracteriza- da por maiores contagens de plaquetas. Isto demonstrou a função po- tencial de CD40-CD40L na patogênese de ITP.
4.2. Modelos de Lúpus In Vivo e In Vitro:
[0097] A expressão de CD40 glomerular e tubular é notavelmente regulada para mais na nefrite proliferativa. Vários estudos relataram a hiperexpressão de CD40L por células T e concentrações de sSCD40L solúvel elevadas no lúpus humano. Kimura e outros, Therapeutic A- pheriss and Dialysis 9: 64-68 (2005); Vakkalanka e outros, Arthritis & Rheumatism 42: 871-881 (1999).
[0098] O lúpus eritematoso sistêmico (SLE) é uma doença autoi- mune crônica caracterizada pela produção de vários autoanticorpos e pela hiperatividade de células B. Grammer e outros, J. Clin. Invest. 112: 1506-1520 (2003) relatam os resultados do tratamento de pacien- tes com SLE com o mAb anti-CD40L humanizado 5c8 (BG9588). Vide também Huang e outros, Arthritis & Reumatism 46: 1554-1562 (2002). Grammer e outros relatam que células B periféricas CD19+ foram e- xaminadas antes e depois do tratamento com o mAb anti-CD40L. An- tes do tratamento, os pacientes com SLE manifestaram células B ati- vadas que expressavam CD40L, CD69, CD38, CD5 e CD27. As célu- las B ativadas desapareceram da periferia durante e pós-tratamento. Antes do tratamento, pacientes com SLE ativa tinham células secreto- rasde CD3g"""a"º |H circulantes que não eram encontradas em indiví-
duos normais. O desaparecimento destas células do plasma durante o tratamento foi associado com decréscimos nos níveis de Ab anti-DNA de filamento duplo (anti-dsDNA), proteinúria e índice de atividade da doença SLE. Coerente com estas descobertas, as células B periféricas cultivadas in vitro se proliferaram e secretaram lg espontaneamente de uma maneira que era inibida pelo mAb anti-CD40L. Os subconjuntos de células B CD38+/++I|gD+, CD38+++ e CD38+IgD- presentes no sangue periférico de pacientes com SLE também desapareceram após o tratamento com o mAb anti-CD40L. Juntos, estes resultados suge- rem que as interações CD40L-CD40 espontâneas nos pacientes ativos com SLE controlam a ativação, a proliferação e a diferenciação das células B em células do plasma que secretam autoanticorpo que me- deiam a proteinúria e a atividade da doença.
[0099] Glomerulonefrite de lúpus proliferativo é uma doença auto- imune prolongada com um curso crescente e decrescente, caracteri- zada pelo nível maior de anticorpos anti-dsDNA, concentrações de C3 no soro diminuídas e hematúria. Boumpas e outros, Arthritis & Rheu- matism 48: 719-727 (2003) relatam resultados de um estudo aberto multicêntrico de fase Il que avalia a toxicidade e a eficácia de BG9688, um anticorpo monoclonal anti-cCD40L humanizado, em pacientes com glomerulonefrite de lúpus proliferativo. Embora o estudo tivesse que ser terminado prematuramente por causa de eventos tromboembólicos que ocorrem nos pacientes em vários protocolos de BG9588, um curso curto do tratamento com o anticorpo anti-CD40L em pacientes com nefrite de lúpus proliferativo reduzia os anticorpos anti-dsDNA, aumen- tava as concentrações de C3 e diminuía a hematúria, sugerindo que o fármaco possui função imunomoduladora.
4.3. Modelos de Doença Inflamatória do Intestino (IBD) /n Vivo:
[00100] A doença de Crohn (CD) e a colite ulcerativa (UC) são IBDs que são caracterizadas por infiltrados leucocíticos na mucosa intestinal inflamada, que consiste primariamente de células CD25+ ativadas, cé- lulas B e macrófagos. Ludwiczek e outros, Int. J. Colorectal Dis. 18: 142-147 (2003) relatam que em pacientes com CD, os níveis no plas- ma de sCD40L eram significativamente mais altos que em indivíduos saudáveis. Além disso, os pacientes com CD com fístulas e/ou abs- cessos tinham níveis significativamente mais altos de SCD40L que os pacientes com CD não complicada. Também foi relatado que a via de CDA40-CD40L contribui para a função pró-inflamatória de células epite- liais intestinais na IBD. Borcherding e outros, Am. J. Pathol. 176: 1816- 1827 (2010). Os pacientes com CD também possuem um nível au- mentado de tromboembolia sistêmica e o estado hiperativo das pla- quetas de tais pacientes resulta provavelmente da liberação aumenta- da de sSCD40L como uma consequência de seu conteúdo endógeno mais alto de CD40L. Menchen e outros, Gut 58: 920-928 (2009); Vide também Danese e outros, Gut 52: 1435-1441 (2003).
[00101] Kasran e outros, Aliment. Pharmacol. Ther. 22: 111-122 (2005) investigaram o uso de um mMAb anti-CD40 humano quimérico ch5D12 para tratar doença de Crohn. O mAb foi administrado a 18 pa- cientes com CD moderada a grave em um estudo de fase |/lia com aumento de dose aberto de uma única dose. Dos 18 pacientes, 13 (ou 72%) sofreram uma resposta favorável para a infusão de anticorpo e 4 pacientes (ou 22%) sofreram uma remissão. O tratamento com o mAb anti-CD40 reduziu a atividade de doença microscópica e a intensidade do infiltrado de células da lâmina própria e o mAb foi bem tolerado.
4.4. Modelos de Artrite Reumatoide (RA), Artrite Idiopática Juvenil (JIA) e Artrite Psoriática (PSA) In Vivo:
[00102] A artrite reumatoide é uma doença autoimune sistêmica com inflamação intra-articular como uma característica dominante que afeta até 1% da população. A doença pode ser subdividida clinicamen- te pela presença ou pela ausência de autoanticorpos (anticorpos para o peptídeo citrulinado cíclico (CCP) ou fator reumatoide (RF), dos quais ambos estão altamente correlacionados com cada outro. Ray- chaudhuri e outros, Nature Genetics 40: 1216-1223 (2008) relataram que eles conduziram uma metaanálise de dois estudos da associação amplado genoma (GWA) publicados totalizando 3.393 casos e 12.462 controles, com a finalidade de identificar os loci de risco de RA em po- pulações Europaias. Eles genotiparam 31 polimorfismos de nucleotí- deos curtos (SNPs) de classificação principal não previamente associ- ados com RA em uma replicação independente de 3.929 casos de RA postivos para autoanticorpo e 5.807 controles combinados provenien- tes de oito coleções separadas. Eles identificaram uma variante co- mum no lócus do gene CDA40, que implicava uma função central para a via de sinalização de CD40 na patogênese de RA. A forte associação do gene CD40 com a suscetibilidade a RA foi repitida de forma robusta em outro estudo em um coorte do UK grande de 3.962 pacientes com RA. Orozso e outros, Ann. Rheum. Dis. 69: 813-816 (2010).
[00103] Uma função importante de CD40L foi também descoberta na patogênese da artrite idiopática juvenil (JIA). Prahalad e outros, Pediatric Rheumatology 6: 1-8 (2008). A JIA é um grupo heterogêneo de artropatias de etiologia desconhecida. Foi descoberto que sSCD40L estava significativamente elevado no soro de crianças com JIA, junto com algumas citocinas. A análise de regressão logística sugeriu que sCD40L, bem como IL-6 e TNFa, estavam positivamente associados com a JIA. sSCD40L estava elevado em todos os subtipos de JIA, com os níveismais altos entre os subtipos mais graves. Estes resultados implicaram sCD40L como um biomarcador potencial para o tratamento e para o monitoramento de pacientes com JIA.
[00104] Foitambém demonstrado que células T ativadas provenien- tes de pacientes com artrite psoriática (PSA) e particularmente daque- les com doença ativa, possuem uma expressão significativamente au-
mentada de CD40L. Daoussis e outros, Rheumatology 46: 227-231 (2007). Estes resultados indicam uma função da via de CD40-CD40L na patogênese de PsA e que uma terapia que se direciona seletiva- mente ao CD40L poderia beneficiar pacientes com PsA.
4.5. Modelos de Esclerose Sistêmica /n Vivo:
[00105] A esclerose sistêmica (SSc) é um distúrbio de tecido con- juntivo autoimune caracterizado por alterações fibrosas e vasculares na pele e nos órgãos viscerais internos. Em um estudo envolvendo 52 pacientes japoneses com SSc, os níveis de SCD40L no soro estavam elevados quando comparados com controles saudáveis. Komura e ou- tros, J. Reumatol. 31: 514-519 (2004). Além disso, os níveis de sSCD40L nos pacientes com SSc eram mais altos nos pacientes com lúpus eritematoso sistêmico (SLE) que tinham níveis de sSCD40L ele- vados comparados com os controles e os níveis de sSCD40L se corre- lacionavam positivamente com os níveis do peptídeo reativo C em pa- cientes com SSc. Foi também relatado que o bloqueio de CD40L com anticorpo anti-CD40L em células T e B cultivadas provenientes de pa- cientes com SSc inibia a produção do anticorpo anti-topoisomerase |. Kuwana e outros, J. Immunol. 155: 2703-2714 (1995). Estes resulta- dos sugerem que a inibição de interações CD40-CD40L pode ser alvos terapêuticos potenciais na terapia de SSc bem como de SLE.
4.6. Modelos de Aterosclerose In Vivo:
[00106] Vários estudos sugeriram uma função da via de sinalização de CD40-CD40L durante a aterogênese. Mach e outros demonstraram que em camundongos, o tratamento com anticorpo monoclonal anti- CD40L limitava a aterosclerose em camundongos que não possuíam receptor para a lipoproteína de baixa densidade que foi alimentada em uma dieta com alto teor de colesterol durante 12 semanas. Nature 394: 200-203 (1998). O anticorpo reduzia o tamanho das lesões ateroscle- róticas da aorta em 59% e seu teor de lipídeos em 79%. Adicionalmen-
te, o ateroma de camundongos tratados com o anticorpo anti-CD40L continha significativamente menos macrófagos e linfócitos T e exibia menor expressão da molécula de adesão à célula vascular-1.
[00107] O tratamento com o anticorpo anti-CD40L de camundongos deficientes em relação ao receptor de lipoproteína de baixa densidade durante a segunda metade de um regime de 26 semanas de uma dieta com alto teor de colesterol não regrediu, mas reduziu significativamen- te a progressão adicional de lesões ateroscleróticas estabelecidas dentro do arco aórtico e particularmente da aorta torácica e abdominal, quando comparado com o tratamento de controle. Schonbeck e outros, Proc. Natl. Acad. Sci. 97: 7458-7463 (2000). Além disso, o tratamento com anti-CD40L alterou a composição de ateroma de maneiras acredi- tadas que favoreçam a estabilidade de placas, por exemplo, conteúdo relativo reduzido de macrófagos e lipídeo, bem como conteúdo relativo aumentado de células de músculo liso e colágeno. Estes estudos for- neceram suporta para a importância da via de sinalização de CD40- CDA40L na aterosclerose e suas complicações, tal como doença da ar- téria coronária.
4.7. Modelos de Rejeição a Aloenxerto In Vivo:
[00108] O direcionamento à via de CD40-CD40L tem sido há muito tempo de muito interesse para a prevenção de rejeição de transplantes de órgãos sólidos (SOT), particularmente em consideração dos dados promissores provenientes de vários estudos de transplantes publica- dos em primatas não humanos. Foi demonstrado que a expressão re- duzidade CD40L sobre linfócitos T CD4+ ativados ex vivo se correla- ciona com excelente função de aloenxerto renal. Lederer e outros, /nt. Arch. Allergy Immunol. 133: 276-284 (2004). Além disso, vários estu- dos demonstraram que os mAbs anti-CD40L podem tanto prevenir quanto reverter a rejeição aguda aloenxerto em primatas. Por exem- plo, Kirke outros, Proc. Natl. Acad. Sci. USA 94: 8789-8794 (1997)
relataram que, em macacos rhesus transplantados com aloenxertos renais, o mAb anti-CD40L 5C8 isoladamente ou em combinação com CTLA4-Ig prolongava significativamente a sobrevivência livre de rejei- ção. O mAb específico para CD40L hu5c8 isoladamente também per- mitiaenxerto de ilhota alogenética e independência à insulina em lon- go prazo em macacos rhesus que foram transplantados com um nú- mero adequado de ilhotas pancreáticas viáveis. Kenyon e outros, Proc. Natl. Acad. Sci. USA 96: 8132-8137 (1999). Preston e outros, Amer. J. Transplantation 5: 1032-1041 (2005) realizaram transplantes renais em macacos rhesus com MHC não combinados e trataram os receptores com combinações de mAb específico para CD40L IDEC-131 e/ou siro- limus e/ou transfusão específica para o doador pré-transplante. IDEC- 131 era altamente eficiente na prevenção da rejeição a aloenxerto re- nal em primatas. Em macacos cynomolgus que sofreram alotransplan- te renal, o tratamento com mAb anti-CD40L ABI793 prevenia eficien- temente a rejeição ao enxerto. Schuler e outros, Transplantation 77: 717-726 (2004). Em adição à prevenção à rejeição a aloenxerto, mAbs específicos para CD40L induziam tolerância específica para o doador nos modelos de transplantes com primatas. Preston e outros, Amer. J. Transplantation 5: 1032-1041 (2005); Kenyon e outros, Proc. Natl. A- cad. Sci. USA 96: 8132-8137 (1999).
[00109] Em pacientes humanos pediátricos que estavam sofrendo rejeição a enxerto aguda após transplante de fígado ou de intestino delgado, foi observada uma correlação entre a expressão de CD40L sobre células T CD8+ e o risco de rejeição a transplante. Ashokkumar e outros, Amer. J. Transplantation 9: 179-191 (2009) e Ashokkumar e outros, Surgery 146: 166-173 (2009). Similarmente, em pacientes adul- tos que estavam sofrendo rejeição a aloenxerto após transplante de fígado ou renal, a análise histológica demonstrou uma associação en- treaexpressãode CD40L e a rejeição aguda ou crônica. Bartlett e ou-
tros, Amer. J. Transplantation 3: 1363-1368 (2003) e Biancone e ou- tros, Nephrol. Diall. Translpant. 13: 716-722 (1998).
[00110] Vários estudos sustentam o direcionamento ao CD40L mais do que ao CD40 para atingir melhor eficácia no transplante. Por exem- plo, a sobrevivência do enxerto é mais longa e mais durável quando o CD40L é seletivamente bloqueado, comparado com o CD40. Gilson e outros, J. Immunol. 183: 1625-35 (2009). Além disso, dados recentes sugerem que o bloqueio de CD40L pode aumentar a indução de Tregs e/ou de células supressoras para promover a sobrevivência do enxer- to. Garcia e outros, J. Clin. Inv. 120: 2486-96 (2010). Ainda, o bloqueio de CD40L, mas não de CD40, demonstrou a indução de tolerância i- munológica de vida mais longa resultando na sobrevivência do enxerto indefinida, particularmente quando combinado com o bloqueio da via de B7. Kenyon e outros, Proc. Natl. Acad. Sci. USA 96: 8132-8137 (1999); Kawai e outros, Amer. J. Transplantation 4: 1391-1398 (2004); Preston e outros, Amer. J. Transplantation 5: 1032-1041 (2005); A- dams e outros, J. Immunol. 174: 542-50 (2005). A sinergia do bloqueio das vias de CD40-40L e de B7-CD28 no aprimoramento da sobrevi- vência do enxerto é especialmente importante, porque esta apresenta os anticorpos para domínio divulgados atualmente como uma escolha natural para a combinação com belatacept (CTLA4-Ig) para SOT.
4.8. Modelo de Doença de Enxerto-Versus-Hospedeiro In Vivo:
[00111] A doença de enxerto-versus-hospedeiro crônica e aguda (cCGVHD e aGVHD) são complicações que podem ocorrer após um transplante de células tronco ou de medula óssea em que as células do doador transplantadas atacam o corpo do receptor do transplante. A GVHD aguda em seres humanos ocorre dentro de aproximadamente 60 dias pós-transplante e resulta em danos na pele, no fígado e nos intestinos através da ação de linfócitos citolíticos. A GVHD crônica o- corre posteriormente e é uma doença autoimune sistêmica que afeta primariamente a pele, resultando na ativação policlonal de células B e na hiperprodução de Ig e autoanticorpos.
[00112] As interações CD40L-CD40 parecem ser críticas no desen- volvimento tanto da CGVHD quanto da aGVHD. Durie e outros, J. Clin. Invest 94: 1333-1338 (1994). Em um modelo de camundongos in vivo, os anticorpos anti-CD40L bloquearam os fenômeros associados à cG- VHD a seguir: esplenomegalia, produção de Ig policlonal in vitro, níveis elevados de IgE no soro e autoanticorpos anti-DNA no soro e a gera- ção de células T citotóxicas antihospedeiro. A produção de anticorpos permanecia inibida durante períodos estendidos de tempo após o final da administração do anticorpo anti-CD40L. Em camundongos com aGVHD, que está associada com a indução de uma resposta de célu- las T citotóxicas (CTL) antialogênicas profunda, o tratamento com anti- CDA40L prevenia a geração de CTL derivadas de H-2b. Os resultados do estudo sugerem que as interações CD40L-CD40 são críticas na GVHD e que o CD40L pode ser um ligante valioso para o direciona- mento de agentes imunoterapêuticos para controlar a GVHD.
4.9. Modelo de Miastenia Grave In Vivo:
[00113] A miastenia grave (MG) e seu modelo com animais, MG autoimune experimental (EAMG), são distúrbios autoimunes depen- dentes de células T causados por autoanticorpos contra os receptores de acetilcolina nicotínicos (AChR) na junção neuromuscular do múscu- lo esquelético. A função de CD40-CD40L na EAMG foi mostrada em camundongos nocauteados em relação ao CD40L (CD40L-/-). Shi e outros, Eur. J. Immunol. 28: 3587-3593 (1998). Os camundongos no- cauteados em relação ao CD40L eram completamente resistentes à indução da EAMG e tinham respostas de Th1 e Th2 diminuídas bem como respostas de células B reativas para AChR dependentes de cé- lulas T gravemente prejudicadas.
[00114] Foitambém demonstrado que o bloqueio da sinalização de
CD40L-CD40 pelos anticorpos anti-CD40L é capaz de suprimir a EAMG. Im e outros, J. Immunol. 166: 6893-6898 (2001). Os anticorpos fornecidos aos ratos no estágio crônico de EAMG suprimem a pro- gressão clínica da resposta autoimune e levam a um decréscimo na resposta humoral específica para AChR e hipersensibilidade do tipo retardado. O efeito do tratamento com anti-CD40L durante a fase crô- nica de EAMG é de relevância particular para a MG humana, que é uma doença crônica. Isto sugere que a antagonização de CD40L pode ser utilizada para imunoterapia de MG e outras doenças autoimunes mediadas por anticorpo. Tromboembolia
[00115] As interações CD40-CD40L sobre células T e apresentado- ras de antígenos são importantes para respostas imunológicas adapta- tivas, tais como proliferação de células B, produção de imunoglobulina (lg), regulação para mais de atividade coestimuladora (CD80, CD86), produção de citocinas e troca de classes de lg. O receptor e o ligante também são expressos sobre as plaquetas (população de células "off- target"), em que CD40 é constitutivamente encontrado sobre as pla- quetas, enquanto CD40L é expresso sobre plaquetas ativadas e cliva- doem sCD40L (>90% do sCD40L circulante são derivados das pla- quetas). Feroni e outros, Curr. Med. Chem. 14: 2170-2180 (2007). Pelo menos três anticorpos monoclonais (mAb) anti-CD40L causavam TE nos estudos clínicos e/ou não clínicos conduzidos em primatas não humanos (NHP). husc8 (BG9588) causava TE em vários testes clíni- cos (lúpuse transplante renal). Boumpas e outros, Arthritis & Rheuma- tism 48: 719-727 (2003). IDEC131 causava TE em um paciente em um teste de doença de Crohn, levando ao término dos testes em anda- mento naquele momento. Sidiropoulus & Boumpas, Lupus 13: 391-397 (2004). Tanto hu5c8 quanto ABI 1793 (que se liga ao CD40 em um epí- topo diferente de 5c8) causavam TE/trombose em estudos de trans-
plante renal em macacos cynomolgus ou rhesus. Schuler e outros, Transplantation 77: 717-726 (2004); Kanmaz e outros, Transplantation 77: 914-920 (2004); Koyama e outros, Transplantation 77: 460-461 (2004). Em uma divulgação não publicada, a Biogen relatou uma inci- dênciade trombose de 1/4 e 6/12 em macacos rhesus que receberam 5 e 20 mg/kg por semana, respectivamente, durante 6 meses, mas não em macacos cynomolgus que receberam 50 mg/kg nas mesmas frequência e duração. A base para a diferença entre as espécies não é clara.
[00116] Uma das hipóteses é que a TE associada com a adminis- tração destes anticorpos é mediada pela ligação cruzada de plaquetas mediada pelo complexo imunológico (IC) anti-CD40Lmab-CD40L, faci- litada pela ligação do IC com FcegRlla, um receptor Fc da IgG, causan- do ativação e agregação (FIG. 10). É, portanto, esperado que o blo- queio da interação do grupamento Fc da IgG com FegRlla alivie a liga- ção cruzada de plaquetas e a trombose. Abordagens e métodos de- senvolvidos para avaliar o risco para TE/trombose são descritos nos Exemplos a seguir.
EXEMPLOS
[00117] A TABELA 1 lista sequências de aminoácidos do domínio VH de anti-CD40L representativas úteis para os polipeptídeos de anti- corpo divulgados. A TABELA 2 divulga os ácidos nucleicos representa- tivos que codificam as sequências de domínio VH listadas na TABELA
1. A TABELA 3 lista sequências de aminoácidos do domínio VK de an- ti-cCD40L humano representativas para os polipeptídeos de anticorpo da presente divulgação. A TABELA 4 por sua vez divulga os ácidos nucleicos representativos que codificam as sequências do domínio VK listadas na TABELA 3. Como é bem conhecido na arte, vários códons podem codificar os mesmo aminoácido. Os ácidos nucleicos que codi- ficam uma sequência de proteína incluem assim ácidos nucleicos que possuem degeneração de códons.
Os polipeptídeos de anticorpo di- vulgados na TABELA 1 e na TABELA 3 se ligam especificamente ao CD40L.
Estes foram produzidos utilizando as metodologias de seleção inicial/primária reiterativa e de afinidade descritas nos exemplos a se- qguir
TABELA 1 Sequências de Aminoácidos do Domínio VH do Anti-CD40L Humano BMS2h-10 (SEQ ID NO: 15)
EVOLLESGGG LVQPGGSLRL SCAASGFTFI AYDMSWVRQA PGKGLEWVSW IDEWGLOTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKKT PEE—-- FDYWGOQGTLV TVSS BMS2h-11 (SEQ ID NO: 16)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG DYEMSWVROA PGKGLEWVSG IDGEGSDTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG RS-—-- FDYWGOQOGTLV TVSS BMS2h-111 (SEQ ID NO: 17)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE RYPMTWVROA PGKGLEWVST IHGSGSATYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGP YTSRHNSLGH FDYWGOQGTLV TVSS BMS2h-112 — (SEQIDNO: 18)
EVOLLESGGG LVOPGGSLRL SCAASGFTFM DYPMGWVROA PGKGLEWVSS IGPVGMSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKYG GTSGRHNTK- FDYWGQGTLV TVSS BMS2h-113 — (SEQIDNO:19)
EVOLLESGGG LVQPGGSLRL SCAASGFTFT EYPMSWVRQA PGKGLEWVSV ISPLGFTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKWT GGSGILNSS- FDYWGQGTLV TVSS BMS2h-114 — (SEQIDNO: 20)
EVOLLESGGG LVOPGGSLRL SCAASGFRVS NYDLTWVRQA PGKGLEWVST ISATNGSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAAVT WWLLRHNDN- LEFWGQGTLV TVSS BMS2h-115 (SEQ ID NO: 21)
EVOLLESGGG LVQPGGSLRL SCAASGFSIS YKNMAWVRQA PGKGLEWVSA IKAANGSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCATGS QKKRTYT--- FDOFWGQGTLV TVSS BMS2h-12 (SEQ ID NO: 22)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR LYEMAWVROA PGKGLEWVSG IDILGSRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKDL SWQG------ FDYWGQGTLV TVSS BMS2h-120 — (SEQID NO: 23)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR SYTMGWVROA PGKGLEWVSS INPMGYOTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKHG VGKGTKPHN FDYWGQGTLV TVSS BMS2h-121 — (SEQIDNO: 24)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE LYRMSWVRQA PGKGLEWVSE ISGSGFPTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSL HDKTAHHQE FDYWGQGTLV TVSS BMS2h-123 — (SEQIDNO: 25)
EVOLLESGGG LVQPGGSLRL SCAASGFTFI EYPMRWVRQA PGKGLEWVSL ISPSGVFTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGD ESST FDYWGQGTLV TVSS BMS2h-124 — (SEQIDNO: 26)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYDMDWVRQA PGKGLEWVST IGSSGYPTYY
ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAERM PGYFPGFARQ FDYWGQGTLV TVSS BMS2h-125'— (SEQIDNO: 27)
EVOLLESGGG LVQPGGSLRL SCAASGFTFW RYAMGWVRQA PGKGLEWVST INDEGRETYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKKR VSSSVNAPYE FDYWGQGTLV TVSS BMS2h-126 — (SEQIDNO: 28)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA NYSMSWVROA PGKGLEWVSS IDRLGTHTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVL ADLIAGHAE FDYWGQGTLV TVSS BMS2h-127 (SEQ ID NO: 29)
EVOLLESGGG LVQPGGSLRL SCAASGFTFP SYDMAWVRQA PGKGLEWVSG ISRSGSMTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGV DAHVYYMEPF FDYWGQGTLV TVSS BMS2h-128 — (SEQIDNO: 30)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE RYQMAWVROQA PGKGLEWVST ISSDGGGTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG TV FDYWGQGTLV TVSS BMS2h-1298 — (SEQIDNO:31)
EVOLLESGGG LVOPGGSLRL SCAASGFTFP KYEMAWVRQA PGKGLEWVSS IDGDGKSTYY
ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAKPD QF FDYWGQGTLV TVSS BMS2h-13 — (SEQIDNO:32)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS YYSMYWVRQA PGKGLEWVSS ISPFGWGTYY
ADSVKGRFTI SRDNSKDTLY LOMNSLRAED TAVYYCAKYG ETSGPISEN FDYWGQGTLV TVSS BMS2h-130 — (SEQIDNO: 33)
EVOLLESGGG LVQPGGSLRL SCTASGFTFA GYQMSWVRQA PGKGLEWVSS ITNEGVSTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG KY FDYWGQGTLV TVSS BMS2h-131 — (SEQIDNO: 34)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFG EYEMVWVRQA PGKGLEWVSS ITSDGLSTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG IRFDYWGQGTLV TVSS BMS2h-132 (SEQ ID NO: 35)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA DYDMAWVRQA PGKGLEWVSG IVDDGLMTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD VAFDYWGQGTLVTVSN BMS2h-133 — (SEQIDNO: 36)
EVOLLESGGG LVOPGGSLRL SCAASGFTFI GYAMAWVROA PGKGLEWVSS IGPLGATTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLP AGTSSHSVDFDYWGQGTLV TVSS BMS2h-134 — (SEQIDNO:37)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA DYEMTWVROA PGKGLEWVSS ITSDGVSTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPS VQ FDYWGQGTLV TVSS BMS2h-135— (SEQID NO: 38)
EVOLLESGGG LVQPGGSLRL SCAASGFTFR RYVMGWVRQA PGKGLEWVSW IEADGRTTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGL TDQHVIE FDYWGOGTLV TVSS BMS2h-136 — (SEQIDNO: 39)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD GYRMGWVRQA PGKGLEWVSS IAPDGNYTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKFW GMQFDYWGQGTLV TVSS BMS2h-137 — (SEQIDNO: 40)
EVOQLLESGGG LVQPGGSLRL SCAASGFTFA SYPMGWVRQA PGKGLEWVSS IGPIGFTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEMK SPYKPQ---- FDYWGQGTLV TVSS BMS2h-138 — (SEQIDNO:41)
EVOLLESGGG LVOPGGSLRL SCAASGFTFL AYWMVWVRQA PGKGLEWVSS ISPSGTHTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRVED TAVYYCAKYT EPGLGS-- FDYWGQGTLV TVSS BMS2h-139 — (SEQIDNO:42)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS NYEMGWVROA PGKGLEWVSV ISEVGSLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPH DSSIG--- FDYWGQGTLV TVSS BMS2h-14 (SEQ ID NO: 43)
EVOQLLESGGG LVOPGGSLRL SCAASGFTFW SYDMTWVRQA PGKGLEWVSS IMASGDDTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKWD RD-------- FDYWGQGTLV TVSS BMS2h-15 (SEQ ID NO: 44)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE EYVMSWVRQA PGKGLEWVST ISPIGLTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEFP LIILPD--- FDOYWGOQGTLV TVSS BMS2h-16 (SEQ ID NO: 45)
EVOLLESGGG LVQPGGSLRL SCAASGFTFM EYAMIWVRQA PGKGLEWVSI ISPLGLSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKYQ DSSDSQYTN- FDYWGQGTLV TVSS BMS2h-17 (SEQ ID NO: 46)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE DYGMGWARQA PGKGLEWVSS IGPLGLWTYY ADSAKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSP LEGLITN-— FDYWGQGTLV TVSS BMS2h-176 — (SEQIDNO:47)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD AYEMGWVRQA PGKGLEWVSI IDWDGNSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG DNVGI—- FDYWGQGTLV TVSS BMS2h-177 — (SEQIDNO: 48)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS NYYMVWVRQA PGKGLEWVSA IDEWGFATYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKHW EFTSDTSR—FDYWGQGTLV TVSS BMS2h-178 — (SEQIDNO:49)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE DFDMAWVRQA PGKGLEWVSS INDQGSLTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPD QF----—-- FDYWGQGTLV TVSS BMS2h-179 — (SEQIDNO: 50)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AYDMMWVROA PGKGLEWVSR ISPQGAORTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKIR GOSRIPMR—FDYWGOQGTLV TVSS BMS2h-18 (SEQ ID NO: 51)
EVOQLLESGGG LVOPGGSLRL SCAASGFTFP EYDMTWVRQA PGKGLEWVSY ISSDGYSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPH GSPRE-—- FDYWGQGTLV TVSS BMS2h-180 — (SEQIDNO: 52)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT DYEMGWVROA PGKGLEWVST ITSLGESTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG RlI------- FDYWGQGTLV TVSS BMS2h-181 — (SEQIDNO:53)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA FYPMMWVRQA PGKGLEWVSW IDATGTRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEGN YGSSYTMGV- FDYWGQGTLV TVSS BMS2h-182 — (SEQIDNO: 54)
EVOQLLESGGG LVQPGGSLRL SCAASGFTFD EYPMYWVRQA PGKGLEWVSS IGPSGPNTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSP YFDVIPSY—FDYWGOQGTLV TVSS BMS2h-188 — (SEQIDNO: 55)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA DYGMGWVRQA PGKGLEWVSS IQSSGLRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKRA NSRRG--- FDYWGOQGTLV TVSS BMS2h-184 — (SEQIDNO: 56)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS DYEMMWVRQA PGKGLEWVSS ITSHGGSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPD KD------ FDYWGQGTLV TVSS BMS2h-185º=— (SEQIDNO:57)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA HYPMSWVROA PGKGLEWVSS IGRLGNRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRA TPVPIKGL—FDYWGQGTLV TVSS BMS2h-188 — (SEQIDNO: 58)
EVOLLESGGG LVOPGGSLRL SCAASGLTFG RYEMAWVRQA PGKGLEWVSS IDSDGWVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQPD SL——-—- FDYWGQGTLV TVSS BMS2h-187 /— (SEQIDNO: 59)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS SYSMVWVRQA PGKGLEWVSG INRGGTRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGW RRG—---- FDOYWGQGTLV TVSS BMS2h-188 — (SEQID NO: 60)
EVOLLESGGG LVQPGGSLRL SCAASGFTFT RYRMSWVRQA PGKGLEWVSG ISRDGYRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGM TAS------- FDYWGQGTLV TVSS BMS2h-189 — (SEQIDNO:61)
EVOLLESGGG LVOPGGSLRL SCAASGFTFQ MYPMGWVRQA PGKGLEWVSM IEPAGDLTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKYQ EQPW--- FDYWGQGTLV TVSS BMS2h-19 (SEQ ID NO: 62)
EVOQLLESGGG LVQPGGSLRL SCAASGFPFP QYQMAWVRQA PGKGLEWVSM ITSDGLDTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPE PL----- FDYWGOQGTLV TVSS BMS2h-190 — (SEQ ID NO: 63)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS MYDMHWVROA PGKGLEWVST ILSDGTDTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYG AM-——--- FDYWGQGTLV TVSS BMS2h-191 — (SEQIDNO: 64)
EVOLLESGGG LVQPGGSLRL SCAASGFTFK LYPMTWVRQA PGKGLEWVSS IDAGGHETYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDW WDYL--—-- FDYWGQGTLV TVSS BMS2h-192 — (SEQ ID NO: 65)
EVOQLLESGGG LVQPGGSLRL SCAASGFTFS RYPMSWVRQA PGKGLEWVSS INRSGMRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEGH QAP-—-- FDYWGQGTLV TVSS BMS2h-193 — (SEQIDNO: 66)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT GYAMSWVRQA PGKGLEWVST INANGIRTYY ADSVKGRFTI SRDNSKNTLY LOMNGLRAED TAVYYCAKGG VWRWGTGHK- FDYWGQGTLV TVSS BMS2h-194 — (SEQIDNO:67)
EVOLLESGGG LVQPGGSLRL SCAASGFTFK QYDMRWVRQA PGKGLEWVST ISQNGTKTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSR TGRY-—-- FDYWGQGTLV TVSS BMS2h-195 — (SEQIDNO: 68)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG TYDMGWVRQA PGKGLEWVSR INWOGDRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG FGHYVDGLG- FDYWGQGTLV TVSS BMS2h-196 — (SEQID NO: 69)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS GYEMAWVRQA PGKGLEWVSS ITDMGDSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG TA——- FDYWGPGTLV TVSS BMS2h-197 — (SEQIDNO: 70)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA KYKMWWVRQA PGKGLEWVSS ITPKGHSTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAKRP MTP---—-- FDOYWGQGTLV TVSS BMS2h-198 — (SEQIDNO:71)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE RYNMSWVRQA PGKGLEWVSS IRPRGGKTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKWR REGYTGSK—FDYWGQGTLV TVSS BMS2h-199 — (SEQIDNO: 72)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE RYGMTWVROA PGKGLEWVSS IWPRGOKTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGN SRYV------ FDOYWGQGTLV TVSS BMS2h-2 (SEQ ID NO: 73)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS DYEMMWVRQA PGKGLEWVST ITSDGISTYY ADSVKGRFTI FRONSKNTLY LOMNSLRAED TAVYYCAKSG RF-—- FDYWGQGTLV TVSS BMS2h-20 — (SEQIDNO:74)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS GYQMAWVROQA PGKGLEWVSG ISSEGLTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLG RR-------- FDYWGQGTLV TVSS BMS2h-200 — (SEQIDNO: 75)
EVOLLESGGG LVAQPGGSLRL SCAASGFTFT NYSMGWVRQA PGKGLEWVST IRPNGTKTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAKRS SAHLQR--- FDYWGQGTLV TVSS BMS2h-201 — (SEQIDNO:76)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG NYSMGWVRQA PGKGLEWVSS IGRHGGRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKKG STYPR---- FDYWGQGTLV TVSS BMS2h-202 — (SEQIDNO: 77)
EVOLLESGGG LVQPGGSLRL SCTASGFTFS HYEMGWVRQA PGKGLEWVSS IEPFGGGTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVY PQGS------ FDOYWGQGTLV TVSS BMS2h-203 — (SEQIDNO:78)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS NYTMGWVRQA PGKGLEWVSS IRPDGKITYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEVY SSCAMCTPLL FDYWGQGTLV TVSS BMS2h-204 (SEQ ID NO: 79)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYSMAWVROA PGKGLEWVSD IGPRGFSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG RGQRDTSQP- FDYWGQGTLV TVSS BMS2h-205 — (SEQ ID NO: 80)
EVOLLESGGG LVQPGGSLRL SCAASGFTFA SYQMAWVRQA PGKGLEWVSG ITSGGLSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG RG-—-- FDYWGQGTLV TVSS BMS2h-206 — (SEQIDNO:81)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFA SYEMTWVROA PGKGLEWVSG ISSDGLSTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAKPG VL-------- FOYWGQGTLV TVSS BMS2h-207 — (SEQIDNO: 82)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD KYLMSWVRQA PGKGLEWVSG IEPLGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKEA SGD--—-- FDYWGOQOGTLV TVSS BMS2h-208 — (SEQIDNO: 383)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT EYEMSWVRQA PGKGLEWVSS IDNVGSSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG KL-------- FOYWGQOGTLV TVSS BMS2h-209 (SEQ ID NO: 84)
EVOLLESGGG LVQPGGSLRL SCAASGFTFA DYEMWWVRQA PGKGLEWVSA ISRQGFATYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKDL ERDD---- FDYWGQGTLV TVSS BMS2h-21 (SEQ ID NO: 85)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA NYEMGWARQA PGKGLEWVSV ISEWGYSTYY ADSAKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLV GGTQYE--- FDOYWGQGTLV TVSS BMS2h-22 — (SEQIDNO: 86)
EVOLLESGGG LVOPGGSLRL SCAASGFTFH NYEMSWVRQA PGKGLEWVSS ISSGGSSTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAKPG VK-------- FDOYWGQGTLV TVSS BMS2h-23 — (SEQIDNO:87)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG LYEMTWVRQA PGKGLEWVSS ITGDGISTYY ADSVKGRFTI SRDNSRNTLY LQMNSLRAED TAVYYCAKAG RK-------- FDOYWGQGTLV TVSS BMS2h-24 — (SEQIDNO: 88)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS NYQMAWVRQA PGKGLEWVSS ITSEGGSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG KN--——-- FDYWGOGTLV TVSS BMS2h-24-1 — (SEQIDNO: 89)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS DYQMAWVRQA PGKGLEWVSS ITSEGGSTYY ADSVKGRFTI SRDNSKNTVY LOMNSLRAED TAVYYCAKPG KN-—-- FDYWGQGTLV TVSS BMS2h-25 (SEQ ID NO: 90)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NYEMTWVROA PGKGLEWVST ITSQGTSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD R$S----—-- FDYWGQGTLV TVSS BMS2h-26 — (SEQIDNO:91)
EVOLLESGGG LVQPGGSLRL SCAASGFTFR SYEMTWVRQA PGKGLEWVSS ITSDGGTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD KT----——-- FDOYWGQGTLV TVSS BMS2h-27 — (SEQIDNO: 92)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN LYEMTWVROA PGKGLEWVSS ITSDGVSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD SP--—--- FDOYWGQGTLV TVSS BMS2h-28 — (SEQIDNO:93)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG HYDMAWVRQA PGKGLEWVST ISDNGNGTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG RD-------- FDYWGQGTLV TVSS BMS2h-29 — (SEQIDNO: 9)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG RYQMAWVROA PGKGLEWVSS ISSDGGGTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG RA--—-- FDYWGQOGTLV TVSS BMS2h-30 (SEQ ID NO: 95)
EVOLLESGGG LVQPGGSLRL SCAASGFTFA RYQMAWVRQA PGKGLEWVST ISDDGDSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLD KL———- FDYWGQGTLV TVSS BMS2h-300 — (SEQ ID NO: 96)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NDEMTWVROA PGKGLEWVSA IDTTGGQTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG KE-------- FDYWGQGTLV TVSS BMS2h-301 — (SEQIDNO: 597)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG ESEMSWVRQA PGKGLEWVSS ILDEGSGTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAKPD KD-------- FDOYWGQGTLV TVSS BMS2h-302 — (SEQ ID NO: 98)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG EEEMSWVRQA PGKGLEWVSA ITDDGDDTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPN AGA-——-- FDOYWGQGTLV TVSS BMS2h-303 — (SEQIDNO: 299)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE VYDMAWVRQA PGKGLEWVSG IVNDGSSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPD KD-------- FDOYWGQGTLV TVSS BMS2h-304 — (SEQIDNO: 100)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFG NTEMTWVRQA PGKGLEWVSS IADDGSSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG QA------- FDYWGQGTLV TVSS BMS2h-31 (SEQ ID NO: 101)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE EYOMAWVRQA PGKGLEWVST ISDDGSSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD LY——-—- FDYWGQGTLV TVSS BMS2h-32 — (SEQIDNO: 102)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE VYQMGWVRQA PGKGLEWVSF IVPGGDLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETW PE---—-- FDYWGQGTLV TVSS BMS2h-4 (SEQ ID NO: 103)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD NYEMTWVROA PGKGLEWVSS ITSDGTSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPN PP--—--- FDOYWGQGTLV TVSS BMS2h-40 — (SEQIDNO: 104)
EVOLLESGGG LVQPGGSLRL SCAASGFTFK AYDMGWVRQA PGKGLEWVSQ IGRDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPR RYAIF---- TEDRGQGTLV TVSS BMS2h-400 — (SEQIDNO: 105)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK QYPMVWVRQA PGKGLEWVST ISTNGVRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKWT DIISSSE--- FDYWGQGTLV TVSS BMS2h-401 (SEQ ID NO: 106)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFF NYDMSWVRQA PGKGLEWVSA ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVF VWSADIDFD- FDYWGQGTLV TVSS BMS2h-402 — (SEQID NO: 107)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS WYDMSWVRQA PGKGLEWVSH IASWGGKTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVT VKDGGYLMD- FDYWGQGTLV TVSS BMS2h-403 — (SEQIDNO: 108)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA EYAMAWVRQA PGKGLEWVSS IGRDGAVTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAKWK AAKERGSW—FDYWGQGTLV TVSS BMS2h-404 — (SEQIDNO: 109)
EVOLLESGGG LVAQPGGSLRL SCAASGFTFQ AYQMQWVRQA PGKGLEWVST ISPNGLFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKWL SS-—-—--- FDYWGQGTLV TVSS BMS2h-407 — (SEQIDNO: 110)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA MYSMAWVRQA PGKGLEWVSG ISPRGVETYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKTN WNGVDL---- FDOYWGQGTLV TVSS BMS2h-408 — (SEQIDNO: 111)
EVOLLESGGG LVQPGGSLRL SCAASGFTFP TYMMSWVRQA PGKGLEWVST INTNGRDTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGD SNMSF-—- FDYWGQGTLV TVSS BMS2h-409 (SEQ ID NO: 112)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE GYSMTWVROA PGKGLEWVSS INASGTLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDG NRSEVF--- FDYWGQGTLV TVSS BMS2h-41 (SEQ ID NO: 113)
EVOLLESGGG LVQPGGSLRL SCAASGFTFF EYEMTWVRQA PGKGLEWVSS IANDGSTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD RQ---—-- FDOYWGQGTLV TVSS BMS2h-410 — (SEQIDNO: 114)
EVOLLESGGG LVOPGGSLRL SCAASGFTFQ DYLMAWVROA PGKGLEWVSE INQDGTVTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAESS PY-------- FOYWGQGTLV TVSS BMS2h-411 — (SEQIDNO:115)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD NYAMSWVRQA PGKGLEWVSS ISRDGHVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLS SKGGTFASS- FDYWGQGTLV TVSS BMS2h-412 — (SEQIDNO: 116)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AVPMTWVROA PGKGLEWVSA ITDDGLRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGH IYGDY---- FOYWGQGTLV TVSS BMS2h-413 (SEQ ID NO: 117)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFE LYRMMWVRQA PGKGLEWVSA ISSDGDTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEHW LGTTLSLRD- FDYWGQGTLV TVSS BMS2h-414 — (SEQIDNO: 118)
EVOLLESGGG LVOPGGSLRL SCAASGFTFY RYTMAWVROA PGKGLEWVSQ ISPRGNITYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSG VAGAESPEY- FDYWGQGTLV TVSS BMS2h-415 — (SEQIDNO: 119)
EVOLLESGGG LVQPGGSLRL SCAASGFTFL GYYMSWIRQA PGKGLEWVST IGPIGGGTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAKSQ NIYGP----- FDOYWGQGTLV TVSS BMS2h-416 — (SEQIDNO: 120)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE QYDMAWVRQA PGKGLEWVSE ISRDGGRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEEY PY-------- FOYWGQGTLV TVSS BMS2h-417 — (SEQIDNO: 121)
EVOLLESGGG LVQPGGSLRL SCAASGFTFP QYSMVWVRQA PGKGLEWVST ISPLGSSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKMS KLLLSRE--- FDOYWGQGTLV TVSS BMS2h-418 — (SEQIDNO: 122)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA MYSMAWVRQA PGKGLEWVSG ISPRGVETYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKTN WNGVDL---- FDYWGQGTLV TVSS BMS2h-419 (SEQ ID NO: 123)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT RHGMAWVROA PGKGLEWVST ITPTGNTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDA HDEGY---- FDYWGQGTLV TVSS BMS2h-42 — (SEQIDNO: 124)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG PYEMTWVRQA PGKGLEWVSS IVGDGLDTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPD RV---—-- FDOYWGQGTLV TVSS BMS2h-420 — (SEQIDNO: 125)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG STPMMWVRQA PGKGLEWVSE IRDTGLATYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCASVS ---------- FDOYWGQGTLV TVSS BMS2h-421 — (SEQIDNO: 126)
EVOLLESGGG LVQPGGSLRL SCAASGFTFH LGDMHWVRQA PGKGLEWVSS ISGTGHTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPM NDQG--- FDYWGQOGTLV TVSS BMS2h-422 — (SEQIDNO: 127)
EVOLLESGGG LVOPGGSLRL SCAASGFTFM DEDMLWVRQA PGKGLEWVSR INSLGTHTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSF MM--—-- FDYWGOGTLV TVSS BMS2h-423 (SEQ ID NO: 128)
EVOLLESGGG LVQPGGSLRL SCAASGFTFR NYQMHWVRQA PGKGLEWVSG IDATGRATYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCARST R$—-—- FDYWGOQGTLV TVSS BMS2h-424 — (SEQIDNO: 129)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT NADMVWVRQA PGKGLEWVSS ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGY LTSH----— FDOYWGQGTLV TVSS BMS2h-425 — (SEQIDNO: 130)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR DYSMAWVRQA PGKGLEWVST ITPSGLTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEWS QAVTRS--- FDYWGQGTLV TVSS BMS2h-426 — (SEQIDNO: 131)
EVOLLESGGD LVQPGGSLRL SCAASGFTFS DEGMMWVRQA PGKGLEWVSE INQQGSATYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKTI GM-— -- FDYWGQGTLV TVSS BMS2h-427 — (SEQIDNO: 132)
EVOLLESGGG LVQPGGSLRL SCAASGFTFT DQPMVWVRQA PGKGLEWVSS IGARGGPTYY ADSVKGRFTV SRDNSKNTLY LOMNSLRAED TAVYYCAKWF DIIAWDPFS- FDYWGOGTLV TVSS BMS2h-428 — (SEQIDNO: 133)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN QYPMMWVRQA PGKGLEWVSS ITPSGFLTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEWN PFITT--— FDYWGQGTLV TVSS BMS2h-429 (SEQ ID NO: 134)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG HQOQMAWVROA PGKGLEWVST ITPNGYYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFD YSLR—--- FDYWGQGTLV TVSS BMS2h-43 — (SEQIDNO:135)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA SYEMAWVRQA PGKGLEWVSS IGSDGGPTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED SAVYYCAKPD RA-—— -- FDYWGOGTLV TVSS BMS2h-430 — (SEQIDNO: 136)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AEQMTWARQA PGKGLEWVST ITPHGDSTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKWR TLVDWPTSES FDYWGQGTLV TVSS BMS2h-44 (SEQ ID NO: 137)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT SYEMGWVRQA PGKGLEWVSS IEPTGITTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPH FTELG-—--- FDYWGQGTLV TVSS BMS2h-449 — (SEQIDNO: 138)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE GEQMAWVRQA PGKGLEWVST ITLPGPYTFY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGN GTF------- FDYWGQGTLV TVSS BMS2h-45 (SEQ ID NO: 139)
EVOQLLESGGG LVQPGGSLRL SCAASGFTFG NYAMAWVROA PGKGLEWVSK IGAQGLHTYY AGSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKQT TMDYER--- FDYWGQOGTLV TVSS BMS2h-450 — (SEQIDNO: 140)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD EVDMSWVROA PGKGLEWVSA IGNNGLKTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSA LSYRPPV--- FDOYWGQGTLV TVSS BMS2h-451 — (SEQIDNO: 141)
EVOLLESGGG LVOPGGSLRL SCAASGFTFQ DDTMSWVRQA PGKGLEWVST ITLKGPSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSR DGLY---— FDYWGQGTLV TVSS BMS2h-452 — (SEQIDNO: 142)
EVOQLLESGGG LVOPGGSLRL SCAASGFTFA SSPMAWVROA PGKGLEWVSS IGRDGSTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPS PYRR---— FDYWGQGTLV TVSS BMS2h-453 — (SEQIDNO: 143)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT DYSMVWVRQA PGKGLEWVST IVSHGGTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGK GYNAQY--- FDOYWGQGTLV TVSS BMS2h-454/ — (SEQIDNO: 144)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG HQOQMAWVRQA PGKGLEWVST ITPNGYYTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKFD YSLR——-- FDYWGOGTLV TVSS BMS2h-455 — (SEQIDNO: 145)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN DYDMIWVROA PGKGLEWVST ISSHGDSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGD VF-------- FDYWGQGTLV TVSS BMS2h-456 — (SEQIDNO: 146)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG HQQMAWVROA PGKGLEWVST ITPNGYYTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEWS DS-------— FDYRGQOGTLV TVSS BMS2h-457/ — (SEQID NO: 147)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA DYEMAWVROQA PGKGLEWVSG IQSNGNITYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKAN SQVEY--- FDYWGQGTLV TVSS BMS2h-458 — (SEQIDNO: 148)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG VEPMSWVRQA PGKGLEWVSN IGRDGSMTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLG KHGT---— FDYWGQOGTLV TVSS BMS2h-459 — (SEQIDNO: 149)
EVOLLESGGG LVOPGGSLRL SCAASGFTFP EYRMMWVRQA PGKGLEWVSW IDERGSLTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKRR KGTKQ-—- FDYWGQGTLV TVSS BMS2h-46 (SEQ ID NO: 150)
EVOQLLESGGG LVOPGGSLRL SCAASGFTFE LYAMAWVRQA PGKGLEWVSG IGAVGETTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKEA NNLSDNLV—FDYWGOQGTLV TVSS BMS2h-460 — (SEQIDNO: 151)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG HQQMAWVROA PGKGLEWVST ITPNGYYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWS VEW---—-- FDYWGQGTLV TVSS BMS2h-461 — (SEQIDNO: 152)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN SYTMNWVROA PGKGLEWVSS INPWGSRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGL VL------ FDYWGQGTLV TVSS BMS2h-462 — (SEQIDNO: 153)
EVOQLLESGGG LVQPGGSLRL SCAASGFTFD GDMMSWVRQA PGKGLEWVSS ITQLGSRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKQN WRTLT----- FDYWGQGTLV TVSS BMS2h-463 — (SEQIDNO: 154)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN AYGMMWVRQA PGKGLEWVSS ILSDGVITYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSA RGANF--- FDYWGQGTLV TVSS BMS2h-464 — (SEQIDNO: 155)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG HYMMVWVRQA PGKGLEWVSS ITPHGTSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEFN AIFSEA---- FDYWGQGTLV TVSS BMS2h-465 — (SEQIDNO: 156)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR DYSMAWVROA PGKGLEWVST ITPSGLTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWS QAVTRS--- FDYWGQGTLV TVSS BMS2h-4668 — (SEQIDNO: 157)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD LYAMAWVRQA PGKGLEWVSM IGRDGRFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLA GSLRGR---- FDYWGQGTLV TVSS BMS2h-467 (SEQ ID NO: 158)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN KASMGWVRQA PGKGLEWVST ITPHGSSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQR WGVE------ FDOYWGQGTLV TVSS BMS2h-468 (SEQ ID NO: 159)
EVOLLESGGG LVOPGGSLRL SCAASGFTFQ GYSMGWVRQA PGKGLEWVSS IAGRGGVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGL YIYHSL---- FDOYWGQGTLV TVSS BMS2h-469 (SEQ ID NO: 160)
EVOLLESGGG LVOPGGSLRL SCAASGFTFP GMEMSWVRQA PGKGLEWVSA ITGTGSTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGY HP-------- FDOYWGQGTLV TVSS BMS2h-470 (SEQ ID NO: 161)
EVOLLESGGG LVQPGGSLRL SCAASGFTFP MVAMSWVRQA PGKGLEWVSS IARDGNVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED AAVYYCAKVS PTG------- FOYWGQGTLV TVSS BMS2h-471 (SEQ ID NO: 162)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFG HQDMSWVRQA PGKGLEWVSG ITDDGESTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGD YD----—-- FDOYWGQGTLV
TVSS BMS2h-472 (SEQ ID NO: 163)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG EYNMMWVROQA PGKGLEWVSQ ITRDGSRTYY ADSVRGRFTI SRDNSRNTLY LQOMNSLRAED SAVYYCAKLS NIG—-—- FDYWGQGTLV TVSS BMS2h-473 (SEQ ID NO: 164)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS DYSMIWARQA PGKGLEWVSS ITPYGSYTIYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTD YL-------- FDOYWGQGTLV TVSS BMS2h-474 (SEQ ID NO: 165)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD TYSMMWVRQA PGKGLEWVST ITPYGSSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWG LV-———- FDYWGQGTLV TVSS BMS2h-475 (SEQ ID NO: 166)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT TGPMMWVRQA PGKGLEWVSA IGIGGDTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLT PSNQ----— FDYWGQGTLV TVSS BMS2h-476 (SEQ ID NO: 167)
EVOLLESGGG LVQPGGSLRL SCAASGFTFK QYQMMWVRQA PGKGLEWVSS ITPSGFLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWN PFIST----- FDOYWGQGTLV TVSS
BMS2h-477 — (SEQIDNO: 168)
EVOLLESGGG LVQPGGSLRL SCAASGFTFP NYDMVWVRQA PGKGLEWVSS ISALGNVTYY ADSVKGRFTI SRDNSKNTLY LOTNSLRAED TAVYYCAKWR SAITGN-——
FDYWGOQGTLV TVSS BMS2h-478 — (SEQIDNO: 169)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK EYQMSWVROA PGKGLEWVST ISPSGMNTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEWR SVVRPWPGV- FDYWGQGTLV TVSS BMS2h-4179 — (SEQIDNO: 170)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD DESMAWVROA PGKGLEWVSS ITPHGTFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLH LKLYESH-- FDYWGQGTLV TVSS BMS2h-480 — (SEQIDNO: 171)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE GGEMGWVRQA PGKGLEWVSM IPMDGSATYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKAG ST-—-—- FDYWGQGTLV TVSS BMS2h-481 — (SEQIDNO: 172)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD FMPMAWVRQA PGKGLEWVSS IGRDGAYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLA SPAQ---— FDYWGQGTLV TVSS BMS2h-482 — (SEQIDNO: 173)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG DEPMLWVRQA PGKGLEWVSS IGGTGTTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGN QGDFINR--- FHYWGOQGTLV TVSS BMS2h-483 — (SEQIDNO: 174)
EVOLLESGGG LVOPGGSLRL SCAASGFTFH AYNMAWVROA PGKGLEWVST ISPRGSYTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKWP PPSSH-—- FDYWGQGTLV TVSS BMS2h-5 (SEQ ID NO: 175)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD GYEMAWVRQA PGKGLEWVSS ITSDGTSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG LR———- FDYWGQGTLV TVSS BMS2h-505 — (SEQIDNO: 176)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE GYMMYWVHQOA PGKGLEWVSS ISPQGHFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAELR ELPRL--— FDYWGQGTLV TVSS BMS2h-5086 — (SEQIDNO: 177)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS SYAMGWVROA PGKGLEWVSS IDASGGPTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKAN GKKFPFTKY- FDYWGQGTLV TVSS BMS2h-507 — (SEQIDNO: 178)
EVOLLESGGG LVAQPGGSLRL SCAASGFTFP SVHMAWVRQA PGKGLEWVSG INLTGVDTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSA TTRQAHPLY- FDYWGQGTLV TVSS
BMS2h-515 — (SEQIDNO: 179)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK EGEMYWVROA PGKGLEWVST ISTNGLTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKST RDLG——- FAYWGQGTLV TVSS BMS2h-516 — (SEQIDNO: 180)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE EYEMAWARQA PGKGLEWVSF ISPRGHFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPA KT——-—- FDYWGQGTLV TVSS BMS2h-517 — (SEQIDNO: 181)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD TYEMLWVRQA PGKGLEWVSR ISVDGSITYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTR MR---—-- FDYWGQGTLV TVSS BMS2h-518 — (SEQIDNO: 182)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSN ISRDGSKTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEAQ SGGLRSGLTT FDYWGQGTLV TVSS BMS2h-519 — (SEQIDNO: 183)
EVOLLESGGG LVOPGGSLRL SCADSGFTFS SYAMSWVRQA PGKGLEWVSS IGRDGAYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG PKGIA-—-- FDYWGQGTLV TVSS BMS2h-520 — (SEQ ID NO: 184)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS PHAMAWVRQA PGKGLEWVSG IDGGGSMTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSD PP-—-—- FDYWGQGTLV TVSS BMS2h-521 — (SEQIDNO: 185)
EVOLLESGGG LVOPGGSLRL SCAASGFTFH AGEMHWVROA PGKGLEWVSS ITLPGDMTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPN TGYT—- FDYWGQGTLV TVSS BMS2h-522 — (SEQID NO: 186)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG NYGMSWVROA PGKGLEWVSS ISWDGSLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQNT RL——-—- FDYWGQGTLV TVSS BMS2h-523 — (SEQIDNO: 187)
EVOLLESGGG LVQPGGSLRL SCAASGFTFH DADMLWVRQA PGKGLEWVSG ILSPGEDTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFG LP——- FDYWGQGTLV TVSS BMS2h-524 — (SEQIDNO: 188)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR TDQMNWVROQA PGKGLEWVSS ISPSGAYTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGL GA----—- FDYWGQGTLV TVSS BMS2h-525""— (SEQIDNO: 189)
EVOLLESGGG LVQPGGSLRL SCAASGFIFE QYQMVWVRQA PGKGLEWVSW ISPDGTHTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKFS LRKMEK---- FDYWGQGTLV TVSS
BMS2h-526 — (SEQIDNO: 190)
EVOLLESGGG LVOPGGSLRL SCAASGFTFOQ DEQMAWVROA PGKGLEWVSS IASDGMSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAQPG KN-—-- FDHWGQGTLV TVSS BMS2h-527 (SEQ ID NO: 191)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS DYAMSWVRQA PGKGLEWVSS ITTGGERTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKRW NLYTES--- FDYWGQGTLV TVSS BMS2h-528 — (SEQIDNO: 192)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG GQPMDWVRQA PGKGLEWVSS IAPDGIHTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKNL GQG-——-- FDYWGQGTLV TVSS BMS2h-5298 — (SEQIDNO: 193)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE RYQMTWVRQA PGKGLEWVSS ISPSGTFTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAEWK AL——--- FDOYWGQGTLV TVSS BMS2h-530 — (SEQIDNO: 194)
EVOLLESGGG LVQPGGSLRL SCAASGFTFP HSTMYWVRQA PGKGLEWVSL ILPSGSRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFS DER-——-- FDYWGQGTLV TVSS BMS2h-531 — (SEQIDNO: 195)
EVOLSESGGG LVOPGGSLRL SCAASGFTFG DGNMDWVROQA PGKGLEWVSG ISSDGVTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKDR GQG------- FOYWGQGTLV TVSS BMS2h-532 (SEQ ID NO: 196)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD DYMMWWVRQA PGKGLEWVSS ISPHGVYTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKWL HT—-—-- FDYWGQGTLV TVSS BMS2h-533 (SEQ ID NO: 197)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS NYTMAWGROA PGKGLEWVSF IAGPGNYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG STATYNNGQ- FDYWGQGTLV TVSS BMS2h-534 — (SEQIDNO: 198)
EVOLLESGGG LVQPGGSLRL SCAASGFTFT EYSMVWVRQA PGKGLEWVSS ISGSGRVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWL KLVRAPNP—FDYWGQGTLV TVSS BMS2h-535 — (SEQIDNO: 199)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS NYOMAWVRQA PGKGLEWVSG ISKTGHSTYY ADSVKGRFTI SRDNSRNTLY LQMNSLRAED TAVYYCAKAS HSLGPL--- FDYWGQGTLV TVSS BMS2h-54º — (SEQIDNO: 200)
EVOLLESGGG LVQPGGSLRL SCAASGFTFT AYRMAWVRQA PGKGLEWVSW ISPSGSGTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKTL TDSPSGHYE- FDYWGQGTLV TVSS
BMS2h-55 = (SEQIDNO: 201)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA RYEMGWVRQA PGKGLEWVSR ITAQGLGTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKYL TDFSSGHQE- FDYWGQGTLV TVSS BMS2h-553 (SEQ ID NO: 202)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD DYGMSWVRQV PGKGLEWVSG ISHNGMLTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKYW PSTSWETD—FDYWGQGTLV TVSS BMS2h-554º — (SEQID NO: 203)
EVOLLESGGG SVOPGGSLRL SCAASGFTFG NEPMAWVROQA PGKGLEWVSS IEMQGKNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDR GQG------ FDOYWGQGTLV TVSS BMS2h-555 (SEQ ID NO: 204)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG EEEMSWVRQA PGKGLEWVSC IDNLGSPTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED AAVYYCAKTI SHQYDR---- FDOYWGQGTLV TVSS BMS2h-556/ — (SEQIDNO: 205)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG EEEMSWVRQA PGKGLEWVSS IDEGGRWTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWT PHKQLS-—- FDYWGQGTLV TVSS BMS2h-557/ — (SEQID NO: 206)
EVOLLESGGG LVOPGGSLRL SCAASGFSFA DEYMVWARQA PGKGLEWVSE IDPLGTGTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKYG TA———- FDYWGQGTLV TVSS BMS2h-558 (SEQ ID NO: 207)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS THDMMWVRQA PGKGLEWVSS ISDDGISTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD MSLIE-—— FDYWGQGTLV TVSS BMS2h-5598º — (SEQID NO: 208)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD GTPMVWVROA PGKGLEWVSG ISGDGRNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPY ALTSSKP-- FDYWGQGTLV TVSS BMS2h-56/ — (SEQIDNO: 209)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN DYTMGWVROA PGKGLEWVSW IHGTGGATYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAL ADRSGGVVE- FDYWGQGTLV TVSS BMS2h-560 — (SEQ ID NO: 210)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE AETMAWVRQA PGKGLEWVSC ISNDGNTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKES LISPGL--- FDYWGQGTLV TVSS BMS2h-561 — (SEQIDNO:211)
EVOLLESGGG LVQPGGSLRL SCAASGFTFT GEYMNWVRQA PGKGLEWVST INETGYMTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLS TRGVP----- FDOYWGQGTLV TVSS
BMS2h-562 — (SEQID NO: 212)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR SYDMGWVROA PGKGLEWVST ISPMGVFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSN QHAHDP--- FDYWGQGTLV TVSS BMS2h-568 — (SEQIDNO:213)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS DYDMGWVROA PGKGLEWVSS ISPMGTFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKAA LTEPM----- FDYWGQGTLV TVSS BMS2h-564º — (SEQIDNO: 214)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR DYDMGWVROA PGKGLEWVST ISPLGHFTYY ADSVKGRSTI SRDONSKNTLY LOMNSLRAED TAVYYCAKAE EA———- FDYWGQGTLV TVSS BMS2h-565º — (SEQIDNO: 215)
EVOLLESGGG LVOPGGSLRL SCAASGFAFP RYGMTWVRQA PGKGLEWVSN IDQFGMKTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEEY AS---—-- FDYWGQGTLV TVSS BMS2h-568 — (SEQIDNO: 216)
EVOQLLESGGG LVQPGGSLRL SCAASGFTFD KYDMGWVRQA PGKGLEWVST ISPMGVFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGR GNTSD--- FDYWGQGTLV TVSS BMS2h-567/ — (SEQIDNO: 217)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS NYDMAWVRQA PGKGLEWVST ISGAGHFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSF PRDE—- FDYWGQGTLV TVSS BMS2h-568 — (SEQIDNO: 218)
EVOLLESGGG LVOPGGSLRL SCAASGFTFP KYEMRWVROA PGKGLEWVSE IGLDGSPTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLG DPNG---- FDYWGQGTLV TVSS BMS2h-569º— (SEQID NO: 219)
EVOLLESGGG LVOPGGSLRL SCAASGFTFP TSEMDWVROA PGKGLEWVSG IGPDGLTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHA DW—--- FDYWGQGTLV TVSS BMS2h-57 (SEQ ID NO: 220)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS EYDMYWVRQA PGKGLEWVSW IDTDGGDTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG LK----- FDYWGQGTLV TVSS BMS2h-570 — (SEQIDNO: 221)
EVOLLESGGG LVOPGGSLRL SCTASGFTFE NASMQWVRQA PGKGLEWVSS IEGQOGNATYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSS SWS-——-- FDYWGQGTLV TVSS BMS2h-571 — (SEQIDNO: 222)
EVOLLESGGG LVQPGGSLRL SCAASGFTFT RNEMGWVRQA PGKGLEWVST ITPTGTFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKTD PGNRY--- FDYWGQGTLV TVSS
BMS2h-572 — (SEQIDNO: 223)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOQOLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN--—- FDYRGQGTLV TVSS BMS2h-572-1 (SEQ ID NO: 224)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOQOLMGWFROA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN-—-- FDYRGQGTLV TVSS BMS2h-572-10 — (SEQID NO: 225)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOQOLMGWVROA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTV SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN----- SDYRGQGTLV TVSS BMS2h-572-11 (SEQIDNO: 226)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCVKVG KESN-—-- SDYRGQGTQV TVSS BMS2h-572-12 — (SEQID NO: 227)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFN WOQOLMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN-—-- SDYRGQGTLV TVSS BMS2h-57213 —(SEQIDNO: 228)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOQLMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKDRFTI SRDNSKNTLY LLMNSLRAED TAVYYCAKVG KESN---—-- FDOYWGQGTLV TVSS BMS2h-572-14 (SEQ ID NO: 229)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN WOQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNTKNTLY LOMNSLRAED TAVYYCVKVG KESN---— SDYRGQGTLV TVSS BMS2h-572-15 (SEQ ID NO: 230)
EVRLLESGGG LVOPGGSLRL SCAASGFNFN WOLMGWIROA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN-—-- SDYRGQGTLV TVSS BMS2h-572-16 (SEQIDNO: 231)
EVOQLLESGGG LVRPGGSLRL SCVASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN---- FDYRGQGTLV TVSS BMS2h-572-17 — (SEQID NO: 232)
EVOLLESGGG LVOTGGSLRL SCAASGFTYN WOLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRADD TAVYYCVKVG KESN------ FOYRGHGTLV TVSS BMS2h-572-18 (SEQID NO: 233)
EVOQLLESGGG LVOPGGSLRL SCAASGFTFN WOQOLMGWVRKA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN-——- FDYRGOGTLV TVSS
BMS2h-572-19 — (SEQID NO: 234)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOQLMGWVROA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNTKNTLY LQMNSLRAED TAVYYCAKVG KESN---— FDYRGQGTLV TVSS BMS2h-572-2 — (SEQIDNO: 235)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOLMGWVROA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESK---— FDYLGQGTLV TVSS BMS2h-572-21 — (SEQID NO: 236)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOQOLMGWVROA PGKGLEWVSG IEGPGDVTYY AESVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN---— LDYRGQGTLV TVSS BMS2h-572-22 — (SEQID NO: 237)
EVOLFESGGG SVOPGGSLRL SCAASGFTFN WOLMGWVROA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN---- SDYRGOGTLV TVSS BMS2h-572-23 — (SEQID NO: 238)
EVQLLESGGG LVOPGGSLRL TCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFII SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN—- SDYRGQGTLV TVSS BMS2h-572-24 — (SEQID NO: 239)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOQOLMGWVROA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSTNTLY LOMNSLRAED TAVYYCAKVG KESE-—-- FDYRGOGTLV TVSS BMS2h-572-3 — (SEQID NO: 240)
EVRLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI TRONSKNTLY LOMNSLRAED TAVYYCVKVG KESN---— LDYRGQGTLV TVSS BMS2h-572-4 — (SEQIDNO: 241)
EVOLLVSGGG LVOPGGSLRL SCAASGFTFN WOLMGWVROA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN---- FDYRGQGTLV TVSS BMS2h-572-5º— (SEQIDNO: 242)
EVOLLVSGGG LVOPGGSLRL SCAASGFTFN WOLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNMLY LQOMNGLRAED TAVYYCAKVG KESN----— FDYRGQGTLV TVSS BMS2h-572-6 — (SEQIDNO: 243)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOLMGWVROA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN---- SDYRGOGTLV TVSS BMS2h-572-601 (SEQ ID NO: 244)
EVOLLESGGG LVQPGGSLRL SCAASGFTFK WQLMGWARQA PGKGLEWVSG IEGPGDVTYY ADPVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KESN---- SDYRGOGTLV TVSS
BMS2h-572-602 (SEQ ID NO: 245)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK WHLMGWVROQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KESS---— SDYRGQGTLV TVSS BMS2h-572-603 — (SEQ ID NO: 246)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WHLMAWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KESN-—-- SDYRGQGTLV
TVSS BMS2h-572-604 (SEQ ID NO: 247)
EVOLLESGGG LVQPGGSLRL SCAASGFTFK WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KESN-——- SDYRGQGTLV TVSS BMS2h-572-605 — (SEQ ID NO: 248)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK WQLMAWARQA PGKGLEWVSG IEGPGDITYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KESN---- SDYRGQGTLV TVSS BMS2h-572-606 (SEQ ID NO: 249)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN WHLMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KESN---- SDYRGQGTLV TVSS BMS2h-572-607 (SEQ ID NO: 250)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK WQLMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN-——- SDYRGQGTLV TVSS BMS2h-572-608 (SEQ ID NO: 251)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN WELMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KESN---- SDYRGQGTLV TVSS BMS2h-572-609 — (SEQ ID NO: 252)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN-——- SDYRGQGTLV TVSS BMS2h-572-610 (SEQ ID NO: 253)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KDSK---- SDYRGQGTLV TVSS BMS2h-572-611 (SEQID NO: 254)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRRA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KDSK-—- SDYRGQGTLV TVSS BMS2h-572-612 (SEQ ID NO: 255)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOQOLMGWVROA PGKGLEWVSG IEGPGDVTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSN---— SDYRGQGTLV TVSS BMS2h-572-613 (SEQID NO: 256)
EVOLLESGGG LAQPGGSLRL SCAASGFTFN WOQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KDSK-—-- SDYRGQOGTLV TVSS BMS2h-572-614 (SEQ ID NO: 257)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KDAK---- SDYRGQGTLV TVSS BMS2h-572-615 (SEQ ID NO: 258)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KDKN------ SDYRGQGTLV TVSS BMS2h-572-616 (SEQ ID NO: 259)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KESK---— SDYRGQGTLV TVSS BMS2h-572-617 (SEQ ID NO: 260)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG RDSK------ SDYRGQGTLV TVSS BMS2h-572-618 (SEQ ID NO: 261)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOQOLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KYSN---- SDYRGQGTLV TVSS BMS2h-572-619 (SEQ ID NO: 262)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KDSR------ SIDYRGQGTLV TVSS BMS2h-572-620 (SEQ ID NO: 263)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDDS---— SDYRGQGTLV TVSS BMS2h-572-621 (SEQ ID NO: 264)
EVOLLEFGGG LVOPGGSLRF SCAASGFTFN WOQLMGWFRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG RDSN-—-- SDYRGQGTLV TVSS BMS2h-572-622 (SEQ ID NO: 265)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN WOLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KDST---— SDYRGQGTLV TVSS BMS2h-572-623 (SEQ ID NO: 266)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOQOLMGWVROA PGKGLEWVSG IEGPGDVTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESS---— SDYRGQGTLV TVSS BMS2h-572-624 (SEQID NO: 267)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOLMGWVROA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI FRDONSKNTLY LOMNSLRAED TAVYYCVKVG KDSA---— SDYRGQGTLV TVSS BMS2h-572-625 (SEQ ID NO: 268)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG NDSY------ SDYRGQGTLV TVSS BMS2h-572-626 (SEQ ID NO: 269)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQOMNGLRAED TAVYYCVKVG KDSS-—-- SDYRGQGTLV TVSS BMS2h-572-627 — (SEQ ID NO: 270)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAIYYCVKVG KDSA----— SDYRGQGTLV TVSS BMS2h-572-6380 (SEQ ID NO: 271)
EVOLLESGGG LVAOPGGSLRL SCAASGFTFK WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDAK-——- SDYRGQGTLV TVSS BMS2h-572-631 (SEQID NO: 272)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSR------ SDYRGQGTLV TVSS BMS2h-572-632 (SEQ ID NO: 273)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KDSK-——- SDYRGQGTLV TVSS BMS2h-572-633 — (SEQ ID NO: 274)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFN WELMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDAK---- SDYRGQGTLV TVSS BMS2h-572-634 (SEQ ID NO: 275)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WELMGWARQA PGKGLEWVSG IEGPGDVTIYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KDSR------ SDYRGQGTLV TVSS BMS2h-572-635 (SEQ ID NO: 276)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WELMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCVKVG KDSK---- SDYRGQGTLV TVSS BMS2h-572-7/— (SEQID NO: 277)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WQLMGWARQA PGKGLEWVSG IEGPGDVTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED SAVYYCAKVG KESN---— FDYLGQGTLV TVSS BMS2h-5728 — (SEQIDNO: 278)
EVOLLESGGG LVOPGGSLRL SCVASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN-——- SDYRGOGTLV TVSS BMS2h-572-9 — (SEQID NO: 279)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN WOLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVG KESN---- SDYRGQGTLV TVSS BMS2h-573 — (SEQIDNO: 280)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS GWEMGWVRQA PGKGLEWVSS IDESGLNTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEGA PQYQIT---- FDYWGOQGTLV TVSS BMS2h-574 — (SEQIDNO: 281)
EVOLLESGGG LVOPGGSLRL SCAASGFTFP NYGMYWVRQA PGKGLEWVSY ISRRGLLTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKTS HYMNNG---- FDYWGQGTLV TVSS BMS2h-575 — (SEQIDNO: 282)
EVOLLESGGG LVQPGGSLRL SCAASGFTFV DYTMAWVRQA PGKGLEWVSS ISPIGTFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKDP YGMEDGLTW- FDYWGOGTLV TVSS BMS2h-576 — (SEQIDNO: 283)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD AYDMOQWVROA PGKGLEWVST ITSEGLSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPS DL———- FDYWGQGTLV TVSS BMS2h-577 — (SEQIDNO: 284)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD GYDMGWVROA PGKGLEWVST ISRGGWFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGT SOSSTGS--- FDYWGQGTLV TVSS BMS2h-578 — (SEQIDNO: 285)
EVOLLESGGG LVQPGGSLRL SCAASGFTFR RYDMLWARQA PGKGLEWVSE ISPTGALTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLG ST——-—- FDYWGQGTLV TVSS BMS2h-579 — (SEQIDNO: 286)
EVOLLESGGG LVOPGGSLRL SCAASGFTFF PYYMSWVRQA PGKGLEWVSS ISGTGGLTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKTT QNATL---- FDYWGQGTLV TVSS BMS2h-58 (SEQ ID NO: 287)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE VYTMAWVRQA PGKGLEWVST IDESGRDTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG VW-—-—-- FDYWGQGTLV TVSS BMS2h-580 — (SEQIDNO: 288)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA FYKMGWVRQA PGKGLEWVST ITPKGHHTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVF KGKGWTRPSG FDYWGQGTLV TVSS BMS2h-581 — (SEQIDNO: 289)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN EYSMMWVRQA PGKGLEWVSS IGRRGWLTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKAV LLDSTK- FDYWGQGTLV TVSS BMS2h-582 — (SEQID NO: 290)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD EYPMTWVROA PGKGLEWVST ISARGPFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGR HWLRNGR-—- FDYWGQGTLV TVSS BMS2h-583 — (SEQIDNO: 291)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG MQSMQWVRQA PGKGLEWVSS ITDDGTSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPD RV---—-- FDYWGQGTLV TVSS BMS2h-584 — (SEQIDNO: 292)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG AADMQWVRQA PGKGLEWVSL ITNDGISTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKAG DR---—-- FDYWGQGTLV TVSS BMS2h-5868 — (SEQIDNO: 293)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN KYRMOQWVRQA PGKGLEWVSS IDSSGELTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEEV PMGNQTF-- FDYWGOQGTLV TVSS BMS2h-587 /— (SEQIDNO: 294)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT DYTMGWVRQA PGKGLEWVSS ITSQGAFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAT GTDSS--- FDYWGQGTLV TVSS BMS2h-588 — (SEQIDNO: 295)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE DYEMSWVRQA PGKGLEWVSC IGPGGKPTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVD GH---—-- FDYWGQGTLV TVSS BMS2h-589 — (SEQID NO: 296)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS QYDMGWVRQA PGKGLEWVST ISSRGWLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGP GGRRR——-- FDYWGQGTLV TVSS BMS2h-59 (SEQ ID NO: 297)
EVOLLESGGG LVOPGGSLRL SCAASGFTFL DYAMGWVRQA PGKGLEWVST ISPMGMGTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSS AISFTSDISN FDYWGQGTLV TVSS BMS2h-5900 — (SEQ ID NO: 298)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS DYPMSWVRQA PGKGLEWVSS ISWSGFOTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG VARMPTGIA- FDYWGQGTLV TVSS BMS2h-591 — (SEQIDNO: 299)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AYEMOWVROA PGKGLEWVSS IDSAGTFTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF GM---—-- FDOYWGQGTLV TVSS BMS2h-592º — (SEQ ID NO: 300)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS EYPMKWVROA PGKGLEWVST IDRQGDRTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKTV RRGLPRPSRY FDYWGQGTLV TVSS BMS2h-593 — (SEQIDNO: 301)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS DYDMGWVROA PGKGLEWVSS ISPMGTFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGL SVYSGLD-- FDYWGQGTLV TVSS BMS2h-594 — (SEQIDNO: 302)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS HYDMGWVRQA PGKGLEWVSD IDYIGKTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKAS DEVGVNTSK- FDYWGOQGTLV TVSS BMS2h-595" — (SEQID NO: 303)
EVOLLESGGG LVQPGGSLRL SCAASGFTFA RYDMGWVRQA PGKGLEWVST ISPTGVLTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGF ED---—-- FDOYWGQGTLV TVSS BMS2h-596 — (SEQIDNO: 304)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE AYPMSWVRQA PGKGLEWVSL ISHTGHATYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGH WP-----—- FDYRGQGTLI TVSS BMS2h-567 — (SEQIDNO: 305)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE DEWMSWVRQA PGKGLEWVSD ISPGGWTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGY RPFDE--— FDYWGQGTLV TVSS BMS2h-598 — (SEQIDNO: 306)
EVOLLESGGG LVOPGGSLRL SCAASGVTFD AIEMSWVRQA PGKGLEWVSS ISRHGEYTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEDA WSRH---— FDYWGQGTLV TVSS BMS2h-599 — (SEQ ID NO: 307)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD STDMSWVRQA PGKGLEWVSG ILDNGSNTYY ADSVKGRFTI SRDONSKNMLY LQMNSLRAED TAVYYCAKGA RD------—- FDYWGQGTLV TVSS BMS2h-600 — (SEQ ID NO: 308)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG RQOSMQWVRQA PGKGLEWVSS IDDDGFSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGD PWG------- FDYWGQGTLV TVSS BMS2h-601 — (SEQID NO: 309)
EVOLLESGGG LVQPGGSLRL SCTASGFTFS DTQMAWVRQA PGKGLEWVSG IDDGGVSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPD RH-—-- FDYWGQGTLV TVSS BMS2h-6802 — (SEQ ID NO: 310)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG STTMGWVROA PGKGLEWVSV ISDDGGFTYY
ADSVKGRFTI SRDNSRNTLY LOMNSLRAED TAVYYCAKVD GYGV---— FDYWGQGTLV TVSS BMS2h-603 — (SEQIDNO:311)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR SGDMNWVRQA PGKGLEWVST ITNDGTSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSD SD------— FDYWGQGTLV TVSS BMS2h-61 (SEQ ID NO: 312)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA AYAMTWVROA PGKGLEWVSY ISPNGTATYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEYV GMRWNS--- FDYWGQGTLV TVSS BMS2h-62 (SEQ ID NO: 313)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS SYEMAWVROA PGKGLEWVSS ITSLGTSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG RK-——-- FDYWGQGTLV TVSS BMS2h-65 (SEQ ID NO: 314)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN EYEMTWVROA PGKGLEWVST ITSEGSGTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPN GK-——-- FDYWGQGTLV TVSS BMS2h-66 (SEQ ID NO: 315)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS DYEMLWVRQA PGKGLEWVST ITSEGHSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG TS——-—- FDYWGQGTLV TVSS BMS2h-67 (SEQ ID NO: 316)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS DYEMSWVROA PGKGLEWVST IDSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG VK------- FDYWGQGTLV TVSS BMS2h-68 (SEQ ID NO: 317)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK DYEMTWVROA PGKGLEWVSS ISSTGOSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG NK-——-- FDYWGQGTLV TVSS BMS2h-69 (SEQ ID NO: 318)
EVOLLESGGG LVQPGGSLRL SCAASGFTFL DYGMAWVRQA PGKGLEWVSA ISPLGLSTYY
ADSVKSRFTI SRDNSKNTLY LAMNSLRAED TAVYYCAKEV RVGRGVHPPK FDYWGQGTLV TVSS BMS2h-7 (SEQ ID NO: 319)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN LYEMTWVROQA PGKGLEWVSS ITSDGVSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG VI-—-- FDYWGQGTLV TVSS BMS2h-70 (SEQ ID NO: 320)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE NYAMSWVROA PGKGLEWVST IAPLGVPTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKKK VGAWLOSRS- FDYWGQGTLV TVSS BMS2h-701 — (SEQIDNO: 321)
EVOLLESGGG LVQPGGSLRL SCAASGFTFM DYEMHWVRQA PGKGLEWVST IGASGHYTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYL DMLLFG---- FDOYWGQGTLV TVSS BMS2h-702 — (SEQID NO: 322)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA EYEMMWARQA PGKGLEWVSR IAGNGSRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAIML SH——-- FDYWGQGTLV TVSS BMS2h-703 — (SEQIDNO: 323)
EVOLLESGGG LVOPGGSLRL SCAASGFTFY NYDMSWVROA PGKGLEWVSG IDSMGLVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGS NASDWVV--- FDYWGQGTLV TVSS BMS2h-704 — (SEQIDNO: 324)
EVOLLESGGG LVQPGGSLRL SCAASGFTFA SYHMTWVRQA PGKGLEWVSS IADTGDRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLR GMARVWG-- FDYWGQGTLV TVSS BMS2h-705 — (SEQIDNO: 325)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS YYDMMWVROA PGKGLEWISS ISDRGLOTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKFT EIPLDWLEV- FDYWGQGTLV TVSS BMS2h-706 — (SEQIDNO: 326)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG SYKMLWVRQA PGKGLEWVSS ITNSGTETYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSM YPDLEIVH—FDYWGQGTLV TVSS BMS2h-707 — (SEQIDNO: 327)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE TYRMSWVRQA PGKGLEWVSA IDQEGSATYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKNS GTRPGLR--- FOYWGQGTLV TVSS BMS2h-708 — (SEQIDNO: 328)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS SYDMLWVROA PGKGLEWVSR IDASGYFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAQLL KLSLNPN--- FDYWGQGTLV TVSS BMS2h-709 — (SEQIDNO: 329)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSS IHNTGLSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGT QHRFVV--- FDYWGQGTLV TVSS BMS2h-71 (SEQ ID NO: 330)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE GYPMSWVRQA PGKGLEWVST ISPLGPDTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLL MGEYLNSRT- FDYWGQGTLV TVSS BMS2h-710 — (SEQIDNO: 331)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN TYSMSWVRQA PGKGLEWVSW IDADGWVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAQTG HT-—--- FDYWGQGTLV TVSS BMS2h-711 — (SEQIDNO: 332)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT DGEMGWARQA PGKGLEWVSR IVDPGDSTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG DQ-—-- FDYWGQGTLV TVSS BMS2h-712 — (SEQIDNO: 333)
EVOLLESGGG LVQPGGSLRL SCAASGFTFP EYEMKWVRQA PGKGLEWVST ITPSGGHTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED AAVYYCAIPL SS---—-- FDYWGRGTLV TVSS BMS2h-713 — (SEQIDNO: 334)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS NYVMIWVROA PGKGLEWVSL INGAGDMTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEGG ARSFGVPPN- FDYWGQGTLV TVSS BMS2h-714 — (SEQIDNO: 335)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT DGEMGWARQA PGKGLEWVSR IVDPGDSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKAG DQ-——-—- FDYWGQGTLV TVSS BMS2h-715 — (SEQIDNO: 336)
EVOLLESGGG LVQPGGSLRL SCVASGFTFT LYNMSWVRQA PGKGLEWVSV ISSKGDSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAQTS SV—-—- FDYWGQGTLV TVSS BMS2h-716 (SEQ ID NO: 337)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE AYYMSWVRQA PGKGLEWVSG IVNNGLLTYY ADSVKGRFTI SRDNSKNMLY LQMNSLRAED TAVYYCAKSA VHPSYRAEL- FDYWGOQGTLV TVSS BMS2h-717 — (SEQIDNO: 338)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS SYEMAWVRQA PGKGLEWVSR IEPDGSNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGP DNFTM---- FDYWGQGTLV TVSS BMS2h-718 (SEQ ID NO: 339)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN KYMMGWVRQA PGKGLEWVSS IDSLGHYTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEAE FP———- FDYWGQGTLV TVSS BMS2h-719 — (SEQIDNO: 340)
EVOLLESGGG LVQPGGSLRL SCAASGFTFK RYEMTWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE----—-- FDYWGQGTLV TVSS BMS2h-7191 — (SEQIDNO: 341)
EVOLLESGGG MVOPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPF TE------- FDOYWGQGTQV TVSS BMS2h-719-10 — (SEQID NO: 342)
EVOLLESGGG MVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPF TE---—-- FDYWGQGTLV TVSS BMS2h-719-11 — (SEQID NO: 343)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYEMMWVRKA PGKGLEWVSS ISSDGSFTYY
ADSVKGRFTI SRDNSENTLY LQMNSLRAED TAVYYCADPF TE———- FDYWGQGTLV TVSS BMS2h-71912 — (SEQID NO: 344)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTV SRDNSKNTLY LOMNSLRAED TAVYYCADPF TE------ FDYWGQGTLV TVSS BMS2h-719-13 — (SEQID NO: 345)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYEMMWVROA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNTKNTLY LQMNSLRAED TAVYYCADPF TE-------- LDOYWGHGTLV TVSS BMS2h-719-14 — (SEQID NO: 346)
EVOLLESGGG LVRPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYFCADPF TE-------- FDOYWGQOGTLV TVSS BMS2h-719-15 (SEQID NO: 347)
EVOLLESGGG LVOPGGSLRL SCAASGFAFK RYEMTWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LHMNSLRAED TAVYYCADPF TE------- IDYWGQGTLV TVSS BMS2h-719-16 (SEQ ID NO: 348)
EVOLLESGGG LVAQPGGSLRL SCAASGFPFK RYEMTWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAEPF TE-------- FDOYRAQGTLV TVSS BMS2h-71217 — (SEQID NO: 349)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYEMSWVROA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-—-—- IDYWGQGTAV TVSS BMS2h-719-18 (SEQ ID NO: 350)
EVOLLESGGG LVHPGGSLRL SCAASGFTFK RYEMMWVROA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRDED TAVYYCAEPF TE——-—-- FDYGGQGTLV TVSS BMS2h-719-19 — (SEQID NO: 351)
EVOLLESGGG WVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-——- FDYWGQGTLV TVSS BMS2h-719-2 — (SEQID NO: 352)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPF TE------- FDYWGHGTLV TVSS BMS2h-719-20 — (SEQ ID NO: 353)
EVOLLESGGG LVQOPGGSLRL SCAASGFTFK RYEMTWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPF TE------ IDYRGOGTLV TVSS BMS2h-719-202 (SEQ ID NO: 354)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK KYEMMWVROQA PGKGLEWVSS ISSDGSFTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGHGTLV TVSS BMS2h-719-203 (SEQ ID NO: 355)
EVOLLESGGG LVQPGGSLRL SCAASGFTFN SYEMMWVROA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPF TE------ FDYWGHGTLV TVSS BMS2h-719-21 — (SEQID NO: 356)
EVOLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVROA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCADPF TE——-—- FDYWGQGTLV TVSS BMS2h-719-213 (SEQ ID NO: 357)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFK RYEMMWVROQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE———- MDYWGHGTLV TVSS BMS2h-719-214 (SEQ ID NO: 358)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCADPF TE——- FDYWGHGTLV TVSS BMS2h-719-215 (SEQ ID NO: 359)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYEMMWVROA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- LOYWGHGTLV TVSS BMS2h-719-218 (SEQID NO: 360)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYEMMWVROA PGKGLEWVSS ISSDGSFTYY AESVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPF TE——- FDYWGHGTLV TVSS BMS2h-719-225" (SEQ ID NO: 361)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN TYEMOWVROQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPF TE-------- FDOYWGHGTLV TVSS BMS2h-719-226 (SEQ ID NO: 362)
EVOLLESGGG LVOPGGSLRL SCAASGFTFN KYEMMWARQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSRNTLY LOMNSLRAED TAVYYCAEPF TE———- FDYWGHGTLV TVSS BMS2h-719-3 — (SEQID NO: 363)
EVOLSESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCADPF TE——- FDYWGQGTLV TVSS BMS2h-7194 — (SEQID NO: 364)
EVOLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVROQT PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPF TE-------- FDOYWGQGTLV TVSS BMS2h-719-5" (SEQID NO: 365)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYEMMWVROA PGKGLEWVSS ISSDGSFTYY
ADSVKGRFTI SRDNSKNTLY LEMNSMRAED TAVYYCAEPF TE——— FDONWGQGTLV TVSS BMS2h-7196 — (SEQID NO: 366)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPF TE------ FDYWGQGTOV TVSS BMS2h-719-7 — (SEQID NO: 367)
EVOLLESGGG LVOPGGSLRL SCAASGFNFK RYEMTWVROA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCADPF TE———- FDYWGQGTLV TVSS BMS2h-719:8 — (SEQID NO: 368)
EVOLLESGGD LVOPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPF TE-----—-- FDOYRGQOGTLV TVSS BMS2h-719-9 — (SEQID NO: 369)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYEMSWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPF TE------- FDOYWGRGTLV TVSS BMS2h-72 (SEQ ID NO: 370)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE AYPMSWVRQA PGKGLEWVSS ISPLGLWTYY
ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAKLS AGAETHVYRL FDYWGQGTLV TVSS BMS2h-720 — (SEQIDNO: 371)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFG NYEMMWVROA PGKGLEWVSS IGVLGHTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLM SLRTFENL—FDYWGOQGTLV TVSS BMS2h-722 (SEQ ID NO: 372)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT KYPMAWVRQA PGKGLEWVSG IDANGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEGT WRRHFAI-- FDOYWGQGTLV TVSS BMS2h-723 — (SEQIDNO: 373)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD LYDMMWVRQA PGKGLEWVSS ISDLGTLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKNG FRVTSNDRR- FDYWGQGTLV TVSS BMS2h-724 — (SEQIDNO: 374)
EVOLLESGGG LVQPGGSLRL SCAASGFTFT GGDMWWVRQA PGKGLEWVSM IEGGGVTTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCAELD LRTGQ----- FDOYWGQGTLV TVSS BMS2h-725"— (SEQIDNO: 375)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPS DPTK--— FDYWGQGTLV TVSS BMS2h-725-1 — (SEQIDNO: 376)
EVOLLESGGG LVOPGGSLHL SCAASGFTFS AYTMGWVROQA PGKGLEWVSL IGDRGSWTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYFCADPS DPTK---—— FDYWGQGTLV TVSS BMS2h-725-10 (SEQID NO: 377)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCADPS DPTK——- FDYWGQGTLV TVSS BMS2h-725-11 — (SEQID NO: 378)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LQOMSSLRAED TAVYYCADPS DPTK----—- FDYWGQGTLV TVSS BMS2h-725-12 — (SEQID NO: 379)
EVOLLESGGG LVOPGGSLRL SCAASGFTFP AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDDSKNTLY LOMNSLRVED TAVYYCAEPS DPTM-—-- FVYYWGQGTLV TVSS BMS2h-725-13 — (SEQID NO: 380)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPS DPTM---- FVYYWGQGTLV TVSS BMS2h-725-14 (SEQ ID NO: 381)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LQOMNSLRAED TAVYYCADPS DPTM------ FDOYWGQGTLV TVSS BMS2h-725-15 (SEQID NO: 382)
EVOLLESGGG MVOPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LQMNSMRAED TAVYYCADPS DPTK---— FDYWGQGTLV TVSS BMS2h-725-16 (SEQ ID NO: 383)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVTL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPS DPTM---- FDYWGQGTLV TVSS BMS2h-725-17 (SEQID NO: 384)
EVOLLESGGG LVQPGGSLRL SCAASGFTFT AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK----- LOYWGQGTLV TVSS BMS2h-725-18 — (SEQID NO: 385)
EVOLSESGGG LVQPGGSLRL TCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCADPS DPTK——- FVYWGQGTLV TVSS BMS2h-725-19 — (SEQID NO: 386)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCADPS DPTK—- FVYWGQGTLV TVSS BMS2h-725-2 — (SEQ1ID NO: 387)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AYTMGWVROQA PGKGLEWVSL IGDRGSWTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK---— FVYWGQGTPV TVSS BMS2h-725-3 — (SEQIDNO: 388)
VOLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDONSRNMLY LQMKSLRAED TAVYYCADPS DPTK-—- FVYWGQGTQV TVSS BMS2h-725-4 — (SEQID NO: 389)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI FRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTK----— FVYYWGQGTLV TVSS BMS2h-725-5 — (SEQID NO: 390)
EVOLLESGGG LLOPGGSLRL SCAASGFTFS DYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPS DPTK----- FOYWGRGTLV TVSS BMS2h-725-86 — (SEQIDNO: 391)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPS DPTK----— FVYYWGQGTLV TVSS BMS2h-725-7 (SEQ ID NO: 392)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGTWTYY ADPVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCADPS DPTK——- FDYWGQGTLV TVSS BMS2h-725-8 — (SEQIDNO: 393)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTV SRDNSKNTLY LOMNSLRAED TAVYYCAEPS DPTK----- FDYWGQGTLV TVSS BMS2h-725-9 (SEQ ID NO: 394)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGMGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPS DPTK----— FDYWGQGTLV TVSS BMS2h-726 — (SEQIDNO: 395)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD NYKMYWVRQA PGKGLEWVSS ISEIGNLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAIAL TR-——-—- FDYWGQGTLV TVSS BMS2h-727 — (SEQIDNO: 396)
EVOLLESGGG LVQPGGSLRL SCAASGFTFA SYRMYWVRQA PGKGLEWVSY IDPPGSRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSL NLSFPYIN—FDYWGQGTLV TVSS BMS2h-728 — (SEQIDNO: 397)
EVOLLESGGG LVAOPGGSLRL SCAASGFTFE RYEMLWVRQA PGKGLEWVSR ISHSGRTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAQLD GP-—-- FDYWGQGTLV TVSS BMS2h-729 — (SEQIDNO: 398)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK RYYMDWVROA PGKGLEWVSR INHNGSVTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKMP QGTSDWYY—FDYWGQGTLV TVSS BMS2h-73 (SEQ ID NO: 399)
EVOLLESGGG LVQPGGSLRL SCAASGFTFS KYDMSWVROA PGKGLEWVST ILEDGLTTIYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG RL———- FDYWGOGTLV TVSS BMS2h-74 (SEQ ID NO: 400)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS DYPMTWVROA PGKGLEWVST ILSPGTETYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKAE KD——-—- FDYWGQGTLV TVSS BMS2h-741 — (SEQIDNO:401)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE GGEMGWVRQA PGKGLEWVSM IPMDGSATYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKAG EV-----— FDYWGOGTLV TVSS BMS2h-742 — (SEQIDNO: 402)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR EYHMKWARQA PGKGLEWVSG ISRDGMNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAIQL AL———- FDYWGOQGTLV TVSS BMS2h-743 — (SEQIDNO: 403)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR DYEMLWARQA PGKGLEWVSG ILPSGGATYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKAG SGNGPIL--- FDOYWGOGTLV TVSS BMS2h-744 — (SEQIDNO: 404)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK EHDMFWVRQA PGKGLEWVSG IGAEGVWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPT MSNGSQSR—FDYWGQGTLV TVSS BMS2h-745 — (SEQIDNO: 405)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWVROA PGKGLEWVSG IIEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGQGTLV TVSS BMS2h-745-1 — (SEQID NO: 406)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGOQOGTLV TVSS BMS2h-745-10 (SEQID NO: 407)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWVROA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNNLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGOQGTLV TVSS BMS2h-745-11 — (SEQID NO: 408)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNFKNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGOGTLV TVSS BMS2h-745-12º (SEQID NO: 409)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWVROA PGKGLEWVSG ITEDGNRTYY
ADSVKGRFTI SRDONSMNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FVYYWGQOGTLV TVSS BMS2h-745-13 — (SEQID NO: 410)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWIROA PGKGLEWVSG IEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGOGTLV TVSS BMS2h-745-14 — (SEQID NO: 411)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWIROA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS BMS2h-745-15— (SEQID NO: 412)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSKNALY LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGLGTLV TVSS BMS2h-745-16 — (SEQID NO: 413)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVROA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNTKNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FVYYWGQGTLV TVSS BMS2h-745-17 — (SEQID NO: 414)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWIROA PGKGLEWVSG IEDGNRTYY ADSVKGRFTI SRDNSKNRLY LQMNSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGQGTLV TVSS BMS2h-745-18 — (SEQID NO: 415)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVROA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYHCAKIR NLHWDVGROQ- FDYWGOQOGTLV TVSS BMS2h-745-19 — (SEQID NO: 416)
EVOLLESGGG LVQPEGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG IIEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGQGTLV TVSS BMS2h-745-2º — (SEQ1D NO: 417)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ISEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED SAVYYCAKIR NLHWDVGRO- FVYYWGOQOGTLV TVSS BMS2h-745-3 — (SEQIDNO: 418)
EVOLLESGGG LVEPGGSLRL SCAASGFTFD NTEMAWVROA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMSSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGOGTLV TVSS BMS2h-745-4 — (SEQIDNO: 419)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ISEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYHCAKIR NLHWDVGROQ- FDYWGOGTLV TVSS BMS2h-745-5"— (SEQIDNO: 420)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWVROA PGKGLEWVSG ITEDGNRTYY
ADSVKGRFII SRDONSKNTLN LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGQGTLV TVSS BMS2h-745-6 — (SEQIDNO: 421)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWIRQA PGRGLEWVSG VTEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGOGTLV TVSS BMS2h-745-7/— (SEQID NO: 422)
EVOLLESGGG LVOPGGSLRL SCEASGFTFD NTEMAWIROA PGKGLEWVSG IIEDGNRTYY ADSVKGRFTI SRDNTKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGOQGTLV TVSS BMS2h-745-8 — (SEQID NO: 423)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSG ITEDGDRTYY ADSVKGRFTI SRDNSKSSLY LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGQGTLV TVSS BMS2h-745-9 — (SEQID NO: 424)
EVOLLESGGG SVOPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FVYYWGOGTLV TVSS BMS2h-746 — (SEQIDNO: 425)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG SAEMGWVROA PGKGLEWVSG ISRPGQVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGROQ- FDYWGQGTLV TVSS BMS2h-747 — (SEQIDNO: 426)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD DGTMGWAROA PGKGLEWVSL ILPSGSRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKHS LTNRP---- FDYWGQGTLV TVSS BMS2h-748 — (SEQIDNO: 427)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS KYDMRWAROQA PGKGLEWVSD IDAVGTRTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAIPG GT------- FDOYWGQGTLV TVSS BMS2h-749 — (SEQIDNO: 428)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE MYGMMWARQA PGKGLEWVSS IEGAGHATYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAIVL GM------- FDOYWGQGTLV TVSS BMS2h-75 (SEQ ID NO: 429)
EVOLLESGGG LVOPGGSLRL SCAASGFTFL QYPMGWVROA PGKGLEWVST ISPVGLTTIYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLF EGSRIQRDVG FDYWGQGTLV TVSS BMS2h-750 — (SEQID NO: 430)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE KYQMGWARQA PGKGLEWVSS IRGSGLVTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVH TTLHTEVIG- FDYWGOGTLV TVSS BMS2h-751 — (SEQIDNO: 431)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS QYTMYWARQA PGKGLEWVSE ISHSGSNTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAISG LH----—- FDYWGQGTLV TVSS BMS2h-752 — (SEQIDNO: 432)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFS DYAMAWVRQA PGKGLEWVSR IGVEGGDTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLL RLYRLG-- FDYWGOQGTLV TVSS BMS2h-753 — (SEQIDNO: 433)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA KYDMTWVRQA PGKGLEWVSK INSDGGLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGL HGRGFVI--- FDOYWGQGTLV TVSS BMS2h-754— (SEQIDNO: 434)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS RYDMVWVRQA PGKGLEWVSR INSMGLATYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKDY SVAPHGYPLG FDYWGOGTLV TVSS BMS2h-755 — (SEQID NO: 435)
EVOLLESGGG LVQPGGSLRL SCAASGFTFK DYSMMWVRQA PGKGLEWVST ITDNGTSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKHM SLATYLQF—FDYWGOGTLV TVSS BMS2h-758/ — (SEQID NO: 436)
EVOLLESGGG LVOPGGSLRL SCAASGFTFM EYDMLWVRQA PGKALEWVSR ISSDGLWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGV SALAPFDIG- FDYWGOQGTLV TVSS BMS2h-757" — (SEQID NO: 437)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK EYNMAWVROA PGKGLEWVSS INFAGRTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLS LPLDIFS-- FDYWGOQOGTLV TVSS BMS2h-758 — (SEQIDNO: 438)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS GY-——— FDYWGQGTLV TVSS BMS2h-758-1 — (SEQID NO: 439)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY ADSVKGRFTI SRDNSKNMLY LRMNSLRAED TAVYYCAETS GY----—- YEYWGQGTLV TVSS BMS2h-758-2º — (SEQID NO: 440)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG DYGMNWVROA PGKGLEWVSH ISSNGRFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS GY-—-— FEYWGOQGTLV TVSS BMS2h-758-3 — (SEQIDNO: 441)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAETS SY—-—- FEYWGQGTLV TVSS BMS2h-758-4 — (SEQIDNO: 442)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY
ADSVKGRFTI SRDNSKNTLF LOMNSLRAED TAVYYCAETS GY---—- YEYWGHGTLV TVSS BMS2h-758-5 — (SEQIDNO: 443)
EVOLLESGGG LVOPGGSLRL SCAASGFAFG DYGMNWVROA PGKGLEWVSH ISSNGRFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAETS GY-—-— FEYWGQOGTLV TVSS BMS2h-758-6 — (SEQIDNO: 444)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFIYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS GY-——- FEYWGQGTLV TVSS BMS2h-759 — (SEQIDNO: 445)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR EYVMGWVROA PGKGLEWVST INGLGNVTIYY ADSVKGRFTI SRDNTKNTLY LOMNSLRAEE TAVYYCAIQL PN----—- FDYWGOQGTLV TVSS BMS2h-760 — (SEQID NO: 446)
EVOLLESGGG LVQPGGSLRL SCAASGFTFG NDGMWWVRQA PGKGLEWVSF INVDGRETYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWS PGRVQ--— FDYWGOGTLV TVSS BMS2h-761 — (SEQIDNO: 447)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG GWDMAWVRQA PGKGLEWVSS IAHEGGETYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKYV PGSPL--— FDYWGORTLV TVSS BMS2h-762 — (SEQIDNO: 448)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFD QGWMYWVRQA PGKGLEWVSG IGSNGPRTSY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSG EY------ FDYWGOGTLV TVSS BMS2h-763 — (SEQIDNO: 449)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR QSDMWWVROA PGKGLEWVSV IGNNGEFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKDN WLL-—-- FDYWGQGTLV TVSS BMS2h-764 — (SEQIDNO: 450)
EVOLLESGGG LVQOPGGSLRL SCAASGFTFD LSTMYWVRQA PGKGLEWVST IGGDGSHTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEGT QY----- FDYWGOGTLV TVSS BMS2h-765 — (SEQIDNO: 451)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS AYTMEWVROA PGKGLEWVSS IGVTGYDTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGG QG----- FDYWGQGTLV TVSS BMS2h-766 — (SEQID NO: 452)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG DYGMSWVRQA PGKGLEWVSY IDPLGRLTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEDL SSLQYGVSPN FDYWGOQOGTLV TVSS BMS2h-767/— (SEQIDNO: 453)
EVOLLESGGG LVOPGGSLRL SCAASGFTFF HYSMSWVROA PGKGLEWVSS IGPVGRETYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKMI QSPLFKD-- FDYWGQGTLV TVSS BMS2h-768 — (SEQIDNO: 454)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE WYDMYWVRQA PGKGLEWVSR IDSGGNQTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEAS LWKWRL--- FDYWGQGTLV TVSS BMS2h-77 (SEQ ID NO: 455)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE EYGMAWVROA PGKGLEWVST ISPLGISTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHA TSQESLRS—FDYWGOQGTLV TVSS BMS2h-770 — (SEQIDNO: 456)
EVOLLESGGG LVOPGGSLRL SCAASGFTFS KYEMMWVROA PGKGLEWVSA ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGP LPDAFWTRG- FDYWGQGTLV TVSS BMS2h-771 — (SEQIDNO: 457)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG TYSMAWVROQA PGKGLEWVST IDRHGLATYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTP GSSWOTV-- FGYWGQGTLV TVSS BMS2h-772 — (SEQIDNO: 458)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE SYPMGWVROA PGKGLEWVSS IDHHGHSTYY ADSAKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLL RVSMIFG--- FDYWGOGTLV TVSS BMS2h-773 — (SEQIDNO: 459)
EVOLLESGGG LVOPGGSLRL SCAASGFTFV QYGMSWVRQA PGKGLEWVSW ISSSGTYTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAETS RM-——-- FDYWGQGTLV TVSS BMS2h-774 — (SEQIDNO: 460)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR EYDMGWVRQA PGKGLEWVSL ISPPGRTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKVV ILGYTNR--- FDOYWGQGTLV TVSS BMS2h-775 — (SEQIDNO: 461)
EVOLLESGGG LVOPGGSLRL SCAASGFTFP NYGMLWVRQA PGKGLEWVSS INSSGMETYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKFF RLNDHNSVFG FDYWGOQGTLV TVSS BMS2h-776 — (SEQIDNO: 462)
EVOLLESGGG LVOPGGSLRL SCAASGFTFK DYKMMWIRQA PGKGLEWVSS IVGSGSMTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGP GY---—- FDYWGQGTLV TVSS BMS2h-777/— (SEQIDNO: 463)
EVOLLESGGG LVOPGGSLRL SCAASGFTFH NYAMGWVRRA PGKGLEWVSS IDEHGTITYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKDS LDRVWI---- FDOYWGQGTLV TVSS BMS2h-778 — (SEQIDNO: 464)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA DYPMTWVROA PGKGLEWVSS IYSAGSPTYY
ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLY HREPILFG—FDYWGQGTLV TVSS BMS2h-78 (SEQ ID NO: 465)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFE RYQMAWVROA PGKGLEWVST ISSDGGGTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPG HR-------- FDOYWGQGTLV TVSS BMS2h-780 — (SEQID NO: 466)
EVOLLESGGG LVOQPGGSLRL SCAASGFTFG SYTMMWVRQA PGKGLEWVSE IDRTGERTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAEPG FASLP—--- FDYWGQGTLV TVSS BMS2h-781 — (SEQIDNO: 467)
EVOLLESGGG LVOPGGSLRL SCAASGFTFT DYTMYWVRQA PGKGLEWVSK ISPSGRSTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKDP FG-------- FOYWGQGTLV TVSS BMS2h-782 — (SEQID NO: 468)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD DAEMFWVRQA PGKGLEWVSS IDARGLTTYY ADPVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEAT SAMYP--- FDYWGQGTLV TVSS BMS2h-783 — (SEQIDNO: 469)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR DYDMGWVRQA PGKGLEWVST ISPLGHFTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKSG FHEYTEG-- FDYWGQGTLV TVSS BMS2h-784 — (SEQIDNO: 470)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD RAGMGWVROA PGKGLEWVSL IGRGGDITYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQOGTLV TVSS BMS2h-80 (SEQ ID NO: 471)
EVOLLESGGG LVOPGGSLRL SCAASGFTFG RYQMAWVROQA PGKGLEWVSS ISSDGGGTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPS RR---—-- FDYWGQGTLV TVSS BMS2h-81 (SEQ ID NO: 472)
EVOLLESGGG LVOPGGFLRL SCAASGFTFE LYPMAWVRQA PGKGLEWVSS ISPVGFLTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKGH EGSYTPRSA- FDYWGQGTLV TVSS BMS2h-82 (SEQ ID NO: 473)
EVOLLESGGG LVOPGGSLRL SCAASGFTFV AYPMAWVROA PGKGLEWVST IAPLGGNTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKRP EGLQIDSQN- FDYWGQGTLV TVSS BMS2h-83 (SEQ ID NO: 474)
EVOLLESGGG LVOPGGSLRL SCAASGFTFA LYQMAWVRQA PGKGLEWVSS IDSSGSDTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKPE RD---—-- FDYWGOGTLV TVSS BMS2h-84 (SEQ ID NO: 475)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR QYQMAWARQA PGKGLEWVST IASDGVSTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG RD---—-- FDYWGQGTLV TVSS BMS2h-85 (SEQ ID NO: 476)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE QYDMRWVRQA PGKGLEWVSW IDEAGHETYY ADSVKGRFTI SRONSRNTLY LOMNSLRAED TAVYYCAKGM DG-—--- FDYWGQGTLV TVSS BMS2h-92 (SEQ ID NO: 477)
EVOLLESGGG LVOPGGSLRL SCAASGFTFV DYPMGWVRQA PGKGLEWVST ISTGGFSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAR YYYLSQIKN- FDYWGQGTLV TVSS BMS2h-93 (SEQ ID NO: 478)
EVOLLESGGG LVQPGGSLRL SCAASGFTFD IYGMTWVROA PGKGLEWVSS ISPLGLVTIYY ADPVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKLK EHGDVP---- FDYWGQGTLV TVSS BMS2h-94 (SEQ ID NO: 479)
EVOLLESGGG LVAQPGGSLRL SCAASGFTFE LYPMSWVRQA PGKGLEWVST ISPTGLLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFK RSGKTDDTN- FDYWGQGTLV TVSS BMS2h-95 (SEQ ID NO: 480)
EVOLLESGGG LVOPGGSLRL SCAASGFTFR EYDMLWVROA PGKGLEWVST IVGDGNGTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKQD RQ---—-- FDYWGQGTLV TVSS BMS2h-97 (SEQ ID NO: 481)
EVOLLESGGG LVQPGGSLRL SCAASGFTFE EYGMSWVRQA PGKGLEWVST ISPIGVTTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKNA YDRKSN--- FDYWGQGTLV TVSS BMS2h-98 (SEQ ID NO: 482)
EVOLLESGGG LVOPGGSLRL SCAASGFTFD RYVMVWVRQA PGKDLEWVSG ITPSGRRTYY
ADSVKGRFTI SRDNSKDTLY LOMNSLRAED TAVYYCAKVL GRHFDPLLPS FDYWGQGTLV TVSS BMS2h-99 (SEQ ID NO: 483)
EVOLLESGGG LVOPGGSLRL SCAASGFTFE DYAMSWVRQA PGKGLEWVST ITPGGFWTYY ADSVKGRFTI SRDNSKNTLY LOMNSLRAED TAVYYCAKTS SGELQLVED-FDYWGQGTLV TVSS
TABELA 2 Sequências de Nucleotídeos Que Codificam o Domínio VH do Anti- CD40L Humano BMS2h-10 (SEQ ID NO: 484)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTAGTACAGCCTGGEGEGTCCOTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTATTGCTTATGATATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATGGATTGATGAGTGGGGTCTGCAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAAGACG
CCTGAGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-11 (SEQID NO: 485)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGAGATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTGATGGTGAGGGTTCTGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCGGGEG
AGGAGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-111 (SEQ ID NO: 486)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGCGTTATCCTATGACGTGGETCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTCATGGTTCTGGTAGTGCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCETECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCCG TATACTAGTCGGCATAATAGTCTTGGGCATTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-112 (SEQ ID NO: 487)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTATGGATTATCCTATGGGGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGCCTGTTGGTATGAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATATGGG GGGACTAGTGGTAGGCATAATACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-113 (SEQ ID NO: 488)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTACTGAGTATCCTATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGTTATTTCTCCTCTTGGTTTTACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGACT GGTGGGAGTGGTATTTTGAATTCTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-114 (SEQ ID NO: 489)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGEGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTTAGGGTTAGCAATTACGATTTGACCTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTATCAACCATTAGTGCCACAAACGGTAGCACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTATTGCGCGGCAGTGACG TGGTGGTTGTTGCGTCATAACGACAACTTGGGGTTTTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-115 (SEQ ID NO: 490)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTTAGCATTAGCTATAAGAATATGGCCTEGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTATCAGCCATTAAGGCGGCAAACGGTAGCACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTATTGCGCGACAGGGAGT CAGAAGAAGCGGACCTACACGTTCGACTTTTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-12 (SEQ1ID NO: 491)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGGTTGTATGAGATGGCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTGATATTTTGGGTTCGAGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGATCTG
TCGTGGCAGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-120 (SEQ ID NO: 492)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGGTCTTATACGATGGGTTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAATCCTATGGGTTATCAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTEGCCGAGGATACCGCGGTATATTACTGTGCGAAACATGGG GTGGGGAAGGGTACTAAGCCGCATAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-121 (SEQ ID NO: 493)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGCTGTATAGGATGTCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTAGTGGTAGTGGTTTTCCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAMAGTCTG CATGATAAGACTCAGCATCATCAGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-123 (SEQ ID NO: 494)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGEGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTATTGAGTATCCTATGCGGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACTTATTTCTCCGTCTGGTGTGTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGAT
GAGTCTAGTACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-124 (SEQ ID NO: 495)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGCGGTATGATATGGATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGGGAGTTCGGGTTATCCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGGAAAGGATG CCTGGTTATTTTCCTGGGTTTGCTCGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-125 (SEQ ID NO: 496)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTGGCGGTATGCTATGGGGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTAATGATGAGGGTCGGGAGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAAGCGG GTGTCTAGTTCTGTGAATGCTCCGTATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-126 (SEQ ID NO: 497)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGAATTATAGTATGAGTTGGGTCCGCCAGECC CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGATCGTCTTGGTACGCATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAATACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGTGCTG GCTGATCTTATTGCTGGGCATGCGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-127 (SEQ ID NO: 498)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCGTCGTATGATATGGCGTGGETCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTTCGAGGTCTGGTTCTATGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT TTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGTT GATGCGCATGTTTATTATATGGAGCCTTTTTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-128 (SEQ ID NO: 499)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGAGGTATCAGATGGCGTGGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTAGTTCTGATGGTGGGGGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT
ACTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-129 (SEQ ID NO: 500)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACATTTCCGAAGTATGAGATGGCGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGATGGTGATGGTAAGTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCcCGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCGGAT
CAGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-13 (SEQID NO: 501)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCTTATTATTCGATGTATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTTCGCCTTTTGGTTGGGGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGGACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGGG GAGACGAGTGGTCCGATTTCTGAGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-130 (SEQ ID NO: 502)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTACAGCCTCCGGATTCACCTTTGCGGGTTATCAGATGTCGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTAATGAGGGTGTTTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGG
AAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-131 (SEQ ID NO: 503)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGTATGAGATGGTGTGGETCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTACGTCGGATGGTCTGAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT ATTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-132 (SEQ ID NO: 504)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATGATATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGTTGATGATGGTCTTATGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGAT
GTTGCTTTTGACTACTGGGGTCAGGGGACCCTGGTCACCGTCTCGAAC BMS2h-133 (SEQ ID NO: 505)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTATTGGTTATGCTATGGCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGGTCCTTTGGGTGCGACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGCCT GCTGGTACGAGTAGTCATAGTGTGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-134 (SEQ ID NO: 506)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGGATTATGAGATGACTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACTAGTGATGGTGTTTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGTCG
GTTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-135 (SEQ ID NO: 507)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCGTAGGTATGTTATGGGGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTGAGGCTGATGGTCGTACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCeGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCTT ACGGATCAGCATGTTATTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-136 (SEQ ID NO: 508)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGGTTATCGTATGGGGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGCTCCGGATGGTAATTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTTGG
GGGATGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-137 (SEQ ID NO: 509)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTTCGTATCCGATGGGTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGGTCCTATTGGTTTTACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAATGAAG
TCGCCTTATAAGCCGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-138 (SEQ ID NO: 510)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTTGGCTTATTGGATGGTTTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCTCCGTCGGGTACGCATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGTCGAGGACACCGCGGTATATTACTGTGCGAAATATACT
GAGCCGGGGTTGGGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-139 (SEQ ID NO: 511)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGAATTATGAGATGGGGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGTGATTTCTGAGGTGGGTTCTCTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTCAT
GATAGTTCGATTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-14 (SEQID NO: 512)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGEGCTTGGTACAGCCTGGGGEGTCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTGGTCTTATGATATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTATGGCTTCGGGTGATGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGGAT
CGGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-15 (SEQ ID NO: 513)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGTTATGTCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTTCTCCTATTGGTCTGACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATTTCCT
TTGATTATTCTTCCTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-16 (SEQ ID NO: 514)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGEGGGGTCCCTEGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTATGGAGTATGCGATGATTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAATTATTTCTCCGCTTGGTTTGTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATCAG GATTCGTCTGATAGTCAGTATACGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-17 (SEQ ID NO: 515)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTCTCCET GTGCAGCCTCCGGATTCACCTTTGAGGATTATGGGATGGGGTEGECCCGCCAGGCTCCAGGGAA GGGTCTAGAGTGGGTCTCAAGTATTGGTCCTCTGGGTCTTTGGACATACTACGCAGACTCCGCGA AGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTG CETGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTCCGCTTGAGGGTTTGATTACGAATTTT
GACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-176 (SEQ ID NO: 516)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGCGTATGAGATGGGGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAATTATTGATTGGGATGGTAATTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCoGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGG
GATAATGTTGGTATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-177 (SEQ ID NO: 517)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATTATATGGTGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCGATTGATGAGTGGGGTTTTGCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATTGG GAGTTTACGTCTGATACGTCGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-178 (SEQ ID NO: 518)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGATTTTGATATGGCTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAATGATCAGGGTTCTCTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECoGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGAT
CAGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-179 (SEQ ID NO: 519)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGCTTATGATATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTAGTCCTCAGGGTCAGCGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT GGGCAGTCGCGGATTCCTATGAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGC
BMS2h-18 (SEQ1D NO: 520)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCTGAGTATGATATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATATATTAGTTCTGATGGTTATTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGCAT
GGGAGTCCGCGGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-180 (SEQ ID NO: 521)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGGATTATGAGATGGGGTEGETCCEGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACTAGTTTGGGTGAGAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT
CGTATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-181 (SEQ ID NO: 522)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTTTITATCCTATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTGATGCTACGGGTACGAGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGTAAT TATGGGAGTTCGTATACTATGGGGGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-182 (SEQ ID NO: 523)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGAGTATCCGATGTATTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGGTCCTTCTGGTCCGAATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTCCG TATTTTGATGTTATTCCTAGTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGETC
TCGAGC BMS2h-183 (SEQ ID NO: 524)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGGATTACGGTATGGGTTGGETCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTCAGTCGTCGGGTTTGCGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACGGGCT
AATTCTCGTAGGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-184 (SEQ ID NO: 525)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCTGATTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACTAGTCATGGTGGGTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGAT
AAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-185 (SEQ ID NO: 526)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGCATTATCCGATGTCGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGGTAGGCTGGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACGTGCT ACGCCTGTGCCGATTAAGGGTTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-186 (SEQ ID NO: 527)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGACTCACCTTTGGGAGGTATGAGATGGCGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATTCGGATGGTTGGGTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAACCGGAT
TCGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-187 (SEQ ID NO: 528)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCTAGTTATTCTATGGTGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTAATCEGGGGTGGTACTCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTGG
AGGAGGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-188 (SEQ ID NO: 529)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGCGTTATAGGATGTCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAGGGATTTCGAGGGATGGTTATCGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTATG
ACTGCGTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-189 (SEQ ID NO: 530)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCAGATGTATCCGATGGGGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTGAGCCGGCTGGTGATCTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATCAG
GAGCAGCCTTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-19 (SEQID NO: 531)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCCCCTTTCCGCAGTATCAGATGGCGTGGETCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTACTTCTGATGGTCTTGATACATATTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGAG
CCTCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-190 (SEQ ID NO: 532)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTATGTATGATATGCATTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTTGTCTGATGGTACGGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGGG
GCTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-191 (SEQ ID NO: 533)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGTTGTATCCGATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGATGCGGGGGGTCATGAGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGATTGG
TGGGATTATCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-192 (SEQ ID NO: 534)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGCGGTATCCGATGAGTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAATCGTTCGGGTATGCGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGGCAT
CAGGCGCCETTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-193 (SEQ ID NO: 535)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGGGGTATGCTATGTCTTGGETCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAATGCGAATGGTATTCGGACATACTAC GCCGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACGGCCTGCEGTECCGAGGACACCGCGGTATATTACTGTGCGAAAGGEGEGGE GTTTGGAGGTGGGGGACTEGGCATAAGTTTGACTACTGGGGETCAGGGAACCCTGGTCACC GTCTCGAGC
BMS2h-194 (SEQ ID NO: 536)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGCAGTATGATATGCGGTGEGTCCECCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGCAGAATGGTACTAAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGAGG
ACTGGTAGGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-195 (SEQ ID NO: 537)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGACTTATGATATGGGGTEGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGGATTAATTGGCAGGGTGATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGEG TTTGGTCATTATGTTGATGGTCTTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-196 (SEQ ID NO: 538)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGGGTATGAGATGGCGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACTGATATGGGTGATTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGG
ACTGCGTTTGACTACTGGGGTCCGGGAACCCTGGTCACCGTCTCGAGC BMS2h-197 (SEQ ID NO: 539)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGAAGTATAAGATGTGGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTCCGAAGGGTCATTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAMAGGCCG
ATGACTCCGTTTGACTACTGGGETCAGGGAACCCTGETCACCGTCTCGAGC BMS2h-198 (SEQ ID NO: 540)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGCGGTATAATATGTCTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTCGGCCGCEGGETEGGAAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGCGG CGGGAGGGGTATACTGGTTCTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-199 (SEQ ID NO: 541)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGAGGTATGGTATGACTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTTGGCCGAGGGGTCAGAAGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGAAT
AGTCGGTATGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-2 (SEQ ID NO: 542)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCTGATTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTTCGGATGGTATTTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTTCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAGTGGG
AGGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-20 (SEQ ID NO: 543)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGGTTATCAGATGGCTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTAGTTCGGAGGGTCTTACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGGGGE
CGTAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-200 (SEQ ID NO: 544)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGGEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTACTAATTATAGTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTCGTCCTAATGGTACTAAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACGGTCG
TCTGCGCATCTTCAGAGGTTTGACTACTGGGGTCAGGGAACCCTGETCACCGTCTCGAGC BMS2h-201 (SEQ ID NO: 545)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTAATTATTCGATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGGTCGTCATGGTGGGCGTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAAGGGG
AGTACTTATCCTAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-202 (SEQ ID NO: 546)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTACAGCCTCCGGATTCACCTTTTCGCATTATGAGATGGGGTEGETCCEGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGAGCCTTTTGGTGGTEGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGTGTAT
CCTCAGGGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-203 (SEQ ID NO: 547)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGEGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATACTATGGGGTGGGTCCGTCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTCGGCCTGATGGTAAGATTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGGAAGTTTAT TCTTCGTGTGCGATGTGTACTCCGCTTITTGTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-204 (SEQ ID NO: 548)
GAGGTGCAGCTGTTGGAGTCTGGGGGEGECTTEGGTACAGCCTGGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGCGGTATTCGATGGCGTEGETCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGATATTGGGCCGAGGGGTTTTTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGGGT CETGETCAGCGTGATACTAGTCAGCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-205 (SEQ ID NO: 549)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTTCTTATCAGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTACTTCGGGTGGTCTTAGTACGTACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGGE
AGGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-206 (SEQ ID NO: 550)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGTGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTTCTTATGAGATGACTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTTCTTCTGATGGTCTGTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGEGG
GTGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-207 (SEQ ID NO: 551)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCTGGATTCACCTTTGATAAGTATTTGATGTCGTGGETCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAGGTATTGAGCCTCTGGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGAGGCT TCGGGGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-208 (SEQ ID NO: 552)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGGTTCACCTTTACTGAGTATGAGATGTCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATAATGTGGGTAGTAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGG
AAGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-209 (SEQ ID NO: 553)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATGAGATGTGGTGGETCEGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCGATTTCTAGGCAGGGTTTTGCTACATACTAC GCAGACTCCGTGAAAGGCCGGTTCACCATCOTOECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCTG
GAGCGGGATGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-21 (SEQ1D NO: 554)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGAATTATGAGATGGGGTEGECCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGTTATTTCTGAGTGGGGTTATTCTACATACTAC GCAGACTCCGCGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTGTG
GGTGGGACTCAGTATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-22 (SEQID NO: 555)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCATAATTATGAGATGTCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCTTCGGGTGGTTCTTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGEG
GTTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-23 (SEQID NO: 556)
GAGGTGCAGCTGTTGGAGTCCEGGEGAGECTTGETACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGCTGTATGAGATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACGGGTGATGGTATTTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGEGG
AGGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-24 (SEQID NO: 557)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATCAGATGGCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTAGTGAGGGTGGTTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACACTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT
AAGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-24-1 (SEQ ID NO: 558)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATCAGATGGCGTGGGTTCGCCAGECT CCAGGGAAGGGACTAGAGTGGGTCTCAAGTATTACTAGTGAGGGTGGTTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACAGTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT
AAGAATTTCGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-25 (SEQ ID NO: 559)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATGAGATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACGTCGCAGGGTACTAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTEGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT
CGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-26 (SEQ ID NO: 560)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCGTAGTTATGAGATGACTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTACGTCGGATGGTGGTACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTEGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT
AAGACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-27 (SEQ ID NO: 561)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTTGTATGAGATGACTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACTAGTGATGGTGTTTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTEGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGAT
TCTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-28 (SEQID NO: 562)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGCATTATGATATGGCTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAGTGATAATGGTAATGGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGG CGTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-29 (SEQID NO: 563)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTCGTTATCAGATGGCTTGGETCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATITCTTCTGATGGTGGGEGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGG
CGGGCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-30 (SEQID NO: 564)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGAGGTATCAGATGGCTTGGETCCGCCAGGECT CCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTTCTGATGATGGTGATTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAACTGGAT
AAGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-300 (SEQ ID NO: 565)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATGATGAGATGACGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTGATACGACGGGTGGGCAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT
AAGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-301 (SEQ ID NO: 566)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGAGTGAGATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTCTTGATGAGGGTTCTGGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT
AAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-302 (SEQ ID NO: 567)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGGAGGAGATGAGTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCGATTACTGATGATGGTGATGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTAAT
GCGGGTGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-303 (SEQ ID NO: 568)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGTGTATGATATGGCTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTGTTAATGATGGTTCTTCTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT
AAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-304 (SEQ ID NO: 569)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTAATACGGAGATGACTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGCGGATGATGGTTCTAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT
CAGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-31 (SEQ1D NO: 570)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATCAGATGGCGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGGATGATGGTTCTTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT
CTTTATTTTGACTACTGGGGTCAGGGAACCCTGETCACCGTCTCGAGC BMS2h-32 (SEQID NO: 571)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGTGTATCAGATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATTTATTGTGCCTGGEGGTGATTTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGGAAACGTGEG
CCGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-4 (SEQ ID NO: 572)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATGAGATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACGAGTGATGGTACTTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTAAT
CEGCCETTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-40 (SEQID NO: 573)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGGCGTATGATATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGGGAGGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAACCTCGT CGGTATGCTATTTTTACTTTTGATCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-400 (SEQ ID NO: 574)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGEGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGCAGTATCCGATGGTGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCTACTAATGGTGTGAGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGACG GATATTATTTCGTCTTCGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-401 (SEQ ID NO: 575)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTITAATTATGATATGTCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTTTT GTGTGGTCGGCTGATATTGATTTTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-402 (SEQ ID NO: 576)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGEGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGTGGTATGATATGAGTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCACATATTGCGAGTTGGGGTGGTAAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGACG GTGAAGGATGGGGGGTATCTGATGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-403 (SEQ ID NO: 577)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTGAGTATGCTATGGCGTGGETCCGCCAGGECT CCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTGGGCGGGATGGTGCGGTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGAAG GCEGGCEAAGGAGCGGGGTTCTTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-404 (SEQ ID NO: 578)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCAGGCTTATCAGATGCAGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTTGAGTGGGTCTCAACTATTAGTCCTAATGGTCTTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGTTG AGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-407 (SEQ ID NO: 579)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTATGTATTCGATGGCTTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTCGCCTCGTGGTGTTGAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACTAAT
TGGAATGGTGTGGATCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-408 (SEQ ID NO: 580)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCTACGTATATGATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAATACGAATGGTCGTGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGAT
AGTAATATGTCGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-409 (SEQ ID NO: 581)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTTATTCGATGACGTGGGTCEGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAATGCGTCGGGTACTCTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATGGT
AATAGGTCTGAGGTTTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-41 (SEQ ID NO: 582)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTITGAGTATGAGATGACGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGCGAATGATGGTTCGACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT
CGEGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-410 (SEQ ID NO: 583)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCAGGATTATTTGATGGCGTGEGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTAATCAGGATGGTACTGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAAGTTCT
CCGETATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-411 (SEQID NO: 584)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATGCGATGTCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAGTCGGGATGGTCATGTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTTCT TCTAAGGGGGGGACGTTTGCTAGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-412 (SEQ ID NO: 585)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGCTGTTCCGATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCGATTACGGATGATGGTCTTCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCAT
ATTTATGGGGATTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-413 (SEQ ID NO: 586)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGCTTTATAGGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTAGTAGTGATGGTGATACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACATTGG TTGGGTACTACGTTGTCTTTGAGGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-414 (SEQ ID NO: 587)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTATCGTTATACGATGGCGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCGCCTAGGGGTAATATTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCEGTEGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTGGT GTEGCEGEGECEGAGTCECCTGAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-415 (SEQ ID NO: 588)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGTTTGGTGCAGCCTEGEGEGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTTGGGTTATTATATGAGTTGGATCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGGGCCGATTGGTGGTGGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTCAG
AATATTTATGGTCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-416 (SEQ ID NO: 589)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGCAGTATGATATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTAGTCGTGATGGTGGGCGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGAGTAT
CCTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-417 (SEQ ID NO: 590)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCGCAGTATAGTATGGTGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTTGAGTGGGTCTCAACTATTTCGCCTCTGGGTTCTTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAMATGAGT AAGTTGTTGCTGTCGAGGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-418 (SEQ ID NO: 591)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTATGTATTCGATGGCTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTCGCCTCGTGGTGTTGAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCEGTEGCCGAGGACACCGCGGTATATTACTGTGCGAAAACTAAT
TGGAATGGTGTGGATCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-419 (SEQ ID NO: 592)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGCGTCATGGTATGGCGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACGCCTACTGGTAATACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCEGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATGCT
CATGATGAGGGGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-42 (SEQ ID NO: 593)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTCCGTATGAGATGACTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGTTGGTGATGGTCTGGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTEGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGAT
CGGGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-420 (SEQ ID NO: 594)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTAGTACGCCTATGATGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTAGGGATACGGGTCTGGCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAGTGTTTCG TTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-421 (SEQ ID NO: 595)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCATCTGGGGGATATGCATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTAGTGGGACGGGTCATACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTATG
AATGATCAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-422 (SEQ ID NO: 596)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTATGGATGAGGATATGTTGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGGATTAATTCGCTGGGTACTCATACATACTAC GCAGACTCCGTGAAGGGCCGATTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATCGTTT
ATGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-423 (SEQ ID NO: 597)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCGTAATTATCAGATGCATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGATGCGACTGGTCGGGCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAGATCTACT
AGGTCATTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-424 (SEQ ID NO: 598)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGAATGCGGATATGGTGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTAGTGGTAGTGGTGGTAGCACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTAT
TTGACTTCGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-425 (SEQ ID NO: 599)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGGGATTATTCTATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGTCGGGTCTTACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGTCT
CAGGCGGTTACTCGGTCTTTTGACTACTGGGGTCAGGGAACCCTGETCACCGTCTCGAGC BMS2h-426 (SEQ ID NO: 600)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGACTTGGTACAGCCTGGEGEGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCTGATGAGGGTATGATGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTAATCAGCAGGGTTCGGCGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGATT
GGGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-427 (SEQ ID NO: 601)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTACTGATCAGCCGATGGTGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGGEGCECGTEGTGGGCCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGTTT GATATTATTGCTTGGGATCCTTTTAGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-428 (SEQ ID NO: 602)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATCAGTATCCTATGATGTGGGTTCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTCCTTCTGGTTTTTTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGAAT
CCTTTTATTACTACGTTTGACTACTGGGGTCAGGGAACCCTGGTGACCGTCTCGAGC BMS2h-429 (SEQ ID NO: 603)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGATGGCGTEGGGTCCECCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGAATGGTTATTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTGAT
TATTCGCTTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-43 (SEQID NO: 604)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTTCTTATGAGATGGCGTEGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGGTAGTGATGGTGGGCCGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACTCCGCGGTATATTACTGTGCGAAACCTGAT
AGGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-430 (SEQ ID NO: 605)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCTGCGGAGCAGATGACTTGGGCCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGCATGGTGATTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGCGG ACTTTGGTTGATTGGCCTACGAGTGAGTCGTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-44 (SEQ ID NO: 606)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGTCTTATGAGATGGGGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGAGCCTACTGGTATTACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTCAT
TTTACTGAGCTTGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-449 (SEQ ID NO: 607)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGGGGAGCAGATGGCTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACGCTGCCTGGTCCGTATACATTCTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGAAT
GGGACGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-45 (SEQID NO: 608)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTAATTATGCGATGGCEGTEGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAAGATTGGGGCGCAGGGTCTTCATACATACTAC GCAGGCTCCETGAAGGGCCGGTTCACCATCETOCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGACG
ACGATGGATTATGAGAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-450 (SEQ ID NO: 609)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGAGGTTGATATGTCGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCAGCTATTGGTAATAATGGTCTTAAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGCT CTGTCGTATAGGCCTCCTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-451 (SEQ ID NO: 610)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCAGGATGATACTATGTCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACGCTTAAGGGTCCGTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGAGG GATGGGTTGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-452 (SEQ ID NO: 611)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTTCGTCTCCGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGGTCGGGATGGTAGTACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTTCG
CCTTATCEGGCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-453 (SEQ ID NO: 612)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGEGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTACTGATTATTCGATGGTTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTGTGAGTCATGGTGGTACTACATACTAC GCAGACTCCGTGAAGGGCCGATTCACCATOETECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTAAG
GGTTATAATGCGCAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-454 (SEQ ID NO: 613)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGATGGCGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGAATGGTTATTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTGAT
TATTCGCTTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-455 (SEQ ID NO: 614)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATGATTATGATATGATTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAGTTCGCATGGTGATAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGAT
GTTTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-456 (SEQ ID NO: 615)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGATGGCGTGGETCCEGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGAATGGTTATTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAATGGTCG
GATTCTTTTGACTACAGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-457 (SEQ ID NO: 616)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATGAGATGGCTTGGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTCAGTCTAATGGTAATATTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTAAT
TCTCAGGTTGAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-458 (SEQ ID NO: 617)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGGTGGAGCCTATGTCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAATATTGGTCGTGATGGTTCGATGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGGGGE
AAGCATGGTACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-459 (SEQIDNO: 618)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCGGAGTATCGGATGATGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTGGAGTGGGTCTCATGGATTGATGAGCGGGGTTCGCTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGGCGG
AAGGGTACTAAGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-46 (SEQ1D NO: 619)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGTTGTATGCTATGGCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGGTGCTGTGGGTGAGACTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGAGGCT AATAATCTTTCTGATAATCTTGTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-460 (SEQ ID NO: 620)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGATGGCETEGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGAATGGTTATTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGTCG
GTTGAGTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-461 (SEQ ID NO: 621)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATAGTTATACGATGAATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTAATCCTTGGGGTAGTCGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGTCTG GTGCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-462 O (SEQ ID NO: 622)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGGTGATATGATGTCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACTCAGCTTGGTAGTAGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGAAT
TGGCGGACTCTTACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-463 (SEQ ID NO: 623)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGCGCAGCCTCCGGATTCACCTTTAATGCTTATGGGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTCTTTCTGATGGTGTTATTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTGCT
CGGGGTGCGAATTTTITTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-464 (SEQ ID NO: 624)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGCATTATATGATGGTGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTACGCCTCATGGTACGAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATTTAAT
GCTATTTTTAGTGAGGCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-465 (SEQ ID NO: 625)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGGGATTATTCTATGGCTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGTCGGGTCTTACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCeGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGTCT
CAGGCGGTTACTCGGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-466 (SEQ ID NO: 626)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATCTTTATGCGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTGGGAGGGATGGTCGTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACGGCGGTATATTACTGTGCGAAATTGGCT
GGTTCGCTGAGGGETCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-467 (SEQ ID NO: 627)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATAAGGCTAGTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACGCCTCATGGTTCGTCTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGCGG
TGGGGTGTTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-468 (SEQ ID NO: 628)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCAGGGGTATAGTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGCTGGGCEGTGETEGTETTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTTG
TATATTTATCATAGTCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-469 (SEQ ID NO: 629)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGGTACAGCCTEGEGECTCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCTGGTATGGAGATGTCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTACTGGGACTGGTAGTACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTAT
CATCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-470 (SEQ ID NO: 630)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCGATGGTGGCTATGTCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTIGCTCGGGATGGTAATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACGCCGCGGTATATTACTGTGCGAAAGTTTCG
CCGACTGGTTTTGACTACTGGGETCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-471 (SEQ ID NO: 631)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGGATATGTCGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTACGGATGATGGTGAGAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGAT
TATGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-472 (SEQ ID NO: 632)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGTATAATATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTACGAGGGATGGTTCTAGGACATACTAC GCAGACTCCGTGAGGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACTCCGCGGTATATTACTGTGCGAAACTGTCG AATATTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-473 (SEQID NO: 633)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATTCTATGATTTGGGCCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACGCCGTATGGTTCTTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAACTGAT
TATTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-474 (SEQ ID NO: 634)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATACGTATAGTATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTTGAGTGGGTCTCAACTATTACTCCTTATGGTAGTTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGGGT
CTGGTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-475 (SEQ ID NO: 635)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGEGEGETCCCTGCGACTC TCCTGTGCAGCCTCCGGATTCACCTTTACTACGGGTCCTATGATGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCGATTGGTATTGGGGGTGATACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTCTATTACTGTGCGAAATTGACT
CCGTCTAATCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-476 (SEQ ID NO: 636)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGCAGTATCAGATGATGTGGGTTCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTCCTTCTGGTTTTTTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGAAT
CCTTTTATTAGTACGTTTGACTACTGGGGTCAGGGAACCCTGEGTCACCGTCTCGAGC BMS2h-477 (SEQ ID NO: 637)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCTAATTATGATATGGTTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTTCTGCTTTGGGTAATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAACGAACAGCCTGCGTGCCGAGGACACTGCGGTATATTACTGTGCGAAATGGCGT
AGTGCTATTACTGGTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-478 (SEQ ID NO: 638)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGTATCAGATGTCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCGCCGTCGGGTATGAATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGCEG TCGGTTGTTCGTCCTTGGCCGGETETETTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-479 (SEQ ID NO: 639)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGATGAGAGTATGGCGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACTCCTCATGGTACTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTCAT CTTAAGTTGTATGAGTCTCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-480 (SEQ ID NO: 640)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTGGTGAGATGGGTTGGETCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTCCGATGGATGGTAGTGCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGEG
AGTACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-481 (SEQ ID NO: 641)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATTTTATGCCGATGGCGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGAGGGATGGTGCTTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCEGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTGCT
TCGCCGGCECAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-482 (SEQ ID NO: 642)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTGATGAGCCTATGCTGTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGGGTACGGGTACGACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTAAT CAGGGTGATTTTATTAATCGGTTTCACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-483 (SEQ ID NO: 643)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCATGCGTATAATATGGCGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCTCCGCGGGGTTCTTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGCCG
CCGCCTTCGTCTCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-5 (SEQ ID NO: 644)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGGGTATGAGATGGCGTGGETCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACGAGTGATGGTACGAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGEG
CTGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-505 (SEQ ID NO: 645)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTTATATGATGTATTGGGTCCACCAGGCT CCEGGGEAAGGGTCTAGAGTGGGTCTCATCTATTTCTCCTCAGGGTCATTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACTTCGT
GAGCTTCCTCGTCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-506 (SEQ ID NO: 646)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTAGTTATGCTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGATGCGAGTGGTGGTCCTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGAAT GGGAAGAAGTTTCCTTTTACTAAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-507 (SEQ ID NO: 647)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCTAGTGTGCATATGGCGTEGETCEGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTAATCTGACGGGTGTTGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAMAGTGCT ACTACTAGGCAGGCGCATCCGTTGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-515 (SEQ ID NO: 648)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGGGTGAGATGTATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGACTAATGGTCTTACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTACT
CGTGATCTGGETTTTGCCTACTGGGETCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-516 (SEQ ID NO: 649)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGAGATGGCTTGGGCCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATTTATTTCTCOTCGTGGTCATTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGCT
AAGACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-517 (SEQ ID NO: 650)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATACGTATGAGATGCTTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACGTATTTCTGTTGATGGTAGTATTACATACTAC GCAGACTCCGTGAAGGGCCGGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAMACGCEG
ATGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-518 (SEQ ID NO: 651)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTTCGTATGCTATGTCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAATATTTCTCGTGATGGTTCGAAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGCGCAG TCTGGEGEGCTTCEGTCGGGTTTGACTACGTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-519 (SEQ ID NO: 652)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGACTCCGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGAGGGATGGTGCTTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGEG
CCGAAGGGTATTGCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-520 (SEQ ID NO: 653)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTCCGCATGCTATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAGGTATTGATGGGGGGGGTTCGATGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGAT
CCTCCEGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-521 (SEQ ID NO: 654)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGCGCAGCCTCCGGATTCACCTTTCATGCGGGGGAGATGCATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACGCTGCCTGGTGATATGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGAAT
ACTGGGTATACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-522 (SEQ ID NO: 655)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGAATTATGGTATGTCGTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCGTGGGATGGTTCTCTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAAAATACG
CGGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-523 (SEQ ID NO: 656)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCATGATGCGGATATGCTGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTTGTCTCCGGGTGAGGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTGGT
CTGCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-524 (SEQ ID NO: 657)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCGTACTGATCAGATGAATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCTCCTAGTGGTGCGTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGTCTT
GGTGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-525 (SEQ ID NO: 658)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCATCTTTGAGCAGTATCAGATGGTTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTTCGCCTGATGGTACGCATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTAGT
TTGCGTAAGATGGAGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-526 (SEQ ID NO: 659)
GAGGTGCAGCTGTTGGAATCTGGGGGAGGCTTGGTACAGCCTGGEGEGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCAGGATGAGCAGATGGCGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGCGTCTGATGGTATGTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAATAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAACCTEGG
AAGAATTTTGACCACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-527 (SEQ ID NO: 660)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGCGATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACTACTGGGGGTGAGCGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACGTTGG
AATCTGTATACGGAGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-528 (SEQ ID NO: 661)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTGGTCAGCCGATGGATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATIGCTCCTGATGGTATTCATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAAAATTTG
GGTCAGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-529 (SEQ ID NO: 662)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGCGGTATCAGATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCTCCTAGTGGTACGTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGAAG
GCGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-530 (SEQ ID NO: 663)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTITCCTCATTCGACTATGTATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACTTATTTTGCCGTCGGGTAGTCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTTCT
GATGAGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-531 (SEQ ID NO: 664)
GAGGTGCAGCTGTCGGAGTCTGGEGEAGGCTTGGTACAGCCTGGGEGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTGATGGGAATATGGATTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTCTAGTGATGGTGTGACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAGG
GGETCAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-532 (SEQ ID NO: 665)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCTTCCGGATTCACCTTTGATGATTATATGATGTGGTEGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAGTCCGCATGGTGTTTATACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGTTG
CATACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-533 (SEQ ID NO: 666)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGAATTATACGATGGCGTGEGECCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATTTATTGCTGGTCCGGGTAATTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGG AGTACTGCGACGTATAATAATGGTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-534 (SEQ ID NO: 667)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGGAGTATAGTATGGTGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTAGTGGGAGTGGTCGTGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAATGGCTT AAGCTGGTTAGGGCTCCTAATCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-535 (SEQ ID NO: 668)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATCAGATGGCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTCTAAGACTGGTCATTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTTCG
CATTCGTTGGGGCCTCTTTTTGACTACTGGGETCAGGGAACCCTGETCACCGTCTCGAGC BMS2h-54 (SEQID NO: 669)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGGCGTATAGGATGGCTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTTCGCCTTCTGGTTCGGGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACTTTG ACGGATTCGCCGTCGGGGCATTATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-55 (SEQ ID NO: 670)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGCGGTATGAGATGGGGTEGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTACTGCTCAGGGTCTTGGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAACTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATATCTT ACTGATTTTAGTAGTGGGCATCAGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-553 (SEQ ID NO: 671)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGATTATGGTATGTCGTGGGTCCGCCAGGTT
CCAGGGAAGGGTCTGGAGTGGGTCTCAGGTATTAGTCATAATGGTATGTTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATATTGG CCGTCTACTAGTTGGGAGACTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-554 (SEQ ID NO: 672)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTCGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGAATGAGCCTATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGAGATGCAGGGTAAGAATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAGG
GGTCAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-555 1 (SEQ ID NO: 673)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGGAGGAGATGAGTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCATGTATTGATAATCTGGGTAGTCCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACGCCGCGGTATATTACTGTGCGAAAACGATT
TCTCATCAGTATGATAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-556 (SEQ ID NO: 674)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGGAGGAGATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGATGAGGGGGGTCGGTEGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGACG
CCGCATAAGCAGTTGTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-557 (SEQ ID NO: 675)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCAGCTTTGCTGATGAGTATATGGTTTGGGCCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTGATCCGTTGGGTACTGGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGGG
ACGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-558 (SEQ ID NO: 676)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGEGTCCCTECECCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCTACGCATGATATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTTCTGATGATGGTATTAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATTTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGAT
ATGTCTCTTATTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-559 (SEQ ID NO: 677)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGEGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGGTACTCCGATGGTTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTAGTGGTGATGGTAGGAATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCTTAT GCGCTTACTTCGTCTAAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-56 (SEQ ID NO: 678)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATGATTATACTATGGGTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTCATGGGACTGGTGGTCAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCEGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTTTG GCTGATAGGAGTGGGGGGGTTEGTTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-560 (SEQ ID NO: 679)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGCGGAGACGATGGCTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATGTATTAGTAATGATGGTAATACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGAGTCT
CTGATTAGTCCTGGTCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-561 (SEQ ID NO: 680)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTACTGGTGAGTATATGAATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAATGAGACTGGTTATATGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAATAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTTCT
ACGAGGGGGGTGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-562 (SEQ ID NO: 681)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGGTCGTATGATATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGCCTATGGGTGTTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTAAT
CAGCATGCTCATGATCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-563 (SEQ ID NO: 682)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGATATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTTCGCCTATGGGTACGTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCEGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGCT
TTGACTGAGCCTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-564 (SEQ ID NO: 683)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCGTGATTATGATATGGGTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCTCTTGGTCATTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTCCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGCTGAG
GAGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-565 (SEQ ID NO: 684)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGETCCCTGCECCTC TCCTGTGCAGCCTCCGGATTCGCCTTTCCTAGGTATGGTATGACGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAAATATTGATCAGTTTGGTATGAAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGAGTAT
GCTTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-566 (SEQ ID NO: 685)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAAGTATGATATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGCCTATGGGTGTTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCGG
GGTAATACTTCGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-567 (SEQ ID NO: 686)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGEGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATGATATGGCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTGGGGCGGGTCATTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAMAGTTTT
CCGCGTGATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-568 (SEQ ID NO: 687)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCGAAGTATGAGATGAGGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTGGTCTGGATGGTTCGCCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGGGG
GATCCGAATGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-569 (SEQ ID NO: 688)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCGACTAGTGAGATGGATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAGGTATTGGGCCTGATGGTTTGACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATGCG
GATTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-57 (SEQ1D NO: 689)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCTGAGTATGATATGTATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTGATACTGATGGTGGGGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT
CTGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-570 (SEQ ID NO: 690)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCCTEGTACAGCCTGGEGEGTCCCTGCGTCTC TCCTGTACAGCCTCCGGATTCACCTTTGAGAATGCTTCTATGCAGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGAGGGGCAGGGTAATGCTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAMAGTTCG
TCTTGGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-571 (SEQ ID NO: 691)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGCGTAATGAGATGGGGTGGETCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACGCCGACTGGTACGTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGGAT
CCTGGTAATAGGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572 (SEQ ID NO: 692)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-1 (SEQ ID NO: 693)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGTTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTTTGACTACCGGGGTCAGGGGACCCTGGTCACCGTCTCGAGC BMS2h-572-10 (SEQ ID NO: 694)
GAGGTGCAGCTGTTGGAGTCTGGTGGAGGCTTGGTACAGCCTGGGGEGTCCCTECGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-11 (SEQ ID NO: 695)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCAGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGATTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCAGGTCACCGTCTCGAGC BMS2h-572-12 (SEQ ID NO: 696)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGECCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-13 (SEQ ID NO: 697)
GAGGTGCAGTTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTEGEGEGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGECCEGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGACCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCTAATGAACAGCCTGCEGTEGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTAGGG
AAGGAGAGTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-14 (SEQ ID NO: 698)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTITAATTGGCAGCTGATGGGTTEGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGCATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCAGTGAAGGGCCGGTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-15 (SEQ ID NO: 699)
GAGGTGCGGCTATTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCAACTTTAATTGGCAGCTGATGGGTTGGATCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCAGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-16 (SEQ ID NO: 700)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACGGCCTGGEGGGETCACTGCGTCTC TCCTGTGTAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGETCEGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-17 (SEQ ID NO: 701)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTGGTACAGACTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTATAATTGGCAGCTGATGGGTTEGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGATGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTTTGACTACCGGGGTCACGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-18 (SEQ ID NO: 702)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCAAGGCT CCTEGEAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-19 (SEQ ID NO: 703)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGETCCGCCAGECC CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-2 (SEQ ID NO: 704)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTGGTACAGCCTGGEGEEGTCCCTGCGCCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTTGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAAGTTTGACTACCTGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-21 (SEQ ID NO: 705)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGAATCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATCTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-22 (SEQ ID NO: 706)
GAGGTGCAGCTGTTTGAGTCTGGGGEAGECTCGETACAGCCTEGGEGGTCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTITAATTGGCAGCTGATGGGTTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGGACCCTEGTCACCGTCTCGAGC BMS2h-572-23 (SEQ ID NO: 707)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEEGGTCCCTECGTCTC ACCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCGGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCATCATCTCCCGCGACAATTCCAAGAACACGCTATAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-24 (SEQ ID NO: 708)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCGGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCACGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTGAATTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-3 (SEQ ID NO: 709)
GAGGTGCGGCTETTGGAGTCTGGEGGGAGGCTTGGTACAGCCTGGGEGGGTCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCACCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATCTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-4 (SEQ ID NO: 710)
GAGGTGCAGCTGTTGGTGTCTGEGEGEAGECCTEGTACAGCCTGGEGGEGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-5 (SEQ ID NO: 711)
GAGGTGCAGCTGTTGGTGTCTGGEGGGAGGCTTGGTACAGCCTGGGGGGTCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACATGCTGTAT CTGCAAATGAACGGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-6 (SEQ ID NO: 712)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGETCCGGCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-601 (SEQID NO: 713)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTCATGGGGTEGECCCEGCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACCCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-602 (SEQ ID NO: 714)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCACCTGATGGGGTEGGTCEGECAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAGTTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-603 (SEQ1D NO: 715)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAACTGGCACCTGATGGCCTGGGCCCGECAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-604 (SEQ ID NO: 716)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGATGGGCTGEGTCCGGCAGGCT CCAGGGAAGGGTCTCGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-605 (SEQ ID NO: 717)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGEGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGATGGCCTEGECCCGECAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATATTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-606 (SEQ1ID NO: 718)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAACTGGCACTTGATGGGCTGGGCCCGGCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-607 (SEQ1D NO: 719)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTCATGGGGTEGGCCCGGCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-608 (SEQ ID NO: 720)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGATGGGCTGGECCCGGCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-609 (SEQ ID NO: 721)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAACTGGCAGCTCATGGGCTEGGCCCGGCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCeGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-610 (SEQID NO: 722)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC
AAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-611 (SEQID NO: 723)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCEGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTCGGG
AAGGACAGCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-612 (SEQID NO: 724)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGETCCGGCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCoGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTCGGG
AAGGACAGCAACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-613 (SEQID NO: 725)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGCACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGETCCGGCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC
AAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-614 (SEQ ID NO: 726)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGETCCGGCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG
AAGGACGCCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-615 (SEQ ID NO: 727)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTEGGETCCGGCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGCCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG
AAGGACAAGAACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-616 (SEQID NO: 728)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGETCCGGCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG
AAGGAGAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-617 (SEQ ID NO: 729)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGETCCGECAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG
AGGGACAGCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-618 (SEQ ID NO: 730)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGEGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCGGACTCCEGTGAAGGGCCGGTTCACCATCETOCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTCGGG
AAGTACAGCAACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-619 (SEQID NO: 731)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC
AAGGACAGCAGGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-620 (SEQ ID NO: 732)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCeGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGG
AAGGACGACAGCTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-621 (SEQID NO: 733)
GAGGTGCAGCTGTTGGAGTTTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCTTGCGTTTT TCCTGTGCAGCTTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGTTCCGGCAGGCT CCAGGGAAGGGTTTAGAGTGGGTTTCAGGTATTGAGGGTCCAGGTGATGTTACATATTAC GCAGATTCCGTGAAGGGCCGGTTCACCATTTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCTTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG
AGGGACAGCAATTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-622 (SEQ ID NO: 734)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGG
AAGGACAGCACCTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-623 (SEQID NO: 735)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGETCCGGCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCoGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGG
AAGGAGAGCAGCTCGGACTACCGGGETCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-624 (SEQID NO: 736)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGETCCGECAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTTCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGC
AAGGACAGCGCGTCCGACTACCGGGETCAGGGAACCCTGEGTCACCGTATCGAGC BMS2h-572-625 (SEQ ID NO: 737)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTCGGC
AACGACAGCTACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-626 (SEQ ID NO: 738)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCTGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGECAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACGGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGG
AAGGACAGCAGCTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-627 (SEQID NO: 739)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGETCCGECAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGATATATTACTGTGTGAAAGTGGGC
AAGGACAGCGCGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-630 (SEQ ID NO: 740)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGATGGGCTGGETCCGGCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTEGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG
AAGGACGCCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-631 (SEQ1ID NO: 741)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGATGGGCTEGETCEGGCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC
AAGGACAGCAGGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-632 (SEQ ID NO: 742)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGATGGGCTEGETCCGGCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC
AAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-633 (SEQID NO: 743)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGATGGGCTGGECCCGGCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCeGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGG
AAGGACGCCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-634 (SEQ ID NO: 744)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGATGGGCTGGECCCGGCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC
AAGGACAGCAGGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-635 (SEQ ID NO: 745)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGATGGGCTGGECCCGGCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGC
AAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-7 (SEQ ID NO: 746)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGATGGGCCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGTCGGTTCACCATCETCCCGCGACAATTCCAAGAACACGCTGTAT CTACAAATGAACAGCCTGCGTGCCGAGGACTCCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTTTGACTACCTGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-8 (SEQ ID NO: 747)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGTAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGETCCGCCAGECGE CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTCGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTTTCGAGC BMS2h-572-9 (SEQ ID NO: 748)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTAC GCAGACTCCGTGAAGGGCCGGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGG
AAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-573 (SEQ ID NO: 749)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGGGTGGGAGATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGATGAGTCTGGTCTTAATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGTGCG
CCGCAGTATCAGATTACATTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-574 (SEQ ID NO: 750)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCTAATTATGGGATGTATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATATATTTCGCGGAGGGGTTTGTTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAMACGTCG
CATTATATGAATAATGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-575 (SEQ ID NO: 751)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGTGGATTATACGATGGCTTGGETCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTAGTCCGATTGGTACTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCT TATGGGATGGAGGATGGTCTGACGTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-576 (SEQ ID NO: 752)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGCGTATGATATGCAGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAACGATTACGTCGGAGGGTCTTTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTAGT
GATTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-577 (SEQ ID NO: 753)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGGGTATGATATGGGTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCEGTGGGGGTTGGTTCACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGACG AGTCAGTCGTCTACGGGGAGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-578 (SEQ ID NO: 754)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCGTCGGTATGATATGCTTTGGGCCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTTCGCCTACGGGTGCTCTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTTGGT
TCGACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-579 (SEQ ID NO: 755)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTTITCCGTATTATATGAGTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTEGGGTACGGGTGGGCTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGACG
CAGAATGCGACGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-58 (SEQID NO: 756)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGTTTATACTATGGCGTGGGETCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAACGATTGATGAGTCTGGTCGTGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT
GTTTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-580 (SEQ ID NO: 757)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGTTTTATAAGATGGGGTEGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACTCCTAAGGGTCATCATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAGTTTTT AAGGGTAAGGGTTGGACTCGTCCGAGTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-581 (SEQ ID NO: 758)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATGAGTATAGTATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGAGGCGTGGTTGGCTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGTG
CTGCTGGATTCTACTAAGTTTGACTACTGGGGETCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-582 (SEQ ID NO: 759)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGAGTATCCGATGACTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTITCTGCGCGTGGTCCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTAGG CATTGGCTTCGTAATGGTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-583 (SEQ ID NO: 760)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTATGCAGTCGATGCAGTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTGATGATGGTACTAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAT
CGGGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-584 (SEQ ID NO: 761)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGECEGCTEATATGCAGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACTGATTACTAATGATGGTATTTCTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGET
GATCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-586 (SEQ ID NO: 762)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATAAGTATAGGATGCAGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATAGTTCTGGTGAGCTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGAGGTT CCGATGGGGAATCAGACTTTTTTITGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-587 (SEQ ID NO: 763)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTACTGATTATACTATGGGGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACGTCTCAGGGTGCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTACG
GGTACGGATTCGTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-588 (SEQ ID NO: 764)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGATTATGAGATGTCTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATGTATTGGGCCGGGGGGTAAGCCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGGAT
GGGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-589 (SEQ ID NO: 765)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGEGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTCAGTATGATATGGGGTGEGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCTTCGAGGGGTTGGCTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCCG
GGGGCTCETCGGCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-59 (SEQ ID NO: 766)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCTGGATTATGCGATGGGTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTTCTCCGATGGGTATGGGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCoGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGAGT GCTATTTCGTTTACTTCTGATATTTCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-590 (SEQ ID NO: 767)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATCCGATGTCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCTTGGTCTGGTTTTCAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGT GTTGCGAGGATGCCTACTGGGATTGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGC
BMS2h-591 (SEQ ID NO: 768)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGCTTATGAGATGCAGTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATIGATAGTGCTGGTACTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTCTATTACTGTGCGGAACCTTIT
GGGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-592 (SEQ ID NO: 769)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGAGTATCCGATGAAGTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGATCGGCAGGGTGATCGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAMACGGTG CEGAGGGGTCTTCCTCGTCCGAGTCGTTATTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-593 (SEQ ID NO: 770)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGATATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTTCGCCTATGGGTACGTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCTG AGTGTGTATTCGGGTCTTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-594 (SEQ ID NO: 771)
GAGGTGCAGCTGTTGGAGTCTGGEGGEAGGCCTGGTACAGCCTEGGGEGTCCCTGCETCTC TCCTGCECAGCCTCCGGATTCACCTTTTCTCATTATGATATGGGTTGGETCCGCCAGECT CCAGGGAAGGGTCTGGAGTGGGTCTCAGATATTGATTATATTGGTAAGACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCTCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAGCTTCG GATGAGGTGGGTGTTAATACTTCCAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-595 (SEQ ID NO: 772)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGCGGTATGATATGGGGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCTACTGGTGTGTTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTTT GAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-596 (SEQ ID NO: 773)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGCTTATCCGATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACTGATTTCTCATACGGGTCATGCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCAT
TGGCCTTTTGACTACCGGGGTCAGGGAACCCTGATCACCGTCTCGAGC BMS2h-597 O (SEQ ID NO: 774)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCAGGGGGETCCCTGCEGCCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGATGAGTGGATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGATATTAGCCCGGGTGGTTGGACTACATACTAC GCCGACTCCGTGAAGGGCCGGTTCACCATOETECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTAT
CGTCCGTTTGATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-598 (SEQ ID NO: 775)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGAGTCACCTTTGATGCTATTGAGATGTCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCGATTTCGCGTCATGGTGAGTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGATGCT
TGGTCTCGGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-599 (SEQ ID NO: 776)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAGTACGGATATGAGTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTTGGATAATGGTAGTAATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCoGCGACAATTCCAAGAACATGCTGTAT
CTGCAAATGAATAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGGGCG
AGGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-600 (SEQ ID NO: 777)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTEGCGTCTC TCCTGTGCAGCTTCCGGATTCACCTTTGGTAGGCAGAGTATGCAGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATGATGATGGTTTTTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGAT
CCGTGGGETTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-601 (SEQ ID NO: 778)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTACAGCCTCCGGATTCACCTTTAGTGATACGCAGATGGCGTGEGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGATGATGGGGGTGTGAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGAT
CGTCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-602 (SEQ ID NO: 779)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGAGTACGACGATGGGGTGGGTCCECCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAGTGATTTCGGATGATGGTGGTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGAT
GGTTATGGTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-603 (SEQ ID NO: 780)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCGGAGTGGGGATATGAATTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACGAATGATGGTACGTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAATACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTGAT
TCTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-61 (SEQID NO: 781)
GAGGTGCAGCTGTTGGAGTCTGGEGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTGCTTATGCTATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATATATTAGTCCGAATGGTACGGCGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGGAATATGTG
GGGATGCGTTGGAATTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-62 (SEQ ID NO: 782)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGAGTTATGAGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACGAGTCTTGGTACTTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT
AGGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-65 (SEQ ID NO: 783)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATGAGTATGAGATGACGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACTAGTGAGGGTAGTGGGACATACTAC GCAGACTCCGTAAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAACCTAAT GGTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-66 (SEQ ID NO: 784)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCTGATTATGAGATGTTGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTACTAGTGAGGGTCATTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGG
ACTTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-67 (SEQID NO: 785)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGAGATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGATTCTGATGGTAGTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGT
GTGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-68 (SEQ ID NO: 786)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGGATTATGAGATGACTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCTTCTACTGGTCAGTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAACCGGEGT
AATAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-69 (SEQID NO: 787)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCTTGATTATGGTATGGCTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTTCGCCTCTTGGTCTTAGTACATACTAC GCAGACTCCGTGAAGAGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGAGGTG AGGGTGGGTAGGGGTGTTCATCCTCCGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-7 (SEQ ID NO: 788)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATTTGTATGAGATGACTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACTAGTGATGGTGTTTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGEGG
GTGATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-70 (SEQ1D NO: 789)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGAATTATGCTATGTCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGCTCCGCTEGGTEGTTCCGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAAGAAG GTTGGGECETEGCTGCAGTCGCGGAGTTTTGACTACTGGGETCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-701 (SEQ ID NO: 790)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTITATGGATTATGAGATGCATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGGTGCTTCTGGTCATTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAATATCTT
GATATGCTGCTGTTTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-702 (SEQ ID NO: 791)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTGAGTATGAGATGATGTGGGCCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACGTATTGCTGGTAATGGTTCTCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATAATGCTT
TCTCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-703 (SEQ ID NO: 792)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTATAATTATGATATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGATTCGATGGGTCTTGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGGTCT AATGCGAGTGATTGGGTTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-704 (SEQ ID NO: 793)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGTCGTATCATATGACTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGCGGATACGGGTGATCGTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACTGCGGTATATTACTGTGCGAAATTGCGT GGGATGGCTCEGETTTGGEGGTTTEGACTACTGEGGETCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-705 (SEQ ID NO: 794)
GAGGTGCAGCTGTTGGAGTCTGGEGGAGGCTTEGTACAGCCTGGEEGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTTATTATGATATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGATCTCATCTATTTCGGATCGTGGTCTTCAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATTTACG GAGATTCCGTTGGATTGGTTGGAGGTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-706 (SEQ ID NO: 795)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGAGTTATAAGATGTTGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACTAATTCTGGTACTGAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGATG TATCCGGATTTGGAGATTGTGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-707 (SEQ ID NO: 796)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGACTTATCGTATGAGTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTGATCAGGAGGGTTCTGCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAATAGT GGGACGAGGCCGGGGCTTCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-708 (SEQ ID NO: 797)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGEGGTCCCTGCGCCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTAGTTATGATATGCTTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTGATGCGAGTGGTTATTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAATTGTTG AAGCTGTCGTTGAATCCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-709 1 (SEQ ID NO: 798)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGEGCTTGGTACAGCCTGGGGEGTCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTCATAATACTGGTTTGTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGACT
CAGCATCGTTTTGTTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-71 (SEQ ID NO: 799)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTTATCCTATGTCGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAGTCCTTTGGGTCCTGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTGTTG ATGGGGGAGTATTTGAATTCTAGGACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-710 (SEQ ID NO: 800)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATACGTATAGTATGTCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATGGATTGATGCTGATGGTTGGGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAAACTGGG
CATACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-711 (SEQ ID NO: 801)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGGATGGGGAGATGGGTTGEGCCCECCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGGATTGTGGATCCTGGTGATTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGT
GATCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-712 (SEQ ID NO: 802)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCTGAGTATGAGATGAAGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGTCGGGTGGTCATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACGCCGCGGTATATTACTGTGCGATACCTCTT
TCTAGTTTTGACTACTGGGGTCGGEGAACCCTGGTCACCGTCTCGAGC BMS2h-713 (SEQ ID NO: 803)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCTAATTATGTGATGATTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCACTTATTAATGGTGCTGGTGATATGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGGAAGGGGGST GCGCETTCETTTGGGGTTCCGCCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-714 (SEQ ID NO: 804)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGGATGGGGAGATGGGTTGEGCCCECCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGGATTGTGGATCCTGGTGATTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGT
GATCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-715 (SEQ ID NO: 805)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGTAGCCTCCGGATTCACCTTTACGCTGTATAATATGTCTTGGEGTCCGCCAGGECT CCAGGGAAGGGTCTGGAGTGGGTCTCAGTTATTTCTAGTAAGGGTGATAGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAAACGAGT
AGTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-716 (SEQ ID NO: 806)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGCGTATTATATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGTTAATAATGGTTTGTTGACATACTAC GCAGACTCCGTGAAGGGCCGGETTCACCATCTCCCGCGACAATTCCAAGAACATGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGCT GTTCATCCTTCGTATAGGGCGGAGTTGTTCGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-717 (SEQ ID NO: 807)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTTCGTATGAGATGGCGTEGETCEGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACGTATTGAGCCTGATGGTAGTAATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCCG
GATAATTTTACTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-718 (SEQ ID NO: 808)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAATAAGTATATGATGGGGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGATAGTCTTGGTCATTATACATACTAC GCAGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGGAAGCGGAG
TTTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719 (SEQ ID NO: 809)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-1 (SEQ ID NO: 810)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCATGGTACAGCCTGGGGGETCCCOTGECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAGC BMS2h-719-10 (SEQ ID NO: 811)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCATGGTGCAGCCTGGGGGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCoGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-11 (SEQ ID NO: 812)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCAAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECoGCGACAATTCCGAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGETTT
ACTGAGTTTGACTATTGGGGTCAGGGTACCCTGGTCACCGTCTCGAGC BMS2h-719-12 (SEQ ID NO: 813)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGACCCGTTT
ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-13 (SEQ ID NO: 814)
GAGGTGCAGCTGTTGGAGTCGGGEGGAGGCTTGEGTACAGCCTGGGGGETCCCTECGTCTC TCGTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCEGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATACCAAGAACACGCTGTAT CTACAGATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGACCCGTTT
ACTGAGCTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-14/ (SEQ ID NO: 815)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGGTACGGCCTGGEGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCEGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTTCTGTGCAGATCCGTTT
ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-15 (SEQ ID NO: 816)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCGCCTTTAAGAGGTATGAGATGACATGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCEGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCATATGAACAGCCTGCGTEGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTT
ACTGAGATTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-16 (SEQ ID NO: 817)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCCCCTTTAAGAGGTATGAGATGACGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCcCGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACCGGGCTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-17 (SEQ ID NO: 818)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGEGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGTCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCTTCTATTITTCEGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTOECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTT
ACTGAGATTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAGC BMS2h-719-18 (SEQ ID NO: 819)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACATCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCTTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCEGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGACGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACGGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-19 (SEQ ID NO: 820)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTGGEGTACAGCCTGGGGGEGTCCCTGCGTCTC TCCTGTGCAGCCTCAGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCeGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTT
ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-2 (SEQ ID NO: 821)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-20 (SEQ ID NO: 822)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGACGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGEGTTCACCATCTCECCoGCGACAATTCCAAGAACACTCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGATTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-202 (SEQ ID NO: 823)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAAGTATGAGATGATGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCoGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-203 (SEQID NO: 824)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAACAGCTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-21 (SEQ ID NO: 825)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTOEGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCATTT
ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-213 (SEQID NO: 826)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTOEGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGACCCGTTC
ACGGAGATGGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-214 (SEQID NO: 827)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCEGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGACCCGTTC
ACGGAGTTCGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-215 (SEQ ID NO: 828)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTA TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAGCCGTTC
ACGGAGTTGGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-218 (SEQID NO: 829)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGEGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCC CCAGGGAAGGGTCTGGAGTGGGTCTCATCGATTTEGTCCGACGGTTCCTTCACGTACTAC GCCGAGTCGGTCAAGGGCCGGTTCACCATCTOCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-225 (SEQ ID NO: 830)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAACACGTATGAGATGCAGTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCEGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGEGTTCACCATCTCECCoGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-226 (SEQID NO: 831)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAACAAGTATGAGATGATGTGGGCCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCEGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECoGCGACAATTCCAGGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-3 (SEQ ID NO: 832)
GAGGTGCAGCTETCGGAGTCTGGEGEAGGCTTEGGTACAGCCTGGEGEGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGETTCACCATCTCCCGCGACAATTCCAAGAATACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTT
ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-4 (SEQ ID NO: 833)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGACT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGGCGGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCAGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCAAGC BMS2h-719-5 (SEQ ID NO: 834)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGGAAATGAACAGCATGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACAACTGGGGTCAGGGAACCCTCGTCACCGTCTCGAGC BMS2h-719-6 (SEQ ID NO: 835)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGGEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGATACCGCGGTATATTACTGTGCAGAACCGTTT
ACTGAGTTTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAGC BMS2h-719-7 (SEQ ID NO: 836)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCAACTTTAAGAGGTATGAGATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCAGACCCGTTT
ACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-8 (SEQ ID NO: 837)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGACTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCACGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACAGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-9 (SEQ ID NO: 838)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGEGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGTCGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTT
ACTGAGTTTGACTACTGGGGTCGGGGAACCCTGGTCACCGTCTCGAGC BMS2h-72 (SEQID NO: 839)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGCGTATCCTATGTCGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCCCCTCTTGGTTTGTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTAGT GCTGEGGGCGGAGACTCATGTTTATCGGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-720 (SEQ ID NO: 840)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTAATTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGGTGTTGGGTCATACGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTTATG TCGTTGAGGACGTTTGAGAATCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-722 (SEQ ID NO: 841)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGAAGTATCCTATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGATGCTAATGGTAATAGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGGAAGGGACT TGGCGTAGGCATTTTGCGATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-723 (SEQ ID NO: 842)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATCTGTATGATATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCTGATCTGGGTACGCTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAMAATGGT TTTAGGGTTACGAGTAATGATCGTAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-724 (SEQ ID NO: 843)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTACTGGTGGGGATATGTGGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTGAGGGTGGTGGTGTGACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACTTGAT
CTTCGGACGGGTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725 (SEQ ID NO: 844)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG
GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-1 (SEQ ID NO: 845)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCATCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGETCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTTCTGTGCGGATCCGTCG
GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-10 (SEQ ID NO: 846)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCEGTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCG
GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-11 (SEQ ID NO: 847)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGETCCGCCAGGCT
CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCeGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAGCAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCG
GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-12 (SEQ ID NO: 848)
GAGGTGCAGCTGTTGGAGTCTGGGGGTEGCTTGGTACAGCCTGGGGEGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTCCCGGCTTATACTATGGGTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACGATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGTCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG
GATCCTACTATGTTTGTCTACTGGGGTCAGGGAACCCTTGTCACCGTCTCGAGC BMS2h-725-13 (SEQ ID NO: 849)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGCTGGGTCCGCCAGGECT CCAGGGAAGGGTCTGGAGTGGGTCTCTCTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG
GATCCTACTATGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-14 (SEQ ID NO: 850)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCATCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGETCCGCCAGECT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTEGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCA
GATCCTACTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-15 (SEQ ID NO: 851)
GAGGTGCAGCTGTTGGAGTCTGGGGEGGEGCATGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCATGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCG
GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-16 (SEQ ID NO: 852)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGECT CCAGGGAAGGGTCTGGAGTGGGTCACACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG
GATCCTACTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-17 (SEQ ID NO: 853)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTECAGCCTGGEGEGTCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGGCTTATACTATGGGTTGGEGTCCGCCAGGECT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACACTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGCGCGGAACCGTCG
GATCCTACTAAGTTAGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-18 (SEQ ID NO: 854)
GAGGTGCAGCTGTCGGAGTCTGGEGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCGTCTC ACCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGETCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCG
GATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-19 (SEQ ID NO: 855)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCEGGCTTATACTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGETCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCAGATCCGTCG
GATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-2 (SEQ ID NO: 856)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTCTCCT GTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGEGTCCGCCAGGCTCCAGGGAAG GGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAA GGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGC GTGCCGAGGACACCGCGGTATATTACTGCGCGGAACCGTCGGATCCTACTAAGTTTGTCTACTGG
GGTCAGGGAACCCCGGTCACCGTCTCGAGC BMS2h-725-3 (SEQ ID NO: 857)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGEGTACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTGGAGTGGGTCTCGCTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACATGCTGTAT CTGCAAATGAAAAGCCTGCGTEGCCGAGGACACCGCGGTATATTACTGCGCGGATCCGTCG
GATCCTACTAAGTTTGTCTACTGGGGTCAAGGAACCCAGGTCACCGTCTCGAGC BMS2h-725-4 (SEQ ID NO: 858)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGEGTACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTTCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCG
GATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-5 (SEQ ID NO: 859)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGTTACAGCCTEGGGGGTCCCTECGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGATTATACTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG
GATCCTACTAAGTTCGACTACTGGGGTCGGEGAACCCTGEGTCACCGTCTCGAGC BMS2h-725-6 (SEQ ID NO: 860)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCACGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCC
GATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-7 (SEQ ID NO: 861)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTACTTGGACATATTAC GCAGACCCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACACTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACTGCGGTATATTATTGTGCGGATCCGTCG
GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-8 (SEQ ID NO: 862)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGGEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG
GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-9 (SEQ ID NO: 863)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCT CCAGGGATGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCG
GATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-726 (SEQ ID NO: 864)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCCGGGGEGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATAAGATGTATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTTCGGAGATAGGTAATCTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATAGCTCTG
ACGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-727 (SEQ ID NO: 865)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGEGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGAGTTATCGTATGTATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATATATTGATCCGCCGGGTAGTCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAMAGTTTG AATTTGTCGTTTCCTTATATTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-728 (SEQ ID NO: 866)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGCGGTATGAGATGCTGTGGGTCCECCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACGTATTTCTCATTCGGGTCGGACGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAATTGGAT
GGTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-729 (SEQ ID NO: 867)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATTATATGGATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGGATTAATCATAATGGTTCTGTTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAATGCCG CAGGGTACTTCTGATTGGTATTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-73 (SEQID NO: 868)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCTAAGTATGATATGTCTTGGETCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTCTGGAGGATGGTCTGACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGEGG
CGTTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-74 (SEQID NO: 869)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGATTATCCTATGACGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTCTGTCTCCGGGTACGGAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGAG AAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC
BMS2h-741 (SEQ ID NO: 870)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTGGTGAGATGGGTTGGGTCCECCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTCCGATGGATGGTAGTGCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGT
GAGGTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-742 (SEQID NO: 871)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGGGAGTATCATATGAAGTGGGCCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTAGTAGGGATGGTATGAATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATACAGCTT
GCTTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-743 (SEQ ID NO: 872)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGETCCCTGCGCCTC TCCTGTGCAGCCTCCGGATTCACCTTTCGTGATTATGAGATGCTTTGGGCCEGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTCTTCCGTCGGGTGEGGCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGGT TCGGGGAATGGGCCTATTCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-744 (SEQ ID NO: 873)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGCATGATATGTTTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTGGGGCTEAGGGTETTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETECCGAGGACACCGCGGTATATTACTGTGCGGAACCGACG ATGTCTAATGGTTCTCAGTCGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-745 (SEQ ID NO: 874)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGEGTACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTATTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGC
BMS2h-745-1 (SEQ ID NO: 875)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTTTCAGGTATTACTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAMATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-10 (SEQ ID NO: 876)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTTCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAACCTGCGTGCCGAAGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-11 (SEQ ID NO: 877)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTTCAAGAACACGCTGTAT CTGCAGATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-12 (SEQ ID NO: 878)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTAC GCAGATTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCATGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-13 (SEQ ID NO: 879)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTEGGEGGETCCTTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAACACTGAGATGGCTTGGATCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTATTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGC
BMS2h-745-14 (SEQ ID NO: 880)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGGTTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-15 (SEQ ID NO: 881)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCAGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCTGGATTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACGCGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAMATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCTGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-16 (SEQ ID NO: 882)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-17 (SEQ ID NO: 883)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCCTGGATCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTATTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACAGGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGCACCCTGGTCACC
GTTTCGAGC BMS2h-745-18 (SEQ ID NO: 884)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATCACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTCGTCACC
GTCTCGAGC BMS2h-745-19 (SEQ ID NO: 885)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGAGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTATTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-2 (SEQ ID NO: 886)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGEGCTTGGTACAGCCTGGGGEGTCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTAGTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCAGAGGACTCCGCGGTATATTACTGTGCGAAAMATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-3 (SEQ ID NO: 887)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTAGAGCCTGGEGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGECT CCTGGGAAGEGTCTCGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAGCAGCCTGCGTEGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-4 (SEQ ID NO: 888)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCCTEGTACAGCCTGGEGEGTCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTAGTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATCACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-5 (SEQ ID NO: 889)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTAC GCTGACTCCGTGAAGGGCCGGTTCATCATCTCCCGCGACAATTCCAAGAACACGCTGAAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-6 (SEQ ID NO: 890)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCT CCAGGGAGGGGTCTAGAGTGGGTCTCAGGTGTTACTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTEGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAATTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-745-7 (SEQ ID NO: 891)
GAGGTGCAGCTGTTGGAGTCAGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGAAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTATTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTATTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGT BMS2h-745-8 (SEQ ID NO: 892)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTGATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAGCTCGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCCAGC BMS2h-745-9 (SEQ ID NO: 893)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTCGGTACAGCCTGGGGEGTCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACTCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-746 (SEQ ID NO: 894)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGEGTCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGETCGGCTEAGATGGGGTEGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTCGAGGCCTGGTCAGGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-747 (SEQ ID NO: 895)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGATGGTACTATGGGGTGEGCCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACTTATTTTGCCGTCGGGTAGTCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATTCG
CTGACTAATCGTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-748 (SEQ ID NO: 896)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTAAGTATGATATGCGGTGEGCCCECCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGATATTGATGCTGTTGGTACTCGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATACCGEGGG
GGGACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-749 (SEQ ID NO: 897)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGATGTATGGTATGATGTGGGCCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGAGGGTGCGGGTCATGCGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACTGCGGTATATTACTGTGCGATAGTGCTT
GGTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-75 (SEQ1ID NO: 898)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCGGGATTCACCTTTTTGCAGTATCCGATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCTGTTGGTTTGACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATTGTTT GAGGGGTCGAGGATTCAGCGTGATGTGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-750 (SEQ ID NO: 899)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGAAGTATCAGATGGGTTGGECCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTCGGGGGTCTGGTCTTGTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAGTGCAT ACTACGCTGCATACGGAGGTGATTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-751 (SEQ ID NO: 900)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGTACAGCCGGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTCAGTATACGATGTATTGGGCCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTTCTCATAGTGGTTCTAATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATATCGGGGE
CTGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-752 (SEQ ID NO: 901)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGGATTATGCGATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACGTATTGGTGTGGAGGGTGGGGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGTTG
CGGCTTTATCGTCTGGEGGTTTGACTACTGEGGETCAGGGAACCCTGEGTCACCGTCTCGAGC BMS2h-753 (SEQ ID NO: 902)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCOTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTAAGTATGATATGACGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAAGATTAATTCTGATGGTGGTCTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGTTG CATGGTAGGGGGTTTGTTATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-754 (SEQ ID NO: 903)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCGCGGTATGATATGGTGTGGETCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTAATTCTATGGGTCTGGCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGATACCGCGGTATATTACTGTGCGAAAGATTAT TCGGTTGCGCCGCATGGGTATCCTTTGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-755 (SEQ ID NO: 904)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGGATTATTCGATGATGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACTGATAATGGTACGTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAACATATG TCGCTTGCTACTTATCTGCAGTTTTTTGACTACTGGGGTCAGGGAACCCTGETCACCGTC TCGAGC
BMS2h-756 (SEQ ID NO: 905)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTATGGAGTATGATATGCTTTGGGTCCGCCAGGCT CCAGGGAAGGCTCTAGAGTGGGTCTCACGTATTTCGTCGGATGGTCTTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGTG AGTGCGCTTGCTCCTTTTGATATTGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-757 (SEQ ID NO: 906)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGTATAATATGGCTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTAATTTTGCTGGTCGGACGACATACTAC GCAGACTCCGTGAAGGGCCGGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTGTCT CTTCCTTTGGATATTTTITCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-758 (SEQ ID NO: 907)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT
GGTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-1 (SEQ ID NO: 908)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTITTGGTGATTATGGTATGAATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACATGCTGTAT CTGCGAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT
GGTTATTATGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-2 (SEQ ID NO: 909)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGETCCCTGCGCCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT
GGTTATTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-3 (SEQ ID NO: 910)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGECC CCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT
AGTTATTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-4 (SEQ ID NO: 911)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGGTTCACCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTTT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT
GGTTATTATGAGTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-5 (SEQ ID NO: 912)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGEGTCCAGCCTEGEGEGTCCCTECGETCTC TCCTGTGCTGCCTCCGGATTCGCCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT
GGTTATTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-6 (SEQ ID NO: 913)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGGEGGTCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTATATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGT
GGTTACTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-759 (SEQ ID NO: 914)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGGGAGTATGTTATGGGGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAATGGTTTGGGTAATGTTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATACCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGAGACCGCGGTATATTACTGTGCGATACAGCTG
CCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-760 (SEQ ID NO: 915)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTAATGATGGGATGTGGTGGETCEGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATTTATTAATGTTGATGGTAGGGAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAATGGTCT
CETEGECEGETTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-761 (SEQ ID NO: 916)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTITGGTGGTTGGGATATGGCGTGGGTCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGCTCATGAGGGTGGTGAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGTT
CCTGGGTCTCCTCTGTTTGACTACTGGGGTCAGAGAACCCTGGTCACCGTCTCGAGC BMS2h-762 (SEQ ID NO: 917)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATCAGGGTTGGATGTATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTGGTTCGAATGGTCCTCGGACATCCTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGGG
GAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-763 (SEQIDNO: 918)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGGCAGAGTGATATGTGGTGGETCEGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAGTTATTGGTAATAATGGTGAGTTTACATACTAC GCAGACTCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAAT
TGGCTGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-764 (SEQ ID NO: 919)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATCTTAGTACTATGTATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTGGTGGGGATGGTAGTCATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAAGGTACG
CAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-765 (SEQ ID NO: 920)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTTCEGGCGTATACGATGGAGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGGGGTTACGGGTTATGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGGT
CAGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-766 (SEQ ID NO: 921)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGGGATTATGGGATGTCTTGGETCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATATATTGATCCTCTGGGTCGTCTTACATACTAC GCAGACTCCGTGAAGGGCCGGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGATTTG TCGTCGCTGCAGTATGGGGTETCGCCTAATTTTGACTACTGGGGTCAGGGAACCCTGGETC
ACCGTCTCGAGC BMS2h-767 (SEQ ID NO: 922)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTTITCATTATTCTATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGTCCGETTGGTCGGGAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATGATT CAGTCGCCGTTGTTTAAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-768 (SEQ ID NO: 923)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGTGGTATGATATGTATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACGTATTGATAGTGGGGGTAATCAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAATAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGCGTCG
CTTTGGAAGTGGAGGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-77 (SEQ ID NO: 924)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGEGTACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGGTATGGCGTGGETCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCGCTGGGTATTTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATGCT ACGTCTCAGGAGTCTTTGCGGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-770 (SEQ ID NO: 925)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGTAAGTATGAGATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCCT CTGCCTGATGCGTTTTGGACTAGGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-771 (SEQ ID NO: 926)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTACTTATTCTATGGCGTGEGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTGATCGGCATGGTTTGGCTACATACTAC GCAGACTCCGTGAAGGGCCGGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAMACTCCT GGTTCTTCTTGGCAGACTGTTTTTGGCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-772 (SEQ ID NO: 927)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGTCGTATCCTATGGGTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATCATCATGGTCATTCGACATACTAC GCAGACTCCGCGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGCTT AGGGTTTCGATGATTTTTGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-773 (SEQID NO: 928)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGTGCAGTATGGGATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTAGTAGTAGTGGTACGTATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTACGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACGTCT
AGGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-774 (SEQ ID NO: 929)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGEGTACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCEGCCTCCGGATTCACCTTTCGGGAGTATGATATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACTTATITCGCCTCCTGGTCGTACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGTTGTG ATTCTGGGTTATACGAATAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-775 (SEQ ID NO: 930)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCCTAATTACGGGATGTTGTGGETCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTAATTCTTCGGGTATGGAGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATTTTTT CGTCTGAATGATCATAATTCTGTGTTTGGTTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-776 (SEQ ID NO: 931)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTEGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTAAGGATTATAAGATGATGTGGATCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGTTGGGTCTGGTTCGATGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCCT
GGTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-777 (SEQ ID NO: 932)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTCATAATTATGCTATGGGGTGGGETCCGCCEGECT
CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATGAGCATGGTACTATTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCECCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAGT
CTGGATCGGGTTTGGATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-778 (SEQ ID NO: 933)
GAGGTGCAGCTGTTGGAGTCTGGGGEGEGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATCCGATGACTTGGGTCCGCCAGGCT
CCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTATTCTGCGGGTTCTCCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTECCeGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTTTAT CATCGGGAGCCGATTCTTTTTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC
TCGAGC BMS2h-78 (SEQID NO: 934)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGAGGTATCAGATGGCGTGGGTCCGCCAGGCT
CCGGGEAAGGGTCTAGAGTGGGTCTCAACGATTAGTTCTGATGGTGGGGGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCcGCGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGT
CATCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-780 (SEQ ID NO: 935)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTTCTTATACTATGATGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTGATCGGACGGGTGAGCGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCTGGGE
TTTGCTTCTCTTCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-781 (SEQ ID NO: 936)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGEGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTACGGATTATACTATGTATTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAAAGATTTCTCCGAGTGGTCGTTCTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGATCCG
TTTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-782 (SEQ ID NO: 937)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGETACAGCCTGGGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATGATGCGGAGATGTTTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGATGCTCGTGGTTTGACGACATACTAC GCAGACCCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGCGACG
TCGGCTATGTATCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-783 (SEQ ID NO: 938)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCGTGATTATGATATGGGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCTCTTGGTCATTTTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATCTGGG TTTCATGAGTATACTGAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG
AGC BMS2h-784 (SEQ ID NO: 939)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATCGTGCGGGTATGGGGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCACTGATTGGGCETGGTGGTGATATTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAMATTCGT AATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-80 (SEQ ID NO: 940)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGGTCGTTATCAGATGGCTTGGETCEGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCTATITCTTCTGATGGTGGGGGGACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGTCT
CGTCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-81 (SEQ1D NO: 941)
GAGGTGCAGCTGTTGGAGTCTGGGGEAGGCTTGGTACAGCCTGEGEGETTCCTGCGETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGTTGTATCCGATGGCGTGEGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCATCGATTTCTCCGGTTGGTTTTCTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGGCAT GAGGGGTCGTATACTCCGCGETCEGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-82 (SEQID NO: 942)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGEGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGTGGCGTATCCTATGGCGTEGETCCGCCAGGECT CCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTGCGCCTCTGGGTGGTAATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAACGGCCG GAGGGGCTGCAGATTGATTCTCAGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-83 (SEQID NO: 943)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGCGTTGTATCAGATGGCTTGGETCCGCCAGECT CCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGATTCTTCTGGTAGTGATACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAG
CGTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-84 (SEQID NO: 944)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTAGGCAGTACCAGATGGCTTGGGCCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGCGTCGGATGGTGTTTCTACATACTAC GCAGACTCCGTGAAGGGCCGETTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGT
CGTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-85 (SEQ ID NO: 945)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGETACAGCCTGEGEGETCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGCAGTATGATATGAGGTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTGATGAGGCGGGTCATGAGACATACTAT GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGATG
GATGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-92 (SEQ ID NO: 946)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGTTGATTATCCGATGGGTTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCTACGGGGGGTTTTTCGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTECCGAGGACACCGCGGTATATTACTGTGCGAAAGCGCEG TATTATTATCTTAGTCAGATTAAGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGC
BMS2h-93 (SEQID NO: 947)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTC TCCTGTGCAGCCTCCGGATTCACCTTTGATATTTATGGGATGACTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTTCGCCTCTTGGTCTTGTTACATACTAC GCAGACCCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTGAAG
GAGCATGGGGATGTTCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-94 (SEQID NO: 948)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGETCCCTEGCETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGCTTTATCCGATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCTACGGGTTTGTTGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTAAG AGGAGTGGGAAGACTGATGATACTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC BMS2h-95 (SEQ ID NO: 949)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTCGGGAGTATGATATGCTGTGGGTCCGCCAGGECT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGTGGGGGATGGTAATGGTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGGAT
CGTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-97 (SEQID NO: 950)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTEGGTACAGCCTGGEGGGETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGGTATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGCCTATTGGTGTTACTACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAMAATGCT
TATGATCGGAAGTCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-98 (SEQID NO: 951)
GAGGTGCAGCTGTTGGAGTCTGGGGGAGECTTGGTACAGCCTEGGEGETCCCTECGTCTC TCCTGTGCAGCCTCCGGATTCACCTITGATCGGTATGTGATGGTGTGGETCCGCCAGGCT CCAGGGAAGGATCTAGAGTGGGTCTCAGGTATTACTCCGAGTGGTAGGAGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGGACACGCTGTAT CTGCAAATGAACAGCCTGCETGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGTTG GGGCGTCATTTTGATCCTCTTCTGCCTTCGTTTGACTACTGGGGTCAGGGAACCCTGGTC
ACCGTCTCGAGC BMS2h-99 (SEQID NO: 952)
GAGGTGCAGCTGTTGGAGTCTGGEGGGAGGCTTEGTACAGCCTGGEGEETCCCTECETCTC TCCTGTGCAGCCTCCGGATTCACCTTTGAGGATTATGCTATGAGTTGGGTCCGCCAGGCT CCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGGGTGGTTTTTGGACATACTAC GCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAMACGTCT AGTGGGGAGTTGCAGTTGGTTGAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC
GTCTCGAGC TABELA 3 Sequências de Aminoácidos do Domínio VK do Anti-CD40L Humano BMS2h-100 — (SEQID NO: 953)
DIQMTOSPSS LSASVGDRVT ITCRASQNIK HSLRWYQOKP GKAPRLLIVH RSQLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ VRHRPYTFGQ GTKVEIKR BMS2h-101 — (SEQIDNO: 954)
DIQMTOSPSS LSASVGDRVT ITCRASQAIG HRLRWYQOKP GKAPKLLIVH RSKLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ VALFPYTFGQ GTKVEIKR BMS2h-102 — (SEQID NO: 955)
DIQMTOSPSS LSASVGDRVT ITCRASQHIG HHLRWYQQOKP GKAPKLLIVH RSHLOSGVPS
RFSGSGSGTD FTLTISSLOP EDSATYYCQQO WDRPPYTFGQO GTKVEIKR BMS2h-103 — (SEQIDNO: 956)
DIQMTOSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH
RSKLOSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ VRAVPYTFGQ GTKVEIKR BMS2h-104 (SEQ ID NO: 957)
DIQMTOSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCOQAQ VRFSPYTFGQ GTKVEIKR BMS2h-105 — (SEQIDNO: 958)
DIQMTOSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ SYARPVTFGQ GTKVEIKR BMS2h-1086 — (SEQIDNO: 959)
DIQMTOSPSS LSASVGDRVT ITCRASOSIN HRLYWYQOKP GKAPKLLIVH RSRLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YKVRPNTFGQ GTKVEIKR BMS2h-107 — (SEQID NO: 960)
DIQMTOSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYSSPHTFGQ GTKVEIKR BMS2h-108 — (SEQIDNO: 961)
DIQMTOSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ RAVRPFTFGQ GTKVEIKR BMS2h-109 (SEQ ID NO: 962)
DIQMTOSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYYRPLTFGQ GTKVEIKR BMS2h-110 (SEQ ID NO: 963)
DIQMTOSPAS LSASVGDRVT ITCRASQDID PMLRWYQQKP GKAPKLLIYA GSILASGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TSIRPYTFGQ GTKVEIKR BMS2h-116 (SEQ ID NO: 964) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYQQAKP GKAPKLLIVYQ TSILASGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-1 (SEQ ID NO: 965) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDILWYQAKP GKAPKLLIVYQ TSILASGVPS
RFSGSESGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-10 (SEQID NO: 966) DIQITASPSS — LSASVGDRVT ITCRASQPIG PDLLWYQOKP GKAPKLLIYQ TSILRSGVPS
RFSGSGSGTD FTLTISSLQP EDLATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-11 — (SEQID NO: 967) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS
RFSGRGSGTD FTLTISSLOP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-12. (SEQID NO: 968) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYQQAKP GKAPKLLIVYAQ TSILRSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ YWTFPVYTFGQ GTKVEIKR BMS2h-116-13 — (SEQID NO: 969) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS
RFSGSGSETD FTLTISNLOQP EDFATYYCQQ YWAFPVYTFGQO GTKVVIKR BMS2h-116-1312 (SEQ ID NO: 970) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYQQAKP GKAPKLLIVYA TSILRSGVPS
RFSGSGSETD FTLTISNLQP EDLATYYCQQ YWAFPVTFGK GTKVVIKR BMS2h-116-1313 (SEQ ID NO: 971) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS
RFSGSGSETD FTLTISNLQP EDFATYYCQQ YWAFPVYTFGR GTKVVIKR BMS2h-116-1314 (SEQ ID NO: 972)
DIQMTOSPSS LSASVGDRVT ITCRASQPIG PDLLWYRQKP GKAPKLLIVYQ TSILRSGVPS
RFSGSGSETD FTLTISNLQP EDFATYYCQQ YWAFPVYTFGQ GTKVVIKR BMS2h-116-1319 (SEQ ID NO: 973) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYQOKP GKAPKLLIVYAQ TSIMRSGVPS
RFSGSGSETD FTLTISNLQP EDFATYYCQQ YWTFPVYTFGQ GTKVEIKR BMS2h-116-1320 (SEQ ID NO: 974) DIQMTOSPSS —LSAYVGDRVT ITCRASQPIG PDLLWYQAKP GKAPKLLIVYQ TSILRSGVPS
RFSGSGSETD FTLTISNLQP EDFAKYYCQQ YWAFPVTFGQ GTKVVIKR BMS2h-116-138 (SEQ ID NO: 975) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYQAKP GKAPKLLIVAQ TSILRSGVPS
RFSGSGSETD FTLTISNLOQP VDFATYYCQQ YWAFPVTFGQO GTKVVIKR BMS2h-116-14 — (SEQID NO: 976) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWFOQQKP GKAPKLLIVYAQ TSILASGVPS
RFSGSESGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-15"" (SEQID NO: 977) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYROKP GKAPKLLIYQ TSILASGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ YWTFPVYTFGQ GTKVEIKR BMS2h-116-16 (SEQID NO: 978) DIQMTOSPSS —LSASVGDRVT ITCRASQPID PDLLWYQQAKP GKAPKLLIVYQ TSILASGVPS
RFSGSGSGTV FTLTISSLOP EDFATYYCQQ YWAFPVYTFGQ GTKVEIKR BMS2h-116-17/" (SEQID NO: 979) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYQQAKP GKAPKLLIVYAQ TSILRSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-2 — (SEQID NO: 980)
DIQMTOSPSS LSASVGDRVT ITCRASQPIE PDLLWYQQAKP GKAPKLLIVQ TSILASGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWASPVTFGQ GTKVEIKR BMS2h-116-3 — (SEQID NO: 981)
DIQMTOSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ
TSILOSGVPS RFSGSESGTD FTLTISSLQP EDIATYYCQQ YWAFPVTFGQ GTRVEIKR BMS2h-1164 (SEQ ID NO: 982) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIVYQ TSILOSGVPS
RFSGSESGTD FTLTISSLOQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-5º"— (SEQID NO: 983)
DIQMTASPSS LSASVGDRVA ITCRASQPIG PDILWYQOKP GKAPKLLIVQ TSILRSGVPS
RFSGSGSGTD FTLTISSLQP EDSATYYCQQ YWAFPYTFGQO GTKVEIKR BMS2h-116-68 — (SEQID NO: 984)
DIQMTOSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIVQ TSILRSGVPS
RFSGSGSVTD FTLTISSLOP EDFATYYCQQ YWAFPVYTFGQ GTKVGIKR BMS2h-1167 — (SEQID NO: 985)
DIQMTASPSS LSASVGDRVT ITCRASQPID PDLLWYQOKP GKAPKLLIVQ TSILASGVPS
RFSGSGSRTD FTLTISSLOQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-1168 — (SEQID NO: 986) DIQMTOSPSS —LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIVYQ TSILASGVPS
RFSGSGSGTD FTLTISGLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-9 (SEQ ID NO: 987) DIQMTOSPSS —LSASVGDRVT ITCRASMPIG PDLLWYQQKP GKAPKLLIVQ TSILRSGVPS
RFSGSESGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-141 — (SEQIDNO: 988)
DIQMTOSPSS LSASVGDRVT ITCRASQWIG DTLTWYQQOKL GKAPKLLIVYG GSELOSGVPP
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ CISSPCTFGQ GTKVEIKR BMS2h-142 — (SEQIDNO: 989)
DIQMTASPSS LSASVGDRVT ITCRASQFIG DSLSWYQQOKP GKAPKLLIVYF SSILOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHTSPTTFGR GTKVKIKR BMS2h-143 — (SEQIDNO: 990)
DIQMTOSPSS LSASVGDRVT ITCRASQTIE TNLEWYQQKP GKAPKLLIYD SSQLOSGVPS
RFSGSGSGTD FTLTISSLQP EDLATYYCQQ YHGYPTTFGQO GTKVEIKR BMS2h-144 — (SEQIDNO: 991)
DIQMTAOSPSS LSASVGDRVT ITCRASQMID QDLEWYQQKP GKAPKLLIYN ASWLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ YHGYPITFGQO GTKVEIKR BMS2h-145" — (SEQIDNO: 992)
DIQMTOSPSS LSASVGDRVT ITCRASQTIY TSLSWYQQKP GKAPKLLIHY GSVLOSGVPS
RFSGSGSGTD FTLTISSLQP EDSATYYCQQ VHOAPTTFGQ GTKVEIKR BMS2h-146 (SEQ ID NO: 993)
DIRMTOSPSS LSASVGDRVT ITCRASQWIG DSLAWYQOKP GKAPKLLIVG ISELOSGVPS
RFSGSGSGTD FTLTISSLQP EDSATYYCQL SSSMPHTFGQ GTKVEIKR BMS2h-147 — (SEQIDNO: 994)
DIQMTAOSPSS LSASVGDRVT ITCRASQEIE TNLEWYQOKP GKAPKLLIYVD SSHLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHQNPPTFGQ GTKVEIKR BMS2h-149 — (SEQIDNO: 995)
DIQMTOSPSS LSASVGDRVT ITCRASQWIG RQLVWYQOKP GKAPKLLIVG ATELOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ASKGPLTFGH GTKVEIKR BMS2h-150 — (SEQID NO: 996)
DIQMTAOSPSS LSASVGDRVT ITCRASQGIG TDLNWYQQKP GKAPKLLIYM GSYLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQOQ IYSFPITFGQ GTKVEIKR BMS2h-154º — (SEQIDNO: 997)
DIQMTOSPSS LSASVGDRVT ITCRASQDIE EMLHWYQQKP GKAPKLLIYF GSLLOSGVPS
RFSGSRSGTD FTLTISSLOP EDFATYYCQQ HHTRPYTFGQ GTKVEIKR BMS2h-155 (SEQ ID NO: 998)
DIQMTOSPSS LSASVGDRVT ITCRASQDIG MDLEWYQQIP GKVPKLLIYD ASYLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHKLPATFGO GTKVEIKR BMS2h-156 / — (SEQIDNO: 999)
DIQMTOSPSS LSASVGDRVT ITCRASQDIM DNLEWYQQKP GKAPKLLIYA ASWLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHKLPVTFGQ GTKVEIKR BMS2h-157/ — (SEQID NO: 1000)
DIQMTAOSPSS LSASVGDRVT ITCRASQNIG EDLEWYQQKP GNAPKLLIVYS ASHLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSSYPVTFGQ GTKVEIKR BMS2h-158 — (SEQIDNO: 1001)
DIQMTOSPSS LSASVGDRVT ITCRASQPID EDLEWYQQKP GNAPKLLIYS ASYLOSGVPS
RFSGSGSGTD FTLTISRLQP EDFATYYCQQ YHLLPATFGO GTKVEIKR BMS2h-159 — (SEQID NO: 1002)
DIQMIGSPSS LSASVGDRVT ITCRASQDIN EDLEWYQQKP GKAPKLLIYN ASMLOSGVPS
RFSGSGSGTD FTLTISSLOP KDFATYYCQQ YHTNPTTFGO GTKVEIKR BMS2h-160 — (SEQID NO: 1003)
DIQMTOSPSS LSASVGDRVT ITCRASQDIE ADLEWYQQKP GKAPKLLIYH SSELQOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHMSPVTFGQ GTKVEIKR BMS2h-161 (SEQ ID NO: 1004)
DIQMTOSPSS LSASVGDRVT ITCRASQDID SDLEWYQOKP GKAPMLLIYS SSDLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHSLPVTFGQ GTKVEIKR BMS2h-162 — (SEQ ID NO: 1005)
DIQMTAOSPSS LSASVGDRVT ITCRASQDIS DDLEWYQQOKP GKAPKLLIYN SSFLOSGVPS
RFSGSGSGAD FTLTISSLOP EDFATYYCQQ YHSLPVTFGQ GTKVEIKR BMS2h-168 — (SEQIDNO: 1006)
DIQMTOSPSS LSASVGDRVT ITCRASQDIE GNLEWYQOKP GKAPKLLIYD SSQLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHHLPTTFGO GTKVEIKR BMS2h-164 — (SEQID NO: 1007)
DIQMTAOSPSS LSASVGDRVT ITCRASQSID TDLEWYQQKP GKAPKLLIVD GSWLQOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ YRWIPVYTFGO GTKVEIKR BMS2h-165" — (SEQIDNO: 1008) DIQMTOSPSS —LSASVGDRVT ITCRASQOSIS TDLEWYQOKL GKAPKLLIYD ASLLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSSLPVTFGQ GTKVEIKR BMS2h-166 (SEQ ID NO: 1009)
DIQMTOSPSS LSASVGDRVT ITCRASQPIT TSLEWYQQKP GKAPKLLIYD ASMLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWVTPVTFGO GTKVEIKR BMS2h-167/ — (SEQIDNO: 1010)
DIQMTOSPSS LSASVGDRVT ITCRASQNIH TNLEWYQOKP GKAPKLLIYD GSMLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSANPVTFGQ GTKVGIKR BMS2h-168 — (SEQIDNO: 1011)
DIQMTAOSPSS LSASVGDRVT ITCRASQWIH TDLEWYQOKP GKAPKLLIVD GSMLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSVSPVTFGQ GTKVEIKR BMS2h-169º — (SEQ ID NO: 1012)
DIQMTOSPSS LSASVGDRVT ITCRASQSID NNLEWYQQKP GEAPKLLIYD GSLLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHLHPVTFGQ GTKVEIKR BMS2h-170 — (SEQIDNO: 1013)
DIQMTASPSS LSASVGDRVT ITCRASQDID TNLEWYQQKP GEAPKLLIYD RSTLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ YDSYPVTFGQ GTKVEIKR BMS2h-171 — (SEQIDNO: 1014)
DIQMTOSPSS LSASVGDRVT ITCRASQSIE SNLEWYQQKP GKAPKLLIYN ASELQOSGVPS
RFSGSGSGTD FTLTISSLRP EDFATYYCQQ YDOQWPTTFGQ GTKVEIKR BMS2h-172 (SEQ ID NO: 1015)
DIQMTOSPSS LSASVGDRVT ITCRASQAIG NTLRWYQOKP GKAPKLLIVL SSRLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LKKPPYTFGQ GTKVEIKR BMS2h-173 — (SEQIDNO: 1016)
DIQMTASPSS LSASVGDRVT ITCRASQKIK NRLAWYQQKP GKAPKLLIVE VSHLOSGVPS
RFSGSGSGTD FTLTIGSLQP EDFATYYCQQ RRASPYTFGQ GTKVEIKR BMS2h-174 — (SEQIDNO: 1017)
DIQMTOSPSS LSASVGDRVT ITCRASEDIG EELFWYQOKP GKAPKLLIVYS ASTLOSEVPS
RFSGSGSGTD FTLTISSLQH EDFATYYCQQ VYEWPYTFGQO GTKVEIKR BMS2h-175 — (SEQIDNO: 1018)
DIQMTAOSPSS LSASVGDRVT ITCRASQPIS GGLRWYQQKP GKAPKLLIVYS TSMLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LYSAPYTFGQ GTKVEIKR BMS2h-305 — (SEQ ID NO: 1019)
DIQMTOSPSS LSASVGDRVT ITCRASQDID QDLEWYQQAKP GKAPKLLIYN VSLLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSMNPVTFGQ GTKVEIKR BMS2h-306 (SEQ ID NO: 1020)
DIQMTOSPSS LSASVGDRVT ITCRASQDIG NQLKWYQQKP GKAPKLLIVYAQ ASGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDLRPQTFGQ GTKVEIKR BMS2h-307 — (SEQIDNO: 1021)
DIQMTOSPSF LSASVGDRVT ITCRASQKIS TSLEWYQQOKP GKAPRLLIYD SSWLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YEYNPITFGQ GTKVEIKR BMS2h-33 — (SEQIDNO: 1022)
DIQMTAOSPSS LSASVGDRVT ITCRASQTIG ESLHWYQQOKP GKAPRLLIVF ASLLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HHMLPSTFGQ GTKVEIKR BMS2h-355=— (SEQIDNO: 1023)
DIQMTOSPSS LSASVGDRVT ITCRASQFIG DSLSWYQQAKP GKAPKLLIYF SSILASGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YMDIPITFGO GTKVEIKR BMS2h-36 — (SEQIDNO: 1024)
DIQMTAOSPSS LSASVGDRVT ITCRASQDID HNLEWYQQKP GKAPKLLIYD SSMLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ YHSIPVYTFGQO GTKVEIKR BMS2h-37 — (SEQIDNO: 1025)
DIQMTOSPSS LSASVGDRVT ITCRASQQIE TNLEWYQQKP GKAPKLLIYD GSWLQOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHSLPATFGQ GTKVEIKR BMS2h-38 (SEQ ID NO: 1026)
DIQMTOSPSS LSASVGDRVT ITCRASQDIG NNLEWYQQKP GKAPRLLIVYH GSWLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDFNPTTFGQ GTKVEIKR BMS2h-39 — (SEQIDNO: 1027)
DIQMTAOSPSS LSASVGDCVT ITCRASQNID GLLWWYQQKP GKAPKLLIVA GSGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ KAFEPFTFGQ GTKVEIKR BMS2h-405 — (SEQID NO: 1028)
DIQMTQTPSS LSASVGDRVT ITCRASQSIG HDLEWYQOKP GKAPKLLIYN VSWLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSHNPPTFGQ GTKVEIKR BMS2h-408 — (SEQID NO: 1029)
DIQMTASPSS LSASVGDRVT ITCRASQHE NDLEWYQQKP GKAPKLLIYS ASHLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHLAPTTFGP GTKVEIKR BMS2h-431 — (SEQIDNO: 1030)
DIQMTOSPSS LSASVGDRVT ITCRASQVIE GSLNWYQQKP GKAPKLLIYH RSILOSGVPS
RFSGRGSGTD FTLTISSLOP EDFATYYCQQ TYQLPLTFGQ GTKVEIKR BMS2h-432 (SEQ ID NO: 1031)
DIQMTOSPSS LSASVGDRVT ITCRASRPIN GKLFWYQQKP GKAPKLLIAF ASALQSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCVQ QAVYPITFGQ GTKVEIKR BMS2h-433 — (SEQIDNO: 1032)
DIQMTOSPSS LSASVGDRVT ITCRASQAIE TNLEWYQQKP GKAPKLLIYD GSLLOSGVPS
RFSGRGSGTD FTLTISSLOP EDFATYYCQQ YHYQPATFGQ GTKVEIKR BMS2h-434 — (SEQIDNO: 1033)
DIQMTAOSPSS LSASVGDRVT ITCRASQDIE HDLEWYQQOKP GKAPKLLIYS ASQLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YAQQAPTTFGA GTKVEIKR BMS2h-435 — (SEQIDNO: 1034)
DIQMTOSPSS LSASVGDRVT ITCRASSQIE ESLWWYQQKP GKAPKLLIAD VSLLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCAQ GVVEPRTFGQ GTKVEIKR BMS2h-436 — (SEQIDNO: 1035)
DIQMTAOSPSS LSASVGDRVT ITCRASQYIG LDLEWYQQKP GKAPKLLIVA ASWLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ YFRQPITFGQO GTKVEIKR BMS2h-437 — (SEQIDNO: 1036)
DIQMTOSPSS LSASVGDRVT ITCRASTPIG TMLDWYQQKP GKAPKLLIGH SSWLQOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ HVRPPATFGQ GTKVEIKR BMS2h-437-1 (SEQ ID NO: 1037)
DIQLTOSPTS LSATVGDRVT ITCRASTPIG TMLDWYQOKP GKAPKLLIGH SSWLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ HVRHPATFGQ GTKVEIKR BMS2h-437-2 — (SEQID NO: 1038)
DIQMTOSPSS LSASVGDRVT ITCRASTPIG TMLDWYQOKP GKAPKLLIGH SSWLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ HVRPPATFGQ GTKVGIKR BMS2h-437-3 — (SEQIDNO: 1039)
DIQMTOSPSS LSASVGDRVT ITCRVSTPIG TMLDWYQQKP GKAPKLLIGH SSWLOSGVPP
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ HVRPPATFGQ GTKVEIKR BMS2h-437-4 — (SEQIDNO: 1040)
DIQMTAOSPSS LSASVGDRVT ITCRASTPIG TMLDWYQQKP GKAPKLLIGH SSWLQOSGVPS
RFSGCGSGTD FTLTISSLOP EDFATYYCGQ HVRPPATFGQ GTKVEIKR BMS2h-437-5"— (SEQIDNO: 1041)
DIQMTOSPSS LSASVGDRVT ITCRASTPIG TMIDWYQQKP GKAPKLLIGH SSWLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ HVRPPATFGK GTKVEIKR BMS2h-438 — (SEQIDNO: 1042)
DIQMTOSPSS LSASVGDRVT ITCRASQYID TNLEWYQOKP GKAPRLLIVD GSQLOSGVPS
RFSGSGSGTD FTLIISSLOP EDFATYYCQQ YQVVPVTFGQ GTKVEIKR BMS2h-439 — (SEQIDNO: 1043)
DIOMTOSPSS LSASVGDRVT ITCRASOSIS SYLNWYQOKP GKAPRLLIVD SSGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ DRWSPATFGQ GTKVEIKR BMS2h-440 — (SEQIDNO: 1044)
DIQMTOSPSS LSASVGDRVT ITCRASSRIQ HMLSWYQQKP GKAPKLLIGG HSGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCAQ SCAWPLTFGQ GTKVEIKR BMS2h-441 — (SEQIDNO: 1045)
DIQMTOSPSS LSASVGDRVT ITCRASRGID GDLWWYQOKP GKAPKLLIAD SSLLASGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ GAVRPMTFGQ GTKVEIKR BMS2h-442 — (SEQIDNO: 1046)
DIQMTOSPSS LSASVGDRVT ITCRASRGID TDLWWYQQKP GKAPKLLIAD SSLLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ GAVRPMTFGQ GTKVEIKR BMS2h-443 — (SEQIDNO: 1047)
DIQMTAOSPSS LSASVGDRVT ITCRASYTIP VALDWYQQKP GKAPKLLIAD ASLLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCAQ GWPGPQTFGQ GTKVEIKR BMS2h-444 — (SEQIDNO: 1048)
DIOMTOSPSS LSASVGDRVT ITCRASQOSIA TDLEWYQOKP GKAPKLLIYD TSMLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSYNPSTFGQ GTKVEIKR BMS2h-445 — (SEQIDNO: 1049)
DIQMTOSPSS LSASVGDRVT ITCRASVPIT EGLSWYQQKP GKAPKLLIQOA NSWLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ WEHVPATFGQ GTKVEIKR BMS2h-446 — (SEQIDNO: 1050)
DIQMTOSPSS LSASVGDRVT ITCRASSMIL YGLDWYQQOKP GKAPKLLIGG TSALOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ WETVPATFGQ GTKVEIKR BMS2h-447 — (SEQIDNO: 1051)
DIQMTOSPSS LSASVGDRVT ITCRASQPIN GLLIWYQOKP GKAPKLLIVA MSSLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQA LARIPFTFGO GTKVGIKR BMS2h-448 — (SEQIDNO: 1052)
DIQMTOSPSS LSASVGDRVT ITCRASQLIR TYLAWYQOKP GKAPKLLIVA SSQLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ YNSYPDTFGQ GTKVEIKR BMS2h-47 (SEQ ID NO: 1053)
DIQMTOSPSS LSASVGDRVT ITCRASQWIG DSLSWYQQKP GKAPKLLIVF GSYLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ YLHTPSTFGQ GTKVEIKR BMS2h-484 — (SEQIDNO: 1054)
DIOMTOSPSS LSASVGDRVT ITCRASQDIE ADLEWYQOKP GKAPKLLIYH SSELOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ YGFNPPTFGQ GTKVEIKR BMS2h-485 — (SEQIDNO: 1055)
DIQMTOSPSS LSASVGDRVT ITCRASSPIE YGLDWYQQKP GKAPKLLIGG GSALOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ WEVOQPATFGQ GTKVEIKR BMS2h-488 — (SEQIDNO: 1056)
DIQMTOSPSS LSASVGDRVT ITCRASQRID TDLEWYQOKP GKAPKLLIYD SSQLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ YHSAPATFGQ GTKVEIKR BMS2h-487 — (SEQIDNO: 1057)
DIQMTOSPSS LSASVGDRVT ITCRASGWIG MSLEWHQQKP GKAPKLLIRG ASSLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCSQO SRWPPVTFGQ GTKVEIKR BMS2h-488 — (SEQIDNO: 1058)
DIQMTOSPSS LSASVGDRVT ITCRASRNIS NALSWYQQKP GKAPKLLILG ASWLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCTO WDRPFTFGQ GTKVEIKR BMS2h-488 — (SEQIDNO: 1059)
DIOMTOSPSS LSASVGDRVT ITCRASQDIM SALSWYQOKP GKAPKLLIYS TSILOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ VYLLPVTFGQ GTKVEIKR BMS2h-4900 — (SEQID NO: 1060)
DIQMTASPSS LSASVGDRVT ITCRASQEIG IDLEWYQQKP GKAPKLLIVA ASYLOSGVPS
RFSSSGSGTD FTLTISSLQP EDFATYYCQQ YASNPPTFGR GTKVEIKR BMS2h-491 — (SEQIDNO: 1061)
DIQMTOSPSS LSASVGDRVT ITCRASQMIG DWLNWYQQKP GKAPKLLIVYR SSELOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LYFWPRTFGQ GTKVEIKR BMS2h-492 — (SEQID NO: 1062)
DIQMTAOSPSS LSASVGDRVT ITCRASQAIE LNLEWYQQKP GKAPKLLIVD ASMLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ YDVYPPTFGQ GTKVEIKR BMS2h-4921 — (SEQIDNO: 1063)
DIQMTOSPSS LSASVGDRVT ITCRASQAIE HNLEWYQQOKP GKAPKLLIYD ASMLOSGVPS
RFSGSGSGTD FTLTISSLQP EDLATYYCQQ YDAYPPTYGQ GTKVEIKR BMS2h-492-2 (SEQ ID NO: 1064)
DIQMTOSPSS LSASVGDRVT ITCRASRAIE TNLEWYQQOKP GKAPKLLFYD ASMLOSGVPS
RFGGSGSGTD FTLTISSLQP EDFATYYCLQ YDVYPPTFGQ GTKVEIKR BMS2h-492-3 — (SEQIDNO: 1065)
DIQMTOSPSS LSATVGDRVT ITCRASQAIE TNLEWYQQOKP GKAPKLLIYD ASMLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDAYPPTFGQ GTKVEIKR BMS2h-4924 — (SEQIDNO: 1066)
DIQMTAOSPSS LSASVGDRVT ITCRASQAIE HNLEWYQQKP GKAPKLLIYD ASMLOSGVPS
RFSGRGSGTD FTLTISSLOP EDFATYYCQQ YDAYPPTFGQ GTKVEIKR BMS2h-492-5 (SEQID NO: 1067)
DIQMNQOSPSS LSASVGDRVS ITCRASQAIE HNLEWYQQOKP GKAPKLLIYD ASMLQOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDAYPPTFGQ GTKVEIKR BMS2h-4926 — (SEQIDNO: 1068)
DIQMTAOSPSS LSASVGDRVT ITCRASQAIE SNLEWYQQKP GKAPKLLIVD ASMLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ YDVYPPTFGQ GTKVEIKR BMS2h-492-7 — (SEQID NO: 1069)
DIQMTOSPSS LSASVGDRVT ITCRASQAIE HNLEWYQQKP GKAPKLLIYD ASMLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDAYPPTFGQ GTKVEIKR BMS2h-493 (SEQ ID NO: 1070)
DIQMTOSPSS LSASVGDRVT ITCRASOGID EDLEWYQOKP GKAPRLLIYS SSWLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YFOYPPTFGQ GTKVEIKR BMS2h-494 — (SEQIDNO: 1071)
DIQMTAOSPSS LSASVGDRVT ITCRASQSID EDLEWYQQOKP GKAPRLLIYS SSWLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YFOYPPTFGQ GTKVEIKR BMS2h-494-1 — (SEQIDNO: 1072)
DIQMTOSPSS LSASVGDRVT ITCRASQOSID EDLEWYQOKP GKAPRLLIYS SSWLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSQAQYPPTFGQ GTKVEIKR BMS2h-494-2 — (SEQID NO: 1073)
DIQMTAOSPSS LSASVGDRVT ITCRASQSIE EDLEWYQQKP GKAPRLLIVYS SSWLQOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ YFOYPPTFGH GTKVEIKR BMS2h-494-3 — (SEQIDNO: 1074)
DIQMTOSPSS LSASVGDRVT ITCRASQSID EDLEWYQQOKP GKAPRLLIYS SSWLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYFCQQ YFQYPPTFGQ GTKVEIKR BMS2h-494-4 (SEQ ID NO: 1075)
EIQMTOSPSS LSASVGDRVT MTCRASQSID KDLEWYQQKP GKAPRLLIYS SSWLORGVPS
RFSGSGSGTD FTLTISSLRP EDFATYYCQQ YFOYPPTLGO GTKVEIKR BMS2h-494-5 — (SEQIDNO: 1076)
DIQMTOSPSS LSASVGDRVT ITCRASQSID EDLEWYQQOKP GKAPRLLIYS SSWLOSGVPS
RFSGSGSGTD FTLTISGLQP EDIATYYCKQ YSQYPPTFGQ GTKVEIKR BMS2h-4946 — (SEQIDNO: 1077)
DIQMTAOSPPS LSASVGDRVT ITCRASQSID KDLEWYQQKP GKAPRLLIVYS SSWLQRGVPS
RFSGSGSGTD FTLTISSLQP EDFATYHCQQ YFOYPPTFGQ GTKVEIKR BMS2h-495 — (SEQIDNO: 1078)
DIQMTOSPSS LSASVGDRVT ITCRASEYIN AELAWYQQKP GKAPKLLIYVG SSGLQOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCLO NAMWPITFGQ GTKVEIKR BMS2h-496 — (SEQIDNO: 1079)
DIQMTASPSS LSASVGDRVT ITCRASLDIN NGLIWYQQKP GKAPRLLILG ASGLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCSQ VRSRPFTFGOQO GTKVEIKR BMS2h-497 — (SEQID NO: 1080)
DIQMTOSPSS LSASVGDRVT ITCRASQDIL SALAWYQQKP GKAPKLLIVYVG SSVLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ NYSLPITFGQ GTKVEIKR BMS2h-498 (SEQ ID NO: 1081)
DIQMTOSPSS LSASVGDRVT ITCRASSPIE SYLRWYQOKP GKAPKLLIRY VSVLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WFRAPVYTFGQ GTKVEIKR BMS2h-499 — (SEQID NO: 1082)
DIQMTOSPSS LSASVGDRVT ITCRVSESIN AELHWYQQKP GKAPKLLISG FSGLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCVQ FAMWPFTFGQ GTKVEIKR BMS2h-500 (SEQ ID NO: 1083)
DIQMTOSPSS LSASVGDRVT ITCRASMMIR FGLDWYQQKP GKAPKLLIGG GSSLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ HERWPATFGQ GTKVEIKR BMS2h-501 (SEQ ID NO: 1084)
DIQMTOSPSS LSASVGDRVT ITCRASQOSIG TLLRWYQQOKP GKAPKLLIYL TSVLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ MVYRPYTFGQ GTKVEIKR BMS2h-502 (SEQ ID NO: 1085)
DIQMTOSPSS LSASVGDRVT ITCRASQTIE TNLEWYQQKP GKAPKLLIYD SSQLQOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDKVPATFGQ GTKVEIKR BMS2h-503 (SEQ ID NO: 1086)
DIQMTOSPSS LSASVGDRVT ITCRASHHIQ RYLSWYQQKP GKAPKLLIW GSQLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WWAPPPTFGQ GTKVEIKR BMS2h-503-1 (SEQ ID NO: 1087)
DIQMTOSPSS LSASVGDRVT ITCRASHHIQ RYLSWYQQOKP GKAPKLLIW GSQLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ WWAPPQTFGQ GTKVEIKR BMS2h-503-2 — (SEQID NO: 1088)
DIQMTOSPSS LSASVGDRVT ITCRASHDIQ RYLSWYQQKP GKAPKLLIW GSQLASGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WWAPPQTFGQ GTKVEIKR BMS2h-504 (SEQ ID NO: 1089)
DIQMTOSPSS LSASVGDRVT ITCRASQYID TNLEWYQQOKP GKAPKLLIYD GSLLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ GAVVPVTFGQ GTKVEIKR BMS2h-508 (SEQ ID NO: 1090)
DIQMTOSPSS LSASVGDRVT ITCRASQDIA FDLEWYQQKP GKAPKLLIYS ASMLOSGVPS
RFSGSGSGSD FTLTISSLOP EDFATYYCQQ YNLOPPTFGQ GTKVEIKR BMS2h-509 (SEQ ID NO: 1091)
DIQMTOSPSS LSASVGDRVT ITCRASQNIA TLLRWYQQKP GKAPKLLIYA GSMLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ MWQORPYTFGQ GTKVEIKR BMS2h-51 (SEQ ID NO: 1092) DIQMTOSPSS —LSASVGDRVT ITCRASQPIV DELDWYQQKP GKAPKLLIYA ASILOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCHQ WSTYPTTFGQ GTKVEIKR BMS2h-510 (SEQ ID NO: 1093)
DIQMTAOSPSS LSASVGDRVT ITCRASQOSIS SYLNWYQQOKP GKAPKLLIDE VSGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ DWDWPRTFGQ GTKVEIKR BMS2h-511 — (SEQIDNO: 1094)
DIQMTOSPSS LSASVGDRVT ITCRASRNIR DWLRWYQQKP GKAPKLLIDW GSVLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCAQ TWDDPLTFGQ GTKVEIKR BMS2h-511-1 — (SEQID NO: 1095)
DIQMTOSPSS LSAFVGDRVT ITCRASRNIR DWLRWYQQKP GKAPKLLIDIW GSELQOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCAQ TWYDPLTFGH GTKVEIKR BMS2h-512 — (SEQID NO: 1096)
DIQMTOSPSS LSASVGDRVT ITCRASIDIH GGLTWYQQKP GKAPKLLIVG VSGLOSGVPS
RFSGSGSGTD FTLTISNLOP EDFATYYCAQ VWRRPFTFGQ GTKVEIKR BMS2h-513 (SEQ ID NO: 1097)
DIQMTOSPSS LSASVGDRVT ITCRASQDIG SSLSWYQQAKP GKAPKLLIYA SSLLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYALPVTFGO GTKVEIKR BMS2h-514 — (SEQIDNO: 1098)
DIQMTOSPSS LSASVGDRVT ITCRASQQIE TNLEWYQQKP GKAPKLLIYD GSWLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YKYLPVTFGQ GTKVEIKR BMS2h-52 — (SEQIDNO: 1099)
DIQMTAOSPSS LSASVGDRVT ITCRASQDIG SALRWYQOKP GKAPKLLIVL GSDLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TAYFPTTFGO GTKVEIKR BMS2h-53 — (SEQIDNO: 1100)
DIQMTOSPSS LSASVGDRVT ITCRASQAIY GGLRWYQQKP GKAPKLLIVYG ESMLQOSGVPS
RFSGSGSGTD FTLTISSLHP EDFATYYCQQ VYHKPFTFGQ GTKVEIKR BMS2h-536 — (SEQIDNO: 1101)
DIQMTAOSPSS LSASVGDRVT ITCRASQRIG VWLDWYQQKP GKAPKLLIYD GSFLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ TFSSPSTFGQ GTKVEIKR BMS2h-537 — (SEQIDNO: 1102)
DIQMTOSPSS LSASVGDRVP ITCRASQWIG DELYWYQQOKP GKAPKLLIYS SSTLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SFQFPYTFGQ GTKVEIKR BMS2h-538 (SEQ ID NO: 1103)
DIQMTOSPSS LSASVGDRVT ITCRASSNIT GPLEWYQQKP GKAPKLLIPG WSTLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WGEPVTFGQ GTKVEIKR BMS2h-539 — (SEQIDNO: 1104)
DIQMTOSPSS LSASIGDRVT ITCRASORIA YGLHWYQQKP GKAPRLLIGG RSGLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCVQ PGMPPDTFGQ GTKVEIKR BMS2h-540 — (SEQIDNO: 1105)
DIQMTOSPSS LSASVGDRVT ITCRASKOIV GGLSWYQQKP GKAPKLLIGR HSGLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCVQ GVWWAPGTFGQ GTKVEIKR BMS2h-541 — (SEQIDNO: 1106)
DIQMTOSPSS LSASVGDRVT ITCRASPAIA AKLDWYQQKP GKAPKLLIGA DSGLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ LWAGPPTFGQ GTKVEIKR BMS2h-542 — (SEQIDNO: 1107)
DIQMTOSPSS LSASVGDRVT ITCRASRTIA DGLDWYQOKP GKAPKLLIGA YSGLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ LWEGPPTFGQ GTKVEIKR BMS2h-543 — (SEQIDNO: 1108)
DIQMTOSPSS LSASVGDRVT ITCRASQRIY GFLDWYQQKP GKAPKLLIVG VSSLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TLAWPFTFGQ GTKVEIKR BMS2h-544 — (SEQIDNO: 1109)
DIOMTOSPSS LSASVGDRVT ITCRASQDIR DWLMWYQOKP GKAPKLLIYW GSFLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ LYDTPYTFGQ GTKVEIKR BMS2h-545 — (SEQIDNO: 1110)
DIQMTOSPSS LSASVGDRVT ITCRASQNIN TGLDWYQOKP GKAPKLLIYD SSALOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ TSYYPYTFGQ GTKVEIKR BMS2h-546 — (SEQIDNO: 1111)
DIQMTOSPSS LSASVGDRVT ITCRASQKIF GWLDWYQQKP GKAPKLLIVG TSKLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ VYSLPYTFGQ GTKVEIKR BMS2h-547'/ — (SEQIDNO: 1112)
DIQMTOSPSS LSASVGDRVT ITCRASSNIG ADLDWYQOKP GKAPKLLIGG ASGLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ LWNGPPTFGQ GTKVEIKR BMS2h-548 — (SEQIDNO: 1113)
DIQMTOSPSS LSASVGDRVT ITCRASSPIY DGLDWYQQKP GKAPKLLISG ASWLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCGQ LWLGPPTFGQ GTKVEIKQ BMS2h-5498 — (SEQIDNO: 1114)
DIQMTOSPSS LSASVGDRVT ITCRASSRIY NGLHWYQQKP GKAPKLLIGG RSGLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCAQ VGEAPSTFGQ GTKVEIKR BMS2h-550 — (SEQIDNO: 1115)
DIQMTAOSPSS LSASVGDRVT ITCRASRFIN EELDWYQQKP GKAPKLLISW SSWLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCVQ PGGGPGTFGQ GTKVEIKR BMS2h-551 — (SEQIDNO: 1116)
DIQMTOSPSS LSASVGDRVT ITCRASRDIL DELDWYQOKP GKAPRLLIGG GSGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWHGPPTFGQ GTKVEIKR BMS2h-552º — (SEQ ID NO: 1117)
DIQMTAOSPSS LSASVGDRVT ITCRASSPIY TGLHWYQQKP GKAPKLLIGG RSGLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCMQ VGTAPATFGQO GTKVEIKR BMS2h-5855 = (SEQIDNO: 1118)
DIRMTOSPSS LSASVGDRVT ITCRASQNIS RRLLWYQQKP GKAPKLLIYS SSRLOSGVPS
RFGGSGSGTD FTLTISSLOP EDFATYYCQQ TYSYPHTFGQ GTKVEIKR BMS2h-604 (SEQ ID NO: 1119)
DIQMTOSPSS LSASVGDRVT ITCRASSPIP QDLYWYQAKP GKAPKLLIVG ISQLASGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWSAPATFGQ GTKVEIKR BMS2h-805" — (SEQIDNO: 1120)
DIQMTOSPSS LSASVGDRVT ITCRASKSID GMLDWYQQOKP GKAPKLLIPG FSGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ SVEAPWTFGQ GTKVEIKR BMS2h-606 — (SEQIDNO: 1121)
DIQMTASPSS LSASVGDRVT ITCRASRYIA HPLDWYQQKP GKAPKLLIPG SSVLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ SVVVPWTFGQ GTKVEIKR BMS2h-607 — (SEQIDNO: 1122)
DIQMTOSPSS LSASVGDRVT ITCRASRTIE GGLDWYQQKP GKAPKLLIMG GSGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWVGPPTFGQ GTKVEIKR BMS2h-608 — (SEQIDNO: 1123)
DIQMTAOSPSS LSASVGDRVT ITCRASKFIR DELYWYQQKP GKAPRLLIGG SSLLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCGQ LWRAPATFGQ GTKVEIKR BMS2h-609 — (SEQ ID NO: 1124)
DIQMTOSPSS LSASVGDRVT ITCRASKPIY GGLEWYQQKP GKAPRLLIGG GSVLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WGGPVTFGQ GTKVEIKR BMS2h-610 (SEQ ID NO: 1125)
DIRMTOSPSS LSASVGDRVT ITCRASRPIS GCLDWYQOKP GKAPKLLIDG ASGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WWEYPPTFGQ GTKVEIKR BMS2h-611 — (SEQIDNO: 1126)
DIQMTAOSPSS LSASVGDRVT ITCRASKPIV RDLEWYQQOKP GKAPKLLIHG VSTLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LEAAPATFGQ GTKVEIKR BMS2h-612 — (SEQIDNO: 1127)
DIQMTOSPSS LSASVGDRVT ITCRASRDIG DWLYWYQAKP GKAPRLLIVW ASVLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCAQ WGTPPTTFGQ GTKVEIKR BMS2h-613 — (SEQIDNO: 1128)
DIQMTAOSPSS LSASVGDRVT ITCRASNRIE YGLDWYQQKP GKAPKLLISS SSRLOSGVPS
RFSSSGSGTD FTLTISSLOQP EDFATYYCGQ LEAAPATFGQ GTKVEIKR BMS2h-614 — (SEQIDNO: 1129)
DIQMTOSPSS LSASVGDRVT ITCRASRNIG HFLDWYQQKP GKAPKLLILG GSSLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGOQ LVEPPATFGQ GTKVEIKR BMS2h-615 (SEQ ID NO: 1130)
DIQMTOSPSS LSASVGDRVT ITCRASSSIY SDLYWYQQAKP GKAPKLLIDG WSGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LHRAPATFGQ GTKVEIKR BMS2h-6168 — (SEQIDNO: 1131)
DIQMTOSPSS LSASVGDRVT ITCRASRFIT DRLDWYQQKP GKAPKLLIGG VSGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ SSELPWTFGQ GTKVEIKR BMS2h-617 — (SEQIDNO: 1132)
DIQMTAOSPSS LSASVGDRVT ITCRASRKIG SELYWYQOKP GKAPKLLIGG RSRLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWEPPATFGQ GTKVEIKR BMS2h-618 — (SEQIDNO: 1133)
DIQMTOSPSS LSASVGDRVT ITCRASRNIG NGLDWYQQAKP GKAPKLLIGE GSRLQOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWHTPPTFGQ GTKVEIKR BMS2h-619 — (SEQIDNO: 1134)
DIQMTAOSPSS LSASVGDRVT ITCRASRNIY GWLSWYQQKP GKAPRLLIGG WSGLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCAQ DYTLPGTFGQ GTKVEIKR BMS2h-730 — (SEQIDNO: 1135)
DIQMTOSPSS LSASVGDRVT ITCRASQDIK DWLHWYQQKP GKAPKLLIYF ASGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDSATYYCQQ HYSTPYTSGQ GTKVEIKR BMS2h-731 (SEQ ID NO: 1136)
DIQMTOSPPS LSASVGDRVT ITCRASQLIS SHLDWYQOKP GKAPKLLVYD ASELOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HRSLPFTFGQ GTKVEIKR BMS2h-732 — (SEQIDNO: 1137)
DIQMTAOSPSS LSASVGDRVT ITCRASQWIG GALAWYQQKP GKAPRLLIVQ ISVLOSGIPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YIRSPFTFGQ GTKVEIKR BMS2h-733 — (SEQIDNO: 1138)
DIQMTOSPSS LSASVGDRVT ITCRASQOSIG AALNWYQOKP GKAPKLLIVG LSSLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LFRLPLTFGO GTKVEIKR BMS2h-734 — (SEQIDNO: 1139)
DIQMTASPSS LSASVGDRVT ITCRASQPIG GRLVWYQQKP GKAPKLLIVG SSILOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ YAEAPITFGO GTKVEIKR BMS2h-735 — (SEQIDNO: 1140) DIQMTOSPSS —LSASVGDRVT ITCRASQNIG SSLIWYQQOKP GKAPTLLIYOY SSKLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SLSSPYTVGQ GTKVEIKR BMS2h-736 (SEQ ID NO: 1141)
DIQMTOSPSS LSASVGDRVT ITCRASQWIG SELAWYQQKP GKAPKLLIYNW TSNLOSGVPS
RFSGSGSGTD FTLTISNLOP EDFATYYCQOA ILETPLTFGQ GTKVEIKR BMS2h-737 — (SEQIDNO: 1142)
DIQMTOSPSS LSASVGDRVT ITCRASQKIW DALYWYQQKP GKAPKLLIYR GSILOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FYRWPHTFGQ GTKVEIKR BMS2h-738 — (SEQIDNO: 1143)
DIQMTAOSPSS LSASVGDRVT ITCRASQHIE DSLRWYQQKP GKAPKLLIYY GSVLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ MYKFPITFGQ GTKVEIKR BMS2h-739 — (SEQIDNO: 1144)
DIQTTAOSPSS LSASVGDRVT ITCRASQRIN SSLLWYQQAKP GKAPKLLIYD TSTLOSGVPS
RFSGSRSGTD FTLTISSLQP EDFATYYCQQ IWGSPPTFGQ GTKVEIKR BMS2h-740 — (SEQIDNO: 1145)
DIQMTAOSPSS LSASVGDRVT ITCRASQOSIP VGLNWYQQKP GKAPRLLIVS GSTLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ DWYYPNTFGQ GTKVEIKR BMS2h-785" — (SEQIDNO: 1146)
DIQMTOSPSS LSASVGDRVT ITCRASQPIY GWLNWYQQKP GKAPKLLIYL TSGLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQOQ IHSSPFTFGQ GTKVEIKR BMS2h-8 (SEQ ID NO: 1147)
DIQMTOSPSS LSASVGDRVT ITCRASQFID TSLEWYQOKP GKAPKLLIVD GSHLOSGVPS
RFSGSGSGTD FTLTISSLQP EDLATYYCQQ YWVLPLTFGQ GTKVEIKR BMS2h-86 — (SEQIDNO: 1148)
DIQMTOSPSS LSASVGDRVT ITCRASQDIG DALFWYQOKP GKAPKLLIYOY SSMLOSGVPS
RFSGGGSGTD FTLTISSLOP EDFATYYCQQ RHSTPATFGQ GTKVEIKR BMS2h-87 (SEQ ID NO: 1149)
DIQMTOSPSS LSASVGDRVT ITCRASQDID ESLMWYQOKP GKAPRLLIVG VSYLOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ RWKAPFTFGQ GTKVEIKR BMS2h-88 (SEQ ID NO: 1150)
DIQMTOSPSS LSASVGDRVT ITCRASQEIV EDLYWYQQKP GKAAKLLIVG ASWLOSGVPS
RFSGSGSGTD FTLTISSLOQP EDFATYYCQQ TRRRPYTFGQ GTKVEIKR BMS2h-89 (SEQ ID NO: 1151)
DIQMTOSPAS LSASVGDRVT ITCRASQDID PMLRWYQQKP GKAPKLLIYA GSILOSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TLVTPYTFGQ GTKVEIKR BMS2h-90 (SEQ ID NO: 1152)
DIQMTOSPSS LSASVGDRVT ITCRASQSIS DALFWYQQKP GKAPRLLIYY GSVLOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ RFQEPVTFGQ GTKVEIKR BMS2h-91 (SEQ ID NO: 1153)
DIQMTOSPSS LSASVGDRVT ITCRASQOIS DELNWYQQKP GKAPKLLIYA VSILOSGVPS
RFSGSGSGTD FTLTISSLOP EDFATYYCQQ WLSFPSTFGQ GTKVEIKR TABELA 4 Sequências de Nucleotídeos Que Codificam o Domínio VK do Anti- CD40L Humano BMS2h-100 (SEQ ID NO: 1154)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGAGCAAGTCAGAATATTAAGCATTCGTTACGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATCATCGTTCCCAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGGTTAGGCATCGTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-101 (SEQ ID NO: 1155)
GACATCCAGATGACCCAGTCTCCATCCTCTCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGGTTGCTTTGTTTCCCTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-102 (SEQ ID NO: 1156)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCATATTGGTCATCATTTAAGGTGGTACCAGCAGAAACCA GGGAAAGCCCCCAAGCTCCTGATCTATCATAGGTCCCATTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTCTGCTACGTACTACTGTCAACAGTGGGATAGGCCGCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-103 (SEQ ID NO: 1157)
GACATCCAGATGACCCAGTCCCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGGTGCGGGCTGTGCCTTATACGTTTGGCCAA
GGGACCAAGGTGGAAATTAAACGG BMS2h-104 (SEQ ID NO: 1158)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGGTTCGTTTTTCTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-105 (SEQ ID NO: 1159)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTCTTATGCTAGGCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-106 (SEQ ID NO: 1160)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAAAGTATTAATCATAGGTTATATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAGGTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAGGATTTTGCTACGTACTACTGTCAACAGTATAAGGTTAGGCCTAATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-107 (SEQIDNO: 1161)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATTTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACTTATTCGTCTCCTCATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-108 (SEQ ID NO: 1162)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCATEGGTCCAAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTACAACCT GAAGATTTTGCTACGTACTACTGTCAACAGAGGGCGGTGAGGCCTTTTACGTTCGGCCAA
GGGACCAAAGTGGAAATCAAACGG BMS2h-109 (SEQ ID NO: 1163)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCATCEGGTCCAAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACTTATTATCGTCCTCTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-110 (SEQ ID NO: 1164)
GACATCCAGATGACCCAGTCTCCAGCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGATCCTATGTTAAGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGCGGGTTCCATTTITGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACTAGTATTAGGCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116 (SEQ ID NO: 1165)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-1 (SEQID NO: 1166)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATATACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATCTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGAATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-10 (SEQ ID NO: 1167)
GACATCCAGATAACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATATTGCGAAGTGGAGTCCCATCA CGTTTCAGTGGCAGTGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATCTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-11 (SEQ ID NO: 1168)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTTCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCA CGTTTCAGTGGCAGAGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-12 (SEQ ID NO: 1169)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAACCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCTTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCA CGTTTCAGTGGCAGCGGATCTGGGACTGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGACTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-13 (SEQ ID NO: 1170)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGTAATCAAACGG BMS2h-116-1312 (SEQ ID NO: 1171)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCT GAAGATCTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCAAA
GGGACCAAGGTGGTAATCAAACGG BMS2h-116-1313 (SEQ ID NO: 1172)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCA CEGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCGA
GGGACCAAGGTGGTAATCAAACGG BMS2h-116-1314 (SEQ ID NO: 1173)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGAGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCGGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGTGTCCCATCA CGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGTAATCAAACGG BMS2h-116-1319 (SEQ ID NO: 1174)
GACATCCAGATGACCCAGTCTCCATCCTCCOTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTATGCGAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGACTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-1320 (SEQ ID NO: 1175)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATATGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACCCTCACCATCAGCAATCTGCAACCT GAAGATTTTGCTAAGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGTGATCAAACGG BMS2h-116-138 (SEQID NO: 1176)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCT GTAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTAGTAATCAAACGG BMS2h-116-14 (SEQ ID NO: 1177)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTTCCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGAATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-15 (SEQ ID NO: 1178)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATCGGTCCTGATTTACTGTGGTACCGGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGACTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-16 (SEQ ID NO: 1179)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGATCCTGACTTACTGTGGTACCAGCAGAAACCA GGTAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGTTTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCATTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-17 (SEQ ID NO: 1180)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCAGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAGCCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-2 (SEQ ID NO: 1181)
GACATCCAGATGACCCAGTCTCCATCATCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGAACCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTCTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-3 (SEQ ID NO: 1182)
GACATCCAGATGACCCAGTCACCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCTAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGCGGCAGTGAATCCGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATATTGCAACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAGGGTGGAAATCAAACGG BMS2h-116-4 (SEQ ID NO: 1183)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCTTCA CGTTTCAGTGGCAGTGAATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-5 (SEQ ID NO: 1184)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCGCC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATATACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTCTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGTCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-6 (SEQ ID NO: 1185)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCGTCA CETTTCAGTGGCAGTGGATCTGTGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGGAATCAAGCGG BMS2h-116-7 (SEQ ID NO: 1186)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGATCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTAGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-8 (SEQ ID NO: 1187)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAGCAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-116-9 (SEQ ID NO: 1188)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTATGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCA GGGAAGGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCA CETTTCAGTGGCAGTGAATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-141 (SEQ ID NO: 1189)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTGGATTGGGGATACGTTAACGTGGTACCAGCAGAAACTA GGGAAAGCCCCTAAGCTCCTGATCTATGGTGGTTCCGAGTTGCAAMAGTGGGGTCCCACCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTGTATTAGTAGTCCTTGTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-142 (SEQ ID NO: 1190)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTTTATTGGTGATTCTTTATCTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTTITCTTCCATTTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATACTTCGCCTACTACGTTCGGCCGA
GGGACCAAGGTGAAAATCAAACGG BMS2h-143 (SEQ ID NO: 1191)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGACTATTGAGACTAATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATTCTTCCCAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTAGCTACGTACTACTGTCAACAGTATCATGGGTATCCTACGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-144 (SEQ ID NO: 1192)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGATGATTGATCAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATAATGCGTCCTGGTTGCAAMAGTGGGGTCCCATCA CGTTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATGGTTATCCTATTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-145 (SEQ ID NO: 1193)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGACGATTTATACTTCGTTAAGTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCCATTATGGTTCCGTGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTCTGCTACGTACTACTGTCAACAGGTTCATCAGGCTCCTACGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-146 (SEQ ID NO: 1194)
GACATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTGGATTGGGGATTCTTTAGCGTGGTACCAGCAGAAGCCA GGGAAAGCCCCTAAGCTCCTGATCTATGGTATTTCCGAGTTGCAAAGTGGGGTCCCATCA CEGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTCTGCTACGTACTACTGTCAACTGTCTAGTAGTATGCCTCATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-147 (SEQ ID NO: 1195)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGAGATTGAGACGAATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATTCGTCCCATTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATCAGAATCCTCCGACGTTCGGCCAA
GGAACCAAGGTGGAAATCAAACGG BMS2h-149 (SEQIDNO: 1196)
GACATCCAGATGACCCAGTCTCCATCCTCCOTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTGGATTGGGAGGCAGTTAGTTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGGGGCEGACCGAGTTGCAAAGTGGGGTCCCATCA CGTTTTAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGCAGTCGAAGGGTCCTCTTACGTTCGGCCAT
GGGACCAAGGTGGAAATCAAACGG BMS2h-150 (SEQ ID NO: 1197)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGGGATTGGTACTGATTTAAATTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATATGGGTTCCTATTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGATTTATTCTTTTCCTATTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-154 (SEQ ID NO: 1198)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGAGGAGATGTTACATTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTTTGGTTCCCTGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTAGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGCATCATACTCGTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-155 (SEQ ID NO: 1199)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGGGATGGATTTAGAGTGGTACCAGCAGATACCA GGGAAAGTCCCTAAGCTCCTGATCTATGATGCGTCCTATTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATAAGCTTCCTGCGACGTTTGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-156 (SEQ ID NO: 1200)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTATGGATAATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGCGGCGTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATAAGTTGCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-157 (SEQ ID NO: 1201)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGAGCAAGTCAGAATATTGGGGAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAATGCCCCTAAGCTCCTGATCTATAGTGCGTCCCATTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTCTAGTTATCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-158 (SEQ ID NO: 1202)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCCGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCGATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAATGCCCCTAAGCTCCTGATCTATAGTGCGTCCTATTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGACTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATCTTCTGCCTGCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-159 (SEQID NO: 1203)
GACATCCAGATGATCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTAATGAGGATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATAATGCTTCCATGTTGCAAAGCGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT AAAGATTTTGCTACGTACTACTGTCAACAGTATCATACTAATCCTACTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-160 (SEQ ID NO: 1204)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGAGGCGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCATTCTTCCGAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGAAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATATGTCGCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-161 (SEQ ID NO: 1205)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGATAGTGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTATGCTCCTGATCTATTCTTCGTCCGATTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATAGTCTGCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-162 (SEQ ID NO: 1206)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTTCGGATGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATAATTCGTCCTTTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGGCAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATAGTTTGCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-163 (SEQ ID NO: 1207)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGAGGGTAATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATTCGTCCCAGTTGCAAAGTGGGGTCCCATCA CETTTCAGTGGCAGTGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATCATCTTCCTACGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-164 (SEQ ID NO: 1208)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTGATACGGATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATGGGTCCTGGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCGGTGGATTCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-165 (SEQ ID NO: 1209)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTAGTACTGATTTAGAGTGGTACCAGCAGAAACTA GGGAAAGCCCCTAAGCTCCTGATCTATGATGCTTCCCTTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTCGAGTCTGCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-166 (SEQ ID NO: 1210)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTACGACGTCTTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATGCGTCCATGTTGCAAAGTGGGGTCCCATCA CETTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGTTACGCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-167 (SEQIDNO: 1211)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACCTGCCGGGCAAGTCAGAATATTCATACGAATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCATGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTCGGCTAATCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGGAATCAAACGG BMS2h-168 (SEQ ID NO: 1212)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTGGATTCATACGGATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCATGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATAGTGTGTCGCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-169 (SEQ ID NO: 1213)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTGATAATAATTTAGAGTGGTACCAGCAGAAACCA GGGGAAGCCCCTAAGCTCCTGATCTATGATGGGTCCCTTTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTTACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATCTTCATCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-170 (SEQ ID NO: 1214)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGATACGAATTTAGAGTGGTATCAGCAGAAACCA GGGGAAGCCCCTAAGCTCCTGATCTATGATCGTTCCACGTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGATTCTTATCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-171 (SEQ ID NO: 1215)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTCTATTGAGTCTAATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATAATGCGTCCGAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCGACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGATCAGTGGCCTACGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-172 (SEQ ID NO: 1216)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACT ATCACTTGCCGGGCAAGTCAGGCTATTGGTAATACTTTACGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCTTAGTTCCAGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGCTGAAGAAGCCTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-173 (SEQ ID NO: 1217)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAAGATTAAGAATCGGTTAGCGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGAGGTTTCCCATTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCGGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGAGGAGGCAGTCGCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-174 (SEQIDNO: 1218)
GACATCCAGATGACCCAGTCTCCATCCTCCOTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTGAGGATATTGGGGAGGAGTTATTTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTEGGCGTCCACGTTGCAAAGTGAGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACAT GAAGATTTTGCTACGTACTACTGTCAACAGGTTTATGAGTGGCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-175 (SEQ ID NO: 1219)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTTCTGGGGGTTTAAGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTCTACTTCCATGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGCTTTATTCTGCTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-305(SEQ ID NO: 1220)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGATCAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATAATGTTTCCCTGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTCTATGAATCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-306 (SEQ ID NO: 1221)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGGGAATCAGTTAAAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGGCTTCCGGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGATTTGAGGCCTCAGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-307 (SEQ ID NO: 1222)
GACATCCAGATGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGTGACCGTGTCACC ATCACTTGCCGGGCGAGTCAGAAGATTTCTACGTCTTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATGATTCTTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGAGTATAATCCTATTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-33 (SEQID NO: 1223)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGACGATTGGGGAGAGTTTACATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATTTTGCTTCCCTGTTGCAAAGTGGGGTCCCATCG CGTTTCAGTGGCAGTGGATCTGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGCATCATATGCTTCCTTCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-35. (SEQ ID NO: 1224)
GACATCCAAATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTTTATTGGTGATTCTTTATCTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTTITCTTCCATTTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATATGGATATTCCTATTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-36 (SEQ1ID NO: 1225)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGATCATAATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATAGTTCCATGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATTCTATTCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-37 (SEQID NO: 1226)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCAGATTGAGACGAATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCTGGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATAGTTTGCCTGCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-38 (SEQ ID NO: 1227)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGGTAATAATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATCATGGGTCCTGGTTGCAAAGTGGGGTCCCATCG CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTTACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGATTTTAATCCTACTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-39 (SEQID NO: 1228)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACTGTGTCACC ATCACTTGCCGGGCAAGTCAGAATATTGATGGTCTGTTATGGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGCGGGETCCEGGETTEGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGAAGGCTTTTGAGCCTTTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-405 (SEQ ID NO: 1229)
GACATCCAGATGACCCAGACTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTGGTCATGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATAATGTGTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATAGTCATAATCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-406 (SEQ ID NO: 1230)
GACATCCAGATGACCCAGTCTCCATCCTCCOTGTCTGCATCTGTAGGAGACCGTGTCACT ATCACTTGCCGGGCAAGTCAGCATATTGAGAATGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTCTGCTTCCCATTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATCTTCAGCCTACGACGTTCGGCCCA
GGGACCAAGGTGGAAATCAAACGG BMS2h-431 (SEQ ID NO: 1231)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACT ATCACTTGCCGGGCAAGTCAGGTTATTGAGGGTAGTTTAAATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCATAGGTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCCETEGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACTTATCAGCTTCCTTTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-432 (SEQ ID NO: 1232)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCGTCCTATTAATGGTAAGTTATTTTGGTACCAGCAGAAACCA GGCAAAGCCCCTAAGCTCCTGATCGCGTTTGCTTCCGCTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGTGCAGCAGGCTGTGTATCCTATTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-433 (SEQ ID NO: 1233)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCTATTGAGACGAATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATGGGTCCCTTTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGAGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATTATCAGCCTGCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-434 (SEQ ID NO: 1234)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGAGCATGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTCGGCGTCCCAGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCAGCAGCAGCCTACTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-435 (SEQ ID NO: 1235)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTTCGCAGATTGAGGAGTCTTTATGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGCGGATGTTTCCCTGTTGCAAAGTGGAGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGCTCAGGGTGTGGTGGAGCCTCGTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-436 (SEQ ID NO: 1236)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTATATTGGTCTGGATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGCTGCTTCCTGGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTTTCGGCAGCCTATTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-437 (SEQIDNO: 1237)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGETTECAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCATGTGCGTCCTCCTGCGACGTTEGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-437-1 (SEQ ID NO: 1238)
GACATCCAGTTGACCCAGTCTCCAACCTCCCTGTCTGCAACTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAGATTGGTACCAGCAGAAACCT GGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACTGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCATGTGCGTCATCCTGCGACGTTCGECCAA
GGGACCAAGGTGGAAATCAAGCGG BMS2h-437-2 (SEQ ID NO: 1239)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGACAGCATGTGCGTCCTCCTGCEACETTCGECCAA
GGGACCAAGGTGGGAATCAAACGG BMS2h-437-3 (SEQ ID NO: 1240)
GACATCCAGATGACCCAGTCTCCGTCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGTAAGTACGCCGATTGGTACTATGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGGTTECAMAGTGGGGETCCCACCA CETTTCAGTGGCAGCGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCATGTGCGTCCTCCTGCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-437-4 (SEQ ID NO: 1241)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCTGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCATGTGCGTCCTCCTGCGACGTTCGECCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-437-5' (SEQ ID NO: 1242)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGATAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCATGTGCEGTCCTCCTGCEACGTTCGGCAAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-438 (SEQ ID NO: 1243)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACATGCCGGGCAAGTCAGTATATTGATACTAATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATGATGGTTCCCAGTTGCAAAGTGGGGTCCCATCA CETTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCATCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCAGGTTGTGCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-439 (SEQ ID NO: 1244)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAMATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCGTGGATTCTTCEGGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGTCAGGATCGTTGGTCTCCTGCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-440 (SEQ ID NO: 1245)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTTCGCGGATTCAGCATATGTTATCTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGTGGGCATTCCEGGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGCGCAATCGTGTGCGTGEGCCTCTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-441 (SEQ ID NO: 1246)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGGGGTATTGATGGTGATTTATGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGCGGATTCTTCCCTGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGGGGGCTEGTTCGGCCTATGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-442 (SEQ ID NO: 1247)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGGGGTATTGATACTGATTTATGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGCGGATTCTTCCCTGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGGGGGCTEGTTCGGCCTATGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-443 (SEQ ID NO: 1248)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTTATACTATTCCGGTTGCTTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGCTGATGCGTCCTTGTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGCGCAGGGTTGGCCGGEGCCTCAGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-444 (SEQ ID NO: 1249)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTGCGACGGACTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATACTTCCATGTTGCAAAGCGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATAGTTATAATCCTTCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-445 (SEQ ID NO: 1250)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTGTGCCTATTACTGAGGGTTTATCGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCCAGGCTAATTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTGGGAGCATGTTCCTGCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-446 (SEQ ID NO: 1251)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGTATGATTCTTTATGGTTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGTGGTACTTCCGCEGTTGCAMAGTGGGGTCCCATCA CETTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTGGGAGACGGTTCCTGCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-447 (SEQIDNO: 1252)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTAATGGGCTTTTAATTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGCGATGTCCAGTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTTGGCTCGGATTCCTTTTACGTTCGGCCAA
GGGACCAAGGTGGGAATCAAACGG BMS2h-448 (SEQ ID NO: 1253)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGAGCAAGTCAGCTGATTCGGACTTATTTAGCGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCAGTCTTCTCAGTTGCAAAGTGGTGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATAATTCTTATCCTGATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-47 (SEQID NO: 1254)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTGGATTGGGGATTCGTTAAGTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTTTGGTTCCTATTTGCAAAGTGGGGTCCCATCA CETTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTTGCATACTCCTTCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-484 (SEQ ID NO: 1255)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGAGGCGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCATTCTTCCGAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGGTTTTAATCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-485 (SEQ ID NO: 1256)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTTCTCCTATTGAGTATGGTTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGGEGEGEGTCCGCGTTEGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTGGGAGGTTCAGCCTGCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-486 (SEQ ID NO: 1257)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCGGATTGATACTGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATAGTTCACAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATCATAGTGCGCCTGCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-487 (SEQ ID NO: 1258)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTGGGTGGATTGGTATGTCTTTAGAGTGGCACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCCGTGGGECTTCCTCTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTAGTCAGTCTCGGTGGCCEGCCTEGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-488 (SEQ ID NO: 1259)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCGTAATATTTCGAATGCTTTATCEGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCCTTGGGGCTTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTACTCAGGTGTGGGATAGGCCTTTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-489 (SEQ ID NO: 1260)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTATGTCGGCTTTATCTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTCTACTTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGGTTTATTTGCTGCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-490 (SEQ ID NO: 1261)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGAGATTGGGATTGATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGCTGCTTCTTATTTGCAAAGTGGGGTCCCATCA CGTTTCAGTAGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGCTTCTAATCCTCCTACGTTCGGCCGA
GGGACCAAGGTGGAAATCAAACGG BMS2h-491 (SEQ ID NO: 1262)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGATGATTGGGGATTGGTTAAATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAACTCCTGATCTATCGTAGTTCCGAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTTGTATTTTTGGCCTCGTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-492 (SEQ ID NO: 1263)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCGATTGAGCTTAATTTAGAGTGGTACCAGCAGAAACCA GGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGATGTTTATCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-492-1 (SEQ ID NO: 1264)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCCAGTCAGGCGATTGAGCATAATTTAGAGTGGTACCAGCAGAAGCCA GGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTCCAACCT GAAGATTTAGCTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTACGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-492-2 (SEQ ID NO: 1265)
GACATCCAGATGACACAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCGGGCGATAGAGACTAATTTAGAGTGGTACCAGCAGAAACCA GGGAAGGCCCCTAAGCTCCTGTTCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCA CETTTCEGGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCTACAGTATGATGTTTATCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-492-3 (SEQ ID NO: 1266)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAACTGTAGGAGACCGTGTCACC ATCACTTGTCGTGCAAGTCAGGCGATTGAGACTAATTTAGAGTGGTACCAGCAGAAACCA GGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGACTTCACTCTCACCATTAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-492-4 (SEQ ID NO: 1267)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCGATTGAGCATAACTTAGAGTGGTACCAGCAGAAACCA GGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCA CGTTTCAGTGGCAGAGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-492-5 (SEQ ID NO: 1268)
GACATCCAGATGAACCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCTCC ATCACTTGCAGGGCAAGTCAGGCTATTGAGCATAATTTAGAGTGGTACCAGCAGAAACCA GGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCA CGCTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-492-6 (SEQ ID NO: 1269)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCGATTGAGTCTAATTTAGAGTGGTACCAGCAAAAACCA GGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGATGTTTATCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-492-7/ (SEQ ID NO: 1270)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGTGCAAGTCAGGCGATTGAGCATAATTTAGAGTGGTACCAGCAGAAACCA GGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-493 (SEQ ID NO: 1271)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGGTATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGTGGGGTCCCATCA CEGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-494 (SEQ ID NO: 1272)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-494-1 (SEQ ID NO: 1273)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGACCGTGTCACC ATCACTTGCAGGGCAAGTCAGAGTATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTCTCAGTATCCTCCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-494-2 (SEQ ID NO: 1274)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTGAAGAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGCGGGGTCCCATCA CGTTTCAGTGGGAGTGGCTCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAT
GGGACCAAGGTGGAAATCAAACGG BMS2h-494-3 (SEQ ID NO: 1275)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTTCTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-494-4 (SEQ ID NO: 1276)
GAGATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATGACTTGCCGGGCAAGTCAGAGTATTGATAAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGAGGGGTCCCATCA CGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCGACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTGGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-494-5 (SEQ ID NO: 1277)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGAGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCOTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGGTCTGCAACCT GAAGATATCGCTACGTACTACTGTAAACAGTATTCTCAGTATCCTCCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-494-6 (SEQ ID NO: 1278)
GACATCCAGATGACCCAGTCCCCACCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTGATAAGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGAGGGGTCCCATCA CGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACCACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-495 (SEQ ID NO: 1279)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTGAGTATATTAATGCTGAGTTAGCTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGGGAGTTCCGGGTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCTGCAGAATGCGATGTGGCCTATTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-496 (SEQ ID NO: 1280)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCTGGATATTAATAATGGTTTAATTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTTGGGTECGTCCGGTTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTTCGCAGGTGCGTTCTCGGCCTTTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-497 (SEQIDNO: 1281)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTCTGAGTGCGTTAGCTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGGGAGTTCCGTTTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCAGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGAATTATAGTCTTCCTATTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-498 (SEQ ID NO: 1282)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTTCTCCTATTGAGTCGTATTTAAGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCAGGTATGTGTCCGTGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTGGTTTCGGGCGCCTETTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-499 (SEQ ID NO: 1283)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGTAAGTGAGTCTATTAATGCTGAGTTACATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTCTGGGTTTTCOEGGETTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGTGCAGTTTGCGATGTGGCCTTTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-500 (SEQ ID NO: 1284)
GACATCCAGATGACCCAGTCTCCATCCTCCOTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTATGATGATTAGGTTTGGGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGTGGTEGETCCTCTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCATGAGCGGTGGCCTGCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-501 (SEQ ID NO: 1285)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTGGTACTCTTTTACGTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCTTACTTCCGTTTTGCAAAGTGGGGTCCCATCA CEGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGATGGTTTATCGTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-502 (SEQ ID NO: 1286)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGACTATTGAGACTAATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATTCTTCCCAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGATAAGGTTCCTGCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-503 (SEQ ID NO: 1287)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCATCATATTCAGAGGTATTTATOEGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCCTTTGGGGTTCCCAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTGGTGGGCTCCTCCTCCGACGTTEGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-503-1 (SEQ ID NO: 1288)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCATCATATTCAGAGGTATTTATCGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCCTTTGGGGTTCCCAGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTGGTGGGCTCCTCCTCAGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-503-2 (SEQ ID NO: 1289)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCATGATATTCAGAGGTATTTATCOGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCCTTTGGGGTTCCCAGTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTGGTGGGCTCCTCCTCAGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-504 (SEQ ID NO: 1290)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACATGCCGGGCAAGTCAGTATATTGATACTAATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCCTGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGGGGGCTGTTGTGCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-508 (SEQ ID NO: 1291)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGCTTTTGATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTCGGCGTCCATGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGTCAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATAATCTTCAGCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-509 (SEQ ID NO: 1292)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAATATTGCTACGCTGTTACGTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGCTGGTTCCATGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGATGTGGCAGCGTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-51 (SEQ ID NO: 1293)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGTTGATGAGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGCTGCGTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCATCAGTGGTCTACTTATCCTACGACGTTCGGCCAA
GGGACCAAGGTGGAAATTAAACGG BMS2h-510 (SEQ ID NO: 1294)
GACATCCAGATGACCCAATCTCCATCCTCCCTGTCTGCATOTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTAATCGATGGTGTTTCCGGTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGGATTGGGATTGGCCTCGTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-511 (SEQ ID NO: 1295)
GACATCCAGATGACCCAGTCTCCATCCTCCOTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGGAATATTCGTGATTGGTTACGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGATTGGGGGTCCGTETTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGCTCAGACGTGGGATGATCCTCTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-511-1 (SEQ ID NO: 1296)
GACATCCAGATGACCCAGTCTCCATCCTCCOTGTCTGCATTTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGGAATATTCGTGATTGGTTACGGTGGTACCAACAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGATTGGGGGTCCGAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGCTCAGACGTGGTATGATCCTCTGACGTTCGGCCAC
GGGACCAAGGTGGAAATCAAACGG BMS2h-512 (SEQ ID NO: 1297)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTATTGATATTCATGGTGGTTTAACTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGTGGGGGETTTCCGGTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAATCTGCAACCT GAAGATTTTGCTACGTACTACTGTGCGCAGGTGTGGCGTAGGCCTTTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-513 (SEQ ID NO: 1298)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGGGAGTTCGTTATCTTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGCTTCTTCCCTGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACTTATGCTCTTCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-514 (SEQ ID NO: 1299)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCAGATTGAGACGAATTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATAAGTATCTGCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-52 (SEQID NO: 1300)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGTGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGGGTCTGCGTTAAGGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTTGGGTTCCGATTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACGCAGTATTTTCCTACGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-53 (SEQID NO: 1301)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGCGATTTATGGGGEGGTTACGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGGGGAGTCCATGTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCATCCT GAAGATTTTGCTACGTACTACTGTCAACAGGTTTATCATAAGCCTTTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-536 (SEQ ID NO: 1302)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACGTGCCGGGCAAGTCAGCGTATTGGGGTGTGGTTAGATTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCTTTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACTTTTTCGAGTCCTTCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-537 (SEQ ID NO: 1303)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTETCCCC ATCACTTGCCGGGCAAGTCAGTGGATTGGGGATGAGTTATATTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATAGTTCTTCCACTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTCGTTTCAGTTTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-538 (SEQ ID NO: 1304)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGTAATATTACGGGGCCGTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCCCTGGTTEGGTCCACTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGTCAGGTETEGGGEGAGCCTGTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-539 (SEQ ID NO: 1305)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCGTCTATAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCGTATTGCTTATGGTTTACATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATEGEGEEGCGGTCEGGTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGTGCAGCCTEGGATGCCGCCTGATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-540 (SEQ ID NO: 1306)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAAGCAGATTGTTGGTGGTTTATCTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGGCGTCATTCTGGGTTGCAMAGTGGGGTCCCATCA CETTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGTGCAGGGGGTTTGEGCTCCTGGGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-541 (SEQ ID NO: 1307)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCCTGCTATTGCTGCTAAGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGTGCGGATTCCGGGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGTCAGCTGTGEGCEGEGCCTCEGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-542 (SEQ ID NO: 1308)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCGTACTATTGCTGATGGGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGGGCGTATTCCGGTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGTCAGCTTTGGGAGGGTCCTCCGACGTTCGECCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-543 (SEQ ID NO: 1309)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGGATTTATGGGTTTTTAGATTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGGGGTGTCCTCGTTGCAAAGTGGGGTCCCATCA CETTTTAGTGGCAGCGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACTTTGGCGTGGCCTTTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-544 (SEQ ID NO: 1310)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTCGGGATTGGTTAATGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTGGGGTTCCTTTTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGCTGTATGATACTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-545 (SEQ ID NO: 1311)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAATATTAATACGGGTTTAGATTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATAGTTCCGCTTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACGTCGTATTATCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-546 (SEQ ID NO: 1312)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAAGATTTTTGGTTGGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGGGACTTCCAAGTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGGTTTATTCGCTTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-547 (SEQ ID NO: 1313)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTTCGAATATTGGGGCGGATTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGGEGEGCETCCGEGTTECAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCTGTGGAATGGGCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-548 (SEQ ID NO: 1314)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGTCCGATTTATGATGGTTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTCTGGTGCTTCCTGGTTGCAMAGTGGGGTCCCATCA CGCTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGTCAGTTGTGGTTGGGTCCTCCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACAG BMS2h-549 (SEQ ID NO: 1315)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTTCGCGTATTTATAATGGTTTACATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGTEGTCGETCCGGGTTECAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGCTCAGGTGEGGGGAGGCTCCTTCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-550 (SEQ ID NO: 1316)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGGTTTATTAATGAGGAGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTCGTGGTCTTCOTGGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGTGCAGCCGGGGGGTEGTCOTEGGACETTCEGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-551 (SEQ ID NO: 1317)
GACATCCAGATGACCCAGTCTCCATCCTCCOTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGGGATATTCTGGATGAGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCEGGTEGGGGEGTCEGEGTTECAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGTCAGCTGTGGCATGGGCCTCCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-552 (SEQ ID NO: 1318)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGTCCTATTTATACGGGTTTACATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGETEGECEGTCEGEGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTATGCAGGTTGGGACGGCTCCTGCTACGTTCEGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-585 (SEQ ID NO: 1319)
GACATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAATATTTCTAGGCGGTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTCTTCTTCCCGGTTGCAAAGTGGGGTCCCATCA CGTTTCEGGTGGCAGTGGATCTGGGACGGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACGTATAGCTATCCTCATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-604 (SEQ ID NO: 1320)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGTCCGATTCCGCAGGATTTATATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGTTGGGATTTCCCAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTTGTGGAGTGCGCCTGCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-605 (SEQ ID NO: 1321)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAAGTCTATTGATGGGATGTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCCCTGGTTTTTCCGGTTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTCGGTTGAGGCGCCTTGGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-606 (SEQ ID NO: 1322)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCGGTATATTGCTCATCCTTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCCCGGGTTCGTCCGTTTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGTCAGTCGGTTGTGGTGCCTTGGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-607 (SEQ ID NO: 1323)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCGGACGATTGAGGGTGGTTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCATGGGGEGTTCCGGTTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTTGTGGGTGGGTCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-608 (SEQ ID NO: 1324)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAAGTTTATTAGGGATGAGTTATATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCGGTGGTTCGTCCTTGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCTGTGGCGEGCECCTECEACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-609 (SEQ ID NO: 1325)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAAGCCGATTTATGGTGGTTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCGGEGGEGETTCEGTETTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGGTGTGGGGGGGTCCTGTTACGTTCEGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-610 (SEQ ID NO: 1326)
GACATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCGGCCGATTAGTGGTTGTTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGATGGGECTTCCGGETTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTGGTGGGAGTATCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-811 (SEQ ID NO: 1327)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAAGCCTATTGTGAGGGATTTAGAGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCCATGGTGTGTCCACGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCTTGAGGCGGCECCTGCGACGTTCEGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-612 (SEQ ID NO: 1328)
GACATCCAGATGACCCAGTCTCCATCCTCCOTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCGGGATATTGGTGATTGGTTATATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCGTTTGGECETCCEGTETTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGCGCAGTGGGGGACTCCTCCTACGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-613 (SEQ ID NO: 1329)
GACATCCAGATGACCCAGTCTCCATCCTCCOTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAATCGTATTGAGTATGGTTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTCGGGGETCTTCCCGTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTAGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCTTGAGGCGGCECCTEGCGACETTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-614 (SEQ ID NO: 1330)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCGGAATATTGGGCATTTTTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTTGGGGGGETCCTCGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTTGGTGGAGCCTCCTGCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-6815 (SEQ ID NO: 1331)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTTCGAGTATTTATAGTGATTTATATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGATGGGTGGTCCEGGGTTEGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCTGCATCGTGCTCCTGCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-616 (SEQ ID NO: 1332)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGGTTTATTACTGATCGTTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGTGGTGTTTCCGGGTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGAGTTCGGAGTTGCCTTGGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-617 (SEQ ID NO: 1333)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCGTAAGATTGGTAGTGAGTTATATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGTGGTAGETCCCGGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGTTGTGGGAGCCTCCTGCGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-618 (SEQ ID NO: 1334)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTAGGAATATTGGTAATGGTTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCGGGGAGGGGTCCCGTTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGGGCAGCTTTGGCATACTCCTCCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-619 (SEQID NO: 1335)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCGGAATATTTATGGTTGGTTATCGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCGGTEGGETEGTCCGGTTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTGCGCAGGATTATACGTTGCCTGGTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-730 (SEQ ID NO: 1336)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTAAGGATTGGTTACATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTTTGCGTCCGGTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTCTGCTACGTACTACTGTCAACAGCATTATAGTACGCCTTATACGTCCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-731 (SEQ ID NO: 1337)
GACATCCAGATGACCCAGTCTCCACCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTTGATTTCTTCTCATTTAGATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGGTCTATGATGCTTCCGAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGCATCGCAGTCTGCCTTTTACGTTCGGCCAA
GGGACCAAGGTAGAAATCAAACGG BMS2h-732 (SEQIDNO: 1338)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTGGATTGGTGEGECGTTAGCGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTTATCTATCAGATTTCCGTTTTGCAAAGTGGGATCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATATTCGGTCTCCTTTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-733 (SEQIDNO: 1339)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAGTATTGGGGCGGCGTTAAATTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGGTCTGTCCTCTTTGCAMAGTGGGGTCCCATCA CETTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGCTGTTTAGGCTTCCTTTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-734 (SEQ ID NO: 1340)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTGGGGGTCETTTAGTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGGGTCTTCCATTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTATGCTGAGGCTCCTATTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-735 (SEQ ID NO: 1341)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAATATTGGGTCTAGTTTAATTTGGTACCAGCAGAAACCA GGGAAAGCCCCTACGCTCCTGATCTATTATTCGTCCAAGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTCTTTGTCGAGTCCTTATACGGTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-736 (SEQ ID NO: 1342)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTGGATTGGGAGTGAGTTAGCGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTGGACGTCCAATTTGCAAAGTGGGGTCCCATCA CETTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAATCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGATTCTGGAGACTCCTTTGACGTTTGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-737 (SEQ ID NO: 1343)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGAAGATTTGGGATGCTTTATATTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATCGTGGGTCCATTTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTTTTATCGGTGGCCTCATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-738 (SEQ ID NO: 1344)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCATATTGAGGATTCTTTACGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTATGGTTCCGTGTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGATGTATAAGTTTCCTATTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-739 (SEQ ID NO: 1345)
GACATCCAGACGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCGGATTAATTCTTCTTTACTGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATACTTCCACTTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCAGTAGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTCGCTACGTACTACTGTCAACAGATTTGGGGTTCGCCTCCTACGTTCGGCCAG
GGGACCAAGGTGGAAATCAAACGG BMS2h-740 (SEQ ID NO: 1346)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTCGATTCCTGTTGGTTTAMATTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATTCTGGGTCCACTTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGGATTGGTATTATCCTAATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-785 (SEQ ID NO: 1347)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCCTATTTATGGTTGGTTAAATTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTTGACGTCCGGGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGATTCATAGTTCTCCTTTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-8 (SEQ ID NO: 1348)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTTTATTGATACGTCGTTAGAGTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGATGGGTCCCATTTGCAAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTAGCTACGTACTACTGTCAACAGTATTGGGTTCTTCCTCTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-86 (SEQ ID NO: 1349)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGGGGATGCTTTATTTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATTATTCTTCCATGTTGCAAAGTGGGGTCCCATCA CGTTTCAGTGGCGGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGCGGCATAGTACTCCTGCTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-87 (SEQ ID NO: 1350)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGATGAGTCTTTAATGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATGGGGTGTCCTATTTGCAMAGTGGGGTCCCATCA CETTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTCGCTACGTACTACTGTCAACAGCGGTGGAAGGCTCCTTTTACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-88 (SEQ ID NO: 1351)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTTACC ATCACTTGCCGGGCAAGTCAGGAGATTGTGGAGGATTTATATTGGTATCAGCAGAAACCA GGGAAAGCCGCTAAGCTCCTGATCTATGGTGCGTCCTGGTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACGCGTAGGCGTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-89 (SEQID NO: 1352)
GACATCCAGATGACCCAGTCTCCAGCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGGATATTGATCCTATGTTAAGGTGGTACCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGCGGGTTCCATTTTGCAMAGTGGGGTCCCATCA CGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGACGCTGGTGACTCCTTATACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-90 (SEQID NO: 1353)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGTCGATTTCGGATGCGTTATTTTGGTACCAGCAGAAACCA GGGAAAGCCCCTAGGCTCCTGATCTATTATGGTTCCGTTTTGCAAAGTGGGGTCCCATCA CETTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGCGTTTTCAGGAGCCTGTGACGTTCGGCCAA
GGGACCAAGGTGGAAATCAAACGG BMS2h-91 (SEQID NO: 1354)
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGACCGTGTCACC ATCACTTGCCGGGCAAGTCAGCAGATTAGTGATGAGTTAAATTGGTATCAGCAGAAACCA GGGAAAGCCCCTAAGCTCCTGATCTATGCTGTGTCCATTTTGCAAAGTGGGGTCCCATCA CEGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCT GAAGATTTTGCTACGTACTACTGTCAACAGTGGTTGAGTTTTCCTTCGACGTTTGGCCAA GGGACCAAGGTGGAAATCAAACGG
Exemplo 1 Geração de Domínios Variáveis de Anti-CD40L Humano BMS2h-2 até BMS2h-785
[00118] O exemplo a seguir descreve a geração da linhagem 2h de domínios variáveis de anti-CD40L humano, denominada BMS2h-2 até BMS2h-785. Após a expressão recombinante de um repertório de do- mínios variáveis de imunoglobulina isolados sobre a superfície de fa- go, a seleção é realizada através do contato do repertório do fago com antígeno alvo imobilizado, lavando para remover o fago não ligado e propagando o fago ligado. Este processo é frequentemente referido como "mineiração". Este é aplicável à verificação de domínios variá- veis de imunoglobulina isolados, bem como outros fragmentos de anti- corpo que podem ser expressos sobre uma biblioteca de exibição, por exemplo, scFv, Fab e Fab”. Alternativamente, o fago pode ser pré- selecionado para a expressão de variantes de membros dobrados a- propriadamente através da "mineiração" contra um ligante genérico imobilizado (por exemplo, proteína A ou proteína L) que é apenas liga- do por membros dobrados. Isto possui a vantagem de reduzir a pro- porção de membros não funcionais, aumentando assim a proporção de membros que provavelmente se ligarão a um antígeno alvo. A pré- seleção com ligantes genéricos é ensinada na WO 99/20749, por e- xemplo. A verificação de bibliotecas de anticorpos em fagos é geral- mente descrita, por exemplo, por Harrison e outros, Meth. Enzymol. 267: 83-109 (1996).
[00119] A verificação é comumente realizada utilizando antígeno purificado imobilizado sobre um suporte sólido, por exemplo, tubos de plásticos ou poços ou sobre uma matriz de cromatografia, por exem- plo, Sepharose"" (Pharmacia). A verificação ou a seleção também po- de ser realizada sobre antígenos complexos, tal como a superfície de células (Marks e outros, BioTechnology 11: 1145 (1993); de Kruif e ou-
tros, Proc. Natl. Acad. Sci. USA 92: 3938 (1995)). Outra alternativa en- volve a seleção através da ligação com antígeno biotinilado em solu- ção, seguida pela captura sobre esferas revestidas com estreptavidina. Seleção de dAb para a Série de Clones BMS2h-719 e BMS2h-7xx:
[00120] Três rodadas de seleção utilizando concentrações decres- centes de antígeno (500 nM na rodada 1; 50 nM na rodada 2; 50 nM ou 5 nM na rodada 3 dependendo da produção da biblioteca utilizada) foram realizadas em paralelo contra o triplo mutante de monômero de CD40L humano biotinilado (1,2 mol de biotina/mol de CD40L) (T211E, S222Y, H224K, [108-261] Construção tf7) fornecido pela Bristol-Myers Squibb. O fago proveniente das bibliotecas de dAb naiíve 4G e 6G Domantis foram combinados dentro dos grupos a) até g) indicados a seguir antes do início das seleções:
[00121] 4GVHCDR3 comprimentos entre 7 — 10 aminoácidos.
[00122] 4GVHCDR3 comprimentos entre 11 — 15 aminoácidos.
[00123] 4GVHCDR3 comprimentos entre 7 — 15 aminoácidos.
[00124] 4GVK
[00125] 6GVH CDR3 comprimentos entre 7-9
[00126] 6GVHCDR3 comprimentos entre 10-15
[00127] 6GVK
[00128] Cada rodada de seleção envolvia a adição da concentração desejada de CD40L biotinilado a uma mistura de 200 ul de fago (de um dos grupos de biblioteca naiíve indicados anteriormente ou seleção subsequente do fago de produção) e 1000 ul de 2% de MPBS (Solu- ção Salina Tamponada com Fosfato) contendo 2% (p/v) de Marvel [Premier Foods, UK]J) e incubando à temperatura ambiente durante 1 hora através da mistura em movimento de gangorra. O complexo de fago de antígeno biotinilado foi então capturado através da adição de 100 uL de Dynabeads M-280 Streptavidin [Invitrogen, UK] ressuspen- saseincubados durante 5 minutos com misturador com movimento de gangorra à temperatura ambiente. As Dynabeads foram então recupe- radas utilizando um separador magnético KingFisher [Thermo Fisher Scientific, UK] e lavadas 7 x 1 mL de PBST (PBS contendo 0,1% (v/v) de monolaurato de polioxietilenossorbitana 20 [Sigma-Aldrich, UK]) seguido por 1 x 1 mL de PBS. O fago ligado retido sobre as Dynabe- ads lavadas foram eluídos através da incubação com 500 uL de tripsi- na-PBS (50 ul de 10 mg/mL de tripsina [Sigma-Aldrich, UK] dissolvi- dos em 50 mM de Tris-HCl pH 7,4, 1 mM de CaCl, adicionados a 450 ul de PBS). A solução contendo os fagos foi recuperada e 250 ul foram utilizados para infectar 1,75 mL de E. coli TG1 em fase de cres- cimento logarítmico (a uma DOgo,o de 0,4) durante 30 minutos a 37ºC.
A cultura infectada com fago de E. coli TG1 foi centrifugada a 11.600 g em uma microcentrífuga durante 1 minuto e a pelota de células resul- tante foi ressuspensa em 1 mL de 2xTY (16 g de Triptona, 10 g de Ex trato de Levedura e 5 g de NaCl em 1 litro, autoclavado durante 15 mi- nutos a 121ºC) e plaqueada sobre uma placa de Petri de 9 cm conten- do meio TYE suplementado com 15 pg/mL de tetraciclina. As placas foram incubadas durante toda a noite a 37ºC então 2 mL de 2xTY su- plementado com 15% de glicerol foram adicionados em cada placa e as células desprendidas com um espalhador de vidro e misturadas vi- gorosamente. Cinquenta microlitros das bactérias raspadas foram utili- zados para inocular 50 mL de 2xTY suplementado com 15 ug/mL de tetraciclina e crescidos durante toda a noite a 37ºC com agitação a 250 rpm. A cultura realizada durante toda a noite foi centrifugada a
3.300 g durante 15 min para a obtenção de uma pelota de bactérias. Para precipitar o fago, 10 mL de PEG/NaCl (20% de Polietileno glicol 8000, 2,5 M de NaCl) foram adicionados a 40 mL de sobrenadante. À solução de fago/PEG foi misturada e deixada sobre gelo durante 1 h, então centrifugada a 3.300 g durante 30 min a 4ºC e o sobrenadante foidescartado. A pelota foi ressuspensa em 2 mL de PBS e centrifu-
gada a 11.600 g durante 10 min em uma microcentrífuga para remover os restos celulares bacterianos remanescentes. O sobrenadante con- tendo fago resultante foi então utilizado para a próxima rodada de se- leção contra a concentração apropriada de antígeno de triplo mutante demonômero de CD40L biotinilado. ELISA de Fago:
[00129] ELISAs de fagos monoclonais foram realizados após as ro- dadas de seleção 2 e 3. Todas as lavagens foram realizadas utilizando 3 lavagens de 250 uL de PBST seguidas por 3 lavagens de 250 uL de PBS.As placas foram revestidas durante toda a noite a 4ºC com 50 ul/poço de 1 ug/mL de NeutrAvidin [Thermo Scientific, UK] em 0,2 M de tampão carbonato-bicarbonato, pH 9,4. As placas foram lavadas e então bloqueadas com 2% de MPBS durante 1 hora à temperatura ambiente. As placas foram então lavadas e incubadas com 50 uL/poço de->-1,0 ugmL de triplo mutante de monômero de CDA40L biotinilado em 2% de MPBS. As placas foram lavadas e 25 uL/poço de sobrena- dantes de fago foram adicionados a um volume equivalente de 2% de MPBS e incubados durante 1 hora à temperatura ambiente. As placas foram lavadas e o fago ligado detectado com 50 yuL/poço de conjugado anti-M13-HRP [GE Healthcare, UK] diluído 1:5000 em 2% de MPBS e incubado durante 1 hora à temperatura ambiente. As placas foram la- vadas e o ELISA revelado utilizando 50 ul/poço de solução de Sure- Blue 1-Component TMB MicroWell Peroxidase [KPL Inc, USA]. A rea- ção colorimétrica foi interrompida através da adição de um volume e- quivalente de 1M de HCl e a placa de ELISA foi lida a 450 nm. O fago específico foi identificado através da comparação com poços revesti- dos com NeutrAvidin, mas sem triplo mutante de monômero de CD40L biotinilado. Recuperação de genes de dAb de Plasmídeo MidiPrep pDOM4:
[00130] Os genes V de dAb provenientes dos produtos da rodada 3 a seguir foram recuperados através da digestão com enzima de restri- ção de DNA do vetor de fago pDOM4:
[00131] 4G VH CDR3 comprimentos entre 7 — 10 aminoácidos (50 nM de concentração de antígeno).
[00132] 4G VH CDR3 comprimentos entre 11 — 15 aminoácidos (50 nM de concentração de antígeno).
[00133] 4G VH CDR3 comprimentos entre 11 — 15 aminoácidos (5 nM de concentração de antígeno).
[00134] 4G VH CDR3 comprimentos entre 7 — 15 aminoácidos (50nM de concentração de antígeno)..
[00135] 4G VK (50 nM de concentração de antígeno).
[00136] 4GVK(5nM de concentração de antígeno).
[00137] 6G VH CDR3 comprimentos entre 7-9 (50 nM de concen- tração de antígeno).
[00138] 6GVHCDR3 comprimentos entre 10-15 (5 nM de concen- tração de antígeno).
[00139] Aproximadamente 20 ug de MidiPrep [Qiagen, UK] DNA foram digeridos com Sa/l e Notl como a seguir: 20 ul de DNA (1 ug/uL) foram misturados com 1,5 ul de Sa/l (20 U/uL) [NEB, UK] e 3ul de Notl (10 U/uL) [NEB, UK], 41/L de Tampão 3 [NEB, UK], 0,4 uL de BSA (10 mg/mL) [NEB, UK] e água de grau de cultura de tecido [Sigma, UK] adicionada até 40 ul. As amostras foram incuba- das durante 5 horas a 37ºC em uma incubadora com ar após as quais os genes de dAb digeridos foram isolados correndo a mistura de di- gestão sobre um gel de agarose a 2% [E-gel, Invitrogen, UK], as ban- das de DNA apropriadas foram cortadas e limpas utilizando um kit de purificação de PCR [Qiagen, UK]. Os genes V purificados foram liga- dos dentro de um vetor de expressão pDOMS com digestão dupla com Sall e Notl. ELISA de daAb Solúvel:
[00140] Os dAbs que se ligam foram identificados como a seguir.
Noventa e seis colônias individuais contendo os genes V de dAb clo- nados dentro do vetor de expressão de dAb solúvel pDOMSB5 foram se- lecionadas de cada produção dentro de 200 uL de Terrific Broth con-
tendo meio OnEx Autoinduction [Novagen, UK] e incubadas durante toda a noite a 37º C com agitação a 250 rpm em Costar 96 Well Cell Culture Clusters [Corning Incorporated, USA] seladas com uma tira de plástico adesivo permeável por gás.
As culturas foram centrifugadas para peletizar as células e os sobrenadantes foram analisados através de ELISA de ligação ao antígeno em relação aos dAbs que se ligam ao triplo mutante de monômero de CD40L e mutante IZ-CD40L (CD40L contendo um domínio de trimerização com zíper de isoleucina, fornecido pela Bristol-Myers Squibb). Imunoplacas de 96 poços Maxi- Sorp [Nunc, USA] foram revestidas durante toda a noite a 4ºC com 50 ul/poço de 1 ugiml de NeutrAvidin em 0,2 M de tampão carbonato- bicarbonato, pH 9,4. Todas as lavagens ocorreram como descrito para o ELISA de fago.
As placas foram bloqueadas durante 1 hora à tempe- ratura ambiente com 200 ul de PBS contendo 1% de Tween 20. À placa foi então lavada e incubada durante 1 hora à temperatura ambi-
entecom 50 ul/poço de 1 ug/mL de triplo mutante de monômero de CD40L biotinilado em PBST ou 1 ug/mL de mutante IZ-CD40L humano biotinilado em PBST (ambos os antígenos fornecidos pela Bristol- Myers Squibb). A placa de ELISA foi lavada e o sobrenadante de cultu-
ra contendo dAb foi clarificado por centrifugação a 1.800 g durante 10 mina4ºC, então adicionado à placa de ELISA (30 uL/poço) à qual foi adicionado um volume equivalente de PBST.
As placas foram incuba-
das durante 1 hora à temperatura ambiente e então lavadas.
O dAb ligado foi detectado através da adição de 50 ul/poço de 9E10 [anti-
myc IgG, Sigma-Aldrich, UK] diluído 1:2000 em PBST e da incubação durante 1 hora à temperatura ambiente; a placa de ELISA foi então lavada e 50 ul/poço de Fc-HRP anticamundongo [Sigma-Aldrich, UK] diluído 1:2000 em PBST foram adicionados e incubados durante 1 ho- ra à temperatura ambiente. As placas foram lavadas e o ELISA revela- do através da adição de 50ul/poço de solução SureBlue 1- Component TMB MicroWell Peroxidase [KPL Inc, USA] e foi permitido que a coloração se desenvolvesse. A reação colorimétrica foi inter- rompida através da adição de um volume equivalente de 1 M de HCl e a placa de ELISA foi lida a 450 nm. Os dAbs que se ligam ao antígeno foram identificados através da comparação da intensidade de sinal proveniente dos poços com triplo mutante de monômero de CD40L humano e com mutante IZ-CD40L humano com poços de controle que não continham antígeno. Expressão & Purificação de dAb na Escala de 50 mL:
[00141] dAbs únicos foram identificados através do sequenciamento do DNA de clones positivos para ELISA. Os dAbs únicos foram ex- pressos como a seguir em frascos com chicanas de 250 mL, aos quais foi adicionado:
[00142] 50mL de Terrific Broth [Sigma-Aldrich, UK].
[00143] 100 ug/mL de carbenicilina [Sigma-Aldrich, UK].
[00144] 1gotade antiespumante A204 [Sigma-Aldrich, UK].
[00145] “Novagen Overnight Express Autoinduction Kit [Novagen, UK].
[00146] Um raspado bacteriano proveniente de uma placa com ágar de 9 cm de diâmetro confluente fresca ou proveniente de um estoque emglicerol do clone de dAb desejado foi utilizado para inocular o Terri- fic Broth, então o frasco foi selado com membrana Milliwrap PTFE [Mil- lipore, UK] e incubado durante 48 h, agitação a 250 rpm a 30ºC. A cul- tura bacteriana durante toda a noite foi clarificada por centrifugação e o dAb de VH ou de VK purificado utilizando Streamline Protein A [GE Healthcare, UK] ou Protein L agarose [gerada no local] respectivamen-
te. As proteínas purificadas resultantes foram analisadas por RBA para determinar quais clones poderiam inibir a ligação de CD40L para CD40. Ensaio de Ligação ao Receptor em Esfera de CD40L:
[00147] dAbs inibidores foram inicialmente identificados através da verificação de dAb purificado em um ensaio de ligação ao receptor em esfera (RBA) de CD40L. Esferas de estreptavidina poliestireno Sphero (0,5% p/v, 6,7 um de diâmetro) [Saxon, Europa] foram preparadas e lavadas de acordo com as instruções do fabricante. As esferas foram então peletizadas a 11.600 g durante 1 minuto, o sobrenadante des- cartado e as esferas ressuspensas em 1 mL de PBS através do uso de um vortex. A etapa de lavagem foi repetida mais duas vezes, o sobre- nadante foi descartado e as esferas foram ressuspensas em 1 mL (0,5 mg/mL) de IZ-CD40L humano biotinilado em PBS e incubadas du- rante toda a noite à temperatura ambiente com rotação em movimento de gangorra. Após a incubação, as esferas foram peletizadas e lava- das três vezes com 1 mL de PBS como anteriormente e então ressus- pensas em 0,5 mL de PBS contendo 0,1% de albumina do soro bovino (BSA). As esferas revestidas com antígeno foram então diluídas 1:10 em PBS contendo 0,1% de BSA antes do uso. Os reagentes para o ensaio de RBA foram adicionados como a seguir a poços em duplicata em uma placa FMAT com fundo transparente com preto nas laterais de 384 poços [Applied Biosystems, UK]:
[00148] 12,5uL de proteína dAb ou controle de tampão. A concen- tração de início de titulação de dAb era tipicamente de 10 uM (concen- tração final) que foi diluída 1:3,3 (isto é, 30 ul de amostra adicionados a 70 ul de PBS contendo 0,1% de BSA) para produzir uma curva de efeito de titulação de 8 pontos.
[00149] 12,5uUL de CD40-Fc [fornecido pela Bristol-Myers Squibb, USA; lote CY24Feb06-1] a 0,2 ug/mL (para uma concentração final de
0,05 pug/mL) diluídos em PBS contendo 0,1% de BSA.
[00150] 12,5uL de Mistura de antidcFc humano de camundongo [Sigma-Aldrich, UK] a 2 ug/mL (para uma concentração final de 0,5 pg/mL) e anticamundongo de caprino Alexa Fluor 647 [Invitrogen, UK] a1ugml (para uma concentração final de 0,25 ug/mL) diluídos em PBS contendo 0,1% de BSA.
[00151] 12,5 uL de esferas revestidas com IZ-CD40L descrito ante- riormente foram adicionados no centro do poço de forma que não se dispersassem para a beirada do poço.
[00152] Após a adição dos reagentes na placa de 384 poços, esta foi incubada à temperatura ambiente durante 6 horas na escuridão e então lida em um sistema AB8200 FMAT [Applied Biosystems, UK]. Exemplo 2 Seleção de dAb para o Clone BMS2h-572
[00153] Três rodadas de seleção utilizando concentrações decres- centes de antígeno (300 nM na rodada 1; 30 nM na rodada 2; 3 NM na rodada 3) foram realizadas em paralelo contra zíper de leucina-CD40L humano biotinilado (IZ-hCD40L) (1,42 mol de biotina/mol de trímero) fornecido pela Bristol-Myers Squibb. O fago proveniente das bibliote- cas de dAb naive 4G e 6G Domantis foram combinados dentro dos grupos a) até h) indicados a seguir antes de iniciar as seleções:
[00154] 4GVH CDR3 comprimentos entre 7 — 9 aminoácidos.
[00155] 4GVHCDR3 comprimentos entre 10 — 12 aminoácidos.
[00156] 4GVHCDR3 comprimentos entre 13 — 15 aminoácidos.
[00157] 4GVK
[00158] 6GVHCDR3 comprimentos entre 7-9
[00159] 6G VH CDR3 comprimentos entre 10-12
[00160] 6G VH CDR3 comprimentos entre 13-15
[00161] 6GVK
[00162] Cada rodada de seleção envolvia a adição da concentração desejada de CD40L biotinilado a uma mistura de fago (proveniente de um dos grupos de biblioteca naive indicados anteriormente ou fago de produção de seleção subsequente) em 1000 ul de 2% de MPBS (So- lução Salina Tamponada com Fosfato contendo 2% (p/v) de Marvel [Premier Foods, UK]) e a incubação à temperatura ambiente durante 1 hora através da mistura em movimento de gangorra. O complexo de fago antígeno biotinilado foi então capturado através da adição de 100 ul de Dynabeads M-280 Streptavidin ressuspensas [Invitrogen, UK] (rodadas 1 e 3) ou 50 ul de M-280 tosylactivated Dynabeads (Invi- trogen) que foram acopladas com NeutrAvidin [Thermo Fisher Scienti- fic, UK] (rodada 2) e incubadas durante 5 minutos com mistura em movimento de gangorra à temperatura ambiente. As Dynabeads foram então recuperadas utilizando um separador magnético KingFisher [Thermo Fisher Scientific, UK] e lavadas 7 x 1 mL de PBST (PBS con- tendo 0,1% (v/v) de monolaurato de polioxietilenossorbitana 20 [Sig- ma-Aldrich, UKJ) seguido por 1 x 1 mL PBS. O fago ligado retido sobre as Dynabeads lavadas foram eluídos através da incubação com 500 uL de tripsina-PBS (50 ul de 10 mg/mL de tripsina [Sigma-Aldrich, UK] dissolvidos em 50 mM de Tris-HCI pH 7,4, 1 mM de CaCl, adicio- nados a 450 ul de PBS). A solução contendo fagos foi recuperada e 250 uL foram utilizados para infectar 1,75 mL de E. coli TG1 em fase de crescimento logarítmico (em uma DOçoo de 0,4) durante 30 minutos a 37ºC. A cultura infectada com o fago de E. coli TG1 foi centrifugada a 11.600 g em uma microcentrífuga durante 1 minuto e a pelota de cé- lulas resultante foi ressuspensa em 1 mL de 2xTY (16 g de Triptona, 10 g de Extrato de Levedura e 5 g de NaCl em 1 litro, autoclavado du- rante 15 minutos a 121ºC) e plaqueada sobre uma placa de Petri de 9 cm contendo meio TYE suplementado com 15 pug/mL de tetraciclina.
As placas foram incubadas durante toda a noite a 37ºC então 2 mL de 2xTY suplementado com 15% de glicerol foram adicionados em cada placa e as células foram desprendidas com um espalhador de vidro e misturadas vigorosamente. Cinquenta microlitros das bactérias raspa- das foram utilizados para inocular 50 mL de 2xTY suplementado com 15 pg/mL de tetraciclina e crescidos durante toda a noite a 37 com agitação a 250 rpm. A cultura realizada durante toda a noite foi centri- fugada a 3.300 g durante 15 min para peletizar as bactérias. Para pre- cipitar o fago, 10 mL de PEG/NaCl (20% de Polietileno glicol 8000, 2,5 M de NaCl) foram adicionados a 40 mL de sobrenadante. A solução de fago/PEG foi misturada e deixada sobre gelo durante 1 h, então centri- fugada a 3.300 g durante 30 min a 4ºC e o sobrenadante foi descarta- do. A pelota foi ressuspensa em 2 mL de PBS e centrifugada a 11.600 g durante 10 min em uma microcentrífuga para remover os restos celu- lares bacterianos remanescentes. O sobrenadante contendo fago re- sultante foi então utilizado para a rodada de seleção seguinte contra a concentração apropriada de IZ-hCD40L biotinilado. ELISA de Fago:
[00163] ELISAs de fago monoclonal foram realizados após as roda- das de seleção 2 e 3. Todas as lavagens foram realizadas utilizando 3 lavagens de 250 ul de PBST seguidas por 3 lavagens de 250 uL de PBS.As placas foram revestidas durante toda a noite a 4ºC com 50 ul/poço de 1 ug/mL de IZ-hCD40L em PBS. As placas foram lavadas e então bloqueadas com 2% de MPBS durante 1 hora à temperatura ambiente. As placas foram lavadas e 25 uL/poço de sobrenadantes de fago foram adicionados a um volume equivalente de 2% de MPBS e incubadas durante 1 hora à temperatura ambiente. As placas foram lavadas e o fago ligado foi detectado com 50 ul/poço de conjugado anti-M13-HRP [GE Healthcare, UK] diluído 1:5000 em 2% de MPBS e incubados durante 1 hora à temperatura ambiente. As placas foram lavadas e o ELISA foi revelado utilizando 50 uL/poço de solução Sure- Blue 1-Component TMB MicroWell Peroxidase [KPL Inc, USA]. A rea-
ção colorimétrica foi interrompida através da adição de um volume e- quivalente de 1 M de HCl e a placa de ELISA foi lida a 450 nm. O fago específico foi identificado através da comparação com poços que não foram revestidos com antígeno, mas foram de outra maneira tratados deforma idêntica. Recuperação de genes dAb do plasmídeo pDOM4:
[00164] Os genes V de dAb provenientes dos produtos das rodadas 2 e 3 foram recuperados através da digestão com enzimas de restrição Sall e Notl do vetor de fago pDOMA4 e ligados dentro de um vetor de expressão pDOMSB digerido duplamente com Sa/l e Notl. ELISA de dAb Solúvel:
[00165] Os dAbs de ligação foram identificados como a seguir. No- venta e seis colônias individuais contendo genes V de dAb clonados dentro do vetor de expressão de dAb solúvel pDOMS5 foram seleciona- das de cada produção em 200 uL de Terrific Broth contendo meio O- nEx Autoinduction [Novagen, UK] e incubadas durante toda a noite a 37º C com agitação a 250 rpm em Costar 96 Well Cell Culture Clusters [Corning Incorporated, USA] seladas com uma tira de plástico adesivo permeável a gás. As culturas foram centrifugadas para peletizar as cé- lulaseos sobrenadantes foram analisados através de ELISA com liga- ção de antígeno para dAbs que se ligavam ao IZ-hCD40L. Imunopla- cas com 96 poços MaxiSorp 96 [Nunc, USA] foram revestidas durante toda a noite a 4ºC com 50 ulL/poço de 1 ug/mL de IZ-hCD40L em PBS. Todas as lavagens ocorreram como descrito para o ELISA de fago. As placas foram bloqueadas durante 1 hora à temperatura ambiente com 200 ul de PBS contendo 1% de Tween 20. A placa de ELISA foi lava- da e o sobrenadante de cultura contendo dAb foi clarificado por centri- fugação a 1.800 g durante 10 min a 4ºC, então adicionado à placa de ELISA (30 uL/poço) à qual foi adicionado um volume equivalente de PBST.As placas foram incubadas durante 1 hora à temperatura ambi-
ente e então lavadas. O dAb ligado foi detectado através da adição de 50 ul/poço de 9E10 [anti-myc IgG, Sigma-Aldrich, UK] diluído 1:2000 em PBST e da incubação durante 1 hora à temperatura ambiente; a placa de ELISA foi então lavada e 50 ul/poço de Fc-HRP anticamun- dongo [Sigma-Aldrich, UK] diluídos 1:2000 em PBST foram adiciona- dos e incubados durante 1 hora à temperatura ambiente. As placas foram lavadas e o ELISA revelado através da adição de 50 yL/poço de solução SureBlue 1-Component TMB MicroWell Peroxidase [KPL Inc, USA] e foi permitido que a coloração se desenvolvesse. A reação colo- rimétrica foi interrompida através da adição de um volume equivalente de 1 M de HCl e a placa de ELISA foi lida a 450 nm. Os dAbs que li- gam ao antígeno foram identificados através da comparação da inten- sidade de sinal de poços com IZ-hCD40L com poços de controle que não continham o antígeno. Exemplo3 Identificação dos Clones BMS2h-503-1, BMS2h-719-2 e BMS2h- 572-6
[001668] Os dAbs BMS2h-503, BMS2h-719 e BMS2h-572 foram submetidos à maturação da afinidade propensa a erros para gerar as linhagens BMS2h-503, BMS2h-719 e BMS2h-572, respectivamente. Esta foi realizada utilizando mutagênese aleatória em que na média 3,6 alterações de aminoácidos foram introduzidas por dAb. As bibliote- cas de fago (tamanho médio de 6x10º) foram selecionadas utilizando CD40L monomérico e trimérico humano biotinilado com captura de es- feras alternante de estreptavidina/neutravidina do antígeno (como des- crito). Três rodadas de seleções utilizando concentrações decrescen- tes de antígeno (100 nM na rodada 1; 10 nM na rodada 2; 1 NM na ro- dada 3) foram realizadas. O sequenciamento foi utilizado para monito- rar a diversidade após cada rodada de seleção. As produções da sele- ção (a rodada 2 selecionada no trímero de CD40L para BMS2h-572;
rodada 3 selecionada no trímero de CD40L para BMS2h-503 e rodada 3 selecionada no monômero de CD40L para BMS2h-719) foram sub- clonadas dentro do vetor de expressão solúvel pDOM13 (no tag C terminal) (como descrito) e verificadas na forma de sobrenadantes de microcultura bacteriana monoclonal por BlAcore para aprimorada taxa de dissociação comparada com clones parentais sobre o CD40L tanto monomérico quanto trimérico. Os variantes aprimorados identificados tiveram seu DNA sequenciado e os dAbs únicos foram expressos, pu- rificados e então analisados utilizando o RBA com esferas de BMS2h bem como ensaios controlados por CD40L celular (como descrito). Como um resultado, os dAbs BMS2h-503-1 (sequência listada na TABELA 3), BMS2h-719-2 e BMS2h-572-6 (sequências listadas na TABELA 1) foram identificados. As atividades destes dAbs estão lista- das na TABELA 5 a seguir.
Formatação de BMS2h-503-1, BMS2h-719-2 e BMS2h-572-6 na forma de fusões de Fc
[00167] Os dAbs BMS2h-572-6, BMS2h-503-1 e BMS2h-719-2 fo- ram clonados no vetor pPDOM38 contendo cauda Fc derivada de I9G1 humana para criar DMS0502, DMS0500 e DMSO0501, respectivamente.
Os dAbsBMS2h-572-6, BMS2h-503-1 e BMS2h-719-2 também foram clonados no vetor pDOM38 contendo cauda Fc derivada de IgG4 hu- mana para criar DMS0505, DMSO0506 e DMSO0504, respectivamente. As construções foram expressas de forma transitória em células HEK293 e as proteínas foram purificadas utilizando Proteína A. As fu- sões de Fc purificadas foram analisadas por Biacore em relação à li- gação ao CD40L monomérico e trimérico bem como em vários ensaios celulares (como descrito). Identificação dos clones BMS2h-572-608, BMS2h-572-614 e BMS2h-572-619
[00168] OdAbBMS2h-572-6foisubmetidoà maturação da afinida-
de utilizando a abordagem de "doped" oligo. Quatro bibliotecas "do- ped" foram construídas para este dAb:
[00169] Biblioteca 1 — 5 resíduos na CDR1 diversificados
[00170] Biblioteca 2 — 6 resíduos na CDR?2 diversificados
[00171] Biblioteca3-13 resíduos na CDR2 diversificados
[00172] Biblioteca 4 — 7 resíduos na CDR3 diversificados
[00173] Em cada biblioteca, a diversificação foi realizada utilizando códons nnS em que n mantinha uma fração grande da base original (85%) e separação do resto entre as quantidades equimolares das três bases remanescentes (5% cada) e S representa G ou C. As bibliote- cas de fago (tamanho médio de 8x10º) foram selecionadas utilizando CD40L monomérico e trimérico humano biotinilado com captura de es- feras de estreptavidina/neutravidina alternada do antígeno (como des- crito). As bibliotecas 2 e 3 foram reunidas durante o processo de sele- ção. Três rodadas de seleções utilizando concentrações decrescentes de antígeno (50 nM na rodada 1; 5 nM na rodada 2; 1 NM na rodada 3 com excesso de 200 vezes do competidor — trímero de CD40L não biotinilado) foram realizadas. O sequenciamento foi utilizado para mo- nitorar a diversidade após cada rodada de seleção. As produções de seleção (rodadas 2 e 3) foram subclonadas dentro do vetor de expres- são solúvel pDOM13 (sem tag C terminal) (como descrito) e verifica- das na forma de sobrenadantes de microcultura bacteriana monoclonal por BlAcore em relação a aprimorada taxa de dissociação comparada com o de clones parentais sobre CD40L tanto monomérico quanto tri- mérico. Os variantes aprimorados identificados tiveram o DNA se- quenciado e os dAbs únicos foram expressos, purificados e então ana- lisados utilizando o RBA de esferas de BMS2h bem como ensaios con- trolados por CD40L celular (como descrito). Como um resultado, os dAbs BMS2h-572-608, BMS2h-572-614 e BMS2h-572-619 foram iden- tificados.
Construção do clone BMS2h-572-633
[00174] A análisede sequência revelou que todos as diferenças de aminoácidos entre BMS2h-572-608 e o dAb parental BMS2h-572-6 estavam localizadas na CDR1 e as diferenças entre BMS2h-572-614 e dAb parental BMS2h-572-6 estavam localizadas na CDR3. Ambos os dAbs maturados compartilhavam CDR2 com o dAb parental BMS2h- 572-6. Isto criou uma oportunidade de construir um mutante de combi- nação que tinha CDR1 de BMS2h-572-608 e CDR3 de BMS2h-572-
614. Em primeiro lugar, a região de CDR1 de BMS2h-572-608 foi am- plificada por POR. Em segundo lugar, o fragmento CDR2+CDR3 de BMS2h-572-614 foi amplificado por PCR. Isto foi seguido pela monta- gem de SOE PCR dos dois fragmentos para criar um mutante de com- binação BMS2h-572-633. O produto de PCR de dAb montado foi clo- nado no vetor de expressão solúvel pDOM13 (sem tag C terminal), a sequência foi verificada, expressa, purificada e então analisada utili- zando o RBA com esferas de BMS2h bem como ensaios controlados por CD40L celular (como descrito). Formatação de BMS2h-572-633 como uma fusão de Fc
[00175] OdAb BMS2h-572-633 foi clonado no vetor pDOM38 con- tendo cauda de Fc derivada de IgG1 humana para criar DMS0507. À construção foi expressa de forma transitória em células HEK293 e a proteína foi purificada utilizando Proteína A. A fusão de Fc purificada foi analisada por Biacore em relação à ligação com CD40L monoméri- co e trimérico bem como em vários ensaios celulares (como descrito). Exemplo4 Ensaios Celulares de Atividade de CD40L
[00176] Os dAbs anti-CD40L humano foram analisados funcional- mente em relação a sua capacidade de antagonizar as atividades de CD40L. As atividades de CD40L testadas foram a proliferação de célu- lasBea produção de citocinas através da ativação controlada por hCD40L de células dendríticas (DCs) derivadas de monócitos primá- rios. A não ser que seja citado o contrário, todos os ensaios foram rea- lizados em meio RPMI suplementado com 10% de soro fetal de bezer- ro (FCS). Os resultados de vários ensaios, descritos em detalhes a seguir, são mostrados na TABELA 5 e na TABELA 6. Proliferação de células B humanas primárias controladas por IZ- hCDA40L solúvel:
[00177] 1x10º células B humanas da amígdala foram incubadas com 0,6 ug/mL de IZ-hCD40L junto com titulação variável de dAb ou mMAb em um volume final de 200uL/poço em uma placa de fundo arre- dondado de 96 poços. As placas foram incubadas a 37ºC durante 72 horas após as quais timidina (º?H; 0,5 pci/poço) foi adicionada durante 6 horas. A proliferação de células B foi quantificada com base na in- corporação de timidina. Todos os ensaios, a não ser que seja citado o contrário, foram realizados em meio RPMI suplementado com 10% de soro fetal de bezerro (FCS). Proliferação de células B humanas primárias controlada por CHO- hCDA40L:
[00178] As células CHO foram transfectadas com CD40L humano paragerar uma linhagem de célula estável expressando altos níveis de CD40L sobre a superfície celular. As células CHO-CDA40L foram irradi- adas a 10.000 Rads antes da incubação com células B humanas. 1x10º células B humanas da amígdala foram incubadas com 1x10º cé- lulas CHO-CDA40L (proporção de 1:100 de CHO-CD40L: células B hu- manas) junto com a titulação variável de dAb ou mAb em um volume final de 200uL/poço em uma placa de fundo arredondado de 96 poços. As placas foram incubadas a 37ºC durante 72 horas após as quais ti- midina (?H; 0,5 pci/poço) foi adicionada durante 6 horas. A proliferação de células B foi quantificada com base na incorporação de timidina. Todos os ensaios, a não ser que seja citado o contrário, foram realiza-
dos em meio RPMI suplementado com 10% de soro fetal de bezerro (FCS). Proliferação de células B humanas controlada por células T pri- márias:
[00179] As célulasT foram isoladas de células mononucleares do sangue periférico (PBMCs) humano e enriquecidas utilizando afinidade de células sanguíneas vermelhas de caprino (SRBC). As células T humanas enriquecidas foram cultivadas com PM-LCLs (linhagem de célula B transformada com EBV; irradiada a 10.000 Rads) em uma proporção de 5:1 (T:LCL) durante 6 dias a 37ºC para gerar uma popu- lação de células T alogenéticas. No dia 6, as células T expandidas fo- ram isoladas e irradiadas a 3000 Rads e então cultivadas (5x10º célu- las T/poço) com células B de amígdala humanas primárias (1x10º célu- las B/poço) em uma proporção de 1:2 em placa de fundo chato de 96 poços revestida com mAb anti-CD3 (OKT3). Titulações variáveis de dAbs/mAbs foram adicionadas em cada poço; o volume final em cada poço era de 200 uL. As placas de teste foram incubadas a 37ºC duran- te 3 dias. A proliferação de células B humanas foi determinada através da adição de timidina (º*H; 0,5 pci/poço) nas culturas ao longo das últi- vas18 horas. Todos os ensaios, a não ser que seja citado o contrário, foram realizados em meio RPMI suplementado com 10% de soro fetal de bezerro (FCS). Em alguns casos, o sobrenadante foi coletado e medido em relação à presença de IL-6. Ativação controlada por CHO-hCD40L de células dendríticas (DCs) derivadas de monócitos humanos primários:
[00180] As PBMCs humanas foram enriquecidas em relação aos monócitos através da eliminação de células T via restauração de SRBC. As PBMCs enriquecidas com monócitos foram cultivadas com 10 ng/ml de GM-CSF e 5 ng/mL de IL-4 em placas de 6 poços durante seis dias a 37ºC. As placas cultivadas foram reabastecidas com meio fresco (com GM-CSF e IL-4) nos dias 2 e 5. As DCs imaturas foram utilizadas nos ensaios de células no dia 6. 8x10º DCs imaturas foram cultivadas com 4x10º células CHO-hCD40L (irradiadas a 10.000 Rads) junto com titulações variáveis de dAbs/mAbs em uma placa de fundo chato de 96 poços.
Após 24 horas, os sobrenadantes foram coletados e testados em relação à presença de várias citocinas (IL-12, TNF, IL- 23). A ativação das DCs foi determinada através dos níveis de produ- ção de citocina.
Todos os ensaios, a não ser que seja citado o contrá- rio, foram realizados em meio RPMI suplementado com 10% de soro fetal de bezerro (FCS). TABELA 5 Potência de Moléculas de dAb Monoméricas em Vários Ensaios com Células Primárias Proliferação | Proliferação de de células B células B hu- 4 Ativação de DCs GCions) humanas manas contro- MER) de células controlada por controlada lada por CHO- EC50 (nM) CHO-hcD40L por hiZCD40L hcD40L IL-12 EC50 (nM) EC50 (nM) EC50 (nM) 888,0, >2000,0, 2911613 | 130,0+40,0 | 1309.0, 700,0 | 1000,0 2h116-1312 23,0 +3,0 530,0 + 300,0 234 + 46 112,0 +47,0 2h116-1313 29,0 + 4,0 211,0, 334,0 258 + 79 136,0 + 51,0 2h116-1314 | 41,0+10,0 | 1300,0,4400,0 1687 + 1150 664,0 + 353,0 2h116-1319 | 180,0 +57,0 >7000,0 o 2h116-1320 20,0 + 7,0 138,0 + 60,0 191 +72 32,0 + 10,0 2h437 5700,0 + 1800 [| 2h437-4 203,0 + 90,0 >7000,0 | |] 132904120 2h492 EXU RC E | 204923 |1100,0+400,0 ECT RR 2h492-4 | 1700,0 + 900,0 >7000,0 2h492-5 — | 2300,0 + 700,0 |U | 2h492-6 1400,0 2h492-7 | 1900,0 + 600,0 |U | 6100,0 + 2h494 1200,0 4800,0 + 2h494-2 2300,0 2h494-3 EVORA RR 2h494-4 | 590,0+250,0 >7ooa,0 Po 2h494-6 2100,0 >7000,0 | 29508 |[4200,0+316,0 PTB 2h503-1 24,0 +2,0 2300,0 + 700,0 Fm F56,0+333,0 2h503-104 16,07 190
Proliferação | Proliferação de decélulas B | células Bhu- | nm R de células | Ativação de DCs humanas manas contro- T-B controlada por controlada lada por CHO- EC50 (nM) CHO-hcD40L por hiZCD40L hcp4oL I1L-12 EC50 (nM) EC50 (nM) EC50 (nM) | 205032 | 440+60 /30000+1000.0 | | 15620+960 | ans aaa | 2ns7es | 2om0s7ao | cromo | cromo | O Gsao oo | 2h572-6 208,0 + 73,0 >7000,0 >7000,0 260,0 | 20572-604 | 254,0,3540 | >7000 [UU | 380 | | 29572608 | 960x19,0 | [| >70000 | 1520+610 | | 20572610 | 1090340 | [| =>700060 | 2070:870 | | 20572614 | 930x580 | | =>70000 | 1350:540 | | 20572616 | 20403400 | [| >7000 | G6080+1360 | | 20572617 | 1570,1890 | | =>700060 | 3380+1010 | | 20572622 | 3010209830 | | >70000 | 2810:1270 | | 20572623 | 1810,2861,0 | | >7000 | 2800+730 | | 20572630 | 1030871,0 UP | 2460+2400 | | 2h572-631 || 1080 FP O 230,0+2000 | | 2h572-632 | 1170970 SS 2410+1900 | | 2h572-633 | 2004150 530+600 | | 2h572-634 [310180 770+670 | | 2h572635 | 290190 NA o 620+260 | | 205729 | 3240/2430 20000 -— | | 29057211 | 1400330 | >70000 [| | 6710+1650 | | 2057212 [| 790760 NA ps 2250,>20000 | | 2057214 | 1340720 | >70000 [| "| 8820+3100 | | 2057215 | 1680670 | >70000 [| "| 8760+3910 | | 2h572-22 | 367,0 305,08 ano aaa anos aaa anos aaa ano aaa ano aaa ani aaa az aaa | 20719 | 6000+6400 UU [E "| 1340,6460 | | 207192 | 820+x390 | >70000 [| | 1960+1500 | | 20719-202 | 290120 NNNAAdP 790+290 | | ah719-2038 810, dB | 2h719-213 | 62,0, 980 | 2h719-214 | 660, 80 Lanza aaa a aaa ra BB | 20719-225 | 2530, 1980 AP o 1760+840 | | 20719-226 | 1640.2470 UP | 8120+530 | | 2071912 | 36801590 [PN | 2660+660 | Cores | seoso [EHETBel emesmo | 2h719-13 50,0 + 8,0 4450,0, 1750,0 219,0 + 88,0 | 20719-17 | 1320500 | 2360/2660 | | 7130+490 | 202,0, >7000,0, >7000,0, 2h719-19 138,0 + 31,0 3800,0, 5400,0 184,0 + 99,0 a aaa NNENZ0 RE RR RR
Proliferação | Proliferação de de células B | células Bhu- | nm ÀR de células | Ativação de DCs Clone humanas manas contro- T-B controlada por controlada lada por CHO- EC50 (nM) CHO-hcD40L por hIiZCD40L hcDp40L I1L-12 EC50 (nM) EC50 (nM) EC50 (nM) | amas É o 2h725 1200,0 | an7as-a o raaa a | an7asa ras | anzas- 1a | raaa a Lanza ras Lanza aaa [amar É so 2h731 2500,0 o anzaa o aaa as a 3500,0, 2h745 >7000,0 LL anzas to araaa a LL anzas-2 | >roaa o LL anzas-o o sraaa o | 2n7a5-13 [O >70090 | | anzas ta aaa ara aaa ara aaa asa BB o 2hzsa esa BEBA az | 6400 E BEBO [ams É so 2h758 1500,0 Lanza t o rasa | an7se-2 ras | an7s8-3 ros Lanza ras Lanza 7aaa a Lo anzes raaa o anzes o ras Lanza ras Lanza ras Lanza ras Lanzar aaa Lanza araaa a Lanza aaa Lanza aaa a DE 2h785 >7000,0
. 261 S8s E ao : 25º 8 $EO É 158
SE É as :
TE o 28 = 85 S 3 = gs ê
SE
SEO Z 2585 285 > o 83 : Ss E. A õ É ú 38sdS
E E
E SEG sigo o 2º : s 2892 = a s saE 3 2 28E o E 23808 o 28520 | ”v ca FR SEO à 8 sERS 3: : : Ee Ss S/s 8 6 o = Fal ad: : E Ss = FS ss í : u 3 =| S/a ã | o E : - | a: 7 o o + = : à +" s & : o sos = srasg : ã & +H Oo > = = * : |
E À o : Ss É l . 2: à a a : . ala + (=) o uu eme : : É - 3 + s º $ o S ; Y - - + So] o o zo Tel & : E : o É à + Sos ir = NE les) 5] = | 1 a: ES jo Ss s v S;$6 ã salas : 2228 E EE : e 5 o o : E QZS + f=) 8 = : eo] o O o o E EHTOS & i. É : FE Ss 3 Ss ba E +" =) à PE 8 o o] 8 +" + u 63 53º 7 |8 FÉ : FR - o sIg/2)s 1. : o o == : : : | : : 2 + 4 ; | : ó 2 É Tala o E Te | 3 85 SIE EE 3: o Sm 558 ge] : : : : 3 | E ss E se 8 o ê dus 2s: o - o | +H eo o o de : o o + — 2 É SE s55R ei E) eo o + E SE cSSS US olo eo É E o o ãoE = 212 a: << VV Wu 1º s|s/2) 3) « é E o : 23 iss 3 : Às FEEERE : « 2 : de É ; Á 2 ê + o| co 8 ra õ Sl sl : 1 SS 2/0] 2 o | E EEREE | Tá sl 8) << $ | EN z 3 É 8s E ; : dados & E 3 | S/S É dades 3 el | 53 E |: so ê : : E 5 é : ao uu a <
"| So +H : o
[3] | : Ss = + +" ne. o : : |) o +" : | : So + | o | =) +H GS à : : o o] +" +" eo o - - 3 3 &e AR sl Ss sã à | à +" o F S ê FT =| o 2 & S $ z 7 " = 8 e & F | : =| | o + H " 2 e 3 | u à +" o e 2 é o Ss + SIS a À ++ cs o + 8 ee Ss ss) 3 GS 8 d + n < & $ e o 5 Sã S| Ss S o ã a Ss : : Ss à + + gs | S$ 2 4 à +H Ss | ] | : e 2 É + - ss : | : : : : : - o o S| + o | z : ê : - +" e Ss S S : : õ : - S s 8 o SS 8 2 3 à a: 8 2 à É + Sl =| ê 3 z & à +" 8 = = go : 2 2 o : | : | : o S| e +" s S 3 S K ú e o —| S 2 | Z +" S 7 3 à 2 8 + + Y Ss 3 & 2 É +" +" S SS : S | Z + s : 3 à & ++ : : | - anjo 3 +" Ss F S ê ED e 2 2 3 : : =) e à ê 3 3 o - Ss 8 2 ê à : : à 8 + gs ;| S ê à | É + +" = 1 S | à 1 + Za : ê 2 ê n +" - | Ss oO ole </ 22/22 E S & , L q Sel Ss PE ST Se 5 | à Sl a ço çÇçE 8 2 3 2) tz 25 2º 2a 8s&s 7 o - ; SS SS sós so 28 ge) 2 Se sl 3 m ES SS so Io Sã E. Tx ol? K ES O SS 5 dE SE. : 8 ES 6º Sã dE so Ss SE 32 o le RS SsS2 Ss Ss Om ES 32) 8º Ss sz) SS 53) 53 SS SE Se Ss AS s Ss Se) ss à 1º a c o NL so Ns a Ss ê 2 3 ê Fra 53 E Ss S e Ss & |S a Ss Ss a
Neg SR o So) o ae Ho +" +" e o = = | o] ST" o a ba rio o + + + a = o silo — e o
So | 212 Ss Hj) +H +" 2 o Ns so = o o "| fã oj— o o Hj) +H +" +" elo, Ns | oro ba o o E e o Ss ojo o TF Sil +" +" E o, e o sl — o cs o o o =) + Hr Seo ax o (NF SS Nº — o o Ye mISS os) So os o ro os ml ele) SE 23 <= £o RR EE Sã = FS cs TAS
Exemplo 5 Cinética de Ligação e Afinidade ao CD40L de Vários Anticorpos
[00181] BMS-986004 é uma proteína de fusão dimérica, composta de um fragmento Fc modificado de IgG1 ligado ao terminal C do dAb BMS2h-572-633. A ressonância de plasmon de superfície (SPR) foi utilizada para caracterizar a cinética e a afinidade de BMS-986004 ou a ligação do anticorpo de domínio de componente monovalente BMS2h-572-633 ao CD40L. Os valores de BMS-986004 foram compa- rados com aqueles para os anticorpos de referência 5c8-l9G1 e 5c8- CTeofragmento FAB do componente monovalente de 5c8. Os expe- rimentos de SPR utilizavam uma construção de hcD40L contendo um motivo de zíper de isoleucina N-terminal (IZ-hCD40L) que facilita a montagem específica da molécula de CD40L na forma trimérica nativa. Uma versão biotinilada de IZ-hCD40L (biot-IZ-hCD40L) com atividade de ligação equivalente também foi utilizada para alguns experimentos de SPR.
[00182] O anticorpo de domínio monovalente BMS2h-572-633 se liga ao biot-IZ-hCD40L com uma Kd de 7,8 nM, comparada com uma afinidade de 5,4 nM para o fragmento FAB monovalente de 5cê8, TABELA 7. Devido ao fato de que o BMS-986004 é bivalente e o alvo IZ-hCD40L é trivalente, os dados de ligação de SPR são influenciados independentemente do fato do alvo CD40L estar sobre a superfície de um chip ou em solução. Para estimar a afinidade de ligação influencia- da pela avidez, os dados de SPR para a ligação de BMS-986004 a uma superfície de biot-IZ-hCD40L foram ajustados para um modelo de Langmuir de 1:1, sugerindo uma constante de dissociação de menos que 1 nM, TABELA 7. Resultados similares foram obtidos para 5c8- IgG1 e 5c8-CT. TABELA 7 Cinética e valores de afinidade de IZ-hCD40L que são determina-
dos utilizando SPR (Biacore) CD40L tura (ºC! 986004 11 FAB de 5c8 11
[00183] O valor é influenciado pela avidez devida à bivalência do analito.
[00184] AFIG.5 mostra dados de sensorgrama de SPR para a li- gação de 12,5-0,39 nM de BMS-986004 (série de diluição de 2:1) com biot-IZ-hCD40L capturado sobre um chip sensor de SPR com estrep- tavidina a 25 ºC. As linhas coloridas mostram os dados de sensorgra- ma com referência dupla e as linhas em preto mostram o ajuste de Langmuir 1:1 aos dados, com um valor de Kd aparente influenciado pela avidez de 0,11 nM.
[00185] A afinidade e a termodinâmica da ligação de BMS-986004 ao CD40L também foram caracterizadas em solução utilizando calori- metria de titulação isotérmica (ITC) a temperaturas variando de 15 37ºC. Estes dados sugeriam a presença de vários modos de ligação termodinamicamente distintos (FIG. 6) com valores de Kd para os mo- dos diferentes além do limite de detecção de alta afinidade (Kd <2 nM) (TABELA 8), coerente com os dados de SPR. A afinidade do fragmento FAB monovalente de 5c8 FAB por IZ-hCD40L que é determinada por ITC (3,5 nM) também era coerente com o valor determinado por SPR.
TABELAS Afinidade de IZ-hCD40L que é determinada utilizando ITC
| IZ-hcD40L Exemplo 5 Afinidade do receptor de Fc de Vários Anticorpos
[00186] O domínio Fc de BMS-986004 (denominado "CT") foi enge- nheirado partindo de um domínio Fc de IgG1 do tipo selvagem para manter a capacidade de se ligar a FCRn, mas para interromper a liga- ção a receptores de Fcy. Para confirmar que a molécula engenheirada possui o perfil de ligação do receptor de Fc desejado, as afinidades de ligação de BMS-986004 por FcRn humano e os receptores de Fcy humanos CD64 (FcyRI)) CD32a (FcyRlla),) CD32b/c (FeyRllb/c), CD16a (FeyRllla),) CD16b (FeyRlllb) foram medidas utilizando SPR, em comparação com 5c8-lgG1 e 5c8-CT. Para estes experimentos, o BMS-986004 foi capturado através dos domínios do anticorpo de do- mínio sobre uma superfície de sensor de biot-IZ-hCD40L e as proteí- nas do receptor de Fc solúveis foram testadas em relação à ligação como domínio Fc exposto. Similarmente, 5c8-l9G1 e 5c8-CT foram capturados sobre uma superfície de biot-IZ-hCD40L através dos domí- nios de FAB, com ligação ao FcR solúvel.
[00187] O BMS-986004 se ligava ao FcºRn com Kd de 670 nM em pH 6,0 que é o pH relevante para a ligação dentro do endossomo, TABELA 9. Entretanto, a ligação era significativamente reduzida (Kd >5000 nM) em pH neutro sugerindo a liberação eficiente de FCcRn sob estas condições. BMS-986004 se ligava ao CD64 com uma Kd de 0,6 nM e tinha uma afinidade estatisticamente fraca por CD32a, CD32b/c, CD16a e CD16b (Kd >3000 nM). Tanto 5c8-lgG1 quanto 5c8-CT ti- nham uma afinidade por FcRn similar à do BMS-986004. 5c8-CT, que possui a região de Fc "CT" idêntica à do BMS-986004, também tinha propriedades deligação ao FcyR similares àquelas do BMS-986004, enquanto que 5c8-lgG1, que possui um domínio Fc de IgG1 do tipo selvagem, se ligava mais fortemente aos FcyRs, TABELA 9. TABELA 9 Afinidade ao receptor de Fc que é determinada utilizando SPR (Biacore). Kd de BMS- Kd de 5c8-lgG1 Kd de 5c8-CT 986004 (nM) (nM) (nM) [FR e o 6 sao 720 hFeRn [DR TI | es — 5 | 6:05 |
[00188] Aligaçãode CD32a a 5c8-lg9G1 era bifásica. A Kd foi esti- mada como —-10” M baseada no ajuste de estado estacionário ao e- vento de ligação dominante. Esta Kd está na faixa de KD relatada na literatura para a ligação de CD32a à IgG1. Exemplo 6 Ensaios à Base de Células /n-Vitro
[00189] A potência de BMS-986004 foi avaliada em vários ensaios de células imunológicas primárias para garantir potência robusta atra- vés de tipos de células diferentes. Os ensaios de proliferação de célu- las B humanas primárias foram conduzidos de duas maneiras, que são descritas em detalhes no Exemplo 4 anterior: (1) o trímero de CD40L recombinante foi utilizado para controlar a proliferação de células B; e (2) as células CHO expressando CD40L sobre a membrana (CHO- CD40L) foram utilizadas para induzir a proliferação de células B. A uti- lidade de células CHO-CDA40L era particularmente importante para ga- rantir que sinais provenientes do CD40L ligado à membrana fossem inibidos igualmente bem quando comparado com o trímero de CD40L solúvel. As células CHO-CD40L também foram utilizadas para contro- lar a ativação de DCs humanas primárias diferenciadas partindo da cultura de monócitos derivados de PBMCs na presença de GM-CSF e
IL-4. Similarmente, o ensaio de T-B MLR media a ativação de células B controlada pelo CD40L presente sobre as células T ativadas. Em todos os ensaios primários descritos anteriormente, o BMS-986004 era equipotente ao mAb 5c8 de referência: as potências variavam de nM comum único dígito até sub-nM, dependendo do ensaio (TABELA 10). TABELA 10 Potência de BMS-986004 em Vários Ensaios de Células Primárias ECSO(NM) ECSO(NM) ECSO(NM) ECSO(NM) ECSO(nM) EC50(nM) EC50 (NV) do Ensaio do Ensaio de deT-B dell-6deT- dell-12do dell-6do deTNF-a mo cambios o ME A Disco AsDES MAWdAb-Fc trimero — CD40L AL o AO se6 ha! 8219 20:20 34 501s 021 + 006 082 5964 07305 23H13 Sã 5,0 +0,5 1,0+:0,5º 0,16+005 0,13+04 31+16 19+0,6 36H11 Exemplo 7 Avaliação da Ocupação do Receptor (RO) no Sangue Total
[00190] Um método de ocupação do receptor foi desenvolvido para medir o comprometimento do alvo CD40L pelo BMS-986003 em amos- tras de sangue total de macacos cynomolgus e, subsequentemente, no BMS-986004 em amostras de sangue total humano. O BMS- 986003 é um dAb que compartilha a mesma sequência de aminoáci- dos que ado BMS-986004, exceto por um resíduo de glicina não nati- vo em seu terminal amino.
[00191] A ocupação é medida sobre as células T CD4+ por citome- tria de fluxo utilizando um mMAb anti-CD40L que compete pela ligação ao CD40L com BMS-986003 / BMS-986004 e reage de forma cruzada com CD40L humano e de macaco cynomolgus. Na presença de dAb ligado, o mAb de detecção anti-CD40L é bloqueado de se ligar ao CD40L de uma maneira dependente da concentração, fornecendo uma medida da ocupação do alvo. Considerando que o CD40L basal é expresso em baixos níveis sobre células T em repouso no sangue pe-
riférico, a RO foi avaliada tanto em amostras de sangue não estimula- das quanto em amostras em que a fitohemaglutinina (PHA) foi utilizada para induzir a regulação para mais de CD40L sobre a superfície de células T. As curvas de potência de ligação foram geradas após o tra- tamento do sangue total ex vivo com BMS-986003 e BMS-986004. Os valores médios de ECs5,o e EC9, obtidos são mostrados na TABELA 11. TABELA 11 Potência de Ligação de BMS-986003 e BMS-986004 sobre células T CD4+ no Ensaio de Ocupação do Receptor no Sangue Total ex vivo BMS-986003 | n | ECsomédia,nM|ECs, média, nM | Humano (basal) Humano (induzido por
PHA Cyno (basal) Ps go Cyno (induzido por PHA
RR RR RC BMS-986004 o Humano (basal) Humano (induzido por
[00192] A potência de ligação ao alvo no sangue total para BMS- 986003 e BMS-986004 se correlaciona intimamente entre o ser huma- no e o macaco cynomolgus. Os valores de ECso, para BMS-986003 e BMS-986004 também são similares quando ligados ao CD40L basal e induzido por PHA. Adicionalmente, estes valores são comparáveis com aqueles obtidos em ensaios à base de células humanas in vitro (vide a TABELA 10). Com base nos valores de ECºo medidos, a satu- ração completa do alvo no sangue periférico deve ser atingida em concentrações < 10nM.
[00193] Para sustentar o perfil de PK/PD pré-clínico de BMS- 986003 e BMS-986004, a RO foi avaliada tanto no estudo com KLH em macaco cynomolgus (imunização com hemocianina da lapa do bu- raco da fechadura) com BMS-986003 quanto no estudo de ligação com IV com BMS-986004. Os detalhes adicionais destas descobertas podem ser encontrados nos Exemplos a seguir. Exemplo 8 Farmacologia In vivo
[00194] Para mostrar a eficácia de um dAb de CD40L em modelos de doença em camundongos, um dAb de CD40L de camundongo 2m126-24 foi formatado com Fc de IgG1 de camundongo com a muta- ção pontual D265A para diminuir adicionalmente a função efetora de Fc. Este dAb substituto de camundongo 2m126-24-Fc mostra potência comparável àquela de BMS-986004 e MR-1, um anticorpo anti-CD40L de camundongo de hamster (TABELA 12). TABELA 12 Comparação da Potência In vitro EC50 (nM) do Ensaio — EC50 (nM) do Ensaio EC50 (nM) de IL-6 mandanro Ps Rm Ta O DA com CHO-CD4OL Ser Humano Í Sc8 8,0 3,0 20+20 BMS-986004 5,0 +0,5 1,0 +0,5 1,9+0,6 Camundongo Í 2m126-24-Fc 4,7 +0,9 0,4 +0,06 0,5 +0,2 MR-1 (mAb) 1,7 +04 0,6 +0,2 0,6 +0,3 Inibição da Resposta de Anticorpo Induzida por KLH pelo dAb de CDA40L de Camundongo
[00195] Fêmeas de camundongos BALB/c receberam injeção de forma intraperitoneal (i.p.) de 250 ug de KLH no dia 0. Os camundon- gos foram dosados de forma subcutânea (s.c.) com MR-1 ou BMS-2m- 126-24-Fc nas doses indicadas no dia -1 e no dia 6. O sangue foi cole- tadoeo soro foi analisado em relação à IgM anti-KLH no dia 7 e IgG no dia 14 por ELISA. O soro dos camundongos BALB/c coletado no dia 14 após a imunização com KLH foi agrupado e utilizado como um comparador positivo e os dados são expressos na forma de uma pro- porção do título do soro de teste em relação ao título do soro de BALB/c agrupado. Como mostrado na FIG. 7, BMS-2m-126-24-Fc de-
monstrava uma supressão dependente da dose de títulos de IgG com efeito máximo mostrado em 3 mg/kg, com EDB50 calculada como sen- do de 0,26 mg/kg. Tanto o dAb de CD40L quanto o anticorpo foram testados em 1 mg/kg, mostrando uma redução de 70% vs. 30% na resposta de IgG, respectivamente. Uma exposição similar do dAb e do anticorpo foi observada em 1 mg/kg, sugerindo que o dAb é ligeira- mente mais potente que o anticorpo na supressão da resposta de IgG induzida por KLH. Em conclusão, o dAb de CD40L demonstrou pelo menos o mesmo nível de eficácia que o anticorpo anti-CD40L na inibi- çãode uma resposta de anticorpo dependente de células T. Inibição da Colite Induzida por TNBS pelo dAb de CD40L de Ca- mundongo
[00196] Machos de camundongos SJL/J receberam administração intratecal de 2,5 mg de ácido Trinitrobenzeno sulfônico (TNBS) em 50% de EtOH através de um cateter inserido a 4 cm de distância do ânus. Os camundongos foram dosados uma vez s.c. com MR-1 ou BMS-2m-126-24-Fc nas doses indicadas 4 horas antes da injeção de TNBS. A FIG. 8 apresenta as alterações no peso corporal médio e a porcentagem de sobrevivência de grupos de camundongos tratados com PBS/IgG ou níveis de doses variáveis de MR-1 ou do dAb. O Aba- tacept foi utilizado como um controle positivo (20 mg/kg, i.p. em dias alternados). Um perfil típico de colite induzida por TNBS foi mostrado no grupo de controle de IgG: perda de peso corporal, com máximo no dia 3-4; morte relacionada à colite ocorrendo no dia 3 e mais tarde; e os camundongos que sobreviveram mostrando sinais de recuperação após o dia 4. O tratamento com o dAb de CDA40L ou o anticorpo (am- bos testados em 2, 8 e 20 mg/kg) causou inibição dependente da dose da perda de peso corporal e o aumento na taxa de sobrevivência; am- bos os compostos em 8 mg/kg produziram um grau de eficácia que é comparável aquele do Abatacept em 20 mg/kg. Em conclusão, o dAb de CD40L de camundongo BMS-2m-126-24-Fc demonstrou eficácia comparável àquela do anticorpo anti-CD40L MR-1 em um modelo de colite aguda induzida por TNBS. Efeito Sinérgico entre CTLA4 Ig e o dAb de CD40L de camundon- gqgoemum Modelo de Transplante de "Coração-para-Ouvido" em Camundongos
[00197] Enxertos de coração provenientes de camundongos C57BI/6 neonatais (48-72 h) foram implantados dentro da bolsa subcu- tânea criada nas aurículas do ouvido de camundongos BALB/c. Os camundongos foram tratados com CTLA4-Ig (i.p. 2x/(semana), BMS- 2m126-24-Fc (s.c. 1X/semana) ou combinação de ambos nas doses indicadas, com a primeira dosagem iniciada no dia antes do transplan- te. O tempo de rejeição foi definido pela ausência de contratilidade cardíaca durante três dias consecutivos que é avaliada diariamente pelo dispositivo de eletrocardiograma (ECG) de aloenxerto. Como es- perado, sem qualquer tratamento, os camundongos C57BL/6 que re- ceberam o coração de BALB/c neonatal rejeitaram o enxerto logo após o mesmo, com tempo de sobrevivência médio (MST) de 12 dias. À monoterapia com 3, 20 mg/kg do dAb ou 25 mg/kg de CTLA4-Ig teve nenhum ou pouco impacto sobre o prolongamento da sobrevivência do aloenxerto (MST: 12, 15 e 13 dias respectivamente). Entretanto, nos grupos tratados com combinação de 20 mg/kg do dAb e 25 mg/kg de CTLA4-lg, a sobrevivência do enxerto foi significativamente prolonga- da exibindo MST de 35 dias (FIG. 9). Estes dados forneceram funda- mento lógico para a combinação de dAb de CD40L com belatacept em pacientes humanos de transplante renal. Estudos de transplantes futu- ros em primatas não humanos definirão adicionalmente o nível de do- se e avaliarão o efeito potencia sobre a indução de tolerância com dAb de CD40L BMS-986004. Exemplo9
Farmacocinética (PK) e Farmacodinâmica (PD) Não Clínicas /n vi- vo
[00198] Vários estudos in vivo foram conduzidos para caracterizar a PK e a PD de BMS-986004, BMS-986003 e um substituto de dAb de CD40L-Fc de camundongo BMS-2m-126-24-CT, no cenário não clíni- co. As descobertas principais estão resumidas a seguir.
ELISA para medir dAb BMS-986004
[00199] Métodos bioanalíticos baseados no ensaio de imunoabsor- vância ligada à enzima (ELISA) foram desenvolvidos para apoiar os estudos de PK, os estudos de eficácia aguda e crônica em camundon- gos e estudos de PK/PD exploratórios empregando macacos cyno- molgus. Em todos os casos, o sangue total foi obtido e o plasma foi preparado na presença de EDTA, as amostras foram então submeti- das à análise de ELISA.
[00200] As concentrações no plasma de BMS-986004 foram medi- das com um ensaio de ELISA que utilizava o antígeno CD40L humano para capturar o analito das amostras de teste. As amostras de teste foram descongeladas a 4ºC, misturadas bem e diluídas 1:100 no dilu- ente do ensaio composto de 1x PBS, 0,05% de Tween-20 e 1% de BSA(PTB).Foram feitas diluições subsequentes da amostra utilizando 1% de plasma de macaco normal/PTB como diluente. Isto permitiu que o analito de teste fosse analisado em várias diluições (10º — 10%) en- quanto a matriz da amostra era mantida a 1%.
[00201] O CDA40L trimérico humano recombinante foi obtido da Pro- tein Structure and Science (PSS), LVL e foi ligado a placas de 96 po- ços em uma concentração final de 2 ug/mL. As amostras de teste, as amostras de controle de qualidade (CQ) e os padrões foram detecta- dos com anticorpo policlonal antiestrutura do domínio de cadeia pesa- da (Vh) de coelho purificado por afinidade (Covance Research Pro- ducts, Denver, PA) diluído em uma concentração de 0,25 ug/ml em
PTB, seguido pelo anticorpo secundário policlonal anticoelho de burro marcado com peroxidase de raiz forte (Jackson Immunoresearch, West Grove, PA) com o substrato (TMB - tetrametilbenzidina) adicio- nado e a reação enzimática interrompida com 1 M de ácido fosfórico. À — absorbância foi medida em um comprimento de onda de 450 nm. À análise de BMS-986004 nas amostras de teste foi conduzida utilizando uma curva padrão. Calibradores de curva padrão preparados no dia de cada corrida em 1% de plasma de macaco foram utilizados para definir a faixa dinâmica do método bioanalítico. A faixa da curva padrão resul- tante em 100% de plasma era de 10 - 1200 ng/mL. O padrão de refe- rência para BMS-986004 foi obtido na Biologics Process and Product Development (BPPD), HPW. O material padrão de referência era re- presentativo da batelada de manufatura e foi utilizado no protocolo do estudo. Curvas padrões e CQs foram avaliados utilizando critérios pa- ra acurácia e precisão de < 20% que foram considerados como sendo aceitáveis para o desempenho do ensaio. As amostras de teste foram quantificadas utilizando um modelo de regressão com ajuste logístico de 4 parâmetros pesado pela concentração recíproca (1/x) derivada dos calibradores.
[00202] O desempenho das amostras de CQ, medido através do desvio da concentração calculada partindo de seu valor nominal indi- cou que o material de referência era estável no plasma de macaco pu- ro em concentrações de 30 - 1000 ng/mL quando armazenado a -70º C durante mais de 2 meses.
ELISA para medir o dAb substituto de camundongo
[00203] O dAb específico para CD40L de camundongo BMS-2m- 126-24-CT foi medido em amostras de plasma de camundongo para fornecer dados de exposição no suporte de vários estudos de eficácia agudos e crônicos bem como na avaliação da PK.
[00204] Embora o formato do ensaio para dAbs de camundongo fosse bastante similar aquele para dAbs humanos em amostras de Macaco, havia algumas diferenças. A matriz do plasma de camundon- go foi diluída para 1:10 (10%) no diluente do ensaio e todas as dilui- ções subsequentes das amostras de teste foram feitas utilizando 10% de matriz decamundongo. Similarmente, todos os padrões e os CQs também foram incubados sobre placas de ELISA em 10% de plasma de camundongo. A concentração de BMS-2m-126-24-CT nas amos- tras de teste provenientes dos camundongos foi medida utilizando CDA40L de camundongo para capturar o analito. Uma vez que o dAb de camundongo possui estrutura de Vk, todas as amostras de teste, os COQs e os padrões foram detectados com anticorpo policlonal antido- mínio kappa (Vk) de coelho purificado por afinidade (Covance Resear- ch Products, Denver, PA) diluído a uma concentração de 0,5 ug/mL em PTB. O resto do ensaio e o procedimento de análise eram simila- res ao procedimento para a análise de dAbs de CD40L humano. Os critérios de aprovação para concentrações retro calculadas de padrões e CQs também eram similares aqueles para dAbs de CD40L humano. A faixa quantitativa de BMS-2m-126-24-CT que é determinada partin- do da curva padrão era de 12,5 até 600 ng/mL na matriz de amostra pura. Farmacocinética Não Clínica
[00205] A TABELA 13 resume os parâmetros de PK para BMS- 986004, BMS-986003 e BMS-2m-126-24-CT em espécies de animais não clínicas. TABELA13 Parâmetros de PK de Dose Única (média + SD) Provenientes de Duas Espécies de Animais Não Clínicas Espé- | dAb Rota Dose | Cmax | Tmax | AUCO-inf| T1/2 CLTp Vss F Eee STE TES) EEE e es eos e
FE pe AE
FACIEINICINSEIT Ta 1 [7 [om fo] me [TSE Ss fuer es] o mi Pe is a | [o ja | 3 | [neo | || me a o ds sie | ee E | Jo | 2 | 40 jo oce| |
[00206] BMS-986004 e BMS-986003 exibiam perfis de PK compa- ráveis em macacos (FIG. 11A e FIG. 11B). Após a administração |V, as concentrações no plasma de BMS-986004 e BMS -986003 exibiam um declínio biexponencial de até 504 e 408 h, respectivamente. Uma eliminação acelerada foi observada depois disso em 50% dos maca- cos registrados em ambos os estudos. O teste da imunogenicidade das amostras de plasma coletadas 38 d após o tratamento com BMS- 986004 sugeria que todos os macacos desenvolveram anticorpo anti- fármaco (ADA); e que os macacos com níveis de ADA mais altos exi- biam eliminação mais rápida. Embora nenhum teste de imunogenici- dade tenha sido conduzido para o estudo de PK IV com BMS-986003, um nível similar de imunogenicidade foi observado em macacos após a dosagem subcutânea com BMS-986003 no estudo de PK/PD, suge- rindo que ambas as proteínas eram imunogênicas em macacos. À meia-vida terminal (T1/2) de 124 e 106 h para BMS-986004 e BMS- 986003 foi, portanto, determinada utilizando as exposições coletadas até duas semanas (336 h) apenas. O volume de distribuição no estado estacionário (Vss) de BMS-986004 e BMS-986003 era de 0,098 e 0,074 L/kg, respectivamente. Os valores são maiores que o volume do plasma (0,06 L/kg)) mas menor que o volume do fluido extracelular (0,2 L/kg), sugerindo que as proteínas residem em grande parte no espaço extracelular. A eliminação do plasma corporal total (CLTp) de BMS-986004 e BMS-986003 era de 0,59 e 0,65 mL/h/kg, respectiva- mente.
[00207] Os parâmetros de PK de BMS-986004 em macacos foram comparados com aqueles de abatacept, uma proteína de tamanho si- milar (78,5 vs 78-kDa BMS-986004, com base na sequência de ami- noácidos), com o mesmo formato de Fc de IgG1 humana modificado. Como esperado, os parâmetros de BMS-986004 eram quase idênticos aqueles de abatacept (CLTp de 0,6 mL/h/kg, Vss de 0,087 L/kg, T1/2 de5d), sugerindo que a PK em seres humanos de BMS-986004 e a- batacept provavelmente deve ser similar.
[00208] A absorçãode BMS-986003 após a administração subcutâ- nea (SC) foi avaliada no estudo de PK/PD em macacos. Os macacos receberam administração de BMS-986003 na forma de doses subcu- tâneas únicas de O (controle de veículo), 0,2, 2 e 20 mg/kg, 24 h antes da imunização com hemocianina da lapa do buraco da fechadura (KLH), um antígeno dependente de células T. Após a dosagem, o BMS-986003 foi lentamente absorvido, com um Tmax variando de 6- 96 h (FIG. 12). A exposição de BMS-986003 parecia ser menor que proporcional à dose ao longo de todos os níveis de doses. Com uma proporção de dose de 1:10:100, as proporções médias de Cmax e AUCO-inf eram de 1:12:80 e 1:7:44, respectivamente. Com a exposi- ção após a dose IV (2 mg/kg) como referência e assumindo PK linear após a dosagem |V, a disponibilidade biológica SC de BMS-986003 era de 88%, 74% e 44% em 0,2, 2 e 20 mg/kg, respectivamente. A T1/2 terminal foi cofundida pela imunogenicidade observada com a maioria dos macacos em 2 até 5 semanas após a dosagem. Portanto, a T1/2 foi estimada como sendo de 85, 66 e 105 h em 0,2, 2 e 20 mg/kg, respectivamente.
[00209] A PK de 5c8-lg9G1, um anticorpo monoclonal anti-CD40L humano utilizado como um controle positivo no estudo de PK/PD, foi avaliada após a administração IV em 20 mg/kg (FIG. 12). 5c8-l9G1 exibia exposições no plasma 10 vezes mais altas e T1/2 4 vezes mais longa quando comparado com o BMS-986003 fornecido SC na mesma dose(TABELA 13).
[00210] A PK da proteína de fusão dAb-Fc substituta de camundon- go, BMS-2m-126-24-CT, foi avaliada em camundongos após única administração IV e SC (TABELA 13). Após uma única IV (1 mg/kg), as concentrações no plasma seguiam um declínio monoexponencial com uma T1/2 terminal de 101 h (FIG. 13). A CLTp era de 1,85 mL/h/kg; e Vss estava em 0,26 L/kg, indicando distribuição extracelular distributi- on. Após doses SC únicas de 1 e 10 mg/kg, o BMS-2m-126-24-CT foi lentamente absorvido com um Tmax de 24 h. As exposições sistêmi- cas aumentavam de uma maneira proporcional à dose. Com uma pro- porção de dose de 1:10, a Cmax e a AUCO-inf aumentaram na propor- ção de 1:11. A T1/2 terminal era de 100 e 120 hem 1 e 10 mg/kg, res- pectivamente. A proporção da exposição ajustada pela dose (AUCO- inf) após administração SC e IV era maior que 1, sugerindo absorção completa após a administração SC. Modelagem Farmacocinética / Farmacodinâmica
[00211] APD de BMS-986003 foi medida na forma da supressão da resposta de anticorpo anti-KLH no estudo de PK/PD. O BMS-986003 suprimia 70% da resposta de anticorpo para KLH (% de resposta su- a- AUEC 1008h títulos de IgG Sua tdo *100 + AUVECO1OOShtítulosdelgG grupo com veículo ) | primida = ) na dose mais altade20 mg/kg. A supressão marginal (15%) e nenhuma da resposta de anticorpo ocorreram em 2 e 0,2 mg/kg. Em comparação, 5c8-1I9G1 exibia exposições no plasma 10 vezes mais altas e T1/2 4 vezes mais longa que BMS-986003 no mesmo nível de dose (20 mg/kg). Como um resultado, 5c8-l9G1 suprimia 97% de resposta de anticorpo anti-
KLH. Com a finalidade de comparar a potência in vivo entre BMS- 986003 e 5c8-lgG1, a modelagem de PK/PD foi realizada utilizando SAAM |l (versão 1.2.1, Seattle, WA). As concentrações no plasma de BMS-986003 após a administração SC foram descritas utilizando uma cinética de absorção de primeira ordem acoplada a um modelo de 2 compartimentos, em que a eliminação ocorria em ambos os comparti- mentos central e periférico. Devido às complicações provenientes da imunogenicidade e da absorção não linear possível, os dados de PK foram ajustados individualmente em cada dose.
[00212] Para 5c8-lg9G1, foi utilizado um modelo de dois comparti- mentos com eliminação central. A resposta de anticorpo anti-KLH, ex- pressa na forma do valor médio de títulos de IgG, foi modelada utili- zando um modelo de transdução de sinal de 6 compartimentos. A ciné- tica de KLH no corpo foi assumida como sendo de um modelo de 1 compartimento. A inibição da produção de IgG por BMS-986003 e 5c8- IgG1 foi descrita utilizando um modelo Imax, com uma inibição máxima igual a 100%. Como mostrado na FIG. 14, as curvas ajustadas ao mo- delo eram capazes de descrever o perfil tanto de PK quanto de PD. À IC50 no plasma de BMS-986003 e de 5c8-lgG1 para a supressão da produção de IgG induzida por KLH foi estimada como sendo de 74 + 14 e 60 + 18 nM, respectivamente. Estes resultados demonstraram que a potência destas duas moléculas era comparável in vivo.
[00213] A ocupação do receptor (RO) de CD40L de BMS-986004 foi medida no estudo de PK IV. Após a administração IV de 11 mg/kg, a RO de BMS-986004 sobre as células mononucleares do sangue peri- férico (PBMC) era dependente do tempo e da concentração. A mode- lagem de PK/PD foi realizada para estimar uma EC50 de RO. As con- centrações no plasma foram modeladas utilizando um modelo de dois compartimentos modificado com uma constante de eliminação de pri- meira ordem mediada por ADA adicional introduzida 504 h após a do-
sagem; e a RO foi modelada utilizando um modelo Emax Roy, = Emax' cp” ( Ecso”+CP” ), Como mostrado na FIG. 15, as curvas ajustadas eram capazes de descrever tanto a exposição quanto a RO, com uma EC50 de RO estimada de 3,4 + 0,3 nM e o y (fator hill) de 3,1 + 0,1. Em comparação, a EC50 de RO era —-22 vezes menor que a IC50 de res- posta de anticorpo anti-KLH de 74 + 14 nM, sugerindo que >95% de RO são necessários com a finalidade de atingir supressão de anticor- po anti-KLH apreciável (>50%).
Exemplo 10 Estudo de PK/PD de Dose Única de Toxicologia Não Clínico
[00214] Os objetivos deste estudo eram 1) determinar a capacidade de tolerância de BMS-986003, incluindo sua imunogenicidade potenci- al, quando fornecido de forma subcutânea na forma de uma dose úni- ca a macacos; 2) avaliar sua PD (por exemplo, inibição da resposta de anticorpo a antígeno dependente de células T) e perfis de PK; 3) avali- ar a ocupação de receptor de BMS-986003 e contagens de células T periféricas após dosagem subcutânea; e 4) auxiliar na seleção de do- ses para estudos de transplante renal e dosagem primeira em seres humanos.
[00215] BMS-986003 foi administrado s.c. no tórax posterior na forma de doses únicas de O (controle de veículo), 0,2, 2 ou 20 mg/kg a grupos de 2 macacos cynomolgus por sexo. Dois macacos/sexo adi- cionais receberam uma única dose intravenosa de 20 mg/kg de 5c8- I9G1, um anticorpo monoclonal para CD40L humano que foi utilizado como um controle positivo neste estudo. Todas as doses foram admi- nistradas em 2 mL/kg no veículo (PBS; pH 7,2). Para avaliar os efeitos sobre a resposta de anticorpo dependente de células T, os animais foram imunizados em aproximadamente 24 horas após a dosagem com o artigo de teste ou imediatamente após a dosagem do controle positivo com 10 mg de KLH através de injeção intramuscular (quadri-
ceps posterior ou coxa caudal). Os critérios para avaliação incluíam sobrevivência, PK, imunogenicidade, PD (inibição da resposta de anti- corpo para o antígeno dependente de células T, KLH), sinais clínicos, pesos corporais, consumo de alimentos, imunofenotipagem do sangue periférico, ocupação de receptor e avaliações clínicas-patológicas (hematologia, química do soro e coagulação). Os animais foram devol- vidos para o estoque após um período de observação pós-dose de 6 semanas.
[00216] Em doses < 20 mg/kg, o BMS-986003 foi lentamente ab- sorvido (Tmax = 6-96 h) e os valores de Cmax e AUCtot aumentaram de uma maneira menos que proporcional à dose ao longo de todos os grupos de doses e não havia diferenças de gênero evidentes. Os valo- res de T1/2 estimados variavam de 69-104 h ao longo de todas as do- ses. BMS-986003 era substancialmente imunogênico; todos os maca- cos desenvolveram uma resposta de anticorpo antifármaco (ADA) po- sitiva durante o período pós-dose de 6 semanas. Em 0,2 e 2 mg/kg, a resposta de ADA total média do grupo tinha seu máximo no dia 22 nos títulos de ponto final médios do grupo (EPT) de 4203 e 6469, respecti- vamente. Em 20 mg/kg, a resposta de ADA, embora positiva, era de alguma maneira retardada e parcialmente suprimida, coerente com a farmacologia do alvo, tendo seu máximo no dia 36 em um EPT médio de grupo de 1828. A caracterização adicional dos anticorpos demons- trou a maior parte de ligação à porção de dAb (sem ser Fc) da molécu- la e foi mostrado que estes anticorpos bloqueiam a ligação de BMS- 986003 ao CD40L em 2 formatos de ensaio imunológico diferentes su- gerindo que o ADA era neutralizador. Em adição, a formação de ADA parecia acelerar a eliminação de BMS-986003 em vários macacos.
[00217] Os parâmetros médios de PK para BMS-986003 são apre- sentados na TABELA 14. TABELA 14
Sumário da Farmacocinética 0,2 mg/kg 2 mg/kg 20 mg/kg 20 mg/kg We | Woo Masculi- Masculi- Masculi- Masculi- Ca PE E 5 [to pg:h/mL o vel o 69/1071 45/49 88/91 Não aplicável oco OR A RSS
[00218] O peso molecular utilizado para a conversão era de 78104 Da para BMS-986003, 150000 Da para mAb 5c8-IgG1.
[00219] ND= não determinado; a AUCextra para indivíduos do sexo masculino ficava acima de 20%, portanto a T1/2 não foi relatada.
[00220] Não havia observações ou efeitos clínicos relacionados ao BMS-986003 ou ao 5c8-lgG1 sobre os pesos corporais ou parâmetros de patologia clínica exceto 1 indivíduo do sexo masculino tratado com 5c8-lg9G1 que teve células vermelhas do sangue (0,74 x controle), he- moglobina (0,73x pré-dose) e hematócrito (0,75x pré-dose) reduzidos no dia 8 e 3 de 4 macacos que receberam 5c8-IgG1 tinham linfócitos reduzidos (0,53x até 0,65x pré-dose) no dia 8, sugestivo de eliminação de linfócitos.
[00221] A ocupação de receptor de CD40L era geralmente depen- dente do tempo e da dose e mais sustentada após a administração de mg/kg de BMS-986003, coerente com exposições mais altas e mais sustentadas nesta dose e atividade de PD. Para BMS-986003, ocupa- ção de receptor média máxima sobre as células mononucleares do sangue periférico (PBMC) foi atingida em 24 h (97%), 6 h (99%) ou 48 20 h (99%) pós-dose, diminuindo para <90% de ocupação em 240, 360 ou 696 h e para <50% de ocupação em 360, 696 ou 1032 h, em 0,2, 2 ou 20 mg/kg, respectivamente. Em comparação, para 5c8-lgG1 em 20 mg/kg, a ocupação de receptor média máxima sobre as PBMCs foi a- tingida em 48 horas (> 100%) e foi sustentada a > 97% durante o estu- dointeiro(1032 hou até o dia 44).
[00222] “BMS-986003 suprimia a resposta de anticorpo para KLH somente na dose alta de 20 mg/kg. Nos dias 8-30 em 20 mg/kg, havia uma supressão de 69 até 83% da resposta de anticorpo média de gru- po geomético para KLH, em relação ao grupo de controle, com uma supressão máxima de 83% ocorrendo no dia 16. Não ocorreu supres- são da resposta de anticorpo em 0,2 ou 2 mg/kg de BMS-986003. Es- tes dados demonstram que BMS-986003 em uma ocupação de recep- tor sustentada de >90% durante pelo menos 1 mês e em concentra- ções sustentadas no plasma acima de -10 ug/mL até o dia 11 é capaz de inibir uma resposta de anticorpo dependente de células T em ma- cacos cynomolgus. Para o anticorpo de controle positivo, 5c8-lg9G1, uma supressão de 74-97% da resposta de anticorpo média de grupo geométrico para KLH ocorreu nos dias 8-30, com supressão máxima de 97% no dia 16 que era geralmente sustentada até o dia 30.
[00223] Nenhuma alteração relacionada ao BMS-986003 biologi- camente relevante em números absolutos de células B (CD45+, CD20+, CD3-), células T totais (CD45+, CD3+), células T helper (CD45+, CD3+, CD4+, CDB8-), células T citotóxicas (CD45+, CD3+, CD4-, CD8+) ou células natural killer (CD45+, CD3-, CD16+) ocorreu durante o estudo, o que confirmou a ausência de qualquer função efe- tora de Fc. Entretanto, no dia 8, 3 de 4 macacos tratados com 20 mg/kg de 5c8-lgG1 tinham populações de linfócitos T (0,53x-0,66x pré- dose), tanto de células T helper (0,64x to 0,77x pré-dose) quanto cito- tóxicas (0,40x to 0,61x pré-dose) reduzidas, que sugeria eliminação.
[00224] Em conclusão, o BMS-986003 administrado na forma de doses SC únicas de 0,2, 2 ou 20 mg/kg (AUC < 14195 ug*h/mL) era bem tolerado em macacos cynomolgus sem efeitos adversos relacio- nados ao fármaco. O controle positivo, 5c8-l9G1, em uma dose de 20 mg/kg, resultou na inibição sustentada completa da resposta de anti- corpo para KLH e ocupação de receptor sustentada de aproximada- mente 100% ao longo de 30 dias pós-dose. Uma eliminação suave de células T também foi observada no dia 8 em macacos que receberam 5c8-I9G1 (0,40x até 0,77x pré-dose), que não foi observada com BMS-
986003. BMS-986003 era capaz de suprimir uma resposta de anticor- po paraKLH em 20 mg/kg (supressão máxima de 83%) após a imuni- zação com KLH no dia 1 e tinha ocupação de receptor sustentada de > 90% até o dia 22 e > 50% até o dia 29. Um refreamento similar da i- munogenicidade para BMS-986003 ocorreu em 20 mg/kg. Entretanto, doses mais baixas de BMS-986003 de 0,2 e 2 mg/kg não suprimiram a resposta de anticorpo para KLH ou a resposta de anticorpo antifárma- co. A falta de farmacologia nas doses mais baixas também se correla- cionava com ocupação de receptor reduzida (isto é, <90% no dia 11 [0,2 mg/kg] ou 16 [2 mg/kg]; <50% no dia 16 [0,2 mg/kg] ou 30 [2 mg/kg]l) e eliminação acelerada, presumivelmente devido à formação de ADA. A inibição de TDAR é coerente com o mecanismo de ação deste composto e não foi considerada adversa. Exemplo 11 Avaliação do Risco de TE / Trombose
[00225] Foilevantada uma hipótese de que a TE associada com a administração dos anticorpos monoclonais anti-CD40L é mediada pela ligação cruzada de plaquetas mediada pelo complexo imune (IC) anti- CD40L mAb-CD40L, facilitada pela ligação do IC com FegRlila, um re- ceptor de Fc de IgG, causando a ativação e a agregação (FIG. 10). É experado, portanto, que o bloqueio da interação do grupamento de Fc delgG com FcegRlla diminua a ligação cruzada de plaquetas e a trom-
bose. Os métodos e as abordagens a seguir foram planejados para avaliar o risco de TE e/ou trombose. Ensaios de ativação de plaquetas in vitro
[00226] Vários ensaios in vitro foram conduzidos para testar a hipó- tesede que as plaquetas são ativadas pelo IC CD40L mab/sCD40L de uma maneira dependente de FcgRlla. O controle positivo 5c8-Ig9G1 foi utilizado para validar os ensaios antes de testar BMS-986003 e BMS-
986004. O sangue de doadores humanos ou de camundongos que expressam o receptor de hFcgRlla sobre as plaquetas foi utilizado pa- raestes estudos. A ativação de plaquetas foi detectada por citometria de fluxo utilizando anticorpos contra os marcadores de ativação de plaquetas bem validados P-selectina (CD62P) e PAC-1 (GPIlb/llla ati- vado). Sucintamente, o sangue foi diluído 1:25 em Tyrodes-HEPES modificado contendo 1 mM de CaCl2 ao qual os anticorpos de detec- çãoe os reagentes de teste foram adicionados, incubados e analisa- dos em relação à ativação de plaquetas. Experimentos iniciais deter- minaram que sSCD40L ou 5c8I1gG1 isoladamente não ativavam as pla- quetas, mas proporções de complexos imunes diferentes de 1:1 até 1:8 de 5c8:sCD40L ativavam significativamente as plaquetas. Experi- mentos subsequentes utilizaram 5c8-l9G1 ou IC5c8-mIlgG2a, princi- palmente em uma proproção molar de 1:3 de 5c8:sCD40L. A ativação de plaquetas pelo IC 5c8/sCD40L pode ser bloqueada pelo anticorpo anti-FcegRlila
[00227] Foram conduzidos estudos com o anticorpo de bloqueio de FcecoRIla IV3 para testar se a ativação de plaquetas pelo IC 5c8/sCD40L era verdadeiramente mediada por FCcgRIIA. O sangue de doadores humanos foi pré-incubado com 0,5 ug/ul do anticorpo de bloqueio de FcgRila IV.3 antes da diluição e da incubação com anti- corpos de detecção como descrito anteriormente. Difosfato de adeno- sina (ADP), um ativador de plaquetas através de um mecanismo dife-
rente, foi utilizado como um controle positivo. Como ilustrado na FIG. 16, a ativação de plaquetas pelo IC 5c8/sCD40 foi completamente blo- queada pelo IV.3, enquanto que a ativação pelo ADP não era inibida pelo anticorpo de bloqueio, indicando que a ativação pelo IC é media- daporFecgRlla. Seleção de caudas de Fc inertes
[00228] Uma exigência para moléculas candidatas potenciais era a ausência de ligação a FcgRlla para prevenir a ativação potencial de plaquetas. Várias construções de 5c8 contendo mutações diferentes derivadas de IgG1 (por exemplo, 5c8-CT e N297Q) ou IgG4 (por e- xemplo, 5c8-S228P) foram expressas e verificadas em relação às caudas de Fc que não ativavam as plaquetas utilizando proporções molares diferentes de SCD40L em relação aos mAbs. Construções do tipo selvagem e mutadas principais ativavam as plaquetas exceto para 5c8-CT e 5c8-N297Q (FIG. 17). A ausência de Fc (5c8-Fab2) também não ativava as plaquetas confirmando adicionalmente que a ativação de plaquetas pelo IC é mediada pelo Fc. A cauda de CT foi escolhida para formatar os candidatos de dAb BMS-986003 e BMS-986004. Efeito do polimorfismo de FcgRlla sobre a ativação de plaquetas
[00229] O gene para FcgRlla é variável no códon 131, resultando no polimorfismo de His-Arg (CAT/CGT). A distribuição do genótipo em aproximadamente 100 indivíduos com distribuição aproximadamente igual de caucasianos e afro-americanos era A/A (homozigotos para His; 14%), A/G (heterozigotos para His/Arg; 60%) e G/G (homozigotos para Arginina; 26%) para americanos caucasianos e A/A (30%), A/G (51%) e G/G (19%) para afro-americanos. Reilly e outros, Clin. Diagn. Lab. Immunol. 1: 640-644 (1994). A agregação de plaquetas depen- dente de Fc foi observada em amostras provenientes de indivíduos R131 quando tratadas com anti-CD9 no formato de Fc mIgG2 ou mIgG1, enquanto que as plaquetas provenientes dos indivíduos H131 se agregavam apenas com anti-CD9 como o formato mIgG2; isto su- gere que a agregação dependente de Fc com um mAb de IgG1 pode- ria potencialmente segregar uma população de pacientes em aqueles que respondem pouco e muito, o que foi relatado previamente com este polimorfismo. Tomiyama e outros, Blood 80: 2261-2268 (1992).
Para se dirigir a quaisquer diferenças potenciais na ativação de pla- quetas com a cauda de Fc de IgG1 e CT, 19 doadores foram genoti- pados em relação ao polimorfismo de hFcegRlla e as amostras foram testadas em relação à ativação de plaquetas. O polimorfismo do grupo de doadores (RR; 42%, HH; 21%, HR; 37%) era suficiente para avaliar quaisquer diferenças potenciais na ativação de plaquetas para o for- mato de IgG1. Representativo dos relatórios na literatura, a ativação de plaquetas com o IC 5c8-lgG1/sCD40L era similar ao longo de todos os indivíduos genotipados. Não foi observada ativação com o IC 5c8- CT/sCD40L (FIG. 18), sugerindo nenhum ou um risco mínimo de maior TE em um paciente population com um anticorpo formatado com a cauda de CT. BMS-986004: Ativação de plaquetas em doadores de sangue hu- manos
[00230] Os experimentos descritos anteriormente utilizando 5c8, sustentaram a seleção da cauda de CT como o melhor formato para BMS-986004 (também chamado de BMS2h-572-633-CT-L2). O san- gue obtido de 6 doadores foi tratado com 5c8-lIgG1, 5c8-CT, F(ab); e BMS-986004. As plaquetas foram ativadas por 5c8-lgG1, mas não por qualquer uma das outras construções, incluindo BMS-986004 (FIG. 19), sugerindo que este dAb possui nenhum ou baixo risco de causar ativação de plaquetas e TE em estudos clínicos. BMS-986003: Ativação de plaquetas no sangue de camundongos que expressam hFecgRlla
[00231] Para confirmar adicionalmente que a ativação de plaquetas pelos anticorpos anti-CD40L era mediada pelo receptor de FcgRlla, o sangue de camundongos transgênicos expressando o receptor huma- no (genótipo R131) foi tratado com 5c8-lgG1, 5c8-lgG2a, dAb-IgG1, 5c8-CT e BMS-986003 (também chamado de BMS-2h572-633-CT). As plaquetas foram especificamente ativadas por 5c8-lg9G1, 5c8-lgG2a e IC dAb-IlgG1/sCD40L no sangue proveniente de camundongos ex- pressando hFcegRlla, mas não nos companheiros de ninhada do tipo selvagem. 5c8-CT e BMS-986003 não ativavam as plaquetas, confir- mando adicionalmente um baixo risco de TE com os anticorpos divul- gados aqui (FIG. 20). Exemplo 12 Experimentos de Ligação ao Epítopo
[00232] AFIG.25 mostra dados de sensorgrama de SPR para ex- perimentos planejados para testar se ou não as moléculas de dAb mo- novalentes BMS2h-503-1, BMS2h-572-6, BMS2h-719-17 e o fragmen- to Fab de anti-CD40L monovalente 5c8 competem um com o outro pe- la ligação ao CD40L. Os experimentos foram realizadis utilizando CD40L biotinilado (biot-IZ-hCD40L) que foi capturado sobre a superfí- cie de um chip sensor com estreptavidina. Os testes envolviam a inje- ção sequencial de uma molécula especificada (fase "a"), imediatamen- te seguida pela injeção da mesma molécula na presença de uma se- gunda molécula especificada (fase "b"), seguida pela dissociação (fase "c"). A competição pela ligação é identificada na forma de uma redu- ção (bloqueio) do sinal de ligação para a segunda molécula na pre- sença da primeira, com o nível de bloqueio sendo governado pela ci- nética de associação e dissociação de cada molécula. Para cada par de moléculas testado, foi mostrado que a ligação da segunda molécula era reduzida quando a primeira molécula estava presente. Estes resul- tados sugerem que BMS2h-503-1, BMS2h-572-6, BMS2h-719-17 e 5c8Fabcompetem um com os outros pela ligação ao biot-IZ-hCD40L.
[00233] A FIG. 26 mostra dados de sensorgrama de SPR para a ligação das moléculas de dAb-CT-long e de 5c8-CT-long indicadas ao monômero de CD40L humano (CDA40L triplo mutante (T211E, S222Y, H224K, [108-261])) ou ao trímero de CD40L (IZ-hCD40L). As molécu- lasdedAb-CT-ong e de 5c8-CT-long foram capturadas através de seu domínio de Fc de "CT-long" sobre a superfície de um chip sensor de anticorpo anti-Fc de IgG humana imobilizado (Biacore, GE Healthca- re). Os dados nos 3 painéis superiores mostram que o monômero de CD40L humano se liga especificamente ao BMS2h-719-202-CT-long e ao 5c8-CT-long, mas não se liga a qualquer uma das moléculas de dAb-CT-long indicadas que contêm dAbs da linhagem BMS2h-572-6. Em contraste, os 3 painéis inferiores mostram que o trímero de CD40L (IZ-hCD40L) se liga fortemente a todas as moléculas de dAb-CT-long testadas da linhagem BMS2h-572-6, bem como a BMS2h-719-202-CT- longe a 5c8-CT-long. Estes resultados sugerem que as moléculas da linhagem BMS2h-572-6xx-CT-long são específicas em relação a um epítopo que está presente apenas sobre o trímero de CD40L e não está presente sobre o CD40L humano monomérico, enquanto que BMS2h-719-202-CT-long e 5c8-CT-long se ligam a um epítopo que está presente tanto sobre o monômero quanto o trímero de CD40L.
[00234] Embora as presentes modalidades tenham sido descritas em detalhes com referência aos exemplos anteriores, é entendido que várias modificações podem ser feitas sem se afastar do espírito destas modalidades e seriam facilmente conhecidas pelo versado na técnica.

Claims (16)

REIVINDICAÇÕES
1. Polipeptídeo de anticorpo isolado, caracterizado pelo fato de que compreende um primeiro domínio variável que se liga especifi- camente ao CD40L humano, em que o CD40L compreende a sequên- cia de aminoácidos da SEQ ID NO: 1, em que a sequência de aminoá- cidos do primeiro domínio variável compreende BMS2h-572-633 (SEQ ID NO: 274) ou difere da sequência de aminoácidos de BMS2h-572- 633 (SEQ ID NO: 274) por até 5 aminoácidos, e em que o dito polipep- tídeo de anticorpo é um anticorpo de domínio (dAb).
2. Polipeptídeo de anticorpo de acordo com a reivindicação 1, caracterizado pelo fato de que a sequência de aminoácidos do pri- meiro domínio variável compreende: (a) uma região de CDR1 que possui uma sequência Trp-X,- Leu-Met-Gly (SEQ ID NO: 2), em que X, é Glu ou Gln; (b) uma região de CDR2 que possui uma sequência Gly-lle- Glu-Gly-Pro-Gly-Asp-Val-Thr-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (SEQ ID NO: 3) e (c) uma região de CDR3 que possui uma sequência Lys-X,- Y2- Z2-Ser-Asp-Tyr (SEQ ID NO: 4), em que X, é Asp ou Glu, Y, é Ala ou Ser e Z, é Lys, Asn ou Arg.
3. Polipeptídeo de anticorpo de acordo com a reivindicação 2, caracterizado pelo fato de que a sequência de aminoácidos do pri- meiro domínio variável compreende: (a) uma região de FR1 que possui uma sequência Glu-Val- Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-GlIn-Pro-Gly-Gly-Ser-Leu- Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Asn (SEQ ID NO: 5); (b) uma região de FR2 que possui uma sequência Trp-X,- Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser (SEQ ID NO: 6), em que X, é Ala ou Val; (c) uma região de FR3 que possui uma sequência Arg-Thr-
Phe-lle-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-Met-Asn- Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Val-Lys-Val-Gly (SEQ ID NO: 7) e (d) uma região de FR4 que possui uma sequência Arg-Gly- GIn-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser (SEQ ID NO: 8).
4. Polipeptídeo de anticorpo de acordo com a reivindicação 1, caracterizado pelo fato de que o primeiro domínio variável compre- ende a sequência de aminoácidos de BMS2h-572-633 (SEQ ID NO: 274).
5. Polipeptídeo de anticorpo de acordo com a reivindicação 1, caracterizado pelo fato de que o polipeptídeo de anticorpo é a SEQ ID NO: 1355.
6. Polipeptídeo de anticorpo de acordo com qualquer uma das reivindicações 1 a 4, caracterizado pelo fato de que o polipeptídeo de anticorpo é um polipeptídeo de fusão que compreende o primeiro domínio variável e um domínio Fc.
7. Polipeptídeo de anticorpo de acordo com a reivindicação 6, caracterizado pelo fato de que o polipeptídeo de fusão compreende uma sequencia de aminoácidos selecionada do grupo consistindo em um domínio CT-Long (SEQ ID NO: 1357), um domínio CT-short (SEQ ID NO: 1358), um domínio Fc de N297Q Long (SEQ ID NO: 1359) e um domínio Fc de N297Q Short (SEQ ID NO: 1360).
8. Polipeptídeo de anticorpo de acordo com qualquer uma das reivindicações 1 a 5, caracterizado pelo fato de que o polipeptídeo de anticorpo compreende ainda um segundo domínio variável que se liga especificamente a um segundo antígeno, em que o segundo antí- geno é um antígeno sem ser CD40L humano.
9. Ácido nucleico, caracterizado pelo fato de que codifica o polipeptídeo de anticorpo como definido em qualquer uma das reivin- dicações 1 a 8.
10. Vetor, caracterizado pelo fato de que compreende o ácido nucleico como definido na reivindicação 9.
11. Célula hospedeira isolada, caracterizada pelo fato de que compreende o vetor como definido na reivindicação 10.
12. Composição farmacêutica, caracterizada pelo fato de que compreende uma quantidade terapeuticamente eficaz do polipep- tídeo de anticorpo como definido em qualquer uma das reivindicações 1 a 8, opcionalmente um agente imunossupressor/imunomodulador e/ou anti-inflamatório, e um veículo farmaceuticamente aceitável.
13. Uso de um polipeptídeo de anticorpo isolado como defi- nido em qualquer uma das reivindicações 1 a 8, e opcionalmente em combinação com um agente imunossupressor/imunomodulador e/ou anti-inflamatório, caracterizado pelo fato de que é para a preparação de um medicamento para o tratamento de um paciente, em que o pa- ciente tem ou está em risco de ter uma doença imune, em que a doen- ça imune é selecionada do grupo que consiste em doença de Addison, alergias, espondilite anquilosante, asma, aterosclerose, doenças au- toimunes do ouvido, doenças autoimunes do olho, hepatite autoimune, parotidite autoimune, colite, doença cardíaca coronariana, doença de Crohn, diabetes, incluindo diabetes do Tipo 1 e/ou do Tipo 2, epididimi- te, glomerulonefrite, doença de Graves, síndrome de Guillain-Barre, doença de Hashimoto, anemia hemolítica, púrpura trombocitopênica idiopática, doença inflamatória do intestino, resposta imunológica a produtos de fármacos recombinantes, lúpus eritematoso sistêmico, in- fertilidade do sexo masculino, esclerose múltipla, miastenia grave, pênfigo, psoríase, febre reumática, artrite reumatoide, sarcoidose, es- cleroderma, síndrome de Sjogren, espondiloartropatias, tireoidite, re- jeição a transplante, vasculite, AIDS, alergia atópica, asma bronquial, eczema, lepra, esquizofrenia, depressão herdada, síndrome de fadiga crônica, doença de Alzheimer, doença de Parkinson, enfarte do mio-
cárdio, derrame, autismo, epilepsia, fenômeno de Arthus, anafilaxia, dependência de álcool e dependência de drogas.
14. Uso de acordo com a reivindicação 13, caracterizado pelo fato de que a doença imune é uma rejeição a transplante, e em que a rejeição a transplante é uma doença relacionada a enxerto, e em que o polipeptídeo de anticorpo isolado é opcionalmente coadmi- nistrado com uma molécula de CTLA4 mutante.
15. Uso de acordo com a reivindicação 13, caracterizado pelo fato de que a doença imune é púrpura trombocitopênica idiopáti- ca.
16. Invenção, em quaisquer formas de suas concretizações ou em qualquer categoria aplicável de reivindicação, por exemplo, de produto ou de processo ou uso englobadas pela matéria inicialmente descrita, revelada ou ilustrada no pedido de patente.
BR112014009069-6A 2011-10-13 2012-10-12 polipeptídeos de anticorpo que antagonizam cd40l BR112014009069A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161546800P 2011-10-13 2011-10-13
US61/546,800 2011-10-13
US201261655110P 2012-06-04 2012-06-04
US61/655,110 2012-06-04
PCT/US2012/059977 WO2013056068A1 (en) 2011-10-13 2012-10-12 Antibody polypeptides that antagonize cd40l

Publications (1)

Publication Number Publication Date
BR112014009069A2 true BR112014009069A2 (pt) 2020-10-27

Family

ID=47046896

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009069-6A BR112014009069A2 (pt) 2011-10-13 2012-10-12 polipeptídeos de anticorpo que antagonizam cd40l

Country Status (31)

Country Link
US (7) US8895010B2 (pt)
EP (1) EP2766395B1 (pt)
JP (1) JP6163158B2 (pt)
KR (1) KR101637915B1 (pt)
CN (1) CN104245732B (pt)
AR (1) AR088455A1 (pt)
AU (2) AU2012322093C1 (pt)
BR (1) BR112014009069A2 (pt)
CA (1) CA2851814C (pt)
CL (1) CL2014000958A1 (pt)
CO (1) CO7020864A2 (pt)
CY (1) CY1123618T1 (pt)
DK (1) DK2766395T3 (pt)
EA (1) EA030852B1 (pt)
ES (1) ES2769806T3 (pt)
HK (1) HK1204789A1 (pt)
HR (1) HRP20200230T1 (pt)
HU (1) HUE048365T2 (pt)
IL (1) IL231925B (pt)
LT (1) LT2766395T (pt)
MX (1) MX357231B (pt)
PE (1) PE20141478A1 (pt)
PL (1) PL2766395T3 (pt)
PT (1) PT2766395T (pt)
RS (1) RS60021B1 (pt)
SG (2) SG10201610288TA (pt)
SI (1) SI2766395T1 (pt)
TW (1) TWI585102B (pt)
UY (1) UY34394A (pt)
WO (1) WO2013056068A1 (pt)
ZA (1) ZA201402603B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI585102B (zh) * 2011-10-13 2017-06-01 必治妥美雅史谷比公司 拮抗ｃｄ４０ｌ之抗體多肽
PT2888283T (pt) 2012-08-24 2018-11-16 Univ California Anticorpos e vacinas para serem utilizados no tratamento de cancros que expressam ror1 e inibição de metástases
US20140106405A1 (en) * 2012-10-15 2014-04-17 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP2017509649A (ja) * 2014-03-19 2017-04-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ４０ｌに対するドメイン抗体を用いる移植拒絶を治療する方法
CN104090115B (zh) * 2014-07-10 2016-01-13 上海益诺思生物技术有限公司 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法
AU2015315063A1 (en) * 2014-09-10 2017-04-27 Bristol-Myers Squibb Company Methods of treating autoimmune disease using a domain antibody directed against CD40L
KR101760707B1 (ko) * 2015-01-05 2017-07-24 한림대학교 산학협력단 이종 알부민을 이용한 장기 이식 거부반응 검사용 키트
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
KR101752280B1 (ko) 2015-03-31 2017-06-30 서울대학교산학협력단 영장류 cd154에 특이적인 항체 및 이를 생산하는 융합 세포주
RU2021111382A (ru) * 2015-07-16 2021-05-21 Инхибркс, Инк. Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP7049988B2 (ja) 2015-08-05 2022-04-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ１５４抗体及びこれを使用する方法
CN109069622A (zh) 2015-09-30 2018-12-21 詹森生物科技公司 特异性结合人cd40的拮抗性抗体和使用方法
JP2018536404A (ja) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
CN105353135A (zh) * 2015-11-23 2016-02-24 中国人民解放军第三军医大学第一附属医院 阿尔茨海默病标志物的用途
SG11201803976VA (en) 2015-11-27 2018-06-28 Ablynx Nv Polypeptides inhibiting cd40l
WO2017160975A1 (en) 2016-03-16 2017-09-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN106967171B (zh) * 2017-02-23 2021-04-27 郑州大学 一种全人源重组CD40L单抗Fab片段及其制备方法
WO2018169785A2 (en) 2017-03-13 2018-09-20 The Government Of The United States Of America As Represented By The Secretary Of The Army Therapeutic antibodies to marburg virus
RU2022108410A (ru) 2017-05-24 2022-04-05 ЭйЭлЭс ТЕРАПИ ДЕВЕЛОПМЕНТ ИНСТИТЬЮТ Терапевтические антитела против лиганда cd40
AU2020300002A1 (en) 2019-07-01 2022-02-24 Tonix Pharma Limited Anti-CD154 antibodies and uses thereof
KR20210006301A (ko) * 2019-07-08 2021-01-18 주식회사 프로젠 신규 융합단백질 및 그의 용도
US20210032356A1 (en) * 2019-08-02 2021-02-04 Eastern Virginia Medical School Method for treating seizures
WO2021113648A1 (en) * 2019-12-06 2021-06-10 The University Of North Carolina At Chapel Hill Affinity molecules that direct the metabolism and polarization of macrophages and synergize the immune checkpoint blockade therapy
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2023008055A (es) 2021-01-06 2023-08-22 Tonix Pharma Ltd Métodos para inducir tolerancia inmune con anticuerpos anti-cd154 modificados.
CN114149508B (zh) * 2021-11-25 2023-04-28 苏州普乐康医药科技有限公司 一种结合cd40l的融合蛋白及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
WO2004081026A2 (en) * 2003-06-30 2004-09-23 Domantis Limited Polypeptides
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
CN101443043A (zh) * 2003-10-08 2009-05-27 杜门蒂斯有限公司 抗体组合物和方法
ZA200702427B (en) * 2004-09-17 2008-12-31 Domantis Ltd Compositions monovalent for CD40L binding and methods of use
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
LT1868635T (lt) 2005-04-06 2017-07-10 Bristol-Myers Squibb Company Imuninių sutrikimų, susijusių su transplantato persodinimu, gydymo būdas tirpiomis mutantinėmis ctla4 molekulėmis
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
JP5721951B2 (ja) 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
HUE038788T2 (hu) 2010-03-31 2018-11-28 Boehringer Ingelheim Int Anti-CD40 antitestek
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
AR086360A1 (es) 2011-04-21 2013-12-11 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40
TWI585102B (zh) * 2011-10-13 2017-06-01 必治妥美雅史谷比公司 拮抗ｃｄ４０ｌ之抗體多肽
US20150210763A1 (en) 2012-02-09 2015-07-30 Chugai Seiyaku Kabushiki Kaisha MODIFIED Fc REGION OF ANTIBODY
JP2017509649A (ja) 2014-03-19 2017-04-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ４０ｌに対するドメイン抗体を用いる移植拒絶を治療する方法

Also Published As

Publication number Publication date
EA030852B1 (ru) 2018-10-31
JP2014530611A (ja) 2014-11-20
US9228018B2 (en) 2016-01-05
US8895010B2 (en) 2014-11-25
US20220073636A1 (en) 2022-03-10
US20160075790A1 (en) 2016-03-17
CN104245732B (zh) 2020-04-07
MX2014004293A (es) 2014-07-24
KR101637915B1 (ko) 2016-07-11
US8981072B2 (en) 2015-03-17
AU2012322093A1 (en) 2014-05-29
AU2016202717A1 (en) 2016-05-19
NZ624772A (en) 2016-07-29
US20190100595A1 (en) 2019-04-04
ES2769806T3 (es) 2020-06-29
UY34394A (es) 2013-04-30
DK2766395T3 (da) 2020-02-24
US20130095109A1 (en) 2013-04-18
PT2766395T (pt) 2020-02-04
TWI585102B (zh) 2017-06-01
PE20141478A1 (es) 2014-10-23
PL2766395T3 (pl) 2020-06-01
HK1204789A1 (en) 2015-12-04
US20180051091A1 (en) 2018-02-22
AU2012322093B2 (en) 2016-06-02
US20140099707A1 (en) 2014-04-10
CL2014000958A1 (es) 2014-08-29
HUE048365T2 (hu) 2020-08-28
AU2012322093C1 (en) 2016-12-22
EP2766395B1 (en) 2019-11-20
US10196451B2 (en) 2019-02-05
HRP20200230T1 (hr) 2020-06-26
IL231925B (en) 2019-11-28
WO2013056068A1 (en) 2013-04-18
RS60021B1 (sr) 2020-04-30
TW201321411A (zh) 2013-06-01
SG11201401385YA (en) 2014-09-26
SI2766395T1 (sl) 2020-09-30
CA2851814C (en) 2018-11-06
AR088455A1 (es) 2014-06-11
KR20140069349A (ko) 2014-06-09
SG10201610288TA (en) 2017-02-27
ZA201402603B (en) 2016-10-26
US20150023976A1 (en) 2015-01-22
JP6163158B2 (ja) 2017-07-12
MX357231B (es) 2018-07-02
US9765150B2 (en) 2017-09-19
EP2766395A1 (en) 2014-08-20
US11180567B2 (en) 2021-11-23
CY1123618T1 (el) 2022-03-24
LT2766395T (lt) 2020-03-25
CO7020864A2 (es) 2014-08-11
IL231925A0 (en) 2014-05-28
EA201490745A1 (ru) 2014-11-28
CN104245732A (zh) 2014-12-24
CA2851814A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
US11180567B2 (en) Antibody polypeptides that antagonize CD40L
JP2022116257A (ja) 癌の治療に用いるための細胞傷害誘導治療剤
US20200231676A1 (en) Methods of treating transplant rejection using a domain antibody directed against cd40l
JP6175590B1 (ja) 癌の治療に用いるための細胞傷害誘導治療剤
CN111712518A (zh) 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途
US20150118237A1 (en) Anti-human cd69 antibody, and use thereof for medical purposes
NZ624772B2 (en) Antibody polypeptides that antagonize cd40l

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]